US Patent Applications in Skin Care Actives and Formulations Published in 2010

Thank you for visiting FormulaScan . Please click on the Patent No to study the full patent document

US PATENT APPLICATIONS IN SKIN CARE ACTIVES PUBLISHED IN 2010



Application No.: US20100003198A1  Published: 07/Jan/2010

Title: Antimicrobial Topical and Other Preparations Containing Fluorescent or Illumination Dye and Tracer Agents or Compounds

Applicant/Assignee:

Application No.: 12/498217   Filing Date: 06/Jul/2009

Abstract:A formulation for topical application to human skin and other surface preparation compositions containing antimicrobial, antifungal and antiviral compounds which remain on human skin and other surface compositions to reduce or dominate bacteria, virus and fungi present, prevent future contamination by their presence and substantive character, contain agents or compounds that contain antibacterial, antiviral and antifungal properties and flourescent dyes and tracers that contain illumination properties exhibiting various colons including clear and no color pigment, that when exposed to certain light such as ultraviolet, will produce an illumination effect in various colors including dear and no color for a period of time within a preferred range of thirty minutes to six hours or longer from the time of initial application, and prior to for instance application of ultraviolet light, such flourescent dyes and tracers appear to be clear in color, invisible or have no color pigment showing on the skin or other surfaces, but when exposed to for instance ultraviolet fight, the surface illuminates allowing a person to determine if human skin or other surface has been adequately covered with the antibacterial, antifungal or antiviral composition agent or compound, and to significantly increase the activity to reduce and eliminate bacteria, virus and fungi on the surface, and support programs for antibacterial, antifungal and antiviral quality control, compliance, verification and education for industry and human handwash technique.

Priority: US20080133936P Applic. Date: 2008-07-07

Inventor: STOLMEIER PATRICK JOHN [US]; STOLMEIER JONATHAN P [US]


Application No.: US20100003205A1  Published: 07/Jan/2010

Title: Cosmetic Composition

Applicant/Assignee:

Application No.: 12/496352   Filing Date: 01/Jul/2009

Abstract:Cosmetic composition providing a high coverage of skin while retaining a natural skin appearance comprising iron oxide particles having an average primary particle size of less than or equal to 100 nm, iron-containing titanium dioxide particles having an average primary particle size of at least 105 nm and comprising from 1% to 15% iron by weight of the titanium dioxide, and a cosmetically acceptable carrier and its use as a foundation and/or as a composition to correct skin discoloration surrounding the eye.

Priority: EP20080159451 Applic. Date: 2008-07-01

Inventor: ELLIOTT RUSSELL PHILLIP [GB]; WATSON JOANNE [GB]


Application No.: US20100003206A1  Published: 07/Jan/2010

Title: Cosmetic Composition Containing A Protein And An Enzyme Inhibitor

Applicant/Assignee:

Application No.: 12/541439   Filing Date: 14/Aug/2009

Abstract:The present invention is a cosmetic composition comprising a water-soluble protein-based film-forming agent, the film-forming agent having a tertiary structure capable of undergoing a helix-coil transformation, a protease inhibitor in an amount sufficient to protect the protein on the stratum corneum and a cosmetically acceptable vehicle so that the protease inhibitor prolongs the pulling effect of the film-forming agent.

Priority: US2005-030664 Applic. Date: 2005-01-06; US20040535198P Applic. Date: 2004-01-07

Inventor: GIACOMONI PAOLO ULDERICO [US]; MANIRAZMAN ABUL M [US]; LENTINI PETER J [US]; HARVEY GEDEON [US]


Application No.: US20100003207A1  Published: 07/Jan/2010

Title: Photoprotective compositions comprising photosensitive 1,3,5-triazine compounds, dibenzoylmethane compounds and siliceous s-triazines substituted with two aminobenzoate or aminobenzamide groups

Applicant/Assignee: L'OREAL

Application No.: 11/987212   Filing Date: 28/Nov/2007

Abstract:UV-photoprotective, topically applicable cosmetic/dermatological compositions contain: (a) at least one dibenzoylmethane compound, (b) at least one 1,3,5-triazine compound that is photosensitive in the presence of a dibenzoylmethane compound, and (c) at least one siliceous s-triazine compound substituted with two aminobenzoate or aminobenzamide groups, or a tautomeric form thereof, the 1,3,5-triazine compounds being improvedly photostable in such compositions.

Priority: FR20060055164 Applic. Date: 2006-11-28; US20060873000P Applic. Date: 2006-12-06

Inventor: CANDAU DIDIER [FR]; RICHARD HERVE [FR]


Application No.: US20100003236A1  Published: 07/Jan/2010

Title: USE OF C-GLYCOSIDE DERIVATIVES AS PRO-DESQUAMATING ACTIVE AGENTS

Applicant/Assignee: L'OREAL

Application No.: 12/306565   Filing Date: 29/Jun/2007

Abstract:A cosmetic use of at least one C-glycoside derivative in a composition comprising a physiologically acceptable medium, as a cosmetic agent for promoting the desquamation of the skin and/or the scalp and/or for stimulating epidermal renewal.

Priority: FR20060006016 Applic. Date: 2006-07-03; US20060832943P Applic. Date: 2006-07-25; WO2007IB52527 Applic. Date: 2007-06-29

Inventor: DALKO MARIA [FR]; BOULLE CHRISTOPHE [FR]; BERNARD DOMINIQUE [FR]


Application No.: US20100003260A1  Published: 07/Jan/2010

Title: PHENYLPENTADIENOYL DERIVATIVES AND THEIR USE AS PAR 1 ANTAGONISTS

Applicant/Assignee:

Application No.: 12/305447   Filing Date: 19/Jun/2007

Abstract:The present invention relates to compounds of general formula (I): wherein: R1 and R2, identical or different, represent: an atom of hydrogen or halogen, CN or NO2, with R1 and R2 not representing hydrogen simultaneously, m represents: 1 or 2 n represents: 0, 1 or 2 R3 represents: phenyl substituted or not by one or more residues chosen among halogen, hydroxyl or C1-C6 alkyl

C2-C6 alkyl substituted or not by one or more residues chosen among halogen or hydroxyl

cycloalkyl

pyridine

thiophene

pyrrole substituted or not by C1-C6 alkyl

thiazole or furan

or the therapeutically-acceptable salts or solvates thereof.

Priority: FR20060005418 Applic. Date: 2006-06-19; WO2007EP56078 Applic. Date: 2007-06-19

Inventor: PEREZ MICHEL [FR]; LAMOTHE MARIE [FR]; LE GRAND BRUNO [FR]; LETIENNE ROBERT [FR]


Application No.: US20100003292A1  Published: 07/Jan/2010

Title: FINE-GRANULOMETRY FUNGAL EXTRACT CHITINE-GLUCANE

Applicant/Assignee:

Application No.: 12/312656   Filing Date: 20/Nov/2007

Abstract:The present invention relates to a chitin-glucan copolymer in the form of micrometric particles. The present invention in particular provides a composition containing a chitin-glucan copolymer in the form of micrometric particles for the preparation of cosmetic compositions, and in particular dermatological or dermocosmetic compositions. In particular, the present invention relates to a cosmetic composition for face or body care, such as hydrating, firming or smoothing the skin, and exercising an anti-aging effect, including an anti-wrinkle effect. The purpose of the invention is also to provide a porous material that can for example be used in tissue engineering or cell culture, or that can be used as a material in the cosmetics or pharmaceutical industry.

Priority: FR20060054998 Applic. Date: 2006-11-20; WO2007EP62601 Applic. Date: 2007-11-20

Inventor: GAUTIER SANDRINE [BE]; BRUYERE JEAN-MICHEL [BE]; MAQUET VERONIQUE [BE]


Application No.: US20100003293A1  Published: 07/Jan/2010

Title: Processes for Reducing the Appearance of Pastiness or Ashiness on Skin

Applicant/Assignee:

Application No.: 12/496376   Filing Date: 01/Jul/2009

Abstract:Processes for reducing the appearance of ashiness or pastiness on skin by applying thereto a cosmetic composition comprising transparent iron oxide particles, iron-containing titanium dioxide particles, and a cosmetically acceptable carrier. These processes are useful to provide coverage of skin imperfections and/or skin tonal variations and/or skin discoloration surrounding the eyes on different types of skin, while, at the same time, retaining a natural skin appearance.

Priority: EP20080159454 Applic. Date: 2008-07-01

Inventor: ELLIOTT RUSSELL PHILLIP [GB]; WATSON JOANNE [GB]


Application No.: US20100003754A1  Published: 07/Jan/2010

Title: METHODS OF DIFFERENTIATING STEM CELLS

Applicant/Assignee: OSSACUR AG

Application No.: 12/373757   Filing Date: 13/Sep/2007

Abstract:A method for at least partial differentiating stem cells and/or progenitor cells to at least one tissue type includes treating the stem cells and/or the progenitor cells with extracts which include active substances and/or components for differentiating stem cells and/or progenitor cells, and cultivating and differentiating the stem cells and/or the progenitor cells.

Priority: DE200610045848 Applic. Date: 2006-09-15; DE200610060247 Applic. Date: 2006-12-13; WO2007EP07971 Applic. Date: 2007-09-13

Inventor: BRIEST ARNE [DE]; SINDET-PEDERSEN STEEN [GB]


Application No.: US20100004159A1  Published: 07/Jan/2010

Title: SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATIONS AND USES

Applicant/Assignee: GENFIT

Application No.: 12/309642   Filing Date: 24/Jul/2007

Abstract:The present invention relates to polysubstituted imidazolone derivatives, to the pharmaceutical compositions comprising them and to the therapeutic uses thereof in the human and animal health fields. The present invention also relates to a process for preparing these derivatives.

Priority: FR20060006752 Applic. Date: 2006-07-24; WO2007FR51716 Applic. Date: 2007-07-24

Inventor: BOUEY EDITH [FR]; MASSON CHRISTOPHE [FR]; BERTRAND KARINE [FR]


Application No.: US20100004165A1  Published: 07/Jan/2010

Title: Novel Protein Transduction Domains and Uses Therefor

Applicant/Assignee: THE ARIZONA BOARD OF REGENTS, A BODY CORPORATE ACTING ON BEHALF OF ARIZONA STATE UNIVERSITY

Application No.: 12/090474   Filing Date: 30/Oct/2006

Abstract:The present invention provides novel transduction domains, compositions comprising such transduction domains, and their use for in vivo molecular delivery.

Priority: US20050732365P Applic. Date: 2005-11-01; WO2006US42209 Applic. Date: 2006-10-30

Inventor: BROPHY COLLEEN [US]; PANITCH ALYSSA [US]; FURNISH ELIZABETH [US]; SEAL BRANDON [US]


Application No.: US20100004215A1  Published: 07/Jan/2010

Title: COMPOSITIONS OF PHOSPHODIESTERASE TYPE IV INHIBITORS

Applicant/Assignee:

Application No.: 12/109752   Filing Date: 25/Apr/2008

Abstract:Provided herein are pharmaceutical compositions comprising one or more phosphodiesterase inhibitors of type IV ("PDE-IV"), and at least one other active ingredient such as muscarinic receptor antagonists (MRA), beta2-agonists, p38 MAP Kinase inhibitors, or corticosteroids and optionally one or more pharmaceutically acceptable excipients. In addition, methods of treating autoimmune, inflammatory or allergic diseases or disorders are provided.

Priority: IN2005DE02793 Applic. Date: 2005-10-19

Inventor: RAY ABHIJIT [IN]; DASTIDAR SUNANDA G [IN]; SHIRUMALLA RAJKUMAR [IN]; GUPTA SUMAN [IN]


Application No.: US20100004296A1  Published: 07/Jan/2010

Title: WATERBORNE TOPICAL COMPOSITIONS FOR THE DELIVERY OF AZELAIC ACID

Applicant/Assignee:

Application No.: 12/486625   Filing Date: 17/Jun/2009

Abstract:A waterborne topical composition is designed specifically to address the treatment of acne vulgaris, rosacea, seborrheic dermatitis and other skin conditions. The composition contains effective amounts of essential components azelaic acid, niacinamide, and glycerin to create a rapidly penetrating and non-irritating compound.

Priority: US20080073102P Applic. Date: 2008-06-17

Inventor: DANNAKER CHRISTOPHER J [US]


Application No.: US20100004311A1  Published: 07/Jan/2010

Title: EXCITATORY AMINO ACID INHIBITORS FOR TREATING SENSITIVE SKINS

Applicant/Assignee: L'OREAL

Application No.: 12/556901   Filing Date: 10/Sep/2009

Abstract:Sensitive human skin/scalp/mucous membrane conditions, for example skin irritation and/or dry patches and/or erythemas and/or dysaesthesic sensations and/or sensations of heating and/or pruritus, are therapeutically treated by topically applying thereto an effective condition-alleviating amount of at least one inhibitor of at least one excitatory amino acid.

Priority: FR19970011959 Applic. Date: 1997-09-25; US2003-401685 Applic. Date: 2003-03-31; US1998-160151 Applic. Date: 1998-09-25

Inventor: BRETON LIONEL [FR]; NONOTTE ISABELLE [FR]


Application No.: US20100008870A1  Published: 14/Jan/2010

Title: Benefit agent containing delivery particle

Applicant/Assignee: APPLETON PAPERS INC

Application No.: 12/216941   Filing Date: 14/Jul/2008

Abstract:The present invention relates to benefit agent containing delivery particles, compositions comprising said particles, and processes for making and using the aforementioned particles and compositions. When employed in compositions, for example, cleaning or fabric care compositions, such particles increase the efficiency of benefit agent delivery, there by allowing reduced amounts of benefit agents to be employed. In addition to allowing the amount of benefit agent to be reduced, such particles allow a broad range of benefit agents to be employed.

Priority:

Inventor: DIHORA JITEN ODHAVJI [US]; SANDS PEGGY DOROTHY [US]; FOSSUM RENGE DIANNA [US]; YORK DAVID WILLIAM [GB]; LANG MATTHEW HENRY [US]; GUINEBRETIERE SANDRA JACQUELINE [US]


Application No.: US20100008871A1  Published: 14/Jan/2010

Title: New Biochemical Route to Astaxanthin

Applicant/Assignee:

Application No.: 12/226426   Filing Date: 20/Apr/2007

Abstract:Two sequences of a nucleic acid isolated from a cDNA library of the flowering plant Adonis aestivalis is disclosed (SEQ ID NO: 5). The first DNA sequence, referred to as AdKC28, encodes for a polypeptide (SEQ ID NO: 6) that acts in conjunction with polypeptides encoded by either one of two other closely-related Adonis aestivalis cDNAs, AdKeto1 (SEQ ID NO: 1) and AdKeto2 (SEQ ID NO: 2), to convert beta-carotene (beta,beta-carotene) into astaxanthin (3,3'-dihydroxy-4,4'-diketo-beta, beta-carotene). A second DNA sequence, referred to as AdKCl 7 is also disclosed (FIG. 9). Together, these Adonis aestivalis cDNAs, when operably linked to promoters appropriate to the transgenic host, enable the production of astaxanthin and other carotenoids with 3-hydroxy-4-keto-beta-rings in a variety of host cells and organisms.

Priority: US20060793645P Applic. Date: 2006-04-21; WO2007US09803 Applic. Date: 2007-04-20

Inventor: CUNNINGHAM JR FRANCIS X [US]


Application No.: US20100008877A1  Published: 14/Jan/2010

Title: COMPOSITION FOR IMPROVING SKIN CONDITION

Applicant/Assignee: KIRIN HOLDINGS KABUSHIKI KAISHA

Application No.: 12/438427   Filing Date: 23/Feb/2009

Abstract:This invention relates to a composition for improving skin conditions comprising, as an active ingredient, a yeast cell wall fraction obtained by removing soluble intracellular component from an enzymatically treated and/or non-enzymatically treated yeast. The composition of this invention is effective for improving skin conditions, such as, moistening, whitening, or active oxygen elimination.

Priority: WO2006JP316654 Applic. Date: 2006-08-24

Inventor: YOSHIDA MICHIKO [JP]; KONISHI YUTAKA [JP]


Application No.: US20100008878A1  Published: 14/Jan/2010

Title: PROPYLENE GLYCOL HYALURONATE, AND SKINCARE PREPARATION FOR EXTERNAL USE COMPRISING SAME

Applicant/Assignee: FOODCHEMIFA CO., LTD

Application No.: 12/444889   Filing Date: 01/Aug/2008

Abstract:A propylene glycol hyaluronate having an esterification degree of from 10 to 90% and a limiting viscosity of less than 3 dL/g has an excellent percutaneous absorption-promoting effect, and is widely usable as cosmetics and pharmaceutical products.

Priority: JP20070208503 Applic. Date: 2007-08-09; WO2008JP02079 Applic. Date: 2008-08-01

Inventor: HIRAI HIDEKI [JP]; WATANABE MAKOTO [JP]; NOZAWA TAKASHI [JP]; MURATA KATSUMI [JP]


Application No.: US20100008959A1  Published: 14/Jan/2010

Title: Cosmetic and Therapeutic Stick Products

Applicant/Assignee: AMCOL INTERNATIONAL CORPORATION

Application No.: 12/282535   Filing Date: 02/Apr/2007

Abstract:A composition wherein phase or chemically incompatible components are introduced into a stick composition through the use of a microparticle delivery system.

Priority: US20060788925P Applic. Date: 2006-04-04; WO2007US08164 Applic. Date: 2007-04-02

Inventor: SPINDLER RALPH [US]; URBANEC STEPHEN J [US]; LIU LIMIN [US]; VAKILI-TAHAMI GHOLAM-REZA [US]


Application No.: US20100008991A1  Published: 14/Jan/2010

Title: Transdermal estrogen device and delivery

Applicant/Assignee: NOVEN PHARMACEUTICALS, INC

Application No.: 12/216811   Filing Date: 10/Jul/2008

Abstract:Described are transdermal drug delivery systems for the transdermal administration of estrogen, comprising a polymer matrix and estrogen. Methods of making and using such systems also are described.

Priority:

Inventor: MANTELLE JUAN [US]


Application No.: US20100009018A1  Published: 14/Jan/2010

Title: METHOD OF OBTAINING AN ACTIVE INGREDIENT INCREASING CUTANEOUS CELL AND TISSUE LONGEVITY, ACTIVE INGREDIENTS AND COMPOSITIONS

Applicant/Assignee: SOCIETE IND LIMO D'APPLICATION BIO, DITE SILAB

Application No.: 12/373215   Filing Date: 06/Jul/2007

Abstract:Method for obtaining of an active principle from Myrtus communis in order to increase the longevity of the cells and tissues of the skin.

Priority: FR20060052900 Applic. Date: 2006-07-11; WO2007FR51610 Applic. Date: 2007-07-06

Inventor: PAUFIQUE JEAN [FR]


Application No.: US20100009933A1  Published: 14/Jan/2010

Title: HYDROXYLATED AMIDE SKIN MOISTURIZER

Applicant/Assignee: L'OREAL

Application No.: 12/302398   Filing Date: 03/May/2007

Abstract:The invention relates to the cosmetic use, as a skin moisturizer, of a compound of formula (I): with (i) R1 and R2 represent a hydrogen atom or a C1-C6-alkyl group, or (ii) R1 and R2 can form, together with the nitrogen atom which bears them, a saturated heterocycle with 5 to 7 ring members

R5 representing a hydrogen atom or a (C1-C3) alkyl group

R6 representing a hydrogen atom or a (C1-C4) alkyl group

R3 represents a hydrogen atom or a (C1-C6) alkyl-group, or -OR3 represents a phosphate group

it being possible for the two groups R3 to form, together, an isopropylidene group

R4 represents a hydrogen atom or -OR4 represents a-phosphate group

and the salts, solvates and isomers thereof. The invention also relates to a cosmetic composition comprising a compound (I) and the corresponding new compounds.

Priority: FR20060051987 Applic. Date: 2006-05-31; US20060811094P Applic. Date: 2006-06-06; WO2007EP54278 Applic. Date: 2007-05-03

Inventor: MARAT XAVIER [FR]


Application No.: US20100010084A1  Published: 14/Jan/2010

Title: HIGH PENETRATION PRODRUG COMPOSITIONS OF RETINOIDS AND RETINOID-RELATED COMPOUNDS

Applicant/Assignee:

Application No.: 12/503739   Filing Date: 15/Jul/2009

Abstract:The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of retinoids and retinoid-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.

Priority: WO2007IB50122 Applic. Date: 2007-01-15

Inventor: YU CHONGXI [US]


Application No.: US20100010085A1  Published: 14/Jan/2010

Title: Compositions and Methods for Treating Jellyfish Stings

Applicant/Assignee:

Application No.: 12/442144   Filing Date: 21/Sep/2007

Abstract:Methods and compositions for treating skin conditions, in particular jellyfish stings, are provided.

Priority: US20060846195P Applic. Date: 2006-09-21; WO2007US79180 Applic. Date: 2007-09-21

Inventor: GRAYSON JOHN C [US]


Application No.: US20100014543A1  Published: 21/Jan/2010

Title: LASER AND A METHOD FOR OPERATING THE LASER

Applicant/Assignee: LIGHTHOUSE TECHNOLOGIES PTY LTD

Application No.: 12/282804   Filing Date: 13/Mar/2007

Abstract:A laser comprising: a resonator cavity defined by at least two reflectors, wherein the at least two reflectors are highly reflective at a plurality of fundamental wavelengths

a laser medium disposed in the resonator cavity capable of generating plurality of fundamental wavelengths

an optical pump source for energizing the laser medium, thereby causing laser light at the plurality of fundamental wavelengths to resonate in the resonator cavity simultaneously

and a nonlinear material located in said resonator cavity capable of simultaneously converting each of the plurality of wavelengths of laser light to generate converted laser light having a plurality of converted wavelengths, said converted wavelengths being derived from but different to the fundamental wavelengths

wherein the non-linear material is at least partially phase matched to nonlinearly convert the frequencies of each of the fundamental wavelengths simultaneously such that a plurality of converted wavelengths are able to be simultaneously generated.

Priority: AU20060901269 Applic. Date: 2006-03-13; WO2007AU00309 Applic. Date: 2007-03-13

Inventor: OGILVY HAMISH [AU]; MILDREN RICHARD PAUL [AU]


Application No.: US20100015070A1  Published: 21/Jan/2010

Title: USE OF NATURAL, RECOMBINANT AND SYNTHETIC RESILINS IN COSMETICS

Applicant/Assignee: BASF SE

Application No.: 12/513709   Filing Date: 07/Nov/2007

Abstract:Use of resilin proteins in cosmetics, wherein the resilin proteins comprise between one and 100 repeat units with the consensus sequence SXXYGXP, where S is a serine, X is any desired amino acid, Y is a tyrosine, G is a glycine and P is a proline.

Priority: EP20060123659 Applic. Date: 2006-11-08; WO2007EP62005 Applic. Date: 2007-11-07

Inventor: BOLLSCHWEILER CLAUS [DE]; LIEBMANN BURGHARD [DE]; FEHR MARCUS [DE]; HUEMMERICH DANIEL [DE]; PTOCK ARNE [DE]; RAUNFT EVELYN [DE]


Application No.: US20100015071A1  Published: 21/Jan/2010

Title: Compositions for Improving Skin Conditions Comprising Alpha-Bisabolol as an Active Ingredient

Applicant/Assignee: BIOSPECTRUM INC

Application No.: 12/527756   Filing Date: 27/Feb/2008

Abstract:The present invention relates to a composition for improving skin condition comprising alpha-bisabolol as an active ingredient. alpha-Bisabolol used as an active ingredient has greater skin whitening effect inhibiting melanin synthesis by inhibiting intracellular tyrosinase activities compared to arbutin used as an existing skin whitening agent. In addition, alpha-bisabolol exhibits the inhibition effect on collagenase activity and promotion effect on collagen biosynthesis at a molecular level, contributing to excellent efficacy in improvement of skin wrinkles. Meanwhile, alpha-bisabolol indicates the improvement effects on UV-induced skin damage and the skin growth promotion or hair loss prevention. Therefore, alpha-bisabolol has the excellent improvement effects on skin condition. Furthermore, alpha-bisabolol has the excellent anti-obesity and anti-oxidation effects. The composition of this invention can be applied to cosmetic, pharmaceutical and food composition having no cytotoxicities and side effects with safety.

Priority: KR20070019899 Applic. Date: 2007-02-27; WO2008KR01141 Applic. Date: 2008-02-27

Inventor: PARK DEOK HOON [KR]; KIM SAE BOM [KR]; LEE JONG SUNG [KR]


Application No.: US20100015080A1  Published: 21/Jan/2010

Title: USE OF AT LEAST ONE (DIHYDRO)JASMONIC ACID DERIVATIVE FOR TREATING DRY SKIN

Applicant/Assignee: L'OREAL S.A

Application No.: 12/407359   Filing Date: 19/Mar/2009

Abstract:A cosmetic process for treating dry skin and/or a dry scalp of non-inflammatory origin, for example, in a menopausal woman, comprising topically applying to the skin and/or the scalp a composition comprising, in a physiologically acceptable medium, at least one (dihydro)jasmonic acid derivative

novel (dihydro)jasmonic acid derivatives and to the compositions, for example, suitable for topical application to the skin, comprising them.

Priority: FR20030001146 Applic. Date: 2003-01-31; US2004-768132 Applic. Date: 2004-02-02; US20030452108P Applic. Date: 2003-03-06

Inventor: DALKO MARIA [FR]


Application No.: US20100015224A1  Published: 21/Jan/2010

Title: PROGRAMMABLE BUOYANT DELIVERY TECHNOLOGY

Applicant/Assignee:

Application No.: 12/439775   Filing Date: 03/Sep/2007

Abstract:The present invention is concerned with a system for spatially and temporally programmable delivery of an active agent. When administered orally, the System can be retained in the gastric region for a prolonged period of time. It comprises of a core (I), one or more layers (II, IV, V) coated over the core and a preformed hollow space (III). The invention also concerns with a process for preparation of the System and a method for treating/preventing diseases, by administering to a subject in need thereof, the System of the invention.

Priority: IN2006MU01411 Applic. Date: 2006-09-04; WO2007IN00392 Applic. Date: 2007-09-03

Inventor: SINGH AMARJIT [IN]; SINGH SARABJIT [IN]; PUTHLI SHIVANAND [IN]; TANDALE RAJENDRA [IN]


Application No.: US20100015316A1  Published: 21/Jan/2010

Title: Method for producing grape extract with high ORAC value, and grape extract so produced

Applicant/Assignee:

Application No.: 12/287995   Filing Date: 14/Oct/2008

Abstract:Grape material is processed to yield a grape extract high in concentrated polyphenols, with ORAC values exceeding at least about 10,000 mumol TE/g. The grape material is dried, and soaked in ethanol to commence desired concentrate extraction. Following ethanol removal, inactive residue is at least partially separated from the desired concentrate solution, which passes through a macroporous absorption resin that absorbs desired active ingredients. Ethanol resin washing yields an intermediate extraction solution. After ethanol removal, the intermediate extract solution with the mixed active ingredients is refined. During refinement, high concentration of polyphenols and monomeric phenols are separated, and collected. These collected materials yield a desired high ORAC extract solution. Further drying yields the desired material, which is tested and packaged. This material exhibits good water solubility, mild flavor, and can be added to foodstuffs and nutritional supplements as a beneficial antioxidant.

Priority: CN20081135896 Applic. Date: 2008-07-21

Inventor: YING WEICHAO [CN]; XIONG XIAOYAN [US]; CHEN JIAOMEI [CN]; YANG JIANYING [CN]


Application No.: US20100015447A1  Published: 21/Jan/2010

Title: MICROPHASIC MICRO-COMPONENTS AND METHODS FOR CONTROLLING MORPHOLOGY VIA ELECTRIFIED JETTING

Applicant/Assignee:

Application No.: 12/506712   Filing Date: 21/Jul/2009

Abstract:The disclosure provides methods for preparation of multiphasic micro-components, such as core-shell or anisotropic (e.g., Janus) multiphasic particles with well-defined structures using electrohydrodynamic co-jetting of two polymer solutions containing polyelectrolytes. Suitable polyelectrolytes include polyacrylic acid (PAA), poly(acrylamide acrylic acid (PAAm), and/or poly(acryl amide-co-acrylic acid) (PAAm-AA), sodium polystyrene sulfonate (PSS), polyethylene imine (PEI), polypeptides, copolymers, and combinations of these. Control of certain variables, such as relative conductivities of the two jetting solutions, controls the particle morphologies formed, leading to a predetermined phase orientation for the same polymer system. In certain aspects, after cross-linking, core-shell particles are stable in aqueous solutions and exhibit reproducible swelling behavior, while maintaining the original core-shell geometry. In addition, micro-components formed in accordance with the present teachings are pH-responsive based on external environmental pH. Thus, such micro-components are useful for a variety of different applications, including micro- and nano-active ingredient delivery systems.

Priority: US2007-763842 Applic. Date: 2007-06-15; US2005-272194 Applic. Date: 2005-11-10; US20080082396P Applic. Date: 2008-07-21; US20040626792P Applic. Date: 2004-11-10; US20050651288P Applic. Date: 2005-02-09; US20060814706P Applic. Date: 2006-06-16

Inventor: LAHANN JOERG [US]; KAZEMI ABBASS [US]


Application No.: US20100016198A1  Published: 21/Jan/2010

Title: Compositions Comprising Sulfonated Estolides And Alkyl Ester Sulfonates, Methods Of Making Them, And Compositions And Processes Employing Them

Applicant/Assignee:

Application No.: 12/507011   Filing Date: 21/Jul/2009

Abstract:Compositions comprising sulfo-estolides and alkyl ester sulfonates are described. Detergent formulations, such as laundry detergents, softeners, and other materials, containing any of these materials are disclosed, as well as personal care formulations, hard surface cleaner formulations, and automatic dishwasher detergent formulations. Laundry methods employing these formulations are also disclosed. These formulations are useful as laundry detergents and can be biodegradable, heavy duty liquids, 2x or 3x and up to 6x concentrates, low foaming, and/or effective in a high efficiency washing machine. Methods for laundering fabrics with the compositions are also disclosed.

Priority: WO2009US31455 Applic. Date: 2009-01-20; US20080022662P Applic. Date: 2008-01-22

Inventor: BERNHARDT RANDAL J [US]; ALONSO LOURDES R [US]; DADO GREGORY P [US]; FILIPOVIC EDDIE I [US]; GARIEPY CHRISTOPHER A [US]; MASTERS RONALD A [US]; MURPHY DENNIS S [US]; PYTEL JACQUELINE MAAS [US]; SAJIC BRANKO [US]; SHAPIRO IRENE [US]; WEITGENANT JEREMY AARON [US]


Application No.: US20100016252A1  Published: 21/Jan/2010

Title: Mannich Base N-Oxide Drugs

Applicant/Assignee: STATE OF OREGON ACTING BY AND THROUGH THE OREGON STATE BOARD OF HIGHER EDUCATION ON BEHALF OF THE U

Application No.: 12/563543   Filing Date: 21/Sep/2009

Abstract:Disclosed are Mannich base N-oxides of drugs containing acidic N-H groups. Pharmaceutical compositions comprising a therapeutically effective amount of Mannich base N-oxides, or a N-oxide rearrangement product, pharmaceutically acceptable salt or prodrug thereof, are also disclosed. Further, disclosed are methods of using the compounds, alone or in combination with one or more other active agents or treatments.

Priority: WO2008US03550 Applic. Date: 2008-03-19; US20070907048P Applic. Date: 2007-03-19

Inventor: KEANA JOHN F W [US]; WESTBERG PAUL [US]; CURD JOHN [US]; LALANI ALSHAD S [US]


Application No.: US20100016286A1  Published: 21/Jan/2010

Title: Anti-Inflammatory Agents

Applicant/Assignee: CAMBRIDGE ENTERPRISE LIMITED

Application No.: 11/922277   Filing Date: 14/Jun/2006

Abstract:The invention provides compounds, pharmaceutical compositions and uses of compounds and salts thereof of general formula (I), for the preparation of a medicament for treatment of an inflammatory disorder, but excluding (S)-3-(r-methylcyclohexyl-carbonylamino)-caprolactam: wherein z is 1, 2, 3 or 4

A is -CO- or -SO2-

Q is linear or branched alkyl, alkenyl, alkynyl, alkoxy, oxyalkyl, aminoalkyl, alkylamino, alkylaminoalkyl, haloalkyl, aryl or substituted aryl

T1 and T2 together constitute a cycloalkyl, cycloalkenyl or polycycloalkyl radical composed of n additional carbon atoms, where n is between 2 and 7

and each hydrogen atom bonded to the carbon atoms in the ring generated by T1 and T2 may be independently be substituted by a group R1, where R1 is independently selected from an alkyl, haloalkyl, alkoxy, haloalkoxy, alkenyl, alkynyl or alkylamino radical of 1 to 20 carbon atoms

or each R1 is independently selected from fluoro, chloro, bromo, iodo, hydroxy, oxyalkyl, amino, aminoalkyl or aminodialkyl radical.

Priority: GB20050012241 Applic. Date: 2005-06-15; GB20050016468 Applic. Date: 2005-08-10; WO2006GB02217 Applic. Date: 2006-06-14

Inventor: GRAINGER DAVID J [GB]; FOX DAVID JOHN [GB]


Application No.: US20100016327A1  Published: 21/Jan/2010

Title: QUINOLINE COMPOUNDS

Applicant/Assignee: KOWA COMPANY, LTD

Application No.: 12/430397   Filing Date: 27/Apr/2009

Abstract:[Object] To provide a novel LXRbeta agonist that is useful as a preventative and/or therapeutic agent for atherosclerosis

arteriosclerosis such as those resulting from diabetes

dyslipidemia

hypercholesterolemia

lipid-related diseases

inflammatory diseases that are caused by inflammatory cytokines

skin diseases such as allergic skin diseases

diabetes

or Alzheimer's disease. [Solving Means] A quinoline compound represented by the following general formula (1) or salt thereof, or their solvate.

Priority: US20080049090P Applic. Date: 2008-04-30

Inventor: KOURA MINORU [JP]; OKUDA AYUMU [JP]; MATSUDA TAKAYUKI [JP]; YAMAGUCHI YUKI [JP]; SUMIDA HISASHI [JP]; KUROBUCHI SAYAKA [JP]; WATANABE YUUICHIROU [JP]; ENOMOTO TAKASHI [JP]; SHIBUYA KIMIYUKI [JP]


Application No.: US20100016413A1  Published: 21/Jan/2010

Title: PATHOTROPIC TARGETED GENE DELIVERY SYSTEM FOR CANCER AND OTHER DISORDERS

Applicant/Assignee:

Application No.: 12/446976   Filing Date: 05/Nov/2007

Abstract:Systems for pathotropic (disease-seeking) targeted gene delivery are provided, including viral particles with extremely high titers. In particular, the viral particles are engineered to specifically deliver therapeutic or diagnostic agents to a disease site, such as cancer metastic sites. Personalized dosing regimens are also provided to treat diseases such as cancer efficaciously with reduced adverse side effects.

Priority: US2006-055666 Applic. Date: 2006-11-03; WO2007US23305 Applic. Date: 2007-11-05

Inventor: HALL FREDERICK L [US]; LEVY JOHN P [US]; REED REBECCA A [US]; GORDON ERLINDA M [US]


Application No.: US20100016443A1  Published: 21/Jan/2010

Title: METHOD FOR PREPARING PARTICLES COMPRISING METAL OXIDE COATING AND PARTICLES WITH METAL OXIDE COATING

Applicant/Assignee: SOL-GEL TECHNOLOGIES LTD

Application No.: 12/525331   Filing Date: 03/Feb/2008

Abstract:The invention relates to a process for coating a solid, water-insoluble particulate matter, with a metal oxide comprising: (a) contacting the solid, water-insoluble particulate matter with an ionic additive and an aqueous medium to obtain a dispersion of said particulate matter having positive charges on its surface

(b) subjecting the particulate matter to a coating procedure comprising precipitating a metal oxide salt onto the surface of the particulate matter to form a metal oxide layer thereon to thereby obtain particulate matter coated by a metal oxide coating layer

(c) repeating step (b) at least 4 more times

and (d) aging said coating layer. The invention further relates to particles comprising a particulate matter coated by a metal oxide layer, to a use of the particles for topical administration, and to a method for preventing, reducing, or eliminating pests at a locus, using the particles.

Priority: US20070898700P Applic. Date: 2007-02-01; WO2008IL00141 Applic. Date: 2008-02-03

Inventor: TOLEDANO OFER [IL]; BAR-SIMANTOV HAIM [IL]; BILMAN NISSIM [IL]; SHAPIRO LEORA [IL]; ABU-REZIQ RAED [IL]; SRIADIBHATLA SRIKANTH [US]; SOMMER WILLIAM T [US]


Application No.: US20100021394A1  Published: 28/Jan/2010

Title: HIGH PENETRATION PRODRUG COMPOSITIONS OF 1H-IMIDAZO[4,5-C]QUINOLIN-4-AMINES AND 1H-IMIDAZO[4,5-C]QUINOLIN-4-AMINE-RELATED COMPOUNDS

Applicant/Assignee:

Application No.: 12/534096   Filing Date: 31/Jul/2009

Abstract:The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of 1H-imidazo[4,5-c]quinolin-4-amines and 1H-imidazo[4,5-c]quinolin-4-amine-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.

Priority: WO2007IB50322 Applic. Date: 2007-01-31

Inventor: YU CHONGXI [US]


Application No.: US20100021402A1  Published: 28/Jan/2010

Title: Compounds, Formulations, and Methods for Ameliorating Telangiectasis

Applicant/Assignee: GALDERMA LABORATORIES INC

Application No.: 12/544663   Filing Date: 20/Aug/2009

Abstract:Methods, compounds, and topical formulations for treatment of telangiectasias are disclosed. The methods comprise topically applying a composition comprising an alpha-adrenergic receptor agonist to telangiectatic skin. Amelioration of telangiectasia symptoms begins within minutes after topical application of a disclosed composition. A single application can significantly lessen telangiectasia discoloration for at least about 2 hours.

Priority: US2006-449079 Applic. Date: 2006-06-08; US2004-853585 Applic. Date: 2004-05-25; US20030473611P Applic. Date: 2003-05-27

Inventor: DEJOVIN JACK A [US]; DEJOVIN ISABELLE JEAN [US]; POWALA CHRISTOPHER [US]


Application No.: US20100021403A1  Published: 28/Jan/2010

Title: DISPERSIONS OF INORGANIC PARTICULATES CONTAINING ALKOXYCRYLENE

Applicant/Assignee: HALLSTAR INNOVATIONS CORP

Application No.: 12/554329   Filing Date: 04/Sep/2009

Abstract:A composition comprising an inorganic particulate material in an amount of about 20 wt % to about 70 wt %, a carrier for the particulate material comprising a compound of formula (I) in an amount of about 1 wt % to about 70 wt %, a particulate material coating material in an amount of about 0 wt % to about 5 wt %, and a dispersing agent for the particulate material in an amount of about 0 wt % to about 5 wt %, based on the total weight of the composition, wherein one of R1 and R2 is a straight or branched chain C1-C30 alkoxy radical, and the non-alkoxy R1 or R2 is hydrogen

and R3 is a straight or branched chain C1-C30 alkyl radical.

Priority: US2009-432450 Applic. Date: 2009-04-29; US2008-022758 Applic. Date: 2008-01-30; US2007-891281 Applic. Date: 2007-08-09

Inventor: BONDA CRAIG A [US]; PAVLOVIC ANNA [US]; ZHANG JEAN [US]


Application No.: US20100021404A1  Published: 28/Jan/2010

Title: Cosmetic composition with skin tightening effect

Applicant/Assignee: LVMH RECHERCHE

Application No.: 12/585755   Filing Date: 24/Sep/2009

Abstract:The present invention relates to a mixture, having a skin-tightening effect, which is made up of: 10 to 80% by Weight of a polysaccharide, preferably of an alginate, having a molecular weight of less than 600,000 Daltons, preferably less than 400,000 Daltons and more preferably less than 200,000 Daltons, 15 to 75% by weight of a polyhydroxylated agent selected from sugars and their derivatives, particularly sugar esters and sugar, ethers, preferably sorbitol, 3 to 15% by Weight of polyvinyl alcohol) or polyvinylpyrrolidone, and 0 to 25% by weight of cellulose or of a derivative of cellulose, such as carboxymethylcellulose or hydroxymethylcellulose. The present invention also relates to cosmetic compositions which contain this mixture. These cosmetic compositions enable a mechanical smoothing of the surface of the skin to be obtained progressively with great comfort of use and enables a good fixing of make-up products.

Priority: FR20010011123 Applic. Date: 2001-08-27; US2004-487693 Applic. Date: 2004-02-26; WO2002FR02941 Applic. Date: 2002-08-27

Inventor: DELAGE-GROUILLER HERVE [FR]; NOE BRIGITTE [FR]; MAHE CHRISTIAN [FR]


Application No.: US20100021411A1  Published: 28/Jan/2010

Title: COSMETIC DEPILATORY COMPOSITION

Applicant/Assignee:

Application No.: 12/528016   Filing Date: 21/Feb/2008

Abstract:A cosmetic cold-wax depilatory composition is provided The depilatory composition comprises a hydrocarbon resin, from 50% to 99% by weight and a flexibilizer or plasticizer, from 0 5% to 10% by weight Methods of applying the composition to a strip of material for removal of hair without the need for heating are also provided.

Priority: ES20070000448 Applic. Date: 2007-02-21; WO2008US54565 Applic. Date: 2008-02-21

Inventor: BOSCH JOSE BENAVENT [ES]; FERNANDEZ MARTA TORRES [ES]


Application No.: US20100021415A1  Published: 28/Jan/2010

Title: COSMETIC USE OF ORGANIC RESINATES

Applicant/Assignee: CHANEL PARFUMS BEAUTE

Application No.: 12/531162   Filing Date: 14/Mar/2008

Abstract:A cosmetic method for releasing an active principle in a controlled fashion to uninjured skin, as a function of the ion content in or on skin, by exchange with the ions, in order to provide at least one cosmetic benefit to the skin, the method includes applying onto skin a composition containing, in a cosmetically acceptable medium, at least one resinate including one organic ion-exchange resin and at least one ionizable cosmetic active principle bonded in noncovalent fashion to the resin.

Priority: FR20070001840 Applic. Date: 2007-03-14; US20070941741P Applic. Date: 2007-06-04; WO2008EP53109 Applic. Date: 2008-03-14

Inventor: CASADO-CHAUDANSON AUDREY MARJORIE [FR]; PASTOR AUDREY CELINE MARCELLE [FR]


Application No.: US20100021431A1  Published: 28/Jan/2010

Title: Agent for Promoting the Production of Thioredoxin

Applicant/Assignee: KYOTO UNIVERSITY NIPPON ZOKI PHARMACEUTICAL CO., LTD

Application No.: 12/225415   Filing Date: 29/Mar/2007

Abstract:A novel pharmaceutical application of an extract from a vaccine virus-inoculated and inflamed tissue and relates to a thioredoxin production promoting agent containing the extract as an active ingredient. The extract has an excellent thioredoxin production promoting action against an oxidative stress caused by a stimulus by such as a tobacco smoke extract or hydrogen peroxide and showed a significant lung cell protective effect. Therefore, the pharmaceutical of the invention containing the extract as an active ingredient is highly useful as a preventive or therapeutic agent for a chronic obstructive lung disease considered to be mainly caused by a continuous oxidative stress such as chronic smoking and the pharmaceutical with less side effects and high safety.

Priority: JP20060093602 Applic. Date: 2006-03-30; WO2007JP56827 Applic. Date: 2007-03-29

Inventor: NAKAMURA HAJIME [JP]; YODOI JUNJI [JP]; HOSHINO YUMA [JP]


Application No.: US20100021510A1  Published: 28/Jan/2010

Title: NEURONAL EXOCYTOSIS INHIBITING PEPTIDES

Applicant/Assignee: LIPOTEC, S.A

Application No.: 12/447136   Filing Date: 24/Oct/2007

Abstract:The invention relates to peptides of general formula (I): R1-AA-R2 (I) which can regulate neuronal exocytosis, their stereoisomers and racemic or non-racemic mixtures thereof, and the cosmetically or pharmaceutically acceptable salts thereof, wherein AA is a sequence of 3 to 40 adjacent amino acids contained in the amino acid sequence of the SNAP-25 protein, R1 is selected from the group consisting of H or alkyl, aryl, aralkyl or acyl group

and R2 is selected from the group consisting of amino, hydroxyl or thiol, substituted or non-substituted with aliphatic or cyclic groups, with the condition that when R1 is H or acetyl, R2 is not non-substituted amino, hydroxyl or thiol. The invention also relates to a method of obtaining such peptides, cosmetic or pharmaceutical compositions containing them and their use to treat those conditions requiring neuronal exocytosis regulation, preferably for treating the skin.

Priority: ES20060002720 Applic. Date: 2006-10-25; WO2007ES00603 Applic. Date: 2007-10-24

Inventor: CARRENO SERRAIMA CRISTINA [ES]; PONSATI OBIOLS BERTA [ES]; VAN DEN NEST WIM [ES]; FERNANDEZ CARNEADO JIMENA [ES]; FERRER MONTIEL ANTONIO [ES]; CEBRIAN PUCHE JUAN [ES]; ALMINANA DOMENECH NURIA [ES]


Application No.: US20100021526A1  Published: 28/Jan/2010

Title: PH MODULATED FILMS FOR DELIVERY OF ACTIVES

Applicant/Assignee: MONOSOL RX, LLC

Application No.: 12/575261   Filing Date: 07/Oct/2009

Abstract:The invention relates to pH modulated films and methods of their preparation. The film compositions include at least one component having a non-neutral pH when combined with water

and a pH modulated polymer system selected to reduce or prevent synerisis when combined with the non-neutral component in combination with aqueous media. The films demonstrate a non-self-aggregating uniform heterogeneity. Desirably, the films disintegrate in water and may be formed by a controlled drying process, extrusion process, or other process that maintains the required uniformity of the film.

Priority: US2006-639013 Applic. Date: 2006-12-14; US2002-074272 Applic. Date: 2002-02-14; US20050754092P Applic. Date: 2005-12-27; US20010328868P Applic. Date: 2001-10-12

Inventor: MYERS GARRY L [US]; SANGHVI PRADEEP [US]


Application No.: US20100022432A1  Published: 28/Jan/2010

Title: USE OF SUPEROXIDE DISMUTASES IN WASHING AND CLEANING AGENTS

Applicant/Assignee: HENKEL AG & CO. KGAA

Application No.: 12/548521   Filing Date: 27/Aug/2009

Abstract:The present invention relates to the use of superoxide dismutases to remove Amadori and Maillard products, and to washing and cleaning agents that contain superoxide dismutases.

Priority: DE200710010785 Applic. Date: 2007-03-02; WO2008EP52334 Applic. Date: 2008-02-27

Inventor: MAURER KARL-HEINZ [DE]; O'CONNELL TIMOTHY [DE]; MUSMANN NINA [DE]; PRUESER INKEN [DE]; HUCHEL URSULA [DE]; DEPPE VERONIKA [DE]


Application No.: US20100022461A1  Published: 28/Jan/2010

Title: Novel Derivatives of Cyclic Compound And The Use Thereof

Applicant/Assignee: WONKISOPHARM CO., LTD

Application No.: 12/307153   Filing Date: 02/Jul/2007

Abstract:Disclosed is tonovel cyclic derivatives having potent inhibiting effect on melanin formation and skin hyper-pigmentation activity with no adverse response to skin. They can be used as the therapeutics for treating and preventing the skin disease caused by over-reproduced melanin.

Priority: KR20060062703 Applic. Date: 2006-07-04; WO2007KR03199 Applic. Date: 2007-07-02

Inventor: CHO HYUN CHUL [KR]; CHOI YONGHYUN [KR]; YHEI JONGHAN [KR]


Application No.: US20100022486A1  Published: 28/Jan/2010

Title: COMPOUNDS

Applicant/Assignee:

Application No.: 12/519612   Filing Date: 19/Dec/2007

Abstract:The present invention relates to substituted 3-Aminopyrazole compounds of formula (I): and pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing them and their use in medicine. In particular, the invention relates to compounds for modulating SCD activity.

Priority: GB20060025604 Applic. Date: 2006-12-21; WO2007EP64218 Applic. Date: 2007-12-19

Inventor: BOUILLOT ANNE MARIE JEANNE [FR]; DAUGAN ALAIN CLAUDE-MARIE [FR]; DEAN ANTHONY WILLIAM [GB]; FILLMORE MARTIN CHRISTIAN [GB]


Application No.: US20100022613A1  Published: 28/Jan/2010

Title: Compounds Having CRTH2 Antagonist Activity

Applicant/Assignee: OXAGEN LIMITED

Application No.: 12/357792   Filing Date: 22/Jan/2009

Abstract:Compounds of general formula (I) W is chloro or fluoro

Z is a -SO2YR1 group wherein R1 is C3-C8 heterocyclyl, aryl or heteroaryl any of which may optionally be substituted with one or more substituents selected from halo, -CN, -C1-C6 alkyl, -SOR3, -SO2R3, -SO2N(R2)2, -N(R2)2, -NR2C(O)R3, -CO2R2, -CONR2R3, -NO2, -OR2, -SR2, -O(CH2)pOR2, and -O(CH2)pO(CH2)qOR2 wherein each R2 is independently hydrogen, -C1-C6 alkyl, -C3-C8 cycloalkyl, aryl or heteroaryl

each R3 is independently, -C1-C6 alkyl, -C3-C8 cycloalkyl, aryl or heteroaryl

p and q are each independently an integer from 1 to 3

Y is a straight or branched C1-C4 alkylene chain

and their pharmaceutically acceptable salts, hydrates, solvates, complexes or prodrugs are useful in orally administrable compositions for the treatment of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis.

Priority: GB20080001132 Applic. Date: 2008-01-22; GB20080001671 Applic. Date: 2008-01-30

Inventor: ARMER RICHARD EDWARD [GB]; WYNNE GRAHAM MICHAEL [GB]


Application No.: US20100022657A1  Published: 28/Jan/2010

Title: Treatment of faecal incontinence and other conditions with 1R, 2S-methoxamine

Applicant/Assignee: NORGINE EUROPE BV

Application No.: 12/586973   Filing Date: 30/Sep/2009

Abstract:1R,2S-Methoxamine may be used topically for effective treatment of faecal incontinence at low doses without local or systemic side effects, for example, without affecting blood pressure. 1R,2S-Methoxamine may be used to treat other disturbances and disorders of the gastrointestinal, as a pressor agent, as a nasal decongestant and in ophthalmology, at low does and without significant side effects.

Priority: GB20010030763 Applic. Date: 2001-12-21; WO2002GB05864 Applic. Date: 2002-12-20; US2004-499873 Applic. Date: 2004-12-27

Inventor: BARRAS NORMAN [GB]; THOMPSON JEFFREY MARTIN [GB]


Application No.: US20100023885A1  Published: 28/Jan/2010

Title: SYSTEM FOR EDITING AN AVATAR

Applicant/Assignee: MICROSOFT CORPORATION

Application No.: 12/178535   Filing Date: 23/Jul/2008

Abstract:Systems, methods and computer readable media are disclosed for updating the appearance of an avatar that exists across an online multi-player gaming system, including an executing video game. In addition to the general system, systems, methods and computer readable media for updating the avatar, techniques are disclosed for prompting networked video games to update an avatar that has been modified while the video game has been executing.

Priority:

Inventor: REVILLE BRENDAN K [US]; LAW STACEY [US]; SMITH DEREK [US]; KROYMANN DAN B [US]


Application No.: US20100028270A1  Published: 04/Feb/2010

Title: URETHANE COMPOUND COMPRISING AN INCORPORATED POLYETHER GROUP-CONTAINING SILICONE DERIVATIVE AND A NITROGEN HETEROCYCLE

Applicant/Assignee: BASF AKTIENGESELLSCHAFT

Application No.: 11/722189   Filing Date: 22/Dec/2005

Abstract:The present invention relates to a urethane compound which comprises, in incorporated form, at least one polyether group-containing silicone derivative, at least one nitrogen heterocycle and at least one polyisocyanate, to cosmetic and pharmaceutical compositions which comprise such a urethane compound, and to the use of such a urethane compound.

Priority: DE200410062201 Applic. Date: 2004-12-23; WO2005EP13927 Applic. Date: 2005-12-22

Inventor: NGUYEN-KIM SON [DE]


Application No.: US20100028276A1  Published: 04/Feb/2010

Title: SUNSCREEN COMPOSITIONS

Applicant/Assignee:

Application No.: 12/449932   Filing Date: 05/May/2007

Abstract:Sunscreen and sunblock formulations that provide cytoprotective and immuno-enhancing additives avoiding endocrine disrupting agents, (a) at least one inorganic sun-blocking or sunscreen agent that is a proven non-endocrine disrupter, (b) at least one emollient proven to be a non-endocrine disrupter

and (c) an oil component capable of protecting skin from harmful effects of radiation including sunlight and ultraviolet light wherein the oil is a carrier oil, an essential oil, or both are described. The formulations preferably include an essential oil of a naturally-occurring substance as well as suitable inorganic components including titanium dioxide, zinc oxide, silica or silicon dioxide, fluoropolymers, and mixtures thereof. Suitable organic components include butylmethoxy dibenzoylmethane. Cold-processed Aloe barbadensis Miller-Stockton, a single species of Aloe barbadensis containing glucose-rich mannose-containing oligosaccharide or oligosaccharides, can also be used. Test methodologies and results indicate specific differences from conventional formulations.

Priority: WO2007US05672 Applic. Date: 2007-03-05

Inventor: GRUNE GUERRY L [US]


Application No.: US20100028278A1  Published: 04/Feb/2010

Title: USE OF CHROMAN-4-ONE DERIVATIVES

Applicant/Assignee: MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG

Application No.: 12/531369   Filing Date: 21/Feb/2008

Abstract:The invention relates to the use of compounds of the formula (I) or of a composition comprising at least one compound of the formula (I), containing radicals as described in the claims, for the care, preservation or improvement of the general state of the skin or hair.

Priority: DE200710013366 Applic. Date: 2007-03-16; WO2008EP01352 Applic. Date: 2008-02-21

Inventor: CAROLA CHRISTOPHE [DE]; ROSSKOPF RALF [DE]


Application No.: US20100028313A1  Published: 04/Feb/2010

Title: COMPOSITIONS AND METHODS FOR TREATMENT OF SKIN DISORDERS

Applicant/Assignee: DERMAVRI PTY LTD

Application No.: 12/396649   Filing Date: 03/Mar/2009

Abstract:The present invention concerns methods and compositions for prophylactic or therapeutic treatment of skin disorders by administering therapeutically or prophylactically effective amounts of a probiotic. The present invention is also concerned with the treatment of symptoms of skin disorders.

Priority: AU2002PS00571 Applic. Date: 2002-02-15; US2004-504697 Applic. Date: 2004-08-12; WO2003AU00200 Applic. Date: 2003-02-17

Inventor: CONWAY PATRICIA LYNNE [AU]; COLLIER PAUL ANTHONY [AU]


Application No.: US20100028370A1  Published: 04/Feb/2010

Title: MEGALIN-BASED DELIVERY OF THERAPEUTIC COMPOUNDS TO THE BRAIN AND OTHER TISSUES

Applicant/Assignee: RAPTOR PHARMACEUTICAL INC RAPTOR PHARMACEUTICALS INC

Application No.: 12/508956   Filing Date: 24/Jul/2009

Abstract:The present invention is directed to a methods and compositions for receptor mediated drug delivery, particularly across the blood-brain barrier.

Priority: US2004-812849 Applic. Date: 2004-03-30; US2003-600862 Applic. Date: 2003-06-20

Inventor: ZANKEL TODD [US]; STARR CHRISTOPHER M [US]


Application No.: US20100028392A1  Published: 04/Feb/2010

Title: Personal Care Article

Applicant/Assignee:

Application No.: 12/226118   Filing Date: 05/Apr/2007

Abstract:A personal care article including a substrate having impregnated therein, applied thereon or arranged to substantially encase, a cosmetic composition which includes a hair modification active, wherein the pH of the composition is substantially less than 9.0, and at least a portion of the article has exfoliating properties.

Priority: GB20060006992 Applic. Date: 2006-04-07; GB20060012486 Applic. Date: 2006-06-23; WO2007GB01305 Applic. Date: 2007-04-05

Inventor: CAWTHORNE LEE [GB]; DODD KAREN [GB]; TINDAL ANNE [GB]


Application No.: US20100028399A1  Published: 04/Feb/2010

Title: Use of Polymers

Applicant/Assignee: CROMA-PHARMA GESELLSCHAFT M.B.H

Application No.: 12/520820   Filing Date: 21/Dec/2007

Abstract:The present invention relates to the use of a thiol-group-containing polymer for preparing an implant for tissue augmentation, wherein the basis polymer is a polysaccharide.

Priority: AT20060002136 Applic. Date: 2006-12-22; US20060871534P Applic. Date: 2006-12-22; WO2007AT00585 Applic. Date: 2007-12-21

Inventor: HORNOF MARGIT [AT]


Application No.: US20100028407A1  Published: 04/Feb/2010

Title: LAYERED BIO-ADHESIVE COMPOSITIONS AND USES THEREOF

Applicant/Assignee: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC

Application No.: 12/298698   Filing Date: 24/Apr/2007

Abstract:The invention generally provides compositions and methods for promoting and enhancing wound closure and healing. Specifically, the invention provides a biologic composition which comprises a support layer which serves as transport scaffold, for example made of gelatin, which is coated or impregnated with a bio-adhesive molecule such as rose bengal or glyceraldehyde. The composition can also comprise an artificial or biological matrix, optionally processed (i.e. cleaned and coated with extracellular matrix proteins) to enhance cell attachment and survival. The composition can further comprise a monolayer of epithelial, endothelial cells or mesenchymal cells. The invention provides methods for using the compositions for treating wounds due to disease, trauma or surgery. Specific methods for treating ocular wounds are provided.

Priority: US20060795437P Applic. Date: 2006-04-27; WO2007US09861 Applic. Date: 2007-04-24

Inventor: DEL PRIORE LUCIAN V [US]; KAPLAN HENRY J [US]; TEZEL TONGALP [US]


Application No.: US20100028471A1  Published: 04/Feb/2010

Title: COSMETIC USE OF ACTIVE AGENTS THAT STIMULATE MATRIPTASE EXPRESSION

Applicant/Assignee: CHANEL PARFUMS BEAUTE

Application No.: 12/442251   Filing Date: 18/Sep/2007

Abstract:The present invention relates to a cosmetic process for caring for human skin, intended to moisturize it and/or to protect it against drying out, comprising the topical application to the skin of a composition containing at least one active agent that stimulates the expression of the matriptase MT/SP1. It also relates to the cosmetic use of such an active agent for moisturizing human skin and/or protecting it against drying out. It further relates to the use of such an active agent to manufacture a pharmaceutical composition intended to prevent and/or alleviate skin tautness, stinging and/or itching and/or lip chapping. The active agents are extracts of Ceratonia siliqua, Cananga odorata hook, Cedrelopsis grevei and Cistus ladaniferus L.

Priority: FR20060008245 Applic. Date: 2006-09-20; FR20060008256 Applic. Date: 2006-09-20; US20060850276P Applic. Date: 2006-10-10; US20060850278P Applic. Date: 2006-10-10; WO2007EP59835 Applic. Date: 2007-09-18

Inventor: MAESTRO YANNICK GERARD [FR]; BERGIA DANIEL MICHEL PAUL [FR]; LASSERRE CHRISTELLE MARIE SUZANNE [US]


Application No.: US20100029583A1  Published: 04/Feb/2010

Title: PROCESS FOR OBTAINING AN ACTIVE INGREDIENT WITH AN IMMEDIATE TENSOR EFFECT ON THE SKIN, ACTIVE INGREDIENT AND COMPOSITIONS

Applicant/Assignee: SOCIETE INDUSTRIELLE LIMOUSINE D'APPLICATION BIOLOGIQUE, DITE SILAB

Application No.: 12/442441   Filing Date: 21/Sep/2007

Abstract:The invention relates to a method for obtaining an active ingredient having an immediate anti-wrinkle and skin-tensioning effect, characterised in that it comprises extracting and purifying high molecular weight polysaccharides from oat bran and/or fibres and/or grains, and solutioning and stabilising the polysaccharides in water. The invention also relates to the product thus obtained, to uses thereof, and to cosmetic compositions containing this active ingredient.

Priority: FR20060053903 Applic. Date: 2006-09-22; FR20070053714 Applic. Date: 2007-03-08; WO2007FR51992 Applic. Date: 2007-09-21

Inventor: PAUFIQUE JEAN [FR]


Application No.: US20100029600A1  Published: 04/Feb/2010

Title: DIHYDRO-TRITERPENES IN THE TREATMENT OF VIRAL INFECTIONS, CARDIOVASCULAR DISEASE, INFLAMMATION, HYPERSENSITIVITY OR PAIN

Applicant/Assignee: BSP PHARMA

Application No.: 12/572785   Filing Date: 02/Oct/2009

Abstract:The present invention relates to compositions comprising the triterpenes, dihydrobutyrospermol, dihydrolupeol and/or dihydroparkeol, the composition being applicable as a pharmaceutical, a dietary supplement or as a cosmetic. Further, the invention relates to the use of such compositions for the preparation of a medicament, a dietary supplement or a cosmetic for immunomodulating in a mammal such as suppression of viral infections, cardiovascular diseases, cancer, hypersensitivity and/or inflammatory reactions. The triterpenes may be in form of the free alcohol or derivatised, preferably with cinnamic acid, acetic acid or fatty acids. Furthermore, the triterpenes may be an extract obtainable from a natural source or synthetically made.

Priority: DK20010000049 Applic. Date: 2001-01-12; US2003-466093 Applic. Date: 2003-09-25; WO2002IB00081 Applic. Date: 2002-01-14; US20010261168P Applic. Date: 2001-01-16

Inventor: WEIDNER MORTEN SLOTH [DK]


Application No.: US20100029602A1  Published: 04/Feb/2010

Title: LOW-DOSE MOMETASONE FORMULATIONS

Applicant/Assignee: PERRIGO ISRAEL PHARMACEUTICALS LTD

Application No.: 12/535406   Filing Date: 04/Aug/2009

Abstract:Provided is a topical cream composition for the delivery of mometasone furoate comprising low dose mometasone furoate for the treatment of corticosteroid responsive dermatoses. The composition of the present invention can be safely applied over large surface areas of the skin (including areas with wrinkles and/or hair), and can be used therapeutically for extended periods of time (e.g., greater than 3 weeks). Treatment with the composition of the present invention carries reduced and/or fewer side effects compared with commercially available mometasone furoate cream products. The cream composition of the present invention is safe for the use of babies and infants under 2 years old. Additionally provided are methods of preparing and using the composition of the invention.

Priority: WO2008IL00485 Applic. Date: 2008-04-09; US20070911185P Applic. Date: 2007-04-11

Inventor: ARKIN MOSHE [IL]; ZEEVI AMIRA [IL]; CHERKEZ STEPHEN [IL]; ASCULAI EILON [IL]; UZAN RINA [IL]; BRAGHINSKI BELLA [IL]


Application No.: US20100029634A1  Published: 04/Feb/2010

Title: Chemokine Receptor Modulators

Applicant/Assignee:

Application No.: 12/414352   Filing Date: 30/Mar/2009

Abstract:The invention provides compounds of Formula (I) and pharmaceutically acceptable salts, solvates, tautomers, stereoisomers, and/or esters thereof. These compounds, and pharmaceutical composition comprising such compounds are useful treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers

Priority: US20080040516P Applic. Date: 2008-03-28

Inventor: CLARK MICHAEL P [US]; WAGNER FLORENCE F [US]; DOROH BRANDON C [US]; JOHNSON TRICIA L [US]; TAHIROVIC YESIM ALTAS [US]; WILSON LAWRENCE [US]; WISEMAN JOHN M [US]; SKUDLAREK JASON W [US]; LOCKWOOD MARK A [US]; NATCHUS MICHAEL G [US]


Application No.: US20100029745A1  Published: 04/Feb/2010

Title: DERIVATIVES OF SUBSTITUTED 3-PHENYL-1-(PHENYLTHIENYL)PROPAN-1-ONES AND OF 3-PHENYL-1-(PHENYLFURANYL) PROPAN-1-ONES, PREPARATION AND USE

Applicant/Assignee:

Application No.: 12/448668   Filing Date: 28/Dec/2007

Abstract:The present invention relates to compounds derived from substituted 3-phenyl-1-(thien-2-yl)propan-1-ones, pharmaceutical compositions comprising them as well as their therapeutic applications, notably in the field of human and animal health.

Priority: FR20060056067 Applic. Date: 2006-12-29; WO2007FR52634 Applic. Date: 2007-12-28

Inventor: DELHOMEL JEAN-FRANCOIS [FR]


Application No.: US20100029762A1  Published: 04/Feb/2010

Title: Administration of adapalene and benzoyl peroxide for the long-term treatment of acne vulgaris

Applicant/Assignee:

Application No.: 12/458982   Filing Date: 29/Jul/2009

Abstract:A regimen for the safe and effective long-term treatment of acne vulgaris entails topically applying onto the affected skin area of a subject afflicted therewith, for a period of time of at least four (4) months, e.g., for at least twelve (12) months and advantageously on a daily basis and preferably once a day, a thus effective amount of a topical medicament containing adapalene and benzoyl peroxide, formulated into a pharmaceutically acceptable medium therefor.

Priority: WO2008EP51155 Applic. Date: 2008-01-30; US20070898113P Applic. Date: 2007-01-30

Inventor: GRAEBER MICHAEL [US]; LIU YIN [US]; GORE BARBARA [US]


Application No.: US20100030058A1  Published: 04/Feb/2010

Title: Methods of Treating Wrinkles, Developing Wrinkle Treatments And Evaluating Treatment Efficacy, Based On Newly Discovered Similarities Between Wrinkles And Skin Wounds

Applicant/Assignee:

Application No.: 12/500374   Filing Date: 09/Jul/2009

Abstract:Disclosed are methods of measuring an endogenous wrinkle electric field and methods of characterizing topical applications, or other treatments, in terms of their effect on the endogenous electric field of wrinkles. Also included, are methods of developing topical applications, or other treatments that have a desired effect on the endogenous electric field of a wrinkle. The methods disclosed herein, are based on a new model of wrinkle physiology that exploits previously unknown similarities between skin wounds and wrinkles.

Priority: US20080085213P Applic. Date: 2008-07-31

Inventor: MAMMONE THOMAS [US]; IONITA-MANZATU VASILE [US]; HAWKINS GEOFFREY [US]; REIN GLEN [US]


Application No.: US20100031378A1  Published: 04/Feb/2010

Title: Novel gene disruptions, compositions and methods relating thereto

Applicant/Assignee:

Application No.: 12/221669   Filing Date: 04/Aug/2008

Abstract:The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO227, PRO233, PRO238, PRO1328, PRO4342, PRO7423, PRO10096, PRO21384, PRO353 or PRO1885 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders

cardiovascular, endothelial or angiogenic disorders

eye abnormalities

immunological disorders

oncological disorders

bone metabolic abnormalities or disorders

lipid metabolic disorders

or developmental abnormalities.

Priority:

Inventor: EDWARDS JOEL A [US]; HUANG WENHU [US]; MONTGOMERY CHARLES [US]; QIAN NI NANCY [US]; SHI ZHENG-ZHENG [US]; SPARKS MARY JEAN [US]; VOGEL PETER [US]; OOX MINDY [US]


Application No.: US20100034764A1  Published: 11/Feb/2010

Title: Method for Preparing a Lipophilic Vine Extract

Applicant/Assignee:

Application No.: 12/460742   Filing Date: 23/Jul/2009

Abstract:The present invention relates to a method for preparing a lipophilic extract from lignified portions of vine, such as shoots, stock and roots, characterized in that said method comprises a step for extraction from said lignified portions with an apolar solvent

to an extract obtained by such a method

to the use of such an extract as an excipient in a cosmetic composition

and to a cosmetic composition comprising such an extract.

Priority: FR20080055117 Applic. Date: 2008-07-25

Inventor: PECHER VIRGINIE [FR]; ANDRE PATRICE [FR]


Application No.: US20100034810A1  Published: 11/Feb/2010

Title: PYRIMIDINE DERIVATIVES FOR THE PREVENTION OF HIV INFECTION

Applicant/Assignee:

Application No.: 12/567051   Filing Date: 25/Sep/2009

Abstract:This invention concerns the use of a compound for the manufacture of a medicament for the prevention of HIV infection via sexual intercourse and related intimate contact between partners, wherein the compound is a compound of formula a N-oxide, a pharmaceutically acceptable addition salt, a quaternary amine and a stereochemically isomeric form thereof, wherein the ring containing -a1=a2-a3=a4- and -b1=b2-b3=b4- represents phenyl, pyridyl, pyrimidinyl, pirazinyl, pyridazinyl

n is 0 to 5

m is 1 to 4

R1 is hydrogen

aryl

formyl

C1-6alkylcarbonyl

C1-6alkyl

C1-6alkyloxycarbonyl

substituted C1-6alkyl, C1-6alkylcarbonyl, C1-6alkyloxycarbonyl, C1-6alkylcarbonyloxy

substituted C1-6alkyloxyC1-6alkylcarbonyl

R2 is hydroxy, halo, optionally substituted C1-6alkyl, C3-7cycloalkyl, optionally substituted C2-6alkenyl, optionally substituted C2-6alkynyl, C1-6alkyloxy, C1-6alkyloxycarbonyl, carboxyl, cyano, nitro, amino, mono- or di(C1-6alkyl)amino, polyhalomethyl, polyhalomethyloxy, polyhalomethylthio, -S(-O)pR6, -NH-S(-O)pR6, -C(-O)R6, -NHC(-O)H, -C(-O)NHNH2, -NHC(-O)R6, -C(-NH)R6 or a 5-membered heterocycle

X1 is -NR5-, -NH-NH-, -N-N-, -O-, -C(-O)-, C1-4alkanediyl, -CHOH-, -S-, -S(-O)p-, -X2-C1-4alkanediyl- or -C1-4alkanediyl-X2-

R3 is NHR13

NR13R14

-C(-O)-NHR13

-C(-O)-NR13R14

-C(-O)-R15

-CH-N-NH-C(-O)-R16

substituted C1-6alkyl

optionally substituted C1-6alkyloxyC1-6alkyl

substituted C2-6alkenyl

substituted C2-6alkynyl

C1-6alkyl substituted with hydroxy and a second substituent

-C(-N-O-R8)-C1-4alkyl

R7

or -X3-R7

R4 is halo, hydroxy, C1-6alkyl, C3-7cycloalkyl, C1-6alkyloxy, cyano, nitro, polyhaloC1-6alkyl, polyhaloC1-6alkyloxy, aminocarbonyl, C1-6alkyloxycarbonyl, C1-6alkylcarbonyl, formyl, amino, mono- or di(C1-4alkyl)amino

and pharmaceutical compositions comprising them.

Priority: WO2003EP01291 Applic. Date: 2003-02-07; US2004-544735 Applic. Date: 2004-02-04; WO2004EP01011 Applic. Date: 2004-02-04

Inventor: HEERES JAN [BE]; LEWI PAULUS JOANNES [BE]; JANSSEN PAUL ADRIAAN JAN [BE]; ARTS FRANK XAVIER JOZEF HERWIG [BE]; DE JONGE MARC RENE [NL]; KOYMANS LUCIEN MARIA HENRICUS [BE]; DAEYAERT FREDERIK FRANS DESIRE [BE]; VINKERS HENDRIK MAARTEN [BE]; GULLEMONT JEROME EMILE GEORGES [FR]; PASQUIER ELISABETH THERESA JEANNE [FR]


Application No.: US20100034904A1  Published: 11/Feb/2010

Title: COMPOSITION COMPRISONG RUTIN AND POLYUNSATURATED FATTY ACID HAVING AN INHIBITORY ACTIVITY ON 5-ALPH REDUCTASE

Applicant/Assignee: GIULIANI S.P.A

Application No.: 12/450362   Filing Date: 18/Mar/2008

Abstract:The present invention relates to the use of selected active principles of a natural origin in substitution of extract from Boehmeria Nipononivea for regulating the trophism of hair follicles and the production of sebum on the skin and its use in alopecia, with considerable practical advantages and with respect to the safety profile. The composition of the invention is based on an association of omega 6 polyunsaturated acids and rutin in a pharmaceutically acceptable carrier.

Priority: IT2007MI00555 Applic. Date: 2007-03-21; WO2008IB00772 Applic. Date: 2008-03-18

Inventor: GIULIANI GIAMMARIA [IT]; BENEDUSI ANNA [IT]; BARONI SERGIO [IT]


Application No.: US20100035327A1  Published: 11/Feb/2010

Title: Use of rice-derived products in a universal cell culture medium

Applicant/Assignee:

Application No.: 12/228172   Filing Date: 11/Aug/2008

Abstract:The invention is used as an additive to a culture medium to maintain and grow various cells including stem cells and support their manufactured and secreted products including cytokines, chemokines and growth factors in an environment which provides: a) metabolic enabling or enhancement of measurable parameters within the cellular population b) availability and usage of nutrients to cells c) distinct and positive effect on cellular dynamics (i.e. cellular proliferation and secretion of manufactured products by the cells) d) stabilized environment for maintaining conditions for growth and other cellular and metabolic processes including secretion of manufactured products including signaling factors e) enhanced biological cellular function of inherent cellular processes f) non-interference with normal cellular metabolics (i.e. signaling) g) increased protection from toxic effects to the cell h) additional benefits to the cellular population which in absence of the additive would be lacking.

Priority:

Inventor: STEELE ANN MARIE [US]; SMITH MARK DARGAN [US]; BOONCHUEN SOMCHAI [TH]


Application No.: US20100035760A1  Published: 11/Feb/2010

Title: Nucleic Acid molecules and Collections Thereof, Their Application and Modification

Applicant/Assignee:

Application No.: 12/087649   Filing Date: 10/Jan/2007

Abstract:The invention provides a method for characterising a sample comprising nucleic acid derived from a cell. The method comprises determining whether a sample comprises at least a minimal sequence of at least one new microRNA (miRNA) according to the invention or a mammalian ortholog thereof and characterizing the sample on the basis of the presence or absence of the miRNA. The invention further provides nucleic acid molecules and collections thereof and their use in therapeutic and diagnostic applications. The invention furthermore provides a method for identifying a miRNA molecule or a precursor molecule thereof.

Priority: WO2006NL00010 Applic. Date: 2006-01-10; WO2006NL00491 Applic. Date: 2006-09-29; WO2007NL00012 Applic. Date: 2007-01-10

Inventor: PLASTERK RONALD H A [NL]; BEREZIKOV EUGENE [NL]; CUPPEN EDWIN P J G [NL]


Application No.: US20100035790A1  Published: 11/Feb/2010

Title: Branched Polyorganosiloxanes Modified With Aromatic Substances

Applicant/Assignee: MOMENTIVE PERFORMANCE MATERIALS GMBH

Application No.: 12/531936   Filing Date: 19/Mar/2008

Abstract:The invention relates to fragrance-modified branched polyorganosiloxanes, methods for producing them and their use.

Priority: DE200710012910 Applic. Date: 2007-03-19; WO2008EP53297 Applic. Date: 2008-03-19

Inventor: LANGE HORST [DE]; ROOS CHRISTOPHER [DE]; WAGNER ROLAND [DE]; KROPFGANS MARTIN [DE]


Application No.: US20100035819A1  Published: 11/Feb/2010

Title: METHOD OF PROMOTING SKIN COLLAGEN PRODUCTION

Applicant/Assignee: SNOW BRAND MILK PRODUCTS CO., LTD

Application No.: 12/579100   Filing Date: 14/Oct/2009

Abstract:It is intended to provide a skin collagen production promoter, foods and drinks for promoting skin collagen production and cosmetics for promoting skin collagen production which are useful in preventing skin chapping, wrinkles, worsening in skin fitness, etc. Namely, a skin collagen production promoter, foods and drinks for promoting skin collagen production and cosmetics for promoting skin collagen production which contain as the active ingredient(s) a milk-origin basic protein fraction and/or a basic peptide fraction obtained by digesting the above-described basic protein fraction with a protein digesting enzyme such as pepsin or pancreatin. The above basic protein fraction and basic peptide fraction have an effect of increasing skin collagen level.

Priority: US2003-553830 Applic. Date: 2003-05-07; WO2003JP05707 Applic. Date: 2003-05-07

Inventor: MORITA YOSHIKAZU [JP]; TAKADA YUKIHIRO [JP]; TOBA YASUHIRO [JP]; OOI WATARU [JP]; KAWAKAMI HIROSHI [JP]


Application No.: US20100035863A1  Published: 11/Feb/2010

Title: 2 Amino-Pyrimidine Derivatives As H4 Receptor Antagonists, Processes For Preparing Them And Their Use In Pharmaceutical Compositions

Applicant/Assignee: UCB PHARMA, S.A

Application No.: 12/440899   Filing Date: 11/Sep/2007

Abstract:The present invention concerns novel 2 amino pyrimidine derivatives of formula (I), processes for preparing them, pharmaceutical compositions containing them and their use as harmaceuticals.

Priority: GB20060017966 Applic. Date: 2006-09-12; EP20060019518 Applic. Date: 2006-09-19; WO2007EP07898 Applic. Date: 2007-09-11

Inventor: RAPHY GILLES [GB]; WATSON ROBERT JOHN [GB]; HANNAH DUNCAN [GB]; PEGURIER CECILE [BE]; ORTMANS ISABELLE [BE]; LOCK CHRISTOPHER JAMES [GE]; KNIGHT ROLAND LAURENCE [GB]; OWEN DAVID ALAN [GB]


Application No.: US20100035908A1  Published: 11/Feb/2010

Title: SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS

Applicant/Assignee: LEO PHARMA

Application No.: 12/520325   Filing Date: 21/Dec/2007

Abstract:The present invention relates to a compound according to formula: (I)

wherein X1, X2, X3, X4 and X5 independently of each other represent -CH- or N

or X3, X4 and X5 independently of each other represent -CH- or N, and Xi and X2 independently of each other represent C and form part of an additional 6-membered aromatic ring

R1 represents hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, hydroxyalkyl, or alkylcarbonyl, all of which are optionally substituted

R2 and R3 independently represent hydrogen, -CH2-C(O)NR-R', alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, haloalkyl, hydroxyalkyl, heterocycloalkenyl, alkylaryl, alkylalkoxycarbonyl, alkylcarbonyloxy, or alkoxyalkyl, all of which are optionally substituted

R11 represents hydrogen, halogen, cyano, amino, alkoxy or alkylamino, X1-X5 represent -CH- or N, including N-oxides, enantiomers and diastereomers

and pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention relates further to processes for the preparation of said compounds, to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, e.g. dermal diseases, with said compounds, and to the use of said compounds in the manufacture of medicaments.

Priority: US20060871689P Applic. Date: 2006-12-22; US20070945470P Applic. Date: 2007-06-21; WO2007DK00564 Applic. Date: 2007-12-21

Inventor: FELDING JAKOB [DK]; NIELSEN SIMON FELDBAEK [DK]


Application No.: US20100035939A1  Published: 11/Feb/2010

Title: PENETRATING CARRIER, ANTI-FUNGAL COMPOSITION USING THE SAME AND METHOD FOR TREATMENT OF DERMATOPHYTES

Applicant/Assignee:

Application No.: 12/568833   Filing Date: 29/Sep/2009

Abstract:An antifungal liquid composition for topical administration is provided that contains turpentine and at least one of peppermint oil, mineral oil, and essential oil alcohols, and one or more antifungal medications selected from ciclopirox olamine, terbinafine, tolnaftate, microconazole, itraconazole, ketoconazole, econazole, and fluconazole, and optionally one or more antifungal essential oils, and its use in the topical treatment of fungal infection, particularly of the nail.

Priority: US2007-684869 Applic. Date: 2007-03-12; US2004-956073 Applic. Date: 2004-10-04; US20080194508P Applic. Date: 2008-09-29

Inventor: SELNER MARC [US]


Application No.: US20100035956A1  Published: 11/Feb/2010

Title: Compounds Having CRTH2 Antagonist Activity

Applicant/Assignee: OXAGEN LIMITED

Application No.: 12/374702   Filing Date: 20/Jul/2007

Abstract:Compounds of general formula (I) wherein R is phenyl optionally substituted with one or more halo substituents

and their pharmaceutically acceptable salts, hydrates, solvates, complexes or prodrugs are useful in orally administrable compositions for the treatment of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis.

Priority: GB20060014608 Applic. Date: 2006-07-22; GB20060024176 Applic. Date: 2006-12-04; WO2007GB02761 Applic. Date: 2007-07-20

Inventor: ARMER RICHARD EDWARD [GB]; WYNNE GRAHAM MICHAEL [GB]; DORGAN COLIN RICHARD [GB]; JOHNSON PETER DAVID [GB]


Application No.: US20100035997A1  Published: 11/Feb/2010

Title: KIT FOR APPLYING A POLYMERIZABLE ADHESIVE COMPOSITION TO TISSUES

Applicant/Assignee:

Application No.: 12/579024   Filing Date: 14/Oct/2009

Abstract:The invention relates to a kit for the topical and/or internal application of a polymerisable adhesive composition to tissues, enabling improved control of the polymerisation speed on the surface of the tissue, in addition to the effective disinfection of the wound. The kit consists of at least one receptacle and contains a polymerisable adhesive composition based on cyanacrylate, in addition to a disinfectant composition.

Priority: DE200710019044 Applic. Date: 2007-04-20; WO2008EP54346 Applic. Date: 2008-04-10

Inventor: BROADLEY KENNETH N [IE]; GUTHRIE JOHN [IE]; SWORDS NOELEEN [IE]


Application No.: US20100040537A1  Published: 18/Feb/2010

Title: Prostaglandin E2 Binding Proteins and Uses Thereof

Applicant/Assignee: ABBOTT LABORATORIES

Application No.: 12/499646   Filing Date: 08/Jul/2009

Abstract:The present invention encompasses prostaglandin E2 (PGE2) binding proteins. The invention relates to antibodies that are wild-type, chimeric, CDR grafted and humanized. Preferred antibodies have high affinity for prostaglandin E2 and neutralize prostaglandin E2 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody, or an antigen-binding portion thereof. Methods of making and methods of using the antibodies of the invention are also provided. The antibodies, or antigen-binding portions, of the invention are useful for detecting prostaglandin E2 and for inhibiting prostaglandin E2 activity, e.g., in a human subject suffering from a disorder in which prostaglandin E2 activity is detrimental.

Priority: US20080134264P Applic. Date: 2008-07-08; US20080197258P Applic. Date: 2008-10-23

Inventor: GU JJIJIE [US]; HUTCHINS CHARLES W [US]; ZHU RONG-RONG [US]; SHEN JIANWEI [US]; HARRIS MARIA C [US]; BELANGER EILEEN [US]; MURTAZA ANWAR [US]; TARCSA EDIT [US]; STINE WILLIAM B [US]; HSIEH CHUNG-MING [US]


Application No.: US20100040548A1  Published: 18/Feb/2010

Title: HIGH PENETRATION PRODRUG COMPOSITIONS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS

Applicant/Assignee:

Application No.: 12/482373   Filing Date: 10/Jun/2009

Abstract:The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of antimicrobials and antimicrobial-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.

Priority: WO2006IB54724 Applic. Date: 2006-12-10

Inventor: YU CHONGXI [US]


Application No.: US20100040561A1  Published: 07/Apr/2005

Title: Penetrating pharmaceutical foam

Applicant/Assignee: FOAMIX LTD FOAMIX, LTD

Application No.: 10/922358   Filing Date: 20/Aug/2004

Abstract:The invention relates to an alcohol-free cosmetic or pharmaceutical foam composition comprising water, a hydrophobic solvent, a surface-active agent, a gelling agent, an active component selected from the group of urea, hydroxy acid and a therapeutic enhancer and a propellant. The foam further comprises active agents and excipients with therapeutic properties having enhanced skin penetration.

Priority: IL20020152486 Applic. Date: 2002-10-25; WO2003IB05527 Applic. Date: 2003-10-24; US2004-911367 Applic. Date: 2004-08-04; US20030497648P Applic. Date: 2003-08-25; US20020429546P Applic. Date: 2002-11-29; US20030492385P Applic. Date: 2003-08-04

Inventor: TAMARKIN DOV [IL]; FRIEDMAN DORON [IL]; EINI MEIR [IL]


Application No.: US20100040565A1  Published: 18/Feb/2010

Title: ACTIVE DELIVERY SYSTEMS FORMULATIONS

Applicant/Assignee: CASTLE BEACH, LLC

Application No.: 12/540201   Filing Date: 12/Aug/2009

Abstract:The present invention relates to active delivery system formulations, and methods of making and using the same. Said formulations, when applied to a substrate surface, form a protective coating on the surface and permit constituent active agents to act on the surface and in the surrounding medium.

Priority: US20080104129P Applic. Date: 2008-10-09; US20080088155P Applic. Date: 2008-08-12

Inventor: HOMOLA ANDREW M [US]; PITTS R GARY [US]; DUNTON RONALD K [US]


Application No.: US20100040568A1  Published: 18/Feb/2010

Title: Steroidal compounds as melanogenesis modifiers and uses thereof

Applicant/Assignee: SKINMEDICA, INC

Application No.: 12/587882   Filing Date: 13/Oct/2009

Abstract:Provided are steroidal compounds of formula I, for example, conessine, and the use of such compounds and compositions thereof to modulate (e.g., inhibit) melanogenesis and pigmentation. Also provided are plant extracts containing a compound of formula I, for example, conessine, and the use of such a plant extract to modulate (e.g., inhibit) melanogenesis and pigmentation. The compound or plant extract may be prepared as pharmaceutical and cosmetic compositions, and may be used for the prevention and treatment of conditions that are related to aberrant melanogenesis activity.

Priority: US2009-433322 Applic. Date: 2009-04-30; US20080049114P Applic. Date: 2008-04-30

Inventor: ORLOW SETH J [US]; KOMATSU LI NI [US]


Application No.: US20100040608A1  Published: 18/Feb/2010

Title: Use of HMGB1 antagonists for the treatment of inflammatory skin conditions

Applicant/Assignee:

Application No.: 11/988896   Filing Date: 11/Jul/2006

Abstract:Methods are disclosed for treating an inflammatory skin condition in a subject. The methods comprise administering to a subject an HMGB antagonist, such as a high mobility group box (HMGB) A box or a biologically active fragment thereof, an antibody to HMGB or an antigen-binding fragment thereof, an HMGB small molecule antagonist, an antibody to TLR2 or an antigen-binding fragment thereof, a soluble TLR2 polypeptide, an antibody to RAGE or an antigen-binding fragment thereof, a soluble RAGE polypeptide and a RAGE small molecule antagonist.

Priority: US20050700704P Applic. Date: 2005-07-18; WO2006US27053 Applic. Date: 2006-07-11

Inventor: WAHREN-HERLENIUS MARIE [SE]; NYBERG FILIPPA [SE]; MARCHINI GIOVANNA [SE]


Application No.: US20100040706A1  Published: 18/Feb/2010

Title: METHOD OF ANTI-AGEING COSMETIC CARE BY STIMULATION OF SURVIVIN EXPRESSION

Applicant/Assignee: LVMH RECHERCHE

Application No.: 12/477409   Filing Date: 03/Jun/2009

Abstract:The invention relates to a cosmetic care method comprising the delivery of an effective amount of at least one cosmetically acceptable agent that activates or stimulates survivin expression in the stem cells of the basal layer of the epidermis. The invention makes it possible in particular to prevent or delay the appearance of the signs of skin aging or to treat them.

Priority: FR20080053794 Applic. Date: 2008-06-06

Inventor: DUMAS MARC [FR]; BONTE FREDERIC [FR]; RENIMEL ISABELLE [FR]


Application No.: US20100040709A1  Published: 18/Feb/2010

Title: HERBAL COMPOSITION FOR THE PREVENTION OF WRINKLES AND SKIN DISORDERS, METHODS OF PREPARING THE SAME AND USES THEREOF

Applicant/Assignee: HIMALAYA GLOBAL HOLDINGS, LTD

Application No.: 12/440917   Filing Date: 11/Mar/2009

Abstract:Disclosed is a natural herbal composition for preventing wrinkles and other skin disorders due to aging, stress and environmental factors without any side effect. The composition comprises extracts of Rhodomyrtus tomentosa, Cipadessa baccifera, Woodfordia fruticosa and Camellia sinensis.

Priority: WO2006IN00347 Applic. Date: 2006-09-12

Inventor: MITRA SHANKAR KUMAR [IN]; SAXENA EKTA [IN]


Application No.: US20100040713A1  Published: 18/Feb/2010

Title: FAT ABSORPTION INHIBITOR AND FOOD AND DRINK USING THE SAME

Applicant/Assignee: KRACIE FOODS, LTD

Application No.: 12/377233   Filing Date: 10/Aug/2007

Abstract:The present invention relates to a fat absorption inhibitor containing a chestnut skin extract, and a food and drink containing that fat absorption inhibitor. The present invention can therefore provide a fat absorption inhibitor, and a food and drink using the same, that can be obtained from waste products following primary use, inhibit increases in lipids such as blood neutral fats by inhibiting absorption of dietary lipids, and in turn are effective in preventing accumulation of lipids, have superior suitability for continuous ingestion without having an impact on flavor, and do not require a complex production process.

Priority: JP20060220710 Applic. Date: 2006-08-11; JP20070028811 Applic. Date: 2007-02-08; WO2007JP65985 Applic. Date: 2007-08-10

Inventor: KATAOKA HISASHI [JP]; SHIROMIZU TOMOKO [JP]; KAWASAKI KENJI [JP]


Application No.: US20100040714A1  Published: 18/Feb/2010

Title: Asthma/Allergy Therapy that Targets T-lymphoctyes and/or Eosinophils

Applicant/Assignee:

Application No.: 12/539731   Filing Date: 12/Aug/2009

Abstract:A pharmaceutical composition for the treatment and/or prophylaxis of diseases caused by type I hypersensitivity reactions consisting essentially of Glicophosphopeptical, or pure Nigella Sativa seeds, in a concentration which stimulate Th1 lymphocytes and selectively switch-off the eosinophilic airway inflammation A method of treatment of allergy using Th1 stimulating agents, to be administered to a mammal such as human in need of such treatment in a shot of 5 days only, resulted in significant decrease in symptom score started day 3, and in sputum eosinophils by day 14, followed by long-term clinical remission of a mean of 6 months. The BCG-like Th1 stimulation is also used in treating diseases in which the body defensive mechanism is a Cell Mediated Immunity, including viral infections, as but not limited to influenza and common cold, Chronic and recurrent urinary tract infection, pelvic inflammatory diseases as neuroimmune appendicitis, cancer, crohns disease and facial palsy.

Priority: GB19990004777 Applic. Date: 1999-03-02; US2001-944564 Applic. Date: 2001-09-04

Inventor: NASIF NEDAA ABDUL-GHANI [QA]


Application No.: US20100041590A1  Published: 18/Feb/2010

Title: Compounds

Applicant/Assignee:

Application No.: 12/519777   Filing Date: 19/Dec/2007

Abstract:The present invention relates to substituted 3-Aminopyrazole compounds of formula (I) and pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing them and their use in medicine. In particular, the invention relates to compounds for modulating SCD activity.

Priority: GB20060025654 Applic. Date: 2006-12-21; WO2007EP64220 Applic. Date: 2007-12-19

Inventor: BOUILLOT ANNE MARIE JEANNE [FR]


Application No.: US20100041603A1  Published: 18/Feb/2010

Title: Method of Promoting Wound Healing

Applicant/Assignee: CORTHERA, INC

Application No.: 12/465613   Filing Date: 13/May/2009

Abstract:The present disclosure relates to methods of administering relaxin to promote wound healing and reduce scar formation. The disclosure further contemplates the use of relaxin in reconstructive and plastic surgery.

Priority: US20080127947P Applic. Date: 2008-05-16

Inventor: STEWART DENNIS R [US]


Application No.: US20100041662A1  Published: 18/Feb/2010

Title: Heterocyclic compounds as antiinflammatory agents

Applicant/Assignee:

Application No.: 12/311393   Filing Date: 29/Oct/2007

Abstract:A compound of Formula Ia or Ib in free or salt or solvate form, where R1, R2, R3, R4, R5 R20, R24, R25, X, Y and Z have the meanings as indicated in the specification, are useful for treating diseases mediated by the ALK-5 and/or ALK-4 receptor. These compounds are also useful for treating diseases mediated by the Pi3k receptor, the JAK-2 receptor and the TRK receptor. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

Priority: EP20060123156 Applic. Date: 2006-10-30; WO2007EP09382 Applic. Date: 2007-10-29

Inventor: FERRAND SANDRINE [FR]; GLICKMAN FRASER [CH]; LEBLANC CATHERINE [GB]; RITCHIE CATHY [GB]; SHAW DUNCAN [GB]; STIEFL NIKOLAUS JOHANNES [DE]; FURET PASCAL [FR]; IMBACH PATRICIA [CH]; STAUFFER FREDERIC [FR]; CAPRARO HANS-GEORG [CH]; GESSIER FRANCOIS [FR]; GAUL CHRISTOPH [CH]; ALBAUGH PAMEIA A [US]; CHOPIUK GREG [US]


Application No.: US20100041696A1  Published: 18/Feb/2010

Title: Compounds

Applicant/Assignee:

Application No.: 12/519877   Filing Date: 19/Dec/2007

Abstract:The present invention relates to substituted 4-Aminopyrazole compounds of the formula (I): and pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing them and their use in medicine. In particular, the invention relates to compounds for modulating SCD activity.

Priority: GB20060025594 Applic. Date: 2006-12-21; WO2007EP64192 Applic. Date: 2007-12-19

Inventor: DAUGAN ALAIN CLAUDE-MARIE [FR]; DEAN ANTHONY WILLIAM [GB]


Application No.: US20100041704A1  Published: 18/Feb/2010

Title: DERMAL COMPOSITIONS OF SUBSTITUTED AMIDES AND THE USE THEREOF AS MEDICATION FOR PAIN AND PRURITUS

Applicant/Assignee:

Application No.: 12/448760   Filing Date: 11/Jan/2008

Abstract:Dermal compositions comprising topical formulations of bupivacaine or ropivacaine, characterized by effective dermal absorption and long duration of dermal anesthetic activity, and intended for use in patients suffering from pruritus and dermal pain, including neuropathic pain, are provided. Compositions containing both bupivacaine and capsaicin are provided. Methods of alleviating pain by the topically administration of these compounds are also provided.

Priority: US20070880227P Applic. Date: 2007-01-12; WO2008US00425 Applic. Date: 2008-01-11

Inventor: ABERG A K GUNNAR [US]; JOHNSON KEITH A [US]


Application No.: US20100041754A1  Published: 18/Feb/2010

Title: Novel natural oil gels and their application

Applicant/Assignee: APPLECHEM, INC

Application No.: 12/589358   Filing Date: 21/Oct/2009

Abstract:The invention is an article of manufacture, comprising a blend of: (A) from 1 to 50 weight percent of at least one block copolymer, wherein the block copolymer has at least one polystyrene block and at least one unsaturated rubber segment

and (B) from 99 to 50 weight percent of a natural oil. The natural oil of this invention is of natural animal, plant or vegetable oils or mixtures thereof, and the block copolymers have a polystyrene block and a rubber block where the rubber blocks are unsaturated rubbers such as polyisoprene, polybutadiene, or mixtures thereof. The block copolymers useful for the present invention are triblock polymers, radial (star) polymers, multiblock polymers, diblock polymers, or mixtures thereof.

Priority: US2007-973826 Applic. Date: 2007-10-09; US20060850586P Applic. Date: 2006-10-10; US20070900512P Applic. Date: 2007-02-09; US20070900518P Applic. Date: 2007-02-09

Inventor: LIN SAMUEL [US]


Application No.: US20100047185A1  Published: 25/Feb/2010

Title: ACTVIE SUBSTANCE COMBINATION

Applicant/Assignee: ISDIN S.A

Application No.: 12/522890   Filing Date: 11/Jan/2008

Abstract:The present invention refers to a combination of at least 2 UV-absorbing active substances (A) and (B), wherein the UV-absorbing active substance (A) is at least one heptaazaphenalene compound of the general formula (I), which is defined in the description and the UV-ab-sorbing active substance (B) is at least one compound which has its ab-sorption maximum [lambda]maX(B) in the range of UV-A or UV-B radiation.

Priority: EP20070000631 Applic. Date: 2007-01-12; WO2008EP00172 Applic. Date: 2008-01-11

Inventor: GORCHS CAPA OLGA [ES]; JIMENEZ ALONSO OSCAR [ES]; TRULLAS CABANAS CARLOS RAMON [ES]; CORBERA ARJONA JORDI [ES]; PANYELLA COSTA DAVID [ES]


Application No.: US20100047192A1  Published: 25/Feb/2010

Title: Novel tyrosinase-specific anti-gene oligonucleotides as depigmenting agents

Applicant/Assignee: L.V.M.H. RECHERCHE CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) MUSEUM NATIONAL D'HISTOIRE NATURELLE

Application No.: 11/991317   Filing Date: 01/Sep/2006

Abstract:The present invention relates to an anti-gene oligonucleotide which hybridizes specifically with the gene encoding human tyrosinase by Hoogsteen pairing between the complementary bases, said oligonucleotide forming a triple helix structure with the human tyrosinase gene. The invention also relates to the use of said oligonucleotide as a skin-depigmenting or skin-bleaching agent in a cosmetic composition or in a dermatological composition.

Priority: FR20050008981 Applic. Date: 2005-09-01; WO2006EP65902 Applic. Date: 2006-09-01

Inventor: KURFUERST ROBIN [FR]; BONNET-DUQUENNOY MATHILDE [FR]; LAZOU KRISTELL [FR]; GIOVANNANGELI CARINE [FR]


Application No.: US20100047196A1  Published: 25/Feb/2010

Title: NOVEL MICROSTRUCTURAL PROTEIN PREPARATIONS CONTAINING ADSORBED BIOLOGICALLY ACTIVE SUBSTANCES AND THEIR APPLICATION IN MEDICINE AND COSMETICS

Applicant/Assignee:

Application No.: 12/312576   Filing Date: 20/Nov/2007

Abstract:Protein preparations containing biologically active compounds and the application of the protein preparations obtained, particularly as a component of medicinal and cosmetic preparations as protective substances or in the regeneration of cells and tissues of the human organism, and which can comprise a component of culture media for dermal or hepatic tissues, or for stem cells destined for use in the regeneration of cells and tissues in the human organism.

Priority: PL20060381103 Applic. Date: 2006-11-21; WO2007PL00078 Applic. Date: 2007-11-20

Inventor: LIPKOWSKI ANDRZEJ [PL]; GRABOWSKA ANNA [PL]; KURZEPA KATARZYNA [PL]; SZCZUCINSKA ALEKSANDRA [PL]


Application No.: US20100047239A1  Published: 25/Feb/2010

Title: Dual variable domain immunoglobulin and uses thereof

Applicant/Assignee: ABBOTT LABORATORIES

Application No.: 12/459624   Filing Date: 02/Jul/2009

Abstract:The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention and/or treatment of acute and chronic inflammatory and other diseases.

Priority: US2006-507050 Applic. Date: 2006-08-18; US20050709911P Applic. Date: 2005-08-19; US20050732892P Applic. Date: 2005-11-02

Inventor: WU CHENGBIN [US]; GHAYUR TARIQ [US]; DIXON RICHARD W [US]; SALFELD JOCHEN G [US]


Application No.: US20100047245A1  Published: 25/Feb/2010

Title: IL-12/P40 BINDING PROTEINS

Applicant/Assignee: ABBOTT LABORATORIES

Application No.: 11/478096   Filing Date: 29/Jun/2006

Abstract:The present invention encompasses IL-12p40 binding proteins, particularly antibodies that bind human interleukin-12 (hIL-12) and/or human IL-23 (hIL-23). Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-12 and/or hIL-23 and neutralize h IL-12 and/or hIL-23 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and/or hIL-23 and for inhibiting hIL-12 and/or hIL-23 activity, e.g., in a human subject suffering from a disorder in which hIL-12 and/or hIL-23 activity is detrimental.

Priority: US20050695679P Applic. Date: 2005-06-30

Inventor: LACY SUSAN E [US]; FUNG EMMA [US]; BELK JONATHAN P [US]; DIXON RICHARD W [US]; ROGUSKA MICHAEL [US]; HINTON PAUL R [US]; KUMAR SHANKAR [US]


Application No.: US20100047269A1  Published: 25/Feb/2010

Title: Strain Of Turkey Tail Mushroom, Extract From The Same, And Use Of The Same

Applicant/Assignee: NIKKEN SOHONSHA CORPORATION

Application No.: 11/996961   Filing Date: 28/Jul/2006

Abstract:The present invention provides a new strain of turkey tail mushroom (Trametes versicolor (L.: Fr.) Pilat) having excellent biological activities (Accession number: FERM BP-10633). The strain is excellent in platelet aggregation inhibitory effect, chemokine gene expression inhibitory effect, antimutagenic effect, antitumor effect, antihypertensive effect, and immunomodulatory effect. The effect of the strain is enhanced synergistically by combining with microalgae and other basidiomycetes. The turkey tail mushroom of the present invention has high safety, and a possibility that a side effect is caused because of long-term continuous use is very low. Thus, it is useful for food/drink, cosmetics, pharmaceuticals or the like, the objective of which is the prevention and improvement in inflammation, allergy, tumor, and other diseases. The turkey tail mushroom strain of the present invention has very high hyphal growth property and very high physiological functions compared with conventional strains

therefore, it can be used stably.

Priority: JP20050218554 Applic. Date: 2005-07-28; WO2006JP314978 Applic. Date: 2006-07-28

Inventor: EGUCHI FUMIO [JP]; SUMI RYO [JP]; MORI NOBUO [JP]


Application No.: US20100047291A1  Published: 25/Feb/2010

Title: COSMETIC FORMULATIONS WITH IR PROTECTION

Applicant/Assignee:

Application No.: 11/993607   Filing Date: 21/Jun/2006

Abstract:The present invention relates to cosmetic formulations with IR protection which are distinguished by the fact that they comprise functional pigments. The invention furthermore relates to cosmetic formulations which, besides the IR pigment, comprise colorants, fillers, cosmetic active compounds and cosmetic raw materials and auxiliaries, and to the use thereof in care and decorative cosmetics.

Priority: DE200510029647 Applic. Date: 2005-06-23; WO2006EP05949 Applic. Date: 2006-06-21

Inventor: HOCHSTEIN VERONIKA [DE]; SCHMIDT CHRISTOPH [DE]; SCHOEN SABINE [DE]


Application No.: US20100047294A1  Published: 25/Feb/2010

Title: SEMI-FINISHED PRODUCT IN THE MANUFACTURE OF A COMPOSITION FOR SKIN OR HAIR CARE

Applicant/Assignee: OY GRANULA AB LTD

Application No.: 12/377515   Filing Date: 14/Aug/2007

Abstract:A semi-finished product is manufactured from raw liquid, extract or powder obtained from wood material, an end product composition for skin or hair care being obtained from the semi-finished product by adding one or more components thereto. The semi-finished product optionally contains a UV protector, and is a liquid, emulsion, microemulsion or nanoemulsion or a dispersion, suspension, wax, lotion or gel or a solid substance. The semi-finished product further contains an active ingredient mixture which contains phenolic compounds having antioxidative and/or microbicidal properties and/or abilities to capture free radicals. The active ingredient mixture contains as phenolic compounds at least one oligolignan, and at least two lignans, tannins or flavonoids selected from a group consisting of hydroxymatairesinol, matairesinol, oxomatairesinol, lariciresinol, cyclolariciresinol, secoisolariciresinol nortrachelogenin, pinoresinol, pinosylvine, conidendrine, melacasidine, teracasidine, ellaga-tannin or a reaction product, stereoisomer or derivative of these compounds.

Priority: FI20060000729 Applic. Date: 2006-08-14; WO2007FI00201 Applic. Date: 2007-08-14

Inventor: AHLNAS THOMAS [FI]


Application No.: US20100047296A1  Published: 25/Feb/2010

Title: Low-Residue Cosmetic Or Dermatological Stick Based On An Oil-In-Water Dispersion/Emulsion III

Applicant/Assignee: HENKEL AG & CO. KGAA

Application No.: 12/465983   Filing Date: 14/May/2009

Abstract:Cosmetic or dermatological sticks, especially deodorant or antiperspirant sticks, based on an oil-in-water dispersion/emulsion to be applied to the skin.

Priority: DE200610053886 Applic. Date: 2006-11-14; WO2007EP62236 Applic. Date: 2007-11-13

Inventor: BANOWSKI BERNHARD [DE]; CLAAS MARCUS [DE]; BUSE NADINE [DE]


Application No.: US20100047297A1  Published: 25/Feb/2010

Title: NANOCRYSTALS FOR USE IN TOPICAL COSMETIC FORMULATIONS AND METHOD OF PRODUCTION THEREOF

Applicant/Assignee: ABBOTT GMBH & CO. KG

Application No.: 12/514621   Filing Date: 19/Nov/2007

Abstract:Provided are cosmetic preparations for topical application containing nanocrystals of cosmetic actives leading to an increased bioactivity of the molecules in the skin and methods of making the cosmetic preparations. The nanocrystals can be added to any cosmetic topical formulation, e. g. creams, lotions and liposomal dispersions. The drug nanocrystals are produced by a combination process of low energy pearl milling followed by a high energy high-pressure homogenization leading to nanocrystal suspensions (nanosuspensions) of improved physical stability.

Priority: US20060866233P Applic. Date: 2006-11-17; WO2007EP09943 Applic. Date: 2007-11-19

Inventor: PETERSEN ROLF [DE]


Application No.: US20100047298A1  Published: 25/Feb/2010

Title: PROCESS FOR TREATING THE SKIN BY APPLYING SILICONE COMPOUNDS

Applicant/Assignee: L'OREAL

Application No.: 12/519271   Filing Date: 19/Dec/2007

Abstract:The invention relates to a cosmetic treatment method for improving the superficial appearance of the skin, and especially for reducing the visible and/or tactile irregularities of the skin, such as cutaneous microrelief. According to said method, a filling product is applied to the irregularities, said product resulting from a hydrosilylation reaction, in the presence of a catalyst, between two compounds X and Y, at least one of said compounds being a silicone compound, and both compounds being brought into contact with each other in the presence of a catalyst such that the reaction occurs at least partially on the skin.

Priority: FR20060055727 Applic. Date: 2006-12-20; US20070883171P Applic. Date: 2007-01-03; WO2007FR52563 Applic. Date: 2007-12-19

Inventor: CASSIN GUILLAUME [FR]


Application No.: US20100047357A1  Published: 25/Feb/2010

Title: COMPOSITIONS FOR TOPICAL APPLICATION COMPRISING A PEROXIDE AND RETINOID

Applicant/Assignee: SOL-GEL TECHNOLOGIES LTD

Application No.: 12/525329   Filing Date: 03/Feb/2008

Abstract:The invention relates to a composition for topical application comprising as an active ingredient a peroxide and a retinoid wherein one of said peroxide and retinoid is in the form of first microparticles comprising a solid particulate matter of the active ingredient coated by a metal oxide layer and the other of said peroxide and retinoid is present in an uncoated free form or in a coated form of the active ingredient. The invention further relates to method for treating a surface condition in a subject using said composition, a method for preparing a composition exhibiting improved stability, and a kit comprising: (a) a first composition comprising a peroxide as a first active ingredient

and (b) a second composition comprising a retinoid as a second active ingredient

at least one of said first and said second active ingredient being coated by a metal oxide layer.

Priority: US20070898701P Applic. Date: 2007-02-01; WO2008IL00140 Applic. Date: 2008-02-03

Inventor: TOLEDANO OFER [IL]; SERTCHOOK HANAN [IL]; LOBODA NATALIA [IL]; BAR-SIMANTOV HAIM [IL]; SHAPIRO LEORA [IL]; ABU-REZIQ RAED [IL]


Application No.: US20100047360A1  Published: 25/Feb/2010

Title: Use Of Polyamines In The Treatment Of Psoriasis

Applicant/Assignee: BIOFORSKINING PHARMA AS

Application No.: 12/225060   Filing Date: 14/Mar/2007

Abstract:The present invention provides unbranched aliphatic polyamines for use in therapy, particularly for use in the treatment of psoriasis and compositions containing polyamines.

Priority: GB20060005107 Applic. Date: 2006-03-14; WO2007GB00894 Applic. Date: 2007-03-14

Inventor: KLAVENESS JO [NO]; KVALHEIM GEIR HAVARD [NO]


Application No.: US20100047361A1  Published: 25/Feb/2010

Title: Active Principle which is capable of inducing the conversion of inactive TGFb-Latent into active TGFb

Applicant/Assignee: BASF BEAUTY CARE SOLUTIONS FRANCE S.A.S LABORATOIRE DE DERMOCOSMETIQUE

Application No.: 12/613964   Filing Date: 06/Nov/2009

Abstract:The invention relates to active principles which are capable of inducing the conversion of inactive TGFb-Latent into active TGFb. The invention relates in particular to the use of such an extract for the manufacture of a composition for increasing the concentration of active TGFb1 in the skin, notably in the dermis. The present invention also relates to the uses which are derived from said use, as well as to cosmetic or pharmaceutical compositions which comprise said extract.

Priority: FR20040006047 Applic. Date: 2004-06-04; US2004-966168 Applic. Date: 2004-10-04

Inventor: PERRIER ERIC [FR]; ALTOBELLI CECILE [FR]; CLEMENT ANNE [FR]; REYMERMIER CORINNE [FR]; ABDUL MALAK NABIL [FR]


Application No.: US20100048453A1  Published: 25/Feb/2010

Title: OXAZOLE AND THIAZOLE PPAR MODULATOR

Applicant/Assignee: IRM LLC

Application No.: 12/092967   Filing Date: 07/Nov/2006

Abstract:The invention provides compounds (I) pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated Receptor (PPAR) families, particularly the activity of PPAR[delta].

Priority: US20050734678P Applic. Date: 2005-11-07; WO2006US43586 Applic. Date: 2006-11-07

Inventor: EPPLE ROBERT [US]; COW CHRISTOPHER N [US]; AZIMIOARA MIHAI [US]; RUSSO ROSS [US]


Application No.: US20100048515A1  Published: 25/Feb/2010

Title: Oxidized lipids and uses thereof in the treatment of inflammatory diseases and disorders

Applicant/Assignee: VASCULAR BIOGENICS LTD

Application No.: 12/588371   Filing Date: 14/Oct/2009

Abstract:Novel synthetic oxidized lipids and methods utilizing oxidized lipids for treating and preventing an inflammation associated with an endogenous oxidized lipid are provided.

Priority: US2006-528657 Applic. Date: 2006-09-28; US2008-567543 Applic. Date: 2008-04-25; WO2004IL00453 Applic. Date: 2004-05-27; US2003-445347 Applic. Date: 2003-05-27

Inventor: HARATS DROR [IL]; GEORGE JACOB [IL]; HALPERIN GIDEON [IL]; MENDEL ITZHAK [IL]


Application No.: US20100048560A1  Published: 25/Feb/2010

Title: PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS

Applicant/Assignee: GENKYOTEX SA

Application No.: 12/532336   Filing Date: 20/Mar/2008

Abstract:The present invention is related to pyrazolo pyridine derivatives of Formula (I), pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase).

Priority: EP20070109555 Applic. Date: 2007-06-04; US20070896284P Applic. Date: 2007-03-22; WO2008EP53390 Applic. Date: 2008-03-20

Inventor: PAGE PATRICK [FR]; ORCHARD MIKE [GB]; FIORASO LEITICIA [FR]; MOTTIROMI BIANCA [CH]


Application No.: US20100048598A1  Published: 25/Feb/2010

Title: TOPICAL COMPOSITIONS COMPRISING 5-ALPHA REDUCTASE INHIBITORS

Applicant/Assignee:

Application No.: 12/544737   Filing Date: 20/Aug/2009

Abstract:The present invention relates to topical compositions comprising 5[alpha]-reductase inhibitors. The present invention also includes processes for preparation of such topical compositions and methods of using them.

Priority: IN2008CH02033 Applic. Date: 2008-08-21; US20080106733P Applic. Date: 2008-10-20

Inventor: KANDAVILLI SATEESH [IN]; NALAMOTHU VIJENDRA [US]; PANDYA VISHVABHAVAN [IN]


Application No.: US20100048610A1  Published: 25/Feb/2010

Title: CARBINOL DERIVATIVES HAVING CYCLIC LINKER

Applicant/Assignee: KOWA COMPANY, LTD

Application No.: 12/474799   Filing Date: 29/May/2009

Abstract:[Object] To provide a novel LXR[beta] agonist that is useful as a preventative and/or therapeutic agent for atherosclerosis

arteriosclerosis such as those resulting from diabetes

dyslipidemia

hypercholesterolemia

lipid-related diseases

inflammatory diseases that are caused by inflammatory cytokines

skin diseases such as allergic skin diseases

diabetes

or Alzheimer's disease. [Solving Means] A carbinol compound represented by the following general formula (I) or salt thereof, or their solvate.

Priority: US20080057070P Applic. Date: 2008-05-29

Inventor: YAMAGUCHI YUKI [JP]; KOURA MINORU [JP]; KUROBUCHI SAYAKA [JP]; MATSUDA TAKAYUKI [JP]; OKUDA AYUMU [JP]; SUMIDA HISASHI [JP]; WATANABE YUUICHIROU [JP]; ENOMOTO TAKASHI [JP]; SHIBUYA KIMIYUKI [JP]


Application No.: US20100048617A1  Published: 25/Feb/2010

Title: COMPOUNDS

Applicant/Assignee: SMITHKLINE BEECHAM CORP

Application No.: 12/519621   Filing Date: 19/Dec/2007

Abstract:The present invention relates to substituted 3-Aminopyrazole compounds of formula (I) and pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing them and their use in medicine. In particular, the invention relates to compounds for modulating SCD activity.

Priority: GB20060025605 Applic. Date: 2006-12-21; WO2007EP64219 Applic. Date: 2007-12-19

Inventor: DAUGAN ALAIN CLAUDE-MARIE [FR]


Application No.: US20100048729A1  Published: 25/Feb/2010

Title: Composition based on xanthoxyline and its use in cosmetic

Applicant/Assignee: PIERRE FABRE DERMO-COSMETIQUE

Application No.: 12/310960   Filing Date: 11/Sep/2007

Abstract:The present invention relates to the use of xanthoxyline, and of plant extracts containing it, in cosmetic compositions.

Priority: FR20060008129 Applic. Date: 2006-09-15; WO2007FR01467 Applic. Date: 2007-09-11

Inventor: CHARVERON MARIE [FR]; BELAUBRE FRANCOISE [FR]; BELLE RENE [FR]; DUNOUAU CHRISTOPHE [FR]


Application No.: US20100049021A1  Published: 25/Feb/2010

Title: DEVICES, SYSTEMS, METHODS AND TOOLS FOR CONTINUOUS ANALYTE MONITORING

Applicant/Assignee:

Application No.: 12/545008   Filing Date: 20/Aug/2009

Abstract:One aspect of the invention provides an analyte monitor including a sensing volume, an analyte extraction area in contact with the sensing volume adapted to extract an analyte into the sensing volume, and an analyte sensor adapted to detect a concentration of analyte in the sensing volume. The sensing volume is defined by a first face, a second face opposite to the first face, and a thickness equal to the distance between the two faces. The surface area of the first face is about equal to the surface area of the second face and the extraction area is about equal to the surface area of the first and second face of the sensing volume. The analyte sensor includes a working electrode in contact with the sensing volume, the working electrode having a surface area at least as large as the analyte extraction area, and a second electrode in fluid communication with the sensing volume.

Priority: US2008-275145 Applic. Date: 2008-11-20; US2006-277731 Applic. Date: 2006-03-28; US2006-642196 Applic. Date: 2006-12-20

Inventor: JINA ARVIND N [US]; PARMAR ASHOK [US]; CHUA BEELEE [US]; TAMADA JANET [US]; LEE JONATHAN [US]; TIERNEY MICHAEL J [US]; KAUR NAVNEET [US]; MAGGINETTI PAUL [US]; DESAI SHASHI P [US]


Application No.: US20100049077A1  Published: 25/Feb/2010

Title: Internal Bleeding Detection Apparatus

Applicant/Assignee:

Application No.: 12/086976   Filing Date: 28/Dec/2006

Abstract:Abstract: An EIT system (1) adapted to detect internal bleeding in a body portion, the EIT system (1) comprising a plurality of electrodes (3) adapted in use to extend in a substantially linear orientation across one side only of the body portion and to be applied in electrical contact with the skin of the body portion, a current source adapted to cyclically apply an electric current between one pair of the electrodes (3), a voltage measuring means to measure the voltage across each of the other pairs of the electrodes resulting from the current, a data collection system (2) and a data analysis system (4) to analyse data resulting from the voltages that are measured by the voltage measuring means, wherein the analysis system (4) is configured to obtain quantitative information related to amounts and rates of conductive tissue changes occurring in the body, based on an EIT analysis equivalent to that obtained from data derived from electrodes spaced around the full perimeter of the body portion. Also disclosed is an electrode belt suitable for bioelectrical use and in particular for detection of change of volume of tissue in a body portion.

Priority: WO2006AU01990 Applic. Date: 2006-12-28; AU20050907263 Applic. Date: 2005-12-23

Inventor: SADLEIR ROSALIND [US]; DUNCAN ANDREW [AU]


Application No.: US20100055055A1  Published: 04/Mar/2010

Title: TOPICAL FORMULATIONS OF TELLURIUM-CONTAINING COMPOUNDS

Applicant/Assignee: BIOMAS LTD

Application No.: 12/440727   Filing Date: 10/Sep/2007

Abstract:Novel formulations of tellurium-containing compounds, which are suitable for topical application, are disclosed. The formulations are characterized by high chemical and physical stability and are easy to handle and use.

Priority: US20060843402P Applic. Date: 2006-09-11; WO2007IB04220 Applic. Date: 2007-09-10

Inventor: ALBECK MICHAEL [IL]; SREDNI BENJAMIN [IL]; FIREDMAN DORON [IL]


Application No.: US20100055088A1  Published: 04/Mar/2010

Title: CXCR4 Antagonists for Wound Healing and Re-Epithelialization

Applicant/Assignee: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENTLTD KYOTO UNIVERSITY

Application No.: 11/915428   Filing Date: 21/May/2006

Abstract:The present invention provides novel uses for CXCR4 antagonists, including specifically peptides of the T-140 family, in the treatment of skin burns and other injuries. The invention further provides methods for increasing epithelialisation in a subject in need thereof, and for preventing or inhibiting fibrosis and excessive scar formation, using peptide inhibitors of the T-140 family as well as other CXCR4 antagonists.

Priority: US20050684160P Applic. Date: 2005-05-25; WO2006IL00596 Applic. Date: 2006-05-21

Inventor: PELED AMNON [IL]; FUJII NOBUTAKA [JP]


Application No.: US20100055102A1  Published: 04/Mar/2010

Title: COMPOSITIONS OF PD-1 ANTAGONISTS AND METHODS OF USE

Applicant/Assignee:

Application No.: 12/547129   Filing Date: 25/Aug/2009

Abstract:Methods of treating cancer and infectious diseases utilizing a treatment regimen comprising administering a compound that reduces inhibitory signal transduction in T cells, in combination with a potentiating agent, such as cyclophosphamide, to produce potent T cell mediated responses, are described. Compositions comprising the PD-1 antagonists and potentiating agents useful in the methods of the invention are also disclosed.

Priority: US20090211697P Applic. Date: 2009-04-02; US20080091694P Applic. Date: 2008-08-25; US20080091709P Applic. Date: 2008-08-25; US20080091705P Applic. Date: 2008-08-25

Inventor: LANGERMANN SOLOMON [US]


Application No.: US20100055103A1  Published: 04/Mar/2010

Title: CROSS-REACTIVE AND BISPECIFIC ANTI-IL-17A/F ANTIBODIES

Applicant/Assignee:

Application No.: 12/547728   Filing Date: 26/Aug/2009

Abstract:The present invention relates generally to antibodies cross-reactive with IL-17A and IL-17F, and bispecific anti-IL-17A/F and their uses.

Priority: US20090164709P Applic. Date: 2009-03-30; US20080112644P Applic. Date: 2008-11-07; US20080093212P Applic. Date: 2008-08-29

Inventor: CHEN YONGMEI [US]; HU YAN HELEN [US]; OUYANG WENJUN [US]; STAWICKI SCOTT [US]; WU YAN [US]


Application No.: US20100055137A1  Published: 04/Mar/2010

Title: Microemulsion & sub-micron emulsion process & compositions

Applicant/Assignee: STIEFEL RESEARCH AUSTRALIA PTY LTD

Application No.: 12/457953   Filing Date: 25/Jun/2009

Abstract:An oil in water microemulsion or sub-micron emulsion composition for dermal delivery of at least one pharmaceutically active ingredient, is provided. The composition includes an oil phase dispersed throughout a water phase, the oil phase including at least one member selected from the group consisting of an animal oil, a mineral oil, a vegetable oil, a silane member, a siloxane, an ester, a fatty acid, a fat, a halogen compound, and an alkoxylated alcohol

and at least one lipophilic surfactant, the water phase including at least one hydrophilic surfactant, water and optionally a non-surfactant amphiphilic compound, the weight ratio of the at least one hydrophilic surfactant to the at least one lipophilic surfactant being approximately 9.0:1.0 to 2.0:3.0.

Priority: US2005-216668 Applic. Date: 2005-08-31; US20050670722P Applic. Date: 2005-04-12; US20040606278P Applic. Date: 2004-08-31

Inventor: LARM MARIA GRAZIELLA [AU]; HARDING RONALD [AU]; JOHNSTON MICHAEL [AU]; ABRAM ALBERT ZORKO [AU]; VIJAYAKUMAR PREMA [US]; SUN PHOEBE [US]


Application No.: US20100055205A1  Published: 04/Mar/2010

Title: FUNCTIONAL CONSUMABLE COMPOSITIONS FOR PROMOTING SKIN HEALTH AND METHODS FOR USING THE SAME

Applicant/Assignee:

Application No.: 12/549589   Filing Date: 28/Aug/2009

Abstract:A functional consumable composition for promoting skin health may comprise, for each 100% by dry weight, no more than about 0.2% by dry weight catechin and no more than about 2% by dry weight amino acid. The amino acid may comprise at least one of 1-proline and 1-arginine, and the weight % 1-proline to weight % 1-arginine may be greater than about 2. Another functional consumable composition may comprise no more than about 0.2% by dry weight catechin and at least one of lipoic acid, selenium, vitamin E, vitamin B, and vitamin C. A source of the catechin may comprise at least one of white tea solids and epigallocatechin gallate extract. Methods for using such functional consumable compositions are also described.

Priority: US20080093150P Applic. Date: 2008-08-29

Inventor: MAINS KRISTINA [US]


Application No.: US20100055210A1  Published: 04/Mar/2010

Title: COSMETIC COMPOSITION FOR PROTECTING SKIN AGAINST UV LIGHT AND WRINKLE IMPROVEMENT CONTAINING THE EXTRACT OF MAGNOLIA SIEBOLDII FLOWER EXTRACTS

Applicant/Assignee:

Application No.: 12/448751   Filing Date: 13/Dec/2007

Abstract:Disclosed herein is a cosmetic composition for preventing photoaging, containing an extract of Magnolia sieboldii as an active ingredient. Also disclosed is a cosmetic composition for reducing skin wrinkles containing an extract of Magnolia sieboldii as an active ingredient. The extract of Magnolia sieboldii can protect the skin against UV lights and skin damage by suppressing skin cell death and cell DNA damage, and can reduce skin wrinkles by promoting the biosynthesis of collagen and suppressing the synthesis of collagenases. Also, the cosmetic composition containing the extract of Magnolia sieboldii has an excellent effect of inhibiting skin damage caused by UV lights, and an excellent effect of reducing skin wrinkles.

Priority: KR20070001833 Applic. Date: 2007-01-08; WO2007KR06509 Applic. Date: 2007-12-13

Inventor: LEE GHANG TAI [KR]; LEE JUNG NOH [KR]; YOU YOUNG KYOUNG [KR]; LEE SEUNG JI [KR]; LEE KUN KOOK [KR]


Application No.: US20100055217A1  Published: 04/Mar/2010

Title: COSMETIC COMPOSITION COMPRISING A COMBINATION OF LIPOCHROMAN-6 AND AN EXTRACT OF LONGOZA, AND ITS USE

Applicant/Assignee: LVMH RECHERCHE

Application No.: 12/533106   Filing Date: 31/Jul/2009

Abstract:The invention relates to a cosmetic composition formulated for topical application to the skin, comprising as active agent a combination of lipochroman-6 and an extract of Longoza (Aframomum angustifolium). It also relates to the use of this combination in a cosmetic composition compatible with topical application, or for preparing such a composition, as an active agent intended for preventing or retarding the appearance of signs of skin ageing, such as the appearance of wrinkles or a decrease in the firmness and the elasticity of the skin, or for attenuating the effects thereof and/or for enhancing the radiance of the complexion of the skin, especially of the skin of the face, or for giving it back its natural radiance. It also relates to a method of cosmetic care of the skin, intended to prevent or to retard the appearance of signs of skin ageing, such as the appearance of wrinkles or a decrease in the firmness and elasticity of the skin, or to attenuate the effects thereof, comprising applying to at least one part of the skin of the body or the face a cosmetic composition comprising said combination.

Priority: FR20080055370 Applic. Date: 2008-08-01

Inventor: NIZARD CARINE [FR]; NOBLESSE EMMANUELLE [FR]; SCHAEFFER PHILIPPE [FR]


Application No.: US20100056431A1  Published: 04/Mar/2010

Title: MEDICAL USES

Applicant/Assignee: LIPOPEPTIDE AB

Application No.: 12/305601   Filing Date: 20/Jun/2007

Abstract:The present invention provides the use of a polypeptide comprising an amino acid sequence according to SEQ ID NO: 1 (corresponding to the N-terminal 25 amino acid fragment of the human antimicrobial protein, LL-37) or a biologically active fragment, variant, fusion or derivative thereof, in the preparation of a medicament for the treatment of cancer. In particular, the inventions provides the use such polypeptides, or a fragment, variant, fusion or derivative thereof, to inhibit the proliferation and/or metastasis of cancer cells, such as breast cancer cells. The invention further comprises methods for the treatment of cancer in a patient.

Priority: US20060814877P Applic. Date: 2006-06-20; WO2007GB02289 Applic. Date: 2007-06-20

Inventor: STAHLE MONA [SE]; WEBER GUNTHER [SE]


Application No.: US20100056432A1  Published: 04/Mar/2010

Title: TEMPLATE-FIXED PEPTIDOMIMETICS WITH ANTIBACTERIAL ACTIVITY

Applicant/Assignee: POLYPHOR LTD UNIVERSITAET ZUERICH

Application No.: 12/506794   Filing Date: 21/Jul/2009

Abstract:Template-fixed [beta]-hairpin peptidomimetics of the general formula (I) wherein Z is a template-fixed chain of 12 [alpha]-amino acid residues which, depend on their positions in the chain (counted starting from the N-terminal amino acid) are Gly, or Pro, or of certain types which, as the remaining symbols in the above formula, are defined in the description and the claims, and salts thereof, have the property to selectively inhibit the growth of or to kill microorganisms such as Pseudomonas aeruginosa and Acinetobacter. They can be used as disinfectants for foodstuffs, cosmetics, medicaments or other nutrient-containing materials, or as medicaments to treat or prevent infections. In a specific embodiment, the template is based on the D-Pro-L-Pro dipeptides. These [beta]-hairpin peptidomimetics can be manufactured by processes which are based on a mixed solid-and solution phase synthetic strategy.

Priority: US2005-062021 Applic. Date: 2005-02-18; WO2002EP09278 Applic. Date: 2002-08-20

Inventor: VRIJBLOED JAN WIM [CH]; OBRECHT DANIEL [CH]; ROBINSON JOHN ANTHONY [CH]; SELLIER ODILE [FR]; KESSLER MARC [FR]


Application No.: US20100056435A1  Published: 04/Mar/2010

Title: Depsipeptides and Their Therapeutic Use

Applicant/Assignee:

Application No.: 12/516110   Filing Date: 22/Nov/2007

Abstract:A compound of the general Structure (VII) or (VIII) including isoteres and pharmaceutically acceptable salts thereof, wherein R1, R2 (where X=-CONR6-), R3 and R7 are the same or different and each represents an amino-acid side chain moiety

R2 (where X=-CHZ-), R4 and R6 are the same or different and each represents hydrogen, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl

K represents a linear or branched chain of carbon atoms and containing 1-10 atoms

L represents a moiety capable of chelating zinc in the active site of a histone deacetylase (HDAC) or of conversion to such a moiety in vivo (by hydrolysis or reduction, for example)

M is a linear or branched chain of carbon or other atoms and containing 1-10 atoms, and capable of undergoing in vivo cleavage to give Structure (VII)

and Z is a heteroatom bonded to the macrocycle by a single or double bond, and any other group bonded to Z is H or a protecting group.

Priority: GB20060023357 Applic. Date: 2006-11-22; GB20060023331 Applic. Date: 2006-11-23; WO2007GB04472 Applic. Date: 2007-11-22

Inventor: GANESAN ARASU [GB]; PACKHAM GRAHAM KEITH [GB]; CECIL ALEXANDER RICHARD LIAM [GB]


Application No.: US20100056642A1  Published: 04/Mar/2010

Title: HEPATITIS A VIRICIDE

Applicant/Assignee: ECOLAB INC

Application No.: 12/617468   Filing Date: 12/Nov/2009

Abstract:The invention relates to agents which combat the hepatitis A virus, containing only minimal amounts of chlorine-containing and/or chlorine cleaving active ingredients, or none of said substances. The inventions also relates to the use of these agents and to a method for their production.

Priority: DE19991062353 Applic. Date: 1999-12-23; US2002-168442 Applic. Date: 2002-09-18; WO2000EP12688 Applic. Date: 2000-12-14

Inventor: VON RHEINBABEN FRIEDRICH [DE]; BIERING HOLGER [DE]; BANSEMIR KLAUS-PETER [DE]; GLAESER SABINE [DE]


Application No.: US20100061950A1  Published: 11/Mar/2010

Title: Antiperspirant/Deodorant Compositions and Methods

Applicant/Assignee: REVLON CONSUMER PRODUCTS CORPORATION

Application No.: 12/593019   Filing Date: 25/Mar/2008

Abstract:An aqueous based antiperspirant/deodorant composition comprising (a) an antiperspirant active ingredient

(b) at least one water absorbing polymer pretreated with a non-aqueous polar solvent

and (c) water, wherein the pretreated water absorbing polymer inhibits the water absorbing properties of the polymer in the aqueous based composition prior to application to the skin.

Priority: US2007-691810 Applic. Date: 2007-03-27; WO2008US58139 Applic. Date: 2008-03-25

Inventor: JOSHI VIJAY K [US]; FRANCO PHILIP [US]


Application No.: US20100061963A1  Published: 11/Mar/2010

Title: Methods of Improving Stem Cell Homing and Engraftment

Applicant/Assignee:

Application No.: 12/085406   Filing Date: 29/Nov/2006

Abstract:A method of enhancing cell engraftment potential is provided. The method comprising ex-vivo or in-vitro subjecting a population of cells to an amount of nicotinamide for a period of time sufficient to effect the population of cells, thereby enhancing cell engraftment potential.

Priority: US2005-289004 Applic. Date: 2005-11-29; WO2006IL01381 Applic. Date: 2006-11-29

Inventor: PELED TONY [IL]


Application No.: US20100062009A1  Published: 08/Jan/2009

Title: Novel Stromal Cell-Derived Factor-1 Polypeptides, Polynucleotides, Modulators Thereof and Methods of Use

Applicant/Assignee: FIVE PRIME THERAPEUTICS, INC

Application No.: 11/587651   Filing Date: 29/Apr/2005

Abstract:Disclosed herein is a newly identified SDF-1 splice variant molecule, its polypeptide sequence, and the polynucleotides encoding the polypeptide sequence, and active fragments thereof. Also provided is a procedure for producing such polypeptides by recombinant techniques employing, for example, vectors and host cells. Also disclosed are methods for utilizing such polypeptides and modulators thereof for the treatment of diseases, including cancer, immune diseases, infectious diseases, and ischemic diseases.

Priority: US20040567311P Applic. Date: 2004-04-30; WO2005US14963 Applic. Date: 2005-04-29

Inventor: CHU KETING [US]; WILLIAMS LEWIS T [US]; WONG JUSTIN G P [US]; HESTIR KEVIN [US]; COLLINS AMY L TSUI [US]; LEE ERNESTINE [US]


Application No.: US20100062029A1  Published: 11/Mar/2010

Title: Product for the Targeted Release of Active Substances

Applicant/Assignee:

Application No.: 11/886353   Filing Date: 16/Feb/2006

Abstract:The invention relates to a product for the targeted release of active substances, especially detergents and/or cosmetic active substances. The inventive product has a layer structure, one layer being impermeable to the active substance and another layer being permeable to the active substance. The two layers define a compartment between them which contains the active substance and optionally a gas-releasing component. The product is preferably suitable for single use and can be used as a cosmetic agent and/or as a cleaning agent.

Priority: DE200510012248 Applic. Date: 2005-03-15; WO2006EP01392 Applic. Date: 2006-02-16

Inventor: ROREGER MICHAEL [DE]


Application No.: US20100062052A1  Published: 11/Mar/2010

Title: PEPTIDE-BASED COMPOUNDS AS NEW INHIBITORS OF METALLOECTOPEPTIDASES, COMPOSITIONS COMPRISING SAID COMPOUNDS AND THEIR PHARMACEUTICAL AND COSMETIC USES

Applicant/Assignee: GREENPHARMA

Application No.: 12/524955   Filing Date: 04/Feb/2008

Abstract:The invention relates to a compound that inhibits a metallo-ectopeptidase, selected in the group consisting of x-aa2-aa1-z, x-aa3-aa2-aa1-z, x-aa4-aa3-aa2-aa1-z and x-aa5-aa4-aa3-aa2-aa1-z, wherein: aa1 and aa4, independently from each other, represent an arginine amino acid, an histidine amino acid, an asparagine amino acid or a lysine amino acid, aa2 represents a serine amino acid, a glycine amino acid, a threonine amino acid or an alanine amino acid, aa3 represents a phenylalanine amino acid, a leucine amino acid, an isoleucine amino acid, a tyrosine amino acid or a tryptophan amino acid, aa5 represents a glutamine amino acid, a glutamic acid amino acid, an asparagines amino-acid or a lysine amino acid, x and z, independently from each other, represent: -H

-OH1 SH

-a halogen atom, -an amino group, -an alkyl, haloalkyl or heteroalkyl group containing from 1 to 30 carbon atoms, linear or branched, -an alkenyl or alkynyl group containing from 2 to 30 carbon atoms, linear or branched, -a cycloalkyl, cycloakenyl, cycloalkynyl or an heterocyclic group containing from 3 to 30 carbon atoms, linear or branched, -one or more aryl or heteroaryl groups containing from 3 to 10 carbon atoms per cycle, -a alkoxy, thioalkyl, sulfonylalkyl, aminoalkyl containing from 1 to 30 carbon atoms, linear or branched, -one or more heterocyclic group, containing from 5 to 10 carbon atoms per cycle, said groups being optionally substituted by one or more halogen atoms, alkyl groups, hydroxy groups, alkoxy groups, aryloxy groups, acyloxy groups, carbamoyloxy groups, carboxy groups, mercapto groups, alkylthio groups, acylthio groups, arylthio groups, aryl groups, heterocyclic groups, heteroaryl groups or amino groups.

Priority: US20070899033P Applic. Date: 2007-02-02; WO2008IB01328 Applic. Date: 2008-02-04

Inventor: BERNARD PHILIPPE [FR]


Application No.: US20100062083A1  Published: 11/Mar/2010

Title: DERMAL FILM-FORMING LIQUID FORMULATIONS FOR DRUG RELEASE TO SKIN

Applicant/Assignee: POLICHEM S.A

Application No.: 12/449571   Filing Date: 13/Dec/2007

Abstract:The present invention is directed to liquid compositions containing chitosan, a chitosan derivative or a physiologically acceptable salt thereof, forming a dermal film after application onto the skin, useful for delivery of actives onto the skin surface and in the stratum corneum.

Priority: EP20070102449 Applic. Date: 2007-02-15; US20070901405P Applic. Date: 2007-02-15; WO2007EP63869 Applic. Date: 2007-12-13

Inventor: MAILLAND FEDERICO [IT]; LEGORA MICHELA [IT]


Application No.: US20100062086A1  Published: 11/Mar/2010

Title: Compositions and Methods of Their Use for Improving the Condition and Appearance of Skin

Applicant/Assignee: AVON PRODUCTS, INC

Application No.: 12/621027   Filing Date: 18/Nov/2009

Abstract:The present invention relates to compositions and methods for treating, preventing and improving the condition and aesthetic appearance of skin, particularly, treating, preventing, ameliorating, reducing and/or eliminating fine lines and/or wrinkles of skin, where the compositions include natural plant constituents, or synthetic equivalents thereof, which inhibit or decrease expression of C-reactive protein expression, production or secretion, thereby reducing, inhibiting, or ameliorating dermatological signs of aging. The compositions of the invention may be topically applied to the skin, or are delivered by directed means to a site in need thereof, in an amount effective in improving the condition and aesthetic appearance of skin.

Priority: US2006-647648 Applic. Date: 2006-12-29

Inventor: DRYER LAURENCE [US]; TAFURI SHERRIE R [US]; PTCHELINTSEV DMITRI S [US]


Application No.: US20100062492A1  Published: 11/Mar/2010

Title: Method For Preparing Icariside II, Cosmetic Composition Containing The Same and the Use Thereof For Skin Whitening

Applicant/Assignee: AMOREPACIFIC CORPORATION

Application No.: 12/440984   Filing Date: 19/Sep/2007

Abstract:Disclosed are a method for preparing icariside II represented by Formula 1, which inhibits the glycosylation of glycoprotein enzyme tyrosinase by inhibiting the enzymatic activity of alpha-glucosidase, which is an enzyme in the glycosylation of tyrosinase, as well as a skin whitening composition.

Priority: KR20060090795 Applic. Date: 2006-09-19; WO2007KR04557 Applic. Date: 2007-09-19

Inventor: PARK JUN SEONG [KR]; PARK HYE YOON [KR]; RHO HO SIK [KR]; AHN SOO MI [KR]; KIM DUCK HEE [KR]


Application No.: US20100063008A1  Published: 11/Mar/2010

Title: GELATINOUS ELASTOMER COMPOSITIONS

Applicant/Assignee: SILIPOS, INC

Application No.: 12/557496   Filing Date: 10/Sep/2009

Abstract:The present invention is directed to gelatinous elastomer compositions that are useful for topical application of biologically active agents. In certain embodiments, the invention is directed to a gelatinous elastomer composition comprising about 1.0% to 50.0% block copolymer, about 0% to 98% mineral and/or synthetic oil, and about 0.0% to 98% triglyceride oil, about 0-15.0% free fatty acids, about 0-30% of a tack modification agent, about 0-20.0% of a biologically active agent and, optionally a phytosterol, ceramide and/or bisabolol. The gelatinous elastomer compositions are useful for applying a biologically active agent to a mammal. In certain embodiments, the gelatinous elastomer composition is formed into a molded article.

Priority: US20080095941P Applic. Date: 2008-09-10; US20090171683P Applic. Date: 2009-04-22

Inventor: MATTELIANO CHARLES J [US]; SCHAFFER STEPHEN P [US]; SUTTON STEPHEN P [US]


Application No.: US20100063011A1  Published: 11/Mar/2010

Title: Organic compounds

Applicant/Assignee: GIVAUDAN SA

Application No.: 12/066518   Filing Date: 08/Sep/2006

Abstract:The invention relates to organic compounds having the ability to reduce or suppress the onset of skin irritation induced by extraneous cause selected from the group of 2-heptylcyclopentanone, 2-ethoxynaphthalene

2-methoxynaphthalene

1-methoxy-4-(prop-1-enyl)benzene

1-(cyclopropylmethyl)-4-methoxybenzene

wherein X, Y, and R1 to R11 have the same meaning as given in the description. Furthermore the invention refers to compositions for topical application to the skin comprising them. It further relates to a method of reducing or suppressing the formation of skin irritation.

Priority: GB20050018558 Applic. Date: 2005-09-12; WO2006CH00481 Applic. Date: 2006-09-08

Inventor: NATSCH ANDREAS [CH]; WASESCHA MICHAEL [CH]


Application No.: US20100063090A1  Published: 11/Mar/2010

Title: Composition for Repelling and Deterring Vermin

Applicant/Assignee: NOVARTIS AG

Application No.: 12/515663   Filing Date: 21/Nov/2007

Abstract:The invention describes essentially a non-therapeutical process for deterring vermin, which is based on the usage of the largely known beta amino-alcohol derivatives of formula (I), as defined herein before. Furthermore, it describes the corresponding vermin-deterring compositions which contain these substances as the active ingredient, compounds of the formula (I) for the preparation of vermin-deterring compositions, and the use of compounds of formula (I) in the defense against vermin. Thus, the invention describes how and in which form the compounds of the formula (I) or their acid addition salts are used to deter vermin from materials, places or warm-blooded animals.

Priority: EP20060124771 Applic. Date: 2006-11-24; WO2007EP62619 Applic. Date: 2007-11-21

Inventor: DUCRAY PIERRE [FR]; CAVALIERO TANIA [CH]; LOHRMANN MAIKE [CH]; BOUVIER JACQUES [CH]


Application No.: US20100063103A1  Published: 11/Mar/2010

Title: Compounds Having CRTH2 Antagonist Activity

Applicant/Assignee: OXAGEN LIMITED

Application No.: 12/625497   Filing Date: 24/Nov/2009

Abstract:Compounds of general formula (I) wherein W is chloro or fluoro

R1 is phenyl optionally substituted with one or more substituents, selected from halo, -CN, -C1-C6 alkyl, -SOR3, -SO2R3, -SO2N(R2)2, -N(R2)2, -NR2C(O)R3, -CO2R2, -CONR2R3, -NO2, -OR2, -SR2, -O(CH2)pOR2, or -O(CH2)pO(CH2)qOR2 wherein each R2 is independently hydrogen, -C1-C6 alkyl, -C3-C8 cycloalkyl, aryl or heteroaryl

each R3 is independently, -C1-C6 alkyl, -C3-C8 cycloalkyl, aryl or heteroaryl

p and q are each independently an integer from 1 to 3

and R4 is hydrogen, C1-C6 alkyl, C1-C6 alkyl substituted with aryl, aryl, (CH2)mOC(-O)C1-C6alkyl, ((CH2)mO)nCH2CH2X, (CH2)mN(R5)2 or CH((CH2)mO(C-O)R6)2

m is 1 or 2

n is 1-4

X is OR5 or N(R5)2

R5 is hydrogen or methyl

and R6 is C1-C18 alkyl

and their pharmaceutically acceptable salts, hydrates, solvates, complexes or prodrugs are useful in orally administrable compositions for the treatment of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis.

Priority: GB20080000874 Applic. Date: 2008-01-18; GB20080020526 Applic. Date: 2008-11-10; US2009-356822 Applic. Date: 2009-01-21

Inventor: ARMER RICHARD EDWARD [GB]; PETTIPHER ERIC ROY [GB]; WHITTAKER MARK [GB]; WYNNE GRAHAM MICHAEL [GB]; VILE JULIA [GB]; SCHROER FRANK [GB]


Application No.: US20100063108A1  Published: 11/Mar/2010

Title: Pyridin-4-yl derivatives as immunomodulating agents

Applicant/Assignee: ACTELION PHARMACEUTICALS LTD

Application No.: 12/310801   Filing Date: 06/Sep/2007

Abstract:The invention relates to pyridine derivatives of Formula (I) wherein A, R1, R2, R3, R4, R5, and R6 are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.

Priority: WO2006IB53147 Applic. Date: 2006-09-07; WO2007IB53594 Applic. Date: 2007-09-06

Inventor: BOLLI MARTIN [CH]; LEHMANN DAVID [CH]; MATHYS BORIS [CH]; MUELLER CLAUS [DE]; NAYLER OLIVER [CH]; STEINER BEAT [CH]; VELKER JORG [FR]


Application No.: US20100063119A1  Published: 11/Mar/2010

Title: SUBSTITUTED CARBINOL COMPOUND

Applicant/Assignee: KOWA COMPANY, LTD

Application No.: 12/516944   Filing Date: 29/Nov/2007

Abstract:There is provided a novel LXR[beta] agonist useful as a preventative and/or therapeutic agent for arteriosclerosis

arteriosclerosis such as those resulting from diabetes

hyperlipidemia

hypercholesterolemia

lipid-related diseases

inflammatory diseases caused by inflammatory cytokines, skin diseases such as allergic skin diseases, diabetes or Alzheimer's disease. The agonist is a carbinol derivative represented by the following general formula (1) or salt thereof, or their solvate.

Priority: JP20060322963 Applic. Date: 2006-11-30; WO2007JP01318 Applic. Date: 2007-11-29

Inventor: MATSUDA TAKAYUKI [JP]; OKUDA AYUMU [JP]; KOURA MINORU [JP]; YAMAGUCHI YUKI [JP]; KUROBUCHI SAYAKA [JP]; WATANABE YUUICHIROU [JP]; SHIBUYA KIMIYUKI [JP]


Application No.: US20100068156A1  Published: 18/Mar/2010

Title: AMPHOLYTIC COPOLYMER BASED ON QUATERNIZED NITROGEN-CONTAINING MONOMERS

Applicant/Assignee: BASF SE

Application No.: 12/441288   Filing Date: 14/Sep/2007

Abstract:The present invention relates to an ampholytic copolymer based on quaternized nitrogen-containing monomers which has a molar excess of cationogenic/cationic groups compared to anionogenic/anionic groups, to cosmetic or pharmaceutical compositions which comprise at least one such ampholytic copolymer, and to further uses of these copolymers.

Priority: EP20070111467 Applic. Date: 2007-06-29; EP20060120778 Applic. Date: 2006-09-15; WO2007EP59725 Applic. Date: 2007-09-14

Inventor: KIM SON NGUYEN [DE]


Application No.: US20100068161A1  Published: 18/Mar/2010

Title: TOPICAL COMPOSITION FOR THE PROTECTION AND/OR TREATMENT OF RADIATION RELATED SKIN DAMAGES

Applicant/Assignee:

Application No.: 12/559954   Filing Date: 15/Sep/2009

Abstract:There is provided a topical composition for the protection and/or treatment of radiation related skin damages comprising from 18.4% to 68% by volume of active principles comprising anti-oxidants, moisturizers, humectants, emollients, anti-inflammatory agents, healing promoting agents and dermal circulation enhancers in from 81.6% to 32% by volume of a pharmaceutically acceptable carrier.

Priority: CA20082639525 Applic. Date: 2008-09-16

Inventor: TODARY MICHAEL FAYEK [CA]


Application No.: US20100068245A1  Published: 18/Mar/2010

Title: PREPARATION AND STORAGE OF STABLE, BIOLOGICALLY ACTIVE MATERIALS

Applicant/Assignee:

Application No.: 12/293080   Filing Date: 15/Mar/2007

Abstract:A method for the preparation of biologically active materials is presented. The invention involves taking a base material such as allografts, xenografts, polymers, metals, and ceramics and combining it with a biologically active agent, such as proteins, cytokines, growth factors, and enzymes after which it is irradiated with ionizing radiation to sterilize and stabilize the material. The resulting biologically active material may then be stored at ambient temperature while maintaining its biological activity and the structural integrity of the base material. The invention is particularly useful for eliciting desired biological responses in human and animal medicine, and in certain industrial applications.

Priority: US20060782420P Applic. Date: 2006-03-15; WO2007US06592 Applic. Date: 2007-03-15

Inventor: MANDERS CHRISTIAN D [US]


Application No.: US20100068250A1  Published: 18/Mar/2010

Title: Abuse Potential Reduction in Abusable Substance Dosage Form

Applicant/Assignee: TRAVANTI PHARMA INC

Application No.: 12/621619   Filing Date: 19/Nov/2009

Abstract:The potential for substance abuse involving residual amounts of abusable substances remaining in used skin-worn patches is reduced by the provision of a system and method for combining the abusable substance with a separate anti-abuse substance agent as part of a removal or disposal procedure.

Priority: US2004-763628 Applic. Date: 2004-01-23

Inventor: ANDERSON CARTER R [US]; MORRIS RUSSELL L [US]


Application No.: US20100068290A1  Published: 18/Mar/2010

Title: COATED PELLETS

Applicant/Assignee: GRUENENTHAL GMBH

Application No.: 12/483646   Filing Date: 12/Jun/2009

Abstract:Coated pellets which comprise an active pharmaceutical ingredient that is poorly soluble in water, release at least 80% of the active ingredient under in vitro conditions in phosphate buffer at pH 5.0 after 30 minutes and are bioequivalent to a liquid formulation of the active ingredient under in vitro fed status test conditions and/or are coated with a composition, which includes a lipophilic component (A) and a hydrogel former (B), wherein the pure lipophilic component (A) has (i) an HLB value of !<=5, and/or (ii) a melting range of >=60 DEG C, and/or (iii) a solidification range [Delta] of less than 35 DEG C., and/or (iv) a density of >=0.80 g cm-3.

Priority: DE200610059510 Applic. Date: 2006-12-14; WO2007EP10862 Applic. Date: 2007-12-12

Inventor: ZIEGLER IRIS [DE]; JACOBS IRWIN [US]


Application No.: US20100068307A1  Published: 18/Mar/2010

Title: DERMATOLOGICAL EMULSION AND METHOD FOR THE PREPARATION THEREOF

Applicant/Assignee: PIERRE FABRE DERMO-COSMETIQUE

Application No.: 12/523263   Filing Date: 25/Jan/2008

Abstract:A foaming gelled composition in the form of a stable oil-in-water microemulsion comprising a fatty phase of microdroplets dispersed in an aqueous phase and a dermatological active ingredient, characterized in that it comprises a surfactant system comprising:-at least one ethoxylated nonionic surfactant

-at least one cosurfactant for stabilizing the ethoxylated nonionic surfactant

-at least one nonethoxylated hydrophilic nonionic surfactant

-at least one foaming agent chosen from the group of anionic surfactants.

Priority: FR20070052901 Applic. Date: 2007-01-26; WO2008EP50879 Applic. Date: 2008-01-25

Inventor: NIELLOUD FRANCOISE [FR]


Application No.: US20100068310A1  Published: 18/Mar/2010

Title: EXTERNAL COMPOSITION FOR SKIN CONTAINING SCROPHULARIA BUERGERIANA MIQ. EXTRACT AND THE USE THEREOF FOR THE SKIN MOISTURIZING COSMETICS

Applicant/Assignee: AMOREPACIFIC CORPORATION

Application No.: 12/528774   Filing Date: 19/Sep/2007

Abstract:Disclosed herein is a skin external composition for alleviating dry skin symptoms, which contains an extract of Scrophularia buergeriana Miq. as a main component and further contains an extract of Poria cocos Wolf, as well as the use thereof for skin-moisturizing cosmetics. The composition contains, as active ingredients, the Scrophularia buergeriana Miq. extract and the Poria cocos Wolf extract, which are prepared by extracting each of Scrophularia buergeriana Miq. and Poria cocos Wolf using water, ethanol, methanol, hexane, ethyl acetate or butanol.

Priority: KR20070020263 Applic. Date: 2007-02-28; WO2007KR04556 Applic. Date: 2007-09-19

Inventor: KIM HAN SUNG [KR]; LEE CHAN WOO [KR]; KIM YOUN JOON [KR]; KIM JEE EUN [KR]; KIM DUCK HEE [KR]; CHANG IH SEOP [KR]


Application No.: US20100069311A1  Published: 18/Mar/2010

Title: MEDICAMENT COMPRISING A REDUCING ALKYL-SUGAR MONOMER FOR THE TREATMENT OF INFLAMMATORY DISORDERS

Applicant/Assignee:

Application No.: 12/559107   Filing Date: 14/Sep/2009

Abstract:The invention relates to a medicament comprising at least one reducing alkyl-sugar monomer having a hydroxyl function which is substituted by an alkoxy radical at C2-C40, said medicament being preferably intended to regulate inflammatory mechanisms. The reducing sugar is preferably selected from the group containing rhamnose, fucose and glucose. The invention also relates to a cosmetic treatment method involving the topical application of a composition comprising at lest one reducing alkyl-sugar monomer having a hydroxyl function which is substituted by an alkoxy radical at C2-C40.

Priority: FR20030012798 Applic. Date: 2003-10-31; US2006-577444 Applic. Date: 2006-04-27; WO2004FR02794 Applic. Date: 2004-10-29

Inventor: HOULMONT JEAN-PHILIPPE [FR]; RICO-LATTES ISABELLE [FR]; PEREZ EMILE [FR]; BORDAT PASCAL [FR]


Application No.: US20100069323A1  Published: 18/Mar/2010

Title: COMPOSITION FOR APPLICATION TO SKIN OR MUCOSA

Applicant/Assignee: ROHTO PHARMACEUTICAL CO., LTD

Application No.: 12/513593   Filing Date: 09/Nov/2007

Abstract:Disclosed is a composition for application to skin or mucosa comprising alginic acid and/or salts thereof, which has reduced cytotoxicity against a skin cell or mucosa cell and higher safety, the composition for application to skin or mucosa comprises an alginic acid and/or salts thereof that contains substantially no low-molecular-weight fraction having a molecular weight of 3,500 or less.

Priority: JP20060305995 Applic. Date: 2006-11-10; WO2007JP71830 Applic. Date: 2007-11-09

Inventor: SETO TADASHI [JP]; MIYANO TAKAYUKI [JP]; HARUNA KENICHI [JP]; KUROSE TAKAHIRO [JP]


Application No.: US20100069336A1  Published: 18/Mar/2010

Title: HIGH PENETRATION PRODRUG COMPOSITIONS OF MUSTARDS AND MUSTARD-RELATED COMPOUNDS

Applicant/Assignee:

Application No.: 12/418564   Filing Date: 03/Apr/2009

Abstract:The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) of mustards and mustard-related compounds, which are capable of crossing biological barriers with high penetration efficiency. The HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treatments for the conditions that the parent drugs or metabolites can. Additionally, the HPPs are capable of reaching areas that parent drugs may not be able to access or to render a sufficient concentration at the target areas and therefore render novel treatments. The HPPs can be administered to a subject through various administration routes, e.g., locally delivered to an action site of a condition with a high concentration or systematically administered to a biological subject and enter the general circulation with a faster rate.

Priority: WO2006IB53619 Applic. Date: 2006-10-03

Inventor: YU CHONGXI [US]; XU LINA [CN]


Application No.: US20100069400A1  Published: 18/Mar/2010

Title: METHODS FOR TREATING INFLAMMATION AND RELATED CONDITIONS

Applicant/Assignee: ORE PHARMACEUTICALS INC

Application No.: 12/500761   Filing Date: 10/Jul/2009

Abstract:A method for treating an inflammatory condition or immune disorder comprises administering to a subject having such a condition or disorder a therapeutically effective amount of at least one compound selected from irindalone, physiologically active enantiomers thereof, and pharmaceutically acceptable salts thereof. The invention further provides a method for elevating levels of anti-inflammatory cytokines such as IL-10 and IL-13 while inhibiting expression of pro-inflammatory cytokines. A pharmaceutical composition, useful for example in topical treatment of psoriasis, comprises a therapeutically effective amount of at least one compound selected from irindalone, physiologically active enantiomers thereof, and pharmaceutically acceptable salts thereof, in a vehicle comprising at least one pharmaceutically acceptable excipient, the vehicle being adapted for topical administration to skin of a subject.

Priority: US20080079808P Applic. Date: 2008-07-10

Inventor: MALSTROM SCOTT [US]; AMUGUNI HELLEN MULOMI [US]; CLISH CLARY [US]; DEIK AMY ANDERSON [US]; WHITE DAVID [US]


Application No.: US20100069495A1  Published: 18/Mar/2010

Title: Topical application of adapalene for the long-term treatment of acne vulgaris

Applicant/Assignee: GALDERMA RESEARCH & DEVELOPMENT

Application No.: 12/591343   Filing Date: 17/Nov/2009

Abstract:Administration of adapalene in a topical medicament to a patient so as to sustain its biological response in the treatment of acne vulgaris, wherein the administration pattern of the topical medicament comprises topically applying onto the afflicted skin area a therapeutically effective amount of adapalene at least once every two days for at least 6 months.

Priority: US2007-878736 Applic. Date: 2007-07-26; WO2006EP01140 Applic. Date: 2006-01-23; US20050647306P Applic. Date: 2005-01-26

Inventor: GRAEBER MICHAEL [US]


Application No.: US20100069505A1  Published: 18/Mar/2010

Title: ALCOHOLIC PUMP FOAM

Applicant/Assignee: STOCKHAUSEN GMBH

Application No.: 12/624073   Filing Date: 23/Nov/2009

Abstract:An alcoholic foam composition, which can be dispensed as a foam via a pump-foam system contains a) at least 52 to !<=99 wt % of an alcohol or mixture of alcohols, b) a surfactant or a surfactant mixture, c) at least one polyalkylene glycol, d) optionally, at least one foam stabilizer, e) optionally, at least one member selected from the group consisting of cosmetic auxiliaries, adjuvants, active ingredients, and mixtures thereof, and f) optionally water. The surface tension of component b) lies in the range of +-15 dyn/cm of the surface tension of component a) or corresponds to the surface tension of component a), and the sum of components a) to f) is 100 wt % relative to the total quantity of the foam composition.

Priority: DE200410062775 Applic. Date: 2004-12-21; US2005-312559 Applic. Date: 2005-12-21

Inventor: VEEGER MARCEL [DE]; HIMMING MARKUS [DE]


Application No.: US20100069511A1  Published: 18/Mar/2010

Title: STABLE MIXED EMULSIONS

Applicant/Assignee: COMBE

Application No.: 12/608391   Filing Date: 29/Oct/2009

Abstract:Stable mixed emulsion systems containing at least two discrete and distinctly different dispersed particle size ranges, i.e., both nanoemulsion and macroemulsion semisolid dispersions, as well as a method of making the same, are disclosed. The stable mixed emulsions may be used for cosmetic and dermatological applications and provide unique benefits.

Priority: US2006-369831 Applic. Date: 2006-03-08; US20050659410P Applic. Date: 2005-03-09

Inventor: SPENGLER ERIC [US]; PETRAIA TERESA [US]


Application No.: US20100069782A1  Published: 18/Mar/2010

Title: Passive Microwave Assessment of Human Body Core to Surface Temperature Gradients and Basal Metabolic Rate

Applicant/Assignee: UNIVERSITY OF TENNESSEE RESEARCH FOUNDATION

Application No.: 12/483537   Filing Date: 12/Jun/2009

Abstract:A passive microwave thermography apparatus uses passive microwave antennas designed for operation, for example, at WARC protected frequencies of 1.400 to 1.427 GHz and 2.690 to 2.70 GHz (for core body gradient temperature measurement) and 10.68 to 10.700 GHz or higher microwave frequency (for surface body gradient temperature measurement) and a related directional antenna or antenna array to measure microwave radiation emanating from an animal, especially, a human body. The antennae may be radially directed toward a point within or on the surface of a human body for comparison with known temperature distribution data for that point and a given ambient temperature. Each frequency band may provide a plurality of adjacent noise measuring channels for measuring microwave noise naturally emitted by the human body. The apparatus measures short-term changes in, for example, core and body surface temperatures to establish a basal metabolic rate. Changes in core body temperature may be stimulated by the administration of food or certain organic and drug-related substances or stress to induce a change in basal metabolic rate over time. These changes correlate directly with a human subject's metabolism rate at rest and under certain dietary constraints and can be used to determine courses of treatment for obesity, metabolic disease, and other disorders. The apparatus can also be used to remotely monitor patients and subjects without physical contact.

Priority: US2007-931399 Applic. Date: 2007-10-31; US2008-336822 Applic. Date: 2008-12-17; US20080061513P Applic. Date: 2008-06-13

Inventor: ICOVE DAVID J [US]; ZEMEL MICHAEL B [US]; LYSTER CARL T [US]; FELD NEIL [US]


Application No.: US20100074856A1  Published: 25/Mar/2010

Title: EXTERNAL PREPARATION COMPOSITION

Applicant/Assignee: LION CORPORATION

Application No.: 12/605294   Filing Date: 23/Oct/2009

Abstract:An external preparation composition used for preventing or treating symptoms or diseases related to dermatopathy caused by dryness, UV rays and aging such as wrinkles and sags of the skin, pigmentation of the skin, skin roughness and coarse texture and skin diseases such as psoriasis, lichen, ichthyosis, keratosis, Darier's disease, pustulosis, acne, eczema and atopic dermatitis. The external preparation composition comprises at least one of acyl glucosamine derivatives represented by the following Formula (I): wherein R1, R2, R3, R4 and R5 are defined

and X is any one of groups represented by the following Formulas (A) to (C): wherein Y, n and R6 are also defined.

Priority: US2008-257853 Applic. Date: 2008-10-24; US2005-522032 Applic. Date: 2005-01-21; WO2002JP07549 Applic. Date: 2002-07-25

Inventor: KAMBAYASHI HIROAKI [JP]; KONTA HIROSHI [JP]


Application No.: US20100074857A1  Published: 25/Mar/2010

Title: COMPOSITIONS AND METHODS TO TREAT EPITHELIAL-RELATED CONDITIONS

Applicant/Assignee:

Application No.: 12/565335   Filing Date: 23/Sep/2009

Abstract:The described invention relates to the formulation and delivery of compositions to treat an epithelial-related condition selected from the group consisting of sparse hair growth, short hair growth, thin hair growth, alopecia and hair depigmentation and methods for their use. In some embodiments, the composition contains a first component and a second component wherein the first component is at least one prostaglandin analog and the second component is at least one imidazole analog, such that the at least one imidazole analog improves the efficacy of the at least one prostaglandin analog when delivered to a subject refractory to the effect of the prostaglandin analog alone.

Priority: US20080099226P Applic. Date: 2008-09-23

Inventor: LIPKIN PAMELA [US]; LUBIT BEVERLY [US]


Application No.: US20100074862A1  Published: 25/Mar/2010

Title: N-SULPHONYLPYRROLES AND THEIR USE AS HISTONE DEACETYLASE INHIBITORS

Applicant/Assignee:

Application No.: 12/628690   Filing Date: 01/Dec/2009

Abstract:Compounds of a certain formula (I), in which R1, R2, R3, R4, R5, R6 and R7 have the meanings indicated in the description, are novel effective HDAC inhibitors.

Priority: EP20050102019 Applic. Date: 2005-03-15; EP20050108735 Applic. Date: 2005-09-21; US2007-885832 Applic. Date: 2007-09-07; WO2006EP60712 Applic. Date: 2006-03-14

Inventor: MAIER THOMAS [DE]; BAER THOMAS [DE]; BECKERS THOMAS [DE]; ZIMMERMANN ASTRID [DE]; SCHNEIDER SIEGFRIED [DE]; GEKELER VOLKER [DE]


Application No.: US20100074877A1  Published: 25/Mar/2010

Title: COMPOSITION FOR IMPROVING SKIN QUALITY AND A PROCESS FOR PREPARING THE SAME

Applicant/Assignee: COMPAGNIE GERVAIS DANONE

Application No.: 12/445205   Filing Date: 12/Oct/2007

Abstract:The present invention relates to a composition including, as active substance, a mixture of at least one polyunsaturated fatty acid, different from polyunsaturated fatty acid derived from milk, polyphenols, milk proteins and lactic bacteria, and the composition having a water content of at least 50% by weight

and wherein the polyunsaturated fatty acid presents an increased bioavailability compared with the one of the polyunsaturated fatty acid alone.

Priority: EP20060291607 Applic. Date: 2006-10-13; WO2007EP60922 Applic. Date: 2007-10-12

Inventor: GUYONNET DENIS [FR]; LASSEL TAOUS [FR]; SAMSON-VILLEGER SANDRINE [FR]; TRGO CHRISTIAN [FR]; RAWLINGS ANTHONY [GB]


Application No.: US20100074900A1  Published: 25/Mar/2010

Title: PROSTAGLANDIN E2 DUAL VARIABLE DOMAIN IMMUNOGLOBULINS AND USES THEREOF

Applicant/Assignee: ABBOTT LABORATORIES

Application No.: 12/499652   Filing Date: 08/Jul/2009

Abstract:The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.

Priority: US20080134284P Applic. Date: 2008-07-08; US20080191711P Applic. Date: 2008-09-11

Inventor: GHAYUR TARIQ [US]; GU JIJE [US]; ISAAKSON PETER C [US]


Application No.: US20100074928A1  Published: 25/Mar/2010

Title: Cosmetic Composition

Applicant/Assignee:

Application No.: 12/496305   Filing Date: 01/Jul/2009

Abstract:Cosmetic composition providing a high coverage of skin while retaining a natural skin appearance comprising iron oxide particles having an average surface area from 30 m2/g to 150 m2/g, iron-containing titanium dioxide particles having an average surface area from 1 m2/g to 30 m2/g and comprising from 1% to 15% iron by weight of the titanium dioxide, and a cosmetically acceptable carrier and its use as a foundation and/or as a composition to correct skin discoloration surrounding the eye.

Priority: EP20080159449 Applic. Date: 2008-07-01

Inventor: ELLIOTT RUSSELL PHILIP [GB]; WATSON JOANNE [GB]


Application No.: US20100074943A1  Published: 25/Mar/2010

Title: MEDICINAL COMPOSITION FOR TRANSDERMAL ABSORPTION, MEDICINAL COMPOSITION STORING UNIT AND TRANSDERMAL ABSORPTION PREPARATION USING THE SAME

Applicant/Assignee: TEIKA PHARMACEUTICAL CO., LTD

Application No.: 12/529191   Filing Date: 29/Feb/2008

Abstract:An object of the invention is to provide a transdermal absorption preparation capable of sustaining the blood morphine concentration at an effective level over at least 48 hours, etc. This transdermal absorption preparation comprises a medicinal composition for transdermal absorption in which an active ingredient selected from morphine and salts thereof is blended in such an amount as corresponding to the saturation solubility or more in an active ingredient-holding vehicle having fluidity at a temperature around the human skin surface temperature and at least a portion of the active ingredient is held in a crystalline form, characterized in that, in the case where a preparation obtained from the above-described medicinal composition for transdermal absorption is applied to the uninjured skin of the back of a white rabbit having been shaven with electrical clippers for 72 hours, the available amount of the active ingredient per single dose of the preparation is from 10 mg to 400 mg in terms of morphine base, and the plasma concentrations of the active ingredient 24 hours and 48 hours after the application of the preparation under the above-described conditions are each at least 40 ng/mL in terms of morphine base, and so on.

Priority: JP20070053102 Applic. Date: 2007-03-02; WO2008JP53597 Applic. Date: 2008-02-29

Inventor: KIMURA TAKAHITO [JP]; ORIHASHI MASAHIRO [JP]; FUJISHITA SHIGETO [JP]; TAKABATAKE KOICHI [JP]; KATO TATSUHISA [JP]; SHIOTA SATOSHI [JP]; SHIMA YUICHIRO [JP]


Application No.: US20100074958A1  Published: 25/Mar/2010

Title: METHODS AND COMPOSITIONS FOR TARGETING FENESTRATED VASCULATURE

Applicant/Assignee: BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION

Application No.: 12/443230   Filing Date: 27/Mar/2009

Abstract:Targeting of a fenestrated vasculature at a body site by micro or nanoparticles can be increased by using particles that have a radius substantially equal to a critical radius of a normal vasculature at the body site. The particles can be used for treating or monitoring a physiological condition responsible for the fenestrated vasculature. A method of improving an ability of micro or nanoparticles to target fenestrated blood vessels in a body site by selecting particles from a population of the micro or nanoparticles, where the selected particles have a radius that permits enhanced delivery into the fenestrated blood vessels.

Priority: WO2006US38196 Applic. Date: 2006-09-28

Inventor: DECUZZI PAOLO [IT]; FERRARI MAURO [US]


Application No.: US20100075891A1  Published: 25/Mar/2010

Title: Novel polynucleotides encoding polypeptides and methods using same

Applicant/Assignee:

Application No.: 11/043770   Filing Date: 27/Jan/2005

Abstract:Novel polypeptides and polynucleotides encoding same are provided. Also provided methods and pharmaceutical compositions which can be used to treat various disorders such as cancer, immunological-related, blood-related and skin-related disorders using the polypeptides and polynucleotides of the present invention. Also provided are methods and kits for diagnosing, determining predisposition and/or prognosis of various disorders using as diagnostic markers the novel polypeptides and polynucleotides of the present invention.

Priority: US20040607246P Applic. Date: 2004-09-07; US20040587851P Applic. Date: 2004-07-15; US20040539127P Applic. Date: 2004-01-27

Inventor: AYALON-SOFFER MICHAL [IL]; LEVINE ZURIT [IL]; SELLA-TAVOR OSNAT [IL]; DIBER ALEX [IL]; SHEMESH RONEN [IL]; TOPORIK AMIR [IL]; ROTMAN GALIT [IL]; NEMZER SERGEY [IL]; ROSENBERG AVI [IL]; DAHARY DVIR [IL]; WOOL ASSAF [IL]; COJOCARU GAD S [IL]; AKIVA PINCHAS [IL]; POLLOCK SARAH [IL]; SAVITSKY KINNERET [IL]; BERNSTEIN JEANNE [IL]


Application No.: US20100075914A1  Published: 25/Mar/2010

Title: METHODS FOR TREATING HERPES VIRUS INFECTIONS

Applicant/Assignee: NANOBIO CORPORATION

Application No.: 12/425984   Filing Date: 17/Apr/2009

Abstract:The present invention relates to methods for treating, killing, and/or inhibiting the growth of Herpes viruses in human subjects comprising topically administering to a human subject in need thereof a nanoemulsion composition having antiviral properties.

Priority: US20080046262P Applic. Date: 2008-04-18

Inventor: FLACK MARY R [US]; CIOTTI SUSAN MARIE [US]; HAMOUDA TAREK [US]; SUTCLIFFE JOYCE A [US]; BAKER JR JAMES R [US]


Application No.: US20100076071A1  Published: 25/Mar/2010

Title: USE OF EQUOL FOR TREATING SKIN DISEASES

Applicant/Assignee:

Application No.: 12/533169   Filing Date: 31/Jul/2009

Abstract:Equol (7-hydroxy-3(4'hydroxyphenyl)-chroman), the major metabolite of the phytoestrogen daidzein, specifically binds and blocks the hormonal action of 5[alpha]-dihydrotestosterone (DHT) in vitro and in vivo. Equol can bind circulating free DHT and sequester it from the androgen receptor, thus altering growth and physiological hormone responses that are regulated by androgens. These data suggest a novel model to explain equol's biological properties. The significance of equol's ability to specifically bind and sequester DHT from the androgen receptor have important ramifications in health and disease and may indicate a broad and important usage for equol in the treatment and prevention of androgen-mediated pathologies of skin and hair. Thus, equol can specifically bind DHT and prevent DHT's biological actions in physiological and pathophysiological processes affecting skin and hair.

Priority: US2005-059951 Applic. Date: 2005-02-17; US2005-533045 Applic. Date: 2005-10-20; WO2003US34441 Applic. Date: 2003-10-29; US2003-625989 Applic. Date: 2003-07-24; US2008-167813 Applic. Date: 2008-07-03; US2003-625934 Applic. Date: 2003-07-24; US20040521457P Applic. Date: 2004-04-28; US20020422469P Applic. Date: 2002-10-29; US20020398270P Applic. Date: 2002-07-24

Inventor: LEPHART EDWIN DOUGLAS [US]; LUND TRENT D [US]; SETCHELL KENNETH DAVID REGINALD [US]; HANDA ROBERT J [US]


Application No.: US20100076094A1  Published: 25/Mar/2010

Title: FORMULATION CONTAINING PHOSPHATE DERIVATIVES OF ELECTRON TRANSFER AGENTS

Applicant/Assignee:

Application No.: 12/628443   Filing Date: 01/Dec/2009

Abstract:There is provided an emulsion composition for therapeutic administration comprising: (a) at least one mono-(electron transfer agent) phosphate derivative

(b) at least one di-electron transfer agent phosphate derivative

wherein the amount of transfer agent phosphate derivatives is no less than equimolar to the amount of di-electron transfer agent phosphate

and (c) a suitable carrier.

Priority: AU2001PR05499 Applic. Date: 2001-06-06; US2003-416775 Applic. Date: 2003-12-23; WO2001AU01475 Applic. Date: 2001-11-14; US20000247997P Applic. Date: 2000-11-14

Inventor: WEST SIMON MICHAEL [AU]


Application No.: US20100080762A1  Published: 01/Apr/2010

Title: SKIN CARE COMPOSITION

Applicant/Assignee:

Application No.: 12/440342   Filing Date: 05/Sep/2007

Abstract:The present invention relates to an oral composition containing an optimal combination of nutritional ingredients at high concentrations and at optimal ratios in order to maintain and/or achieve health and/or beautiful look of the skin.

Priority: EP20060018843 Applic. Date: 2006-09-08; EP20060026413 Applic. Date: 2006-12-20; WO2007EP07719 Applic. Date: 2007-09-05

Inventor: GORALCZYK REGINA [DE]


Application No.: US20100080768A1  Published: 01/Apr/2010

Title: Compositions and Methods for the Treatment of Inflammatory Dermatosis and Other Pathological Conditions of the Skin

Applicant/Assignee:

Application No.: 12/238481   Filing Date: 26/Sep/2008

Abstract:The present invention relates to a composition used as a vehicle for percutaneous absorption of Pharmaceutical and Cosmaceutical active agents that comprises Dimethiconol (hydroxyl-terminated polydimethydimethylsiloxane), dimethicone-350 (polydimethylsiloxane-350), cyclomethicone-5 nf (decamethylcyclopentasiloxane), alkymeth siloxane copolyol-lauryl peg/ppg 18/18 methicone (alkymethyl siloxane copolyol), cyclopentasiloxane and dimethicone Crosspolymer (silicone elastomer and decamethylcyclopentasiloxane), stearoxytrimethylsilane and stearyl alcohol (silicone wax), and deionized water. This composition serves several key applications: (1) it is a vehicle for percutaneous absorption of Pharmaceutical and Cosmaceutical active agents

(2) it acts as a method for utilizing other compositions in the treatment of inflammatory conditions of the skin including, but by no means limited to, atopic dermatitis (eczema), allergic contact dermatitis, seborrheic dermatitits, psoriasis, xerosis and atopia

(3) it is a treatment of inflammatory conditions of mucosae

(4) it relates to other compositions and methods for protecting and enhancing the barrier function of the skin.

Priority:

Inventor: MCGRAW THOMAS L [US]; MCGRAW DONALD M [US]; MCGRAW KELI C [US]; MCGRAW DONALD V [US]


Application No.: US20100080831A1  Published: 01/Apr/2010

Title: Composition Comprising Microcapsules

Applicant/Assignee:

Application No.: 12/569026   Filing Date: 29/Sep/2009

Abstract:A liquid composition having a microcapsule, the microcapsule having an aldehyde-containing resin, and one or more formaldehyde scavenger which reacts with formaldehyde to achieve more than about 60% reaction completeness in about 15 minutes time at pH 8 and at about 21 DEG C. A liquid composition having a microcapsule, the microcapsule having an aldehyde-containing resin, one or more sulfur-based formaldehyde scavenger and optionally a non-sulfur-based formaldehyde scavenger.

Priority: EP20080165469 Applic. Date: 2008-09-30

Inventor: BRAECKMAN KARL GHISLAIN [BE]; DEPOOT KAREL JOZEF MARIA [BE]; VAN PACHTENBEKE TIM ROGER MICHEL [BE]; SMETS JOHAN [BE]


Application No.: US20100080834A1  Published: 01/Apr/2010

Title: Film Material With Antimicrobial And/Or Odor-Absorbing Coating and Sanitary Article

Applicant/Assignee: NUOVA PANSAC S.P.A

Application No.: 12/515191   Filing Date: 26/Jun/2009

Abstract:A film material (1) is disclosed herein, particularly a polyolefin-based film material, coated on one side with a water resoluble resin-containing skin (2), and containing antimicrobial and/or odor-absorbing agents susceptible of being activated by organic liquids and blood liquids, such film material is particularly designed to form a disposable sanitary article (4) comprising a liquid-pervious topsheet (5), a liquid-impervious backsheet (6) and an absorbent layer (7) sandwiched between the topsheet (5) and the backsheet (6).

Priority: IT2006MI02253 Applic. Date: 2006-11-24; WO2007IB03588 Applic. Date: 2007-11-22

Inventor: LORI FABRIZIO [IT]; DELLA ZASSA SANTE AURELIO [IT]


Application No.: US20100080842A1  Published: 01/Apr/2010

Title: TRANSDERMAL EXTENDED-DELIVERY DONEPEZIL COMPOSITIONS AND METHODS FOR USING THE SAME

Applicant/Assignee:

Application No.: 12/551231   Filing Date: 31/Aug/2009

Abstract:A transdermal extended-delivery donepezil active agent composition is provided. Aspects of the compositions of the invention include a donepezil active agent layer that is formulated to provide for multi-day delivery of a therapeutically effective amount of a donepezil active agent to a subject when the composition is topically applied to the subject. Also provided are methods of using the formulations, e.g., for administering a donepezil active agent to a subject, and kits containing the formulations.

Priority: US20080101412P Applic. Date: 2008-09-30

Inventor: WEN JIANYE [US]; KATORI YOSHIKO [US]


Application No.: US20100080845A1  Published: 01/Apr/2010

Title: Cosmetic Methods And Compositions For Repairing Human Skin

Applicant/Assignee:

Application No.: 12/631585   Filing Date: 04/Dec/2009

Abstract:The present invention relates to methods and compositions for repairing adverse effects of the environment, daily stress, sun exposure, or pre-mature aging on human skin, comprising applying to the skin, prior to a period of bodily rest, a topical composition that contains resveratrol or a derivative thereof and at least one DNA repair enzyme.

Priority: US2007-837658 Applic. Date: 2007-08-13

Inventor: MAES DANIEL H [US]; MAMMONE THOMAS [US]; GOLDGRABEN KERRI [US]


Application No.: US20100081637A1  Published: 01/Apr/2010

Title: Eczema treatment with vitamin D and analogs thereof method, composition and cream

Applicant/Assignee: INNOVIA SKINCARE CORP

Application No.: 12/587070   Filing Date: 30/Sep/2009

Abstract:An eczema treatment method comprises application of a therapeutically effective composition in the form of an aqueous topical cream to an affected area of an exterior skin region of a patient, the aqueous topical cream comprising water, a water-soluble organic liquid, a surface active agent, and vitamin D3 compound or another claimed analog thereof, the vitamin D3 compound or the analog constituting at least approximately 10 international units per gram (IU/gram), and, most preferably at least approximately 400 IU/gram. An eczema treatment composition comprises a therapeutically effective formulation comprising at least approximately 50%-90% water, between approximately 1-5% PEG-40 stearate, between approximately 1-5% steareth-2, and cholecalciferal at a concentration of at least approximately 50 international units per gram (IU/g) of composition, and, most preferably at least approximately 400 IU/g. A topical vitamin D cream for therapeutic treatment of eczema includes vitamin D or an analog thereof chosen from the group consisting of cholecalciferol, alfacalcidol, calcifedol, and ergocalciferol

water

a water-soluble organic liquid

and a surface active agent, the vitamin D or analog being in a concentration of at least approximately 50 international units per gram (IU/g) of cream. Remarkably, relief from eczema conditions occurs immediately or in less than 3 days.

Priority: US20080194963P Applic. Date: 2008-10-01

Inventor: STRUBE MARILYN [US]


Application No.: US20100083443A1  Published: 08/Apr/2010

Title: Depilatory Composition

Applicant/Assignee: RECKITT & COLMAN (OVERSEAS) LIMITED

Application No.: 12/530426   Filing Date: 03/Mar/2008

Abstract:A depilatory cream composition comprising, a depilatory active, an emollient selected from at least one of mineral oil, silicone oil and emollient esters, and a silicone wax, a talc and/or polyamide resin.

Priority: GB20070004599 Applic. Date: 2007-03-09; WO2008GB00731 Applic. Date: 2008-03-03

Inventor: TINDAL ANNE [GB]; MANGASSI OUMOU [GB]


Application No.: US20100086502A1  Published: 08/Apr/2010

Title: Cosmetic/sunscreen compositions containing dibenzoylmethane compounds and dithiolane compound photostabilizers therefor

Applicant/Assignee: L'OREAL

Application No.: 12/588197   Filing Date: 07/Oct/2009

Abstract:Cosmetic/sunscreen compositions contain a combination of at least one dibenzoylmethane sunscreen compound and a photostabilizing amount of at least one dithiolane compound of formula (I) below:

Priority: FR20080056810 Applic. Date: 2008-10-08; US20080107075P Applic. Date: 2008-10-21

Inventor: LUCET-LEVANNIER KARINE [FR]; MULLER BENOIT [FR]


Application No.: US20100086575A1  Published: 08/Apr/2010

Title: BENEFIT AGENT CONTAINING DELIVERY PARTICLE

Applicant/Assignee:

Application No.: 12/632127   Filing Date: 07/Dec/2009

Abstract:The present invention relates to benefit agent containing delivery particles, compositions comprising said particles, and processes for making and using the aforementioned particles and compositions. When employed in compositions, for example, cleaning or fabric care compositions, such particles increase the efficiency of benefit agent delivery, there by allowing reduced amounts of benefit agents to be employed. In addition to allowing the amount of benefit agent to be reduced, such particles allow a broad range of benefit agents to be employed.

Priority: US2007-706675 Applic. Date: 2007-02-15; US20060834582P Applic. Date: 2006-08-01; US20060777629P Applic. Date: 2006-02-28

Inventor: DIHORA JITEN ODHAVJI [US]; SANDS PEGGY DOROTHY [US]; FOSSUM RENAE DIANNA [US]; YORK DAVID WILLIAM [GB]; LANG MATTHEW HENRY [US]; GUINEBRETIERE SANDRA JACQUELINE [US]


Application No.: US20100086605A1  Published: 08/Apr/2010

Title: MATERIAL, ITEM AND PRODUCTS COMPRISING A COMPOSITION HAVING ANTI-MICROBIAL PROPERTIES

Applicant/Assignee: NM TECH NANOMATERIALS MICRODEVICE TECHNOLOGY LTD

Application No.: 12/445307   Filing Date: 14/Oct/2009

Abstract:A coating product composition has the general formula AOx-(L-Men+)i, wherein AOx is a metal or metalloid oxide in which x indicates the number of the Oxygen atom(s) (O) bonded to the metal (A) atom, Men+ is a metal ion, L is a bifunctional molecule that could bind both metal oxide or metalloid oxide (AOx) and the metal ion (Men+), i is the number of the (L-Men+) groups bound to the metal oxide AOx. The value of the parameter i depends on various factors, such as the size of the nanoparticle of AOx, and the nature of the molecule L.

Priority: WO2006EP67361 Applic. Date: 2006-10-12

Inventor: BIGNOZZI CARLO ALBERTO [IT]; DISSETTE VALERIA [IT]


Application No.: US20100086606A1  Published: 08/Apr/2010

Title: Active Agent Loaded Uniform, Rigid, Spherical, Nanoporous Calcium Phosphate Particles and Methods of Making and Using the Same

Applicant/Assignee:

Application No.: 12/565687   Filing Date: 23/Sep/2009

Abstract:Uniform, rigid, spherical nanoporous calcium phosphate particles that define an internal space and an amount of active agent present in the internal space are provided. Also provided are topical delivery compositions that include the active agent loaded particles, as well as methods of making the particles and topical compositions. The particles and compositions thereof find use in a variety of different applications, including active agent delivery applications.

Priority: US20080099500P Applic. Date: 2008-09-23

Inventor: OGAWA TETSURO [US]


Application No.: US20100086626A1  Published: 08/Apr/2010

Title: CAPSAICINOID DECONTAMINATION COMPOSITIONS AND METHODS OF USE

Applicant/Assignee: KAPSO, LLC

Application No.: 12/634418   Filing Date: 09/Dec/2009

Abstract:A therapeutic composition for inhibiting physiological responses elicited by exposure of skin to an irritant can be used to treat exposure to capsaicinoids or other chemical irritants. The therapeutic composition can include a carrier being present in an effective amount and form sufficient to be applied to skin and deliver active agents to the skin which has been previously exposed to a capsaicinoid. Also, the therapeutic composition can include a cooling agent in an effective amount within the carrier to provide a cooling sensation to the skin. Further, the therapeutic composition can include a capsaicin receptor antagonist in an effective amount within the carrier to inhibit calcium flux associated with activation of the capsaicin receptor by a capsaicinoid. The therapeutic composition can be part of a kit that also includes a cleansing composition, which is capable of cleaning and/or absorbing capsaicinoids from the skin.

Priority: US2006-366327 Applic. Date: 2006-03-02; US20050658822P Applic. Date: 2005-03-04

Inventor: REILLY CHRISTOPHER A [US]


Application No.: US20100087417A1  Published: 08/Apr/2010

Title: AMINO-PYRIDINE DERIVATIVES AS S1P1 /EDG1 RECEPTOR AGONISTS

Applicant/Assignee:

Application No.: 12/531374   Filing Date: 29/Feb/2008

Abstract:The invention relates to novel amino-pyridine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.

Priority: WO2007IB50921 Applic. Date: 2007-03-16; WO2008IB50742 Applic. Date: 2008-02-29

Inventor: BOLLI MARTIN [CH]; MATHYS BORIS [CH]; MUELLER CLAUS [DE]; NAYLER OLIVER [CH]; STEINER BEAT [CH]; VELKER JORG [FR]


Application No.: US20100087495A1  Published: 08/Apr/2010

Title: PHENYL DERIVATIVES AND THEIR USE AS IMMUNOMODULATORS

Applicant/Assignee: ACTELION PHARMACEUTICALS LTD

Application No.: 12/442203   Filing Date: 10/Jul/2007

Abstract:The invention relates to phenyl derivatives of formula (I), their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.

Priority: WO2006IB53426 Applic. Date: 2006-09-21; WO2007IB52746 Applic. Date: 2007-07-10

Inventor: BOLLI MARTIN [CH]; LEHMANN DAVID [CH]; MATHYS BORIS [CH]; MUELLER CLAUS [DE]; NAYLER OLIVER [CH]; STEINER BEAT [CH]; VELKER JORG [FR]


Application No.: US20100087498A1  Published: 08/Apr/2010

Title: USE OF BIOTIN TO PREVENT PHOTOAGING

Applicant/Assignee:

Application No.: 12/597959   Filing Date: 07/May/2008

Abstract:Use of biotin, preferably in a combination of biotin and (-)-epigallocatechin gallate (EGCG) in a specific ratio, to prevent sunlight-induced aging (photoaging) of the skin.

Priority: EP20070009371 Applic. Date: 2007-05-10; WO2008EP03648 Applic. Date: 2008-05-07

Inventor: GORALCZYK REGINA [DE]; SCHWAGER JOSEPH [CH]


Application No.: US20100087790A1  Published: 08/Apr/2010

Title: Direct delivery applicator assembly and method of use

Applicant/Assignee:

Application No.: 12/286811   Filing Date: 02/Oct/2008

Abstract:An applicator directly delivers one or more active ingredients, such as flea, tick, or insect repellant to an animal's skin. The applicator comprises an applicator base connected to an applicator head having at least on prong member constructed with an internal channel therein in communication with a delivery aperture. A separately presented cartridge having a solution tube is appointed to be removably received within the applicator's base which, in turn is uniquely sized and shaped to receive a preselected one of those cartridges currently sold under recognized medicament brands. As the cartridge is squeezed, the solution traverses from the cartridge and applicator base into the applicator head and through the internal channels of the prong members, exiting through the delivery apertures onto the animal. Improved delivery owing to the prong members with channels therein terminating at fine delivery apertures is provided to yield direct delivery of the solution onto the animal's skin local to the fur shafts for a clean application and accurate dispersion of solution onto the animal.

Priority:

Inventor: HURWITZ MARNI MARKELL [US]


Application No.: US20100092404A1  Published: 15/Apr/2010

Title: HYDROGENATION OF CARYOPHELLENE

Applicant/Assignee: E.I. DU PONT DE NEMOURS AND COMAPNY

Application No.: 12/519614   Filing Date: 20/Dec/2007

Abstract:A process for the hydrogenation of a mixture of caryophyllenes by contact with hydrogen in the presence of a supported catalyst. The resulting products are useful for the application to skin.

Priority: US20060876555P Applic. Date: 2006-12-21; WO2007US25983 Applic. Date: 2007-12-20

Inventor: HUTCHENSON KEITH W [US]; JACKSON SCOTT CHRISTOPHER [US]; MANZER LEO ERNEST [US]; SCIALDONE MARK A [US]; SEAPAN MAYIS [US]


Application No.: US20100092408A1  Published: 15/Apr/2010

Title: RESILIENT PERSONAL CARE COMPOSITION COMPRISING POLYALKYL ETHER CONTAINING SILOXANE ELASTOMERS

Applicant/Assignee:

Application No.: 12/251154   Filing Date: 14/Oct/2008

Abstract:A stable personal care composition in the form of a water-in-oil emulsion may comprise a silicone elastomer comprising a polyalkyl ether pendant or a polyalkyl ether crosslink, wherein the alkyl group contains three or more carbon atoms

a non-emulsifying silicone elastomer

an emulsifier

a polar oil

and water. The personal care composition allows for previously unattainable levels of polar oils and/or aqueous phase within a water-in-oil emulsion.

Priority:

Inventor: BREYFOGLE LAURIE ELLEN [US]; TANNER PAUL ROBERT [US]; AISTRUP ELIZABETH REBECCA [US]


Application No.: US20100092454A1  Published: 15/Apr/2010

Title: NOVEL USE OF ANTIDEPRESSANT COMPOUNDS AND RELATED COMPOSITIONS

Applicant/Assignee:

Application No.: 12/520503   Filing Date: 20/Dec/2007

Abstract:What is described is a use of an antidepressant compound, preferably belonging to the class of selective serotonin reuptake inhibitors (SSRI), for regenerating the integumentary system and/or for stimulating the growth, the original trophism and/or original pigmentation of the corresponding cutaneous appendages, particularly body hair and/or head hair, in mammals. For this purpose, the antidepressant can be formulated in a cosmetic preparation, a pharmaceutical composition, a medical device, or in the form of a culture medium, alone or in combination with a further active ingredient such as a proteolytic enzyme and/or a vitamin.

Priority: IT2006TO00918 Applic. Date: 2006-12-22; IT2006TO00920 Applic. Date: 2006-12-22; IT2007TO00603 Applic. Date: 2007-08-20; WO2007IT00891 Applic. Date: 2007-12-20

Inventor: DE VIVO ENRICO [IT]; PONZETTO ANTONIO [IT]; CESANO CHIARA [IT]; GENNERO LUISA [IT]; MERIZZI GIANFRANCO [IT]; MORRA EMANUELLA [IT]


Application No.: US20100092457A1  Published: 15/Apr/2010

Title: Diagnosis and Treatment of Cancer Using Anti-Desmoglein-3 Antibodies

Applicant/Assignee: FORERUNNER PHARMA RESEARCH CO., LTD THE UNIVERSITY OF TOKYO

Application No.: 12/308695   Filing Date: 14/Aug/2007

Abstract:Methods that involve detection of a DSG3 protein for diagnosing cancer are disclosed. In lung cancer, the expression of DSG3 was found to be enhanced at very high frequency at the gene level and protein level. Methods of the present invention can be carried out using an antibody that recognizes a DSG3 protein. Pharmaceutical compositions, cell growth inhibitors, and anticancer agents containing a DSG3-binding antibody as an active ingredient are also disclosed. Methods of inducing cell damage in DSG3-expressing cells and methods of suppressing proliferation of DSG3-expressing cells by contacting the DSG3-expressing cells with DSG3-binding antibodies are also disclosed.

Priority: JP20060221230 Applic. Date: 2006-08-14; JP20070019108 Applic. Date: 2007-01-30; WO2007JP65834 Applic. Date: 2007-08-14

Inventor: ABURATANI HIROYUKI [JP]; ISHIKAWA SHUNPEI [JP]; ITO HIROTAKA [JP]; NAKANO KIYOTAKA [JP]; KAWAI SHIGETO [JP]


Application No.: US20100092475A1  Published: 15/Apr/2010

Title: TREATMENT METHOD USING EGFR ANTIBODIES AND SRC INHIBITORS AND RELATED FORMULATIONS

Applicant/Assignee:

Application No.: 12/450196   Filing Date: 14/Mar/2008

Abstract:The present invention relates to the treatment of EGFR-mediated disease, particularly cancer by inhibiting or blocking EGFR and src in combination or simultaneously. The invention relates to treatment, prevention, or modulation of cancer, particularly EGFR-mediated disease, with one or more EGFR modulator and src inhibitor in combination. The invention further relates to the treatment of cancer with anti-EGFR antibodies and src inhibitors. Methods and compositions for treatment of cancer with the antibody anti-EGFR mAb806 in combination or series with a src inhibitor or src inhibitors are described.

Priority: US20070918084P Applic. Date: 2007-03-15; WO2008US03369 Applic. Date: 2008-03-14

Inventor: JOHNS TERRANCE GRANT [AU]; CAVENEE WEBSTER [US]; FURNARI FRANK [US]; SCOTT ANDREW [AU]


Application No.: US20100092577A1  Published: 15/Apr/2010

Title: TOPICAL COMPOSITIONS CONTAINING MAGALDRATE

Applicant/Assignee:

Application No.: 12/593299   Filing Date: 28/Mar/2008

Abstract:Disclosed are topical compositions containing the active ingredient magaldrate mixed with suitable vehicles and excipients.

Priority: IT2007MI00644 Applic. Date: 2007-03-29; WO2008IB02047 Applic. Date: 2008-03-28

Inventor: GUASTI PIER LUIGI [SM]


Application No.: US20100093582A1  Published: 15/Apr/2010

Title: METHOD FOR USING HYDROPHOBICALLY MODIFIED POLYMERS IN CONSUMER AND INDUSTRIAL APPLICATIONS

Applicant/Assignee:

Application No.: 12/575966   Filing Date: 08/Oct/2009

Abstract:This invention pertains to method of using a composition comprising one or more hydrophobically modified polyacrylamides, wherein the polyacrylamides contain acrylamide, one or more anionic monomers, and excludes a cationic monomer, and the method of combination with other compositions for use in combination for consumer and/or industrial applications.

Priority: US2007-853084 Applic. Date: 2007-09-11

Inventor: HESSEFORT YIN Z [US]; MAREK PATRICK J [US]; CRAMM JEFFREY R [US]; PATEL DAMYANTI J [US]; CARLSON WAYNE M [US]


Application No.: US20100093653A1  Published: 15/Apr/2010

Title: Use of 1,6-Bis [3-(3-carboxymethylphenyl)-4-(2-alpha-D-mannopyranosyl-oxy)-phenyl] hexane for the preparation of cosmetic compositions

Applicant/Assignee: REVOTAR BIOPHARMACEUTICALS AG

Application No.: 12/440316   Filing Date: 07/Sep/2007

Abstract:A compound of formula (I) or a polymorphic form thereof can be used for the preparation of a cosmetic or dermato logical composition for the treatment of skin ageing.

Priority: EP20060120400 Applic. Date: 2006-09-08; WO2007EP59382 Applic. Date: 2007-09-07

Inventor: AYDT EWALD M [DE]; BOCK DANIEL [DE]; VOLLHARDT KARIN [DE]; WOLFF GERHARD [DE]


Application No.: US20100093679A1  Published: 15/Apr/2010

Title: DROSPIRENONE FOR HORMONE REPLACEMENT THERAPY

Applicant/Assignee:

Application No.: 12/640578   Filing Date: 17/Dec/2009

Abstract:A pharmaceutical composition comprising as a first active ingredient an estrogen, such as estradiol or estradiol valerate, in sufficient amounts to treat disorders and symptoms associated with deficient endogenous levels of estrogen in women, and as a second active ingredient 6[beta],7[beta]

15[beta]

16[beta]-dimethylene-3-oxo-17[alpha]-preg-4-ene-21,17-carbolactone (drospirenone, DRSP) in sufficient amounts to protect the endometrium from the adverse effects of estrogen is useful for, amongst others, treating peri-menopausal, menopausal and post-menopausal women. This composition may be used for hormone replacement therapy and may be administered as a multi-phased pharmaceutical preparation. This combination therapy may comprise continuous, sequential or interrupted administration, or combinations thereof, of DRSP and estrogen, each optionally in micronized form.

Priority: US2001-757688 Applic. Date: 2001-01-11

Inventor: HEIL WOLFGANG [DE]; HILMANN JUERGEN [DE]; LIPP RALPH [DE]; SCHUERMANN ROLF [DE]


Application No.: US20100093823A1  Published: 15/Apr/2010

Title: STEROIDAL COMPOUNDS AS MELANOGENESIS MODIFIERS AND USES THEREOF

Applicant/Assignee:

Application No.: 12/433322   Filing Date: 30/Apr/2009

Abstract:A method for the identification of compounds) that control melanin synthesis (melanogenesis), and the preparation and use of such compounds, and compositions and formulations thereof to modify (e.g., inhibit) melanin production are disclosed. A representative compound of the invention is defined by formula I: The compounds may be prepared as pharmaceutical and cosmetic compositions, and in one embodiment, may be prepared in combination with each other, and with other melanogenesis inhibiting formulations. The compounds, compositions and formulations of the invention may be used for the prevention and treatment of conditions that are causally related to aberrant melanogenesis activity including, by way of non-limiting example, hyperpigmentation and others.

Priority: US20080049114P Applic. Date: 2008-04-30

Inventor: ORLOW SETH J [US]; KOMATSU LI NI [US]


Application No.: US20100093827A1  Published: 15/Apr/2010

Title: METHOD FOR TOPICAL TREATMENT OF TAR-RESPONSIVE DERMATOLOGICAL DISORDERS

Applicant/Assignee: TRISTRATA, INC

Application No.: 12/638505   Filing Date: 15/Dec/2009

Abstract:A method of treating a tar-responsive dermatological disorder includes topically applying an anhydrous tar composition to skin of a mammal, preferably a human, that is involved with the disorder, the composition including a wax and a therapeutically effective amount of tar for topical treatment of the tar-responsive dermatological disorder, the composition being in liquid form when at a temperature selected from room temperature and a temperature of skin of a mammal upon application of the composition to the skin of the mammal.

Priority: US2007-680227 Applic. Date: 2007-02-28; US20060778128P Applic. Date: 2006-03-01

Inventor: YU RUEY J [US]; VAN SCOTT EUGENE J [US]; LEE YALING [US]


Application No.: US20100098644A1  Published: 22/Apr/2010

Title: SOLUBILIZING SYSTEMS FOR FLAVORS AND FRAGRANCES

Applicant/Assignee: FIRMENICH SA

Application No.: 12/643269   Filing Date: 21/Dec/2009

Abstract:The present invention provides compositions and clear oil-in-water microemulsion containing up to 80% w/w of an oil, a surfactant system, a w/w oil/surfactant system ratio between 1 and 3, and a solubilizing-aid ingredient which is not a surfactant neither a VOC compound, the latter being present in an amount sufficient to ensure that the ratio oil/(surfactant+solubilizing aid) is comprised between 0.1 and 5. The present invention concerns also the articles and products associated the compositions and microemulsions, and the methods to manufacture them.

Priority: EP20040105185 Applic. Date: 2004-10-20; US2007-689635 Applic. Date: 2007-03-22; WO2005IB03329 Applic. Date: 2005-10-19; US2005-245704 Applic. Date: 2005-10-06; WO2004IB01473 Applic. Date: 2004-04-19; US2003-421216 Applic. Date: 2003-04-21; US20040620557P Applic. Date: 2004-10-20

Inventor: VLAD FLORIN JOSEPH [US]; MOUNIER REMY [FR]; WONG KENNETH [CH]; DAUGERON AUDE [FR]; HERD THOMAS [US]


Application No.: US20100098648A1  Published: 22/Apr/2010

Title: COMPOSITIONS CONTAINING AT LEAST ONE OIL STRUCTURED WITH AT LEAST ONE SILICONE-POLYAMIDE POLYMER, AND AT LEAST ONE CRYSTALLINE SILICONE COMPOUND AND METHODS OF USING THE SAME

Applicant/Assignee: L'OREAL

Application No.: 12/648020   Filing Date: 28/Dec/2009

Abstract:The invention relates to a physiologically acceptable composition, in particular a cosmetic composition, containing at least one liquid fatty phase structured with at least one structuring polymer of the silicone-polyamide type, the polymer being solid at room temperature and soluble in the liquid fatty phase at a temperature of from 25 to 250 DEG C., and at least one crystalline silicone compound, said oil having an affinity with said structuring polymer and/or with said crystalline silicone compound, and the liquid fatty phase, the polymer and the crystalline silicone compound forming a physiologically acceptable medium. This composition may be in the form of a stick of lipstick which is stable, which does not exude and whose application produces a glossy deposit with good staying power over time.

Priority: US2002-320601 Applic. Date: 2002-12-17

Inventor: YU WEI [US]


Application No.: US20100098679A1  Published: 22/Apr/2010

Title: PROMOTION OF PEROXISOMAL CATALASE FUNCTION IN CELLS

Applicant/Assignee: WAYNE STATE UNIVERSITY

Application No.: 12/568960   Filing Date: 29/Sep/2009

Abstract:The molecular mechanisms of peroxisome biogenesis have begun to emerge

in contrast, relatively little is known about how the organelle functions as cells age. The present inventors characterized age-related changes in peroxisomes of human cells and showed that aging compromises peroxisomal targeting signal 1 (PTS1) protein import, with the critical antioxidant enzyme, catalase, especially affected. The number and appearance of peroxisomes are altered in these cells, and the organelles accumulate the PTS1-import receptor, Pex5p, on their membranes. Concomitantly, cells produce increasing amounts of the toxic metabolite, H2O2, and this increased load of reactive oxygen species (ROS) may further reduce peroxisomal protein import and exacerbate the effects of aging. Disclosed are novel compositions and methods for restoring catalase in peroxisomes by use of targeted catalase modified at its C-terminus and/or N-terminus, optionally in combination with polypeptides which promote cellular uptake of proteins, to prevent or overcome the changes that follows aging or that are associated with a number of diseases or disorders.

Priority: US2005-533124 Applic. Date: 2005-12-27; WO2003US34512 Applic. Date: 2003-10-30; US20020422100P Applic. Date: 2002-10-30

Inventor: TERLECKY STANLEY R [US]; WALTON PAUL A [CA]


Application No.: US20100098732A1  Published: 22/Apr/2010

Title: METHODS, PROCESSES AND COMPOSITIONS COMPRISING THE PROTEIN CALMODULIN (CAM) FOR TREATMENT OF DAMAGED OR AGING SKIN, AND/OR HAIR LOSS

Applicant/Assignee:

Application No.: 12/449916   Filing Date: 21/Mar/2007

Abstract:The invention relates to compositions comprising the calcium binding protein, calmodulin (CaM), and the use of this protein additive in compositions suitable for topical application for the maintenance and development of healthy skin

for improving the aesthetic appearance of skin

for treating fine lines, and/or wrinkles, and/or age spots, and/or minor wounds and burns, and/or calloused skin-through its facilitation of natural healing processes initiated by disease, injury or aging

for enhancing hair growth

and as a cosmetic treatment process comprising application to the skin the compositions, preferably on a daily basis. The compositions may comprise, but not be limited to, UV blocking agents and/or penetration enhancers and/or one or more bio-active agents. CaM can be formulated into therapeutic compositions as lotions, creams, ointments, sprays, gels, skin coverings and wound dressings.

Priority: WO2007IB02725 Applic. Date: 2007-03-21

Inventor: TIPPENS DORR FELT [US]


Application No.: US20100098751A1  Published: 22/Apr/2010

Title: Novel Use Of An Extract Of Common Mallow As An Hydrating Agent, And Cosmetic Composition Containing It

Applicant/Assignee: LVMH RECHERCHE

Application No.: 12/500824   Filing Date: 10/Jul/2009

Abstract:The present invention relates to a novel use of an extract of common mallow for restoring, maintaining or reinforcing the state of moisturization of the skin

to a cosmetic composition containing it, and also to cosmetic care methods using said composition.

Priority: FR20080054780 Applic. Date: 2008-07-11

Inventor: DUMAS MARC [FR]; NOBLESSE EMMANUELLE [FR]; KRZYCH VALERIE [FR]; CAUCHARD JEAN HUBERT [FR]


Application No.: US20100098765A1  Published: 22/Apr/2010

Title: Powder Makeup Compositions And Methods

Applicant/Assignee:

Application No.: 12/255975   Filing Date: 22/Oct/2008

Abstract:An anhydrous powder composition wherein the ratio of platelet to non-platelet particulates is greater than about 5 to 1 respectively, which is preferably talc-free, oil-free, paraben-free, and fragrance-free

and a method for preparing the powder composition of the invention.

Priority:

Inventor: MERCADO CLARA G [US]; LOGALBO JOHN F [US]; DAO KHANH NGOC [US]


Application No.: US20100099087A1  Published: 22/Apr/2010

Title: GENE SEQUENCE VARIANCES IN GENES RELATED TO FOLATE METABOLISM HAVING UTILITY IN DETERMINING THE TREATMENT OF DISEASE

Applicant/Assignee:

Application No.: 12/390369   Filing Date: 20/Feb/2009

Abstract:The present disclosure describes the use of genetic variance information for folate transport or metabolism genes or pyrimidine transport or metabolism genes in the selection of effective methods of treatment of a disease or condition. The variance information is indicative of the expected response of a patient to a method of treatment. Methods of determining relevant variance information and additional methods of using such variance information are also described.

Priority: US2005-100921 Applic. Date: 2005-04-07; US2000-638267 Applic. Date: 2000-08-14; US2000-596033 Applic. Date: 2000-06-15; US1999-357743 Applic. Date: 1999-07-20; US1999-357024 Applic. Date: 1999-07-19; US19980093484P Applic. Date: 1998-07-20

Inventor: STANTON JR VINCENT P [US]


Application No.: US20100099632A1  Published: 22/Apr/2010

Title: Oligosaccharide Aldonic Acids and Their Topical Use

Applicant/Assignee:

Application No.: 12/643215   Filing Date: 21/Dec/2009

Abstract:Methods for using compositions comprising oligosaccharide aldonic acids for general care, as well as for treatment and prevention, of various cosmetic conditions and dermatological disorders, including those associated with intrinsic and/or extrinsic aging, as well as with changes or damage caused by extrinsic factors

general care, as well as treatment and prevention of diseases and conditions, of the oral, and vaginal mucosa

for general oral care, as well as treatment and prevention of oral and gum diseases

and for wound healing of the skin. Methods may comprise using compositions comprising oligosaccharide aldonic acids and additional cosmetic, pharmaceutical or other topical agents to enhance or create synergetic effects.

Priority: US2007-872459 Applic. Date: 2007-10-15; US2004-811998 Applic. Date: 2004-03-30; US2001-987023 Applic. Date: 2001-11-13; US2000-487228 Applic. Date: 2000-01-19; US19990141264P Applic. Date: 1999-06-30

Inventor: YU RUEY J [US]; VAN SCOTT EUGENE J [US]


Application No.: US20100099651A1  Published: 22/Apr/2010

Title: PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: 12/446794   Filing Date: 23/Oct/2007

Abstract:The present invention relates to novel pharmaceutical compositions comprising at least one EGFR kinase inhibitor and at least one additional active compound selected from beta-2 mimetics, steroids, PDE-IV inhibitors, p38 MAP kinase inhibitors, NK1 antagonists, anticholinergics and endothelin antagonists, processes for preparing the compositions and the use thereof as medicament in the treatment of respiratory or gastrointestinal complaints, as well as inflammatory diseases of the joints, the skin or the eyes.

Priority: US20060862990P Applic. Date: 2006-10-26; WO2007EP61355 Applic. Date: 2007-10-23

Inventor: JUNG BIRGIT [DE]; HIMMELSBACH FRANK [DE]; POHL GERALD [DE]


Application No.: US20100099688A1  Published: 22/Apr/2010

Title: NOVEL PHOSPHODIESTERASE INHIBITORS

Applicant/Assignee: LEO PHARMA A/S

Application No.: 12/528649   Filing Date: 26/Feb/2008

Abstract:The present invention relates to a compound according to formula I, wherein X, A, G, E, R1, R2, R3 are as shown herein

and pharmaceutically acceptable salts, hydrates, N-oxides or solvates hereof. The invention further relates to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, e.g. dermal diseases, with said compounds, and to the use of said compounds in the manufacture of medicaments.

Priority: US20070903849P Applic. Date: 2007-02-28; US20070946849P Applic. Date: 2007-06-28; WO2008DK00080 Applic. Date: 2008-02-26

Inventor: FELDING JAKOB [DK]; NIELSEN SIMON FELDBAEK [DK]; LARSEN JENS CHRISTIAN HOEJLAND [DK]; BABU BOLLU RAVINDRA [IN]


Application No.: US20100099698A1  Published: 22/Apr/2010

Title: Compositions for Improving Skin Conditions Comprising Matrine or Its Oxidized Derivatives

Applicant/Assignee: BIOSPECTRUM INC

Application No.: 12/527237   Filing Date: 21/Feb/2008

Abstract:The present invention relates to a composition for improving skin conditions comprising matrine and oxymatrine as an active ingredient. Matrine and oxymatrine have lower cytotoxicity than retinol used as anti-wrinkle agents and exhibit the inhibition effect on collagenase activity and promotion effect on collagen biosynthesis at a molecular level, contributing to excellent efficacy in improvement of skin wrinkles. In addition, both matrine and oxymatrine exhibit the inhibition effect on melanin production by inhibiting intracellular tyrosinase activity, the improving effects of UV-induced skin damage and the skin growth promotion or hair loss prevention. Therefore, matrine and oxymatrine have the excellent improvement effects on skin conditions. Furthermore, matrine and oxymatrine have the excellent anti-obesity and anti-oxidation effects. The composition of this invention can be applied to cosmetic, pharmaceutical and food composition having no cytotoxicities and side effects.

Priority: KR20070017400 Applic. Date: 2007-02-21; WO2008KR01021 Applic. Date: 2008-02-21

Inventor: PARK DEOK HOON [KR]; JUNG EUN SUN [KR]; LEE JONG SUNG [KR]


Application No.: US20100100030A1  Published: 22/Apr/2010

Title: Microbe Reductions with Photosensitizers

Applicant/Assignee: CERAMOPTEC INDUSTRIES INC

Application No.: 12/643467   Filing Date: 21/Dec/2009

Abstract:Methods, devices and composition are disclosed for treating oral, skin and nail diseases, including inflammatory periodontal disease, onychomycosis and dermatophytosis. In a preferred embodiment a method for treating oral, skin and nail infections comprises administering a photosensitizing compound in long term effect or timed release formulations, including local highly concentrated formulations, and activating the photosensitizer with radiation to selectively destroy bacteria, fungi and other microbial bodies. In another preferred embodiment, photosensitizers are housed within nanoparticles, and can be gradually released through biodegradation or periodically released by such processes as brushing, irradiation and chemically induced release. The diffusion speed of the photosensitizers can be accelerated by brushing. In another embodiment, the photosensitizer molecule is also modified to more effectively target the molecule to the unwanted oral bacterial and fungal species. In another embodiment devices for treating oral, skin and nail infections includes a laser radiation source and delivery apparatuses such as brush or teethed comb for nail and scalp infections respectively.

Priority: US2006-523203 Applic. Date: 2006-09-19; US2002-241958 Applic. Date: 2002-09-12

Inventor: DRISCOLL TIM [US]; MEGA VERONICA INES [AR]; NEUBERGER WOLFGANG [AE]


Application No.: US20100104515A1  Published: 29/Apr/2010

Title: USE OF ALPHA-HYDROXY CARBONYL COMPOUNDS AS REDUCING AGENTS

Applicant/Assignee:

Application No.: 12/159363   Filing Date: 29/Dec/2006

Abstract:There is provided the use as reducing agents of alpha-hydroxycarbonyl compounds capable of forming cyclic dimers. There is also provided corresponding methods of reducing reducible compounds, particularly reduction-activated prodrugs. Examples of the alpha-hydroxycarbonyl compounds used are dihydroxyacetone, glycolaldehyde, glyceraldehyde, erythrose, xylulose, erythrulose or 3-hydroxy-2-butanone.

Priority: GB20050026552 Applic. Date: 2005-12-29; WO2006GB04947 Applic. Date: 2006-12-29

Inventor: KNOX RICHARD J [GB]


Application No.: US20100104521A1  Published: 29/Apr/2010

Title: COSMETIC AND/OR PHARMACEUTICAL COMPOSITION COMPRISING AS AN ACTIVE PRINCIPLE AT LEAST ONE PEPTIDE AND USE OF THIS PEPTIDE

Applicant/Assignee: SOCIETE D'EXTRACTION DES PRINCIPES ACTIFS SA (VINCIENCE)

Application No.: 12/446958   Filing Date: 26/Oct/2007

Abstract:A cosmetic and/or pharmaceutical composition contains, as an active ingredient, at least one peptide from SEQ ID No1 to SEQ ID No8. The use of this peptide as an active ingredient for preparing compositions for inducing, increasing or restoring melanin synthesis in melanocytes of the skin or dermal papilla is also disclosed.

Priority: FR20060009416 Applic. Date: 2006-10-26; WO2007FR01777 Applic. Date: 2007-10-26

Inventor: DAL FARRA CLAUDE [FR]; DOMLOGE NOUHA [FR]; BOTTO JEAN-MARIE [FR]


Application No.: US20100104523A1  Published: 29/Apr/2010

Title: STABILIZATION OF UV-SENSITIVE ACTIVE INGREDIENTS

Applicant/Assignee: CIBA CORPORATION

Application No.: 12/520880   Filing Date: 16/Jan/2008

Abstract:Disclosed is the use of merocyanine derivatives of formula (1) for stabilizing UV-sensitive active ingredients like dibenzoylmethane derivatives.

Priority: EP20070101171 Applic. Date: 2007-01-25; WO2008EP50440 Applic. Date: 2008-01-16

Inventor: WAGNER BARBARA [DE]; HERZOG BERND [DE]; MULLER STEFAN [DE]; EHLIS THOMAS [DE]


Application No.: US20100104524A1  Published: 29/Apr/2010

Title: COSMETIC COMPOSITION FOR SKIN WHITENING COMPRISING ARCTIIN, ARCTIGENIN OR THE MIXTURE THEREOF AS ACTIVE

Applicant/Assignee:

Application No.: 12/449727   Filing Date: 25/Feb/2008

Abstract:Present Invention relates to a skin whitening cosmetic composition comprising arctiin, arctigenin or a mixture thereof as an active ingredient. The disclosed composition can control or inhibit the synthesis of melanin by acting on a melanin synthesis route of [alpha]-MSH secreted by UV, and thus show an excellent whitening effect compared to a conventional skin whitening cosmetic. Also, the composition has high formulation stability and low skin irritation.

Priority: KR20070020603 Applic. Date: 2007-02-28; WO2008KR01077 Applic. Date: 2008-02-25

Inventor: LEE JUNG NOH [KR]; CHOI JEONG EUN [KR]; KIM SANG WOO [KR]; LEE KANG TAE [KR]; LEE KUN KOOK [KR]


Application No.: US20100104587A1  Published: 29/Apr/2010

Title: METHODS OF MODULATING THE NEGATIVE CHEMOTAXIS OF IMMUNE CELLS

Applicant/Assignee:

Application No.: 12/572445   Filing Date: 02/Oct/2009

Abstract:The current invention is directed to methods of inducing migration of an immune cell toward a cancer cell comprising inhibiting the activity of a chemorepellant released from the cancer cell.

Priority: US20080102177P Applic. Date: 2008-10-02; US20090222217P Applic. Date: 2009-07-01

Inventor: CHAVAN SURENDRA [US]; MOON JONATHAN L [US]; BHATT LOPA [US]


Application No.: US20100104613A1  Published: 29/Apr/2010

Title: ANTIPERSPIRANT OR DEODORANT COMPOSITIONS

Applicant/Assignee: CONOPCO, INC., D/B/A UNILEVER

Application No.: 12/605598   Filing Date: 26/Oct/2009

Abstract:It is desirable for antiperspirant or deodorant roll-on compositions to be able to deliver fragrance over an extended period of time after application, but previously contemplated encapsulates were based on starch or similar water-soluble or dispersible shell materials, rendering them ineffective in aqueous emulsions. Capsules of fragrances in cross-linked coacervated gelatin shells satisfying defined particle size, shell thickness and hardness criteria enable roll-on compositions to be incorporated into aqueous antiperspirant or deodorant compositions encapsulated fragrance that can be released after the composition has been topically applied to skin.

Priority: EP20080167669 Applic. Date: 2008-10-27

Inventor: CHAN CATRIN SIAN [GB]; CROPPER MARTIN PETER [GB]; FRANKLIN KEVIN RONALD [GB]; JOHNSON SIMON ANTHONY [GB]; MCKEOWN ROBERT [GB]


Application No.: US20100104659A1  Published: 29/Apr/2010

Title: BENZOPYRANOPYRAZOLES

Applicant/Assignee:

Application No.: 12/373433   Filing Date: 12/Jul/2007

Abstract:Compounds of a certain formula I, in which Ra, Rb and Rc have the meanings indicated in the description, are effective compounds with anti-proliferative and/or apoptosis inducing activity.

Priority: EP20060117124 Applic. Date: 2006-07-13; WO2007EP57195 Applic. Date: 2007-07-12

Inventor: VENNEMANN MATTHIAS [DE]; BAER THOMAS [DE]; MAIER THOMAS [DE]; LINDENMAIER ANDREAS [DE]; BRAUNGER JUERGEN [AT]; BOEHM MARKUS [DE]; ZIMMERMANN ASTRID [DE]; GEKELER VOLKER [DE]


Application No.: US20100104671A1  Published: 29/Apr/2010

Title: COSMETIC AND/OR PHARMACEUTICAL COMPOSITIONS AND THEIR APPLICATIONS

Applicant/Assignee: LEGACY HEALTHCARE HOLDING LTD

Application No.: 12/526493   Filing Date: 08/Feb/2008

Abstract:Compositions are disclosed containing, as active ingredients, an extract of Allium species, an extract of Citrus species and either an extract of Paullinia species and an extract of Theobroma species, or an extract of Salix species and zinc sulphate, and the method of preparation of these compositions, and cosmetic and/or pharmaceutical application of these compositions.

Priority: FR20070001011 Applic. Date: 2007-02-13; WO2008FR00152 Applic. Date: 2008-02-08

Inventor: ULMANN ANDRE [FR]; STURER JEAN-FREDERIC [FR]


Application No.: US20100105681A1  Published: 29/Apr/2010

Title: 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES AS VLA-4 INHIBITORS

Applicant/Assignee:

Application No.: 12/604959   Filing Date: 23/Oct/2009

Abstract:The present invention concerns 2,6-quinolinyl and 2,6-naphthyl derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.

Priority: EP20020009746 Applic. Date: 2002-04-30; US2005-513347 Applic. Date: 2005-11-21; WO2003EP03909 Applic. Date: 2003-04-15

Inventor: LASSOIE MARIE-AGNES [BE]; KNERR LAURENT [SE]; DEMAUDE THIERRY [BE]; DE LAVELEYE-DEFAIS FRANCOISE [BE]; KOGEJ THIERRY [SE]; QUERE LUC [BE]; ROUTIER SYLVAIN [FR]; GUILLAUMET GERALD [FR]


Application No.: US20100105698A1  Published: 29/Apr/2010

Title: Therapeutic Methods and Compounds

Applicant/Assignee: DMI LIFE SCIENCES, INC

Application No.: 12/472738   Filing Date: 27/May/2009

Abstract:The invention provides diketopiperazines of formula I. The invention also provides pharmaceutical compositions comprising the diketopiperazines, or pharmaceutically-acceptable salts or prodrugs thereof, as the active ingredient. The invention further provides therapeutic treatments that utilize the diketopiperazines of formula I, including inhibition of a proliferative disease or condition, inhibition of angiogenesis, treatment of an angiogenic disease or condition, treatment of cancer and precancerous conditions, treatment of a fibrotic disorder, treatment of a viral infection, treatment of an Akt-mediated disease or condition, inhibition of the production, release or both of matrix metalloproteinase-9, and inhibition of Akt activation.

Priority: US20080056379P Applic. Date: 2008-05-27

Inventor: BAR-OR DAVID [US]


Application No.: US20100105741A1  Published: 29/Apr/2010

Title: ADMINISTRATION OF PYRIDINEDICARBOXYLIC ACID COMPOUNDS FOR STIMULATING OR INDUCING THE GROWTH OF HUMAN KERATINOUS FIBERS AND/OR ARRESTING THEIR LOSS

Applicant/Assignee: L'OREAL

Application No.: 12/650777   Filing Date: 31/Dec/2009

Abstract:The invention relates to the use in a composition for caring for human hair or eyelashes of an effective amount of a pyridinedicarboxylic acid derivative of general formula (I) or of one of its salts, in which R1 and R2 represent, independently of one another, OH, OR', -NH2, -NHR' or -NR'R'', and R' and R'' represent, independently of one another, a saturated or unsaturated and linear or branched C1-C18 alkyl radical or an aryl radical, this alkyl or aryl radical optionally being substituted by at least one OH, alkoxy, acyloxy, amino or alkylamino group, or R' and R'' together represent a heterocycle, the composition being intended to induce and/or stimulate the growth of human keratinous fibers, such as the hair and eyelashes, and/or slow down their loss

the invention also relates to a cosmetic treatment intended to stimulate the growth of human keratinous fibers, such as the hair and eyelashes, and/or slow down their loss.

Priority: FR20020004527 Applic. Date: 2002-04-11; US2009-463602 Applic. Date: 2009-05-11; US2003-410402 Applic. Date: 2003-04-10; US20020372414P Applic. Date: 2002-04-16

Inventor: DALKO MARIA [FR]; LOUSSOUARN GENEVIEVE [FR]; RAWADI CHARLES EL [FR]; BOULLE CHRISTOPHE [FR]; BERNARD BRUNO [FR]


Application No.: US20100111879A1  Published: 06/May/2010

Title: SACCHARIDE FOAMABLE COMPOSITIONS

Applicant/Assignee: FOAMIX LTD

Application No.: 12/646322   Filing Date: 23/Dec/2009

Abstract:A foamable composition, containing a saccharide for use in the treatment of various disorders including: water, a saccharide, about 0.2% to about 5% by weight of a surface-active agent, about 0.01% to about 5% by weight of at least one polymeric agent selected from a bio-adhesive agent, a gelling agent, a film forming agent and a phase change agent, and a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.

Priority: US2006-430437 Applic. Date: 2006-05-09; US20050679020P Applic. Date: 2005-05-09; US20060784793P Applic. Date: 2006-03-21

Inventor: TAMARKIN DOV [IL]; FRIEDMAN DORON [IL]; BESONOV ALEX [IL]


Application No.: US20100111895A1  Published: 06/May/2010

Title: Human sample matching system

Applicant/Assignee:

Application No.: 12/290877   Filing Date: 03/Nov/2008

Abstract:Methods and apparatus for a human sample (S), analyzing the sample (S) and then determining a match with a member of the opposite sex is disclosed. In one embodiment, a customer purchases an AromaMatch(TM) Test Kit (14), which comprises a bottle of cleaning solution (20), a cotton ball (22) a sample patch (24), a sample bag (28) and a mailing envelope (30). The user (10) opens the kit (14), cleans a patch of skin somewhere on his or her body, and then applies the patch (24). After wearing the patch (24) for an appropriate time period, the patch (24) is removed, and placed in the sample bag (28). The user (10) writes his or her password on the sample bag (28), and then mails it in the return envelope (30). A laboratory analyzes the sample patch (24), and determines a set of genetic attributes (G1) that are associated with the sample (S). The user (10) receives an analysis report by mail, or views the results of the analysis on a website (18). In another embodiment, a customized perfume is manufactured that is based on biological agents that are selected to match the set of genetic attributes identified by the analysis.

Priority:

Inventor: TUCK EDWARD F [US]; HASELTON MARTIE G [US]


Application No.: US20100111994A1  Published: 06/May/2010

Title: ANTI-BACTERIAL COMPOSITION AND METHOD OF USING SAME

Applicant/Assignee: ALLERA HEALTH PRODUCTS, INC

Application No.: 12/478157   Filing Date: 04/Jun/2009

Abstract:Disclosed is an alkaline extract of pine cones with anti-bacterial activity.

Priority: US20080058775P Applic. Date: 2008-06-04

Inventor: TUFARO FRANCIS [US]; TANAKA AKIKO [US]; BURROWS MICHAEL P [US]; BRADLEY WILLIAM G [US]; PETERKIN JOANNA [US]


Application No.: US20100112021A1  Published: 06/May/2010

Title: SUSTAINED-RELEASE COMPOSITION

Applicant/Assignee:

Application No.: 12/532218   Filing Date: 19/Mar/2008

Abstract:A composition which comprises (A) a plurality of cross-linked polymer particles, said polymer being the polymerization product of at least two monomer units selected from the group consisting of monoalkenyl aromatic compounds, alkyl esters derived from a saturated alcohol and acrylic or methacrylic acid, and vinyl esters of an aliphatic carboxylic acid

and said cross-line polymer particles being loaded with (B) an active ingredient, the weight ratio of the active ingredient (B) to the polymer particles (A) being from 0.05 to 50:1, is useful to release the active ingredient over an extended period of time while controlling sebum on skin and hair.

Priority: US20070919222P Applic. Date: 2007-03-21; WO2008US57444 Applic. Date: 2008-03-19

Inventor: ZHANG XIAODONG [US]; MEERBOTE MICHAEL [DE]; BATRA ASHISH [US]; KOSENSKY LINDA A [US]; SCHILLER KLAUS [DE]; NIETER ELKE [DE]


Application No.: US20100112087A1  Published: 06/May/2010

Title: OXYGEN-GENERATING COMPOSITIONS FOR ENHANCING CELL AND TISSUE SURVIVAL IN VIVO

Applicant/Assignee:

Application No.: 12/532520   Filing Date: 08/Apr/2008

Abstract:A method of treating hypoxic tissue such as wound tissue comprises contacting a composition to the hypoxic tissue in a hypoxia-treatment effective amount, the composition comprising a biodegradable polymer and an inorganic peroxide incorporated into the polymer.

Priority: US20070910686P Applic. Date: 2007-04-09; WO2008US04502 Applic. Date: 2008-04-08

Inventor: HARRISON BENJAMIN S [US]; YOO JAMES J [US]; ATALA ANTHONY [US]


Application No.: US20100112089A1  Published: 06/May/2010

Title: PEPTIDE COMPOUND AND USE THEREOF

Applicant/Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Application No.: 12/465536   Filing Date: 13/May/2009

Abstract:The present invention provides a method for the prophylaxis or treatment of cancer in a mammal, comprising administering a therapeutically effective amount of CBP501, a prodrug thereof or a pharmaceutically acceptable salt thereof to the mammal, wherein CBP501, a prodrug thereof or a pharmaceutically acceptable salt thereof is administered simultaneously with or before administration of a nucleic acid damaging agent.

Priority: US20080053190P Applic. Date: 2008-05-14; US20080116849P Applic. Date: 2008-11-21

Inventor: KAWABE TAKUMI [JP]; ISHIGAKI MACHIYO [JP]; SATO TAKUJI [JP]


Application No.: US20100113385A1  Published: 06/May/2010

Title: COMPLEX COMBINING AN ORGANIC SILICON DERIVATIVE WITH HYALURONIC ACID CALIBRATED FRAGMENTS, FOR PREVENTIVE AND REPAIRING ACTION OF CUTANEOUS DAMAGES

Applicant/Assignee: EXZYMOL S.A.M

Application No.: 12/572658   Filing Date: 02/Oct/2009

Abstract:The invention concerns a complex based on an organic silicon derivative. The invention is characterized in that said derivative is combined, by weak bonds, with one or several hyaluronic acid calibrated fragments of molecular weight comprised between 150 and 750 kDa, said derivative being of general formula (I): RXSi(OH)4-x (I) wherein: R is a (C1-C4)alkyl, x=1 and 2. The invention also concerns the use of such a complex in the prevention or the repair of cutaneous damages.

Priority: FR20080005479 Applic. Date: 2008-10-03

Inventor: SEGUIN MARIE-CHRISTINE [MC]


Application No.: US20100113442A1  Published: 06/May/2010

Title: TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES

Applicant/Assignee:

Application No.: 12/595922   Filing Date: 16/Apr/2008

Abstract:The present invention relates to a compound according to formula (I), wherein X and Y are either C and N or N and C

Z is CH2, CH2-CH2, CH2-NH, or NH

R1 is halogen, or R1 is alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, cycloalkyl, alkoxycarbonyl, aryl, all of which are optionally substituted

R2 is hydrogen, or R2 is alkyl, cycloalkyl, alkoxy, heterocycloalkyl, aryl, heteroaryl, alkoxycarbonyl, aminocarbonyl, amino, all of which are optionally substituted

A is aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocycloalkyl or heterocycloalkenyl, all of which are optionally substituted

and pharmaceutically acceptable salts, hydrates, or solvates hereof. The invention further relates to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, e.g. dermal diseases, with said compounds, and to the use of said compounds in the manufacture of medicaments, in particular for the treatment of dermal diseases.

Priority: US20070912020P Applic. Date: 2007-04-16; WO2008DK00135 Applic. Date: 2008-04-16

Inventor: FELDING JAKOB [DK]; SORNESEN MORTEN DAHL [DK]


Application No.: US20100114008A1  Published: 06/May/2010

Title: Controlled release transdermal drug delivery

Applicant/Assignee:

Application No.: 12/655938   Filing Date: 11/Jan/2010

Abstract:Provided herein is a device for controlling the release of a substance at a site of interest in a biological membrane comprising a means of monitoring a physiological state at the site of interest

and a means of releasing a variable amount of the substance to the site of interest where the amount varies in response to the status of the monitored physiological state. Also provided are methods of using the device.

Priority: US2003-422288 Applic. Date: 2003-04-24; US20020376112P Applic. Date: 2002-04-29

Inventor: MARCHITTO KEVIN S [US]; FLOCK STEPHEN T [US]


Application No.: US20100114014A1  Published: 06/May/2010

Title: PHARMACEUTICAL COMPOSITIONS STABILISED IN GLASSY PARTICLES

Applicant/Assignee: CAMBRIDGE BIOSTABILITY LIMITED

Application No.: 12/089386   Filing Date: 04/Oct/2006

Abstract:Present proposals for liquid-medium carriers for glass particles comprising pharmaceutical compositions have had problems associated with aggregation of the glass particles. This has been previously solved by matching the density of the particles and a liquid in which they are suspended. However, though this greatly constrains the choice of liquid carrier that can be used. An alternative solution to this problem has been found. By adding just a small amount of liquid (2) to the particles (1), a flowable mixture is formed of a creamy or paste-like consistency. Providing too much liquid (2) is not present, the particles (1) do not separate out and so the choice of liquid carriers available for use in compositions of this type is greatly increased.

Priority: GB20050020129 Applic. Date: 2005-10-04; WO2006GB50312 Applic. Date: 2006-10-04

Inventor: ROSER BRUCE [GB]


Application No.: US20100119461A1  Published: 13/May/2010

Title: ANTIMICROBIAL COMPOSITION

Applicant/Assignee: MERCK PATENT GMBH

Application No.: 12/523938   Filing Date: 10/Dec/2007

Abstract:The present invention relates to compositions comprising zinc oxide, barium sulphate and bound silver ions and their use in various applications, such as cosmetics, inks, lacquers or plastics.

Priority: EP20070001366 Applic. Date: 2007-01-23; WO2007EP10733 Applic. Date: 2007-12-10

Inventor: BICARD-BENHAMOU VALERIE [DE]; RUDOLPH THOMAS [DE]; BRUNNER MARCUS [DE]


Application No.: US20100119463A1  Published: 13/May/2010

Title: ANTIOXIDANT COMPOSITIONS FOR THE CLEANSING AND CONDITIONING OF SKIN

Applicant/Assignee:

Application No.: 12/615842   Filing Date: 10/Nov/2009

Abstract:Antioxidant cosmetic skin care compositions formulated to combat conditions associated with free radical damage and oxidative stress are provided. The compositions contain effective amounts of one of several active agents, including an agent derived from one or more of the plant species: Lycium barbarum, Punica granatum, Vitis vinifera, Aspalathus linearis, and Camellia Sinensis as well as cosmetically acceptable carriers. These cosmetic compositions find use in improving the appearance of aged or damaged skin.

Priority: US20080114019P Applic. Date: 2008-11-12

Inventor: JACOBS JUNE [US]


Application No.: US20100119492A1  Published: 13/May/2010

Title: Method and device for activating stem cells

Applicant/Assignee: SYNTHES USA, LLC

Application No.: 12/589956   Filing Date: 30/Oct/2009

Abstract:Invention embodiments described herein include methods and devices for stimulating mesenchymal stem cells in a stem cell source to differentiate into osteoblasts capable of forming bone. Devices and methods described include exposing a stem cell source, such as bone marrow aspirate, adipose tissue and/or purified allogenic stem cells, to an active agent, in a manner effective to form activated stem cells.

Priority: US20090152335P Applic. Date: 2009-02-13; US20080110096P Applic. Date: 2008-10-31

Inventor: HANS MEREDITH [US]; BUECHTER DOUG [US]; GRUSKIN ELLIOTT [US]; HORNSBY STEPHEN [US]; BROWN MELISSA [US]


Application No.: US20100119561A1  Published: 13/May/2010

Title: Compositions Having a Performance Indicator

Applicant/Assignee: AMCOL INTERNATIONAL CORPORATION

Application No.: 12/443998   Filing Date: 04/Oct/2007

Abstract:Compositions containing a delivery system including polymeric microparticles capable of undergoing a visual change, such as a color change, after application to a substrate are disclosed. The delivery system informs a consumer that the composition has been properly applied and/or has performed its intended function.

Priority: US20060849985P Applic. Date: 2006-10-05; WO2007US80403 Applic. Date: 2007-10-04

Inventor: SPINDLER RALPH [US]; LARIONOVA NATALIYA V [US]


Application No.: US20100119566A1  Published: 13/May/2010

Title: USE OF A SYNERGISTIC COMPOSITIONS AS A THERAPEUTIC AGENT OR DISINFECTANT

Applicant/Assignee: BODE CHEMIE GMBH MULTIBIND BIOTEC GMBH

Application No.: 12/452295   Filing Date: 27/Jun/2008

Abstract:The invention relates to the use of a composition comprising a vitamin, a metal ion, and a surfactant, as a therapeutic agent or disinfectant. The composition has been known as a decontaminant because the same efficiently decomposes DNA. It has now been possible to demonstrate that the agent has surprisingly good compatibility while having a wide-ranging disinfecting effect and is therefore also suitable for other purposes, e.g., for disinfecting or dressing wounds.

Priority: DE200710030103 Applic. Date: 2007-06-28; WO2008EP05292 Applic. Date: 2008-06-27

Inventor: KRUG BARBARA [DE]; EGGERSTEDT SVEN [DE]; OSTERMEYER CHRISTIANE [DE]; LISOWSKY THOMAS [DE]; ESSER KARLHEINZ [DE]; BUERGER FRANK [DE]; BLOSS RICHARD [DE]


Application No.: US20100119585A1  Published: 13/May/2010

Title: TRANSDERMAL THERAPEUTIC SYSTEM FOR ADMINISTERING THE ACTIVE SUBSTANCE BUPRENORPHINE

Applicant/Assignee: LTS LOHMANN THERAPIE-SYSTEME AG

Application No.: 12/515848   Filing Date: 07/Nov/2007

Abstract:The invention relates to a transdermal therapeutic system for administering the active substance buprenorphine. Said system comprises at least one carboxylic acid that determines the solubility of buprenorphine in the matrix layer and that can likewise be absorbed. The transdermal therapeutic system according to the invention is used in the treatment of pain and is characterized by a considerably increased utilization of the active substance.

Priority: DE200610054731 Applic. Date: 2006-11-21; WO2007EP09622 Applic. Date: 2007-11-07

Inventor: HILLE THOMAS [DE]; HORSTMANN MICHAEL [DE]; MUELLER WALTER [DE]


Application No.: US20100119586A1  Published: 13/May/2010

Title: Patch for Cutaneous Application

Applicant/Assignee: DBV TECHNOLOGIES

Application No.: 12/527407   Filing Date: 15/Feb/2008

Abstract:The invention relates to a patch for cutaneous application of a substance, the patch comprising a substance designed to penetrate the epidermis, means for placing the substance in contact with the skin and a peelable cutaneous exfoliation film enabling exfoliation of the skin, after placing the patch, at the level of the contact zone between said substance and the skin.

Priority: FR20070053265 Applic. Date: 2007-02-15; WO2008FR50252 Applic. Date: 2008-02-15

Inventor: DUPONT BERTRAND [FR]


Application No.: US20100119616A1  Published: 13/May/2010

Title: HIGHLY STABLE ELECTROLYTIC WATER WITH REDUCED NMR HALF LINE WIDTH

Applicant/Assignee: AKUATECH S.R.L

Application No.: 12/597587   Filing Date: 25/Apr/2008

Abstract:Electrolytic acid or alkaline water having a NMR half line width using 17O of from about 45 to less than 51 Hz, and an oxide reduction potential of from -1000 to +200 mV, or from +600 to +1300 mV, topical compositions that contain such water, uses for such water to hydrate skin, deliver drugs and treat various skin and mucosal conditions, and methods and apparatus for manufacturing the water.

Priority: US20070926182P Applic. Date: 2007-04-25; WO2008EP03383 Applic. Date: 2008-04-25

Inventor: CHEN YONGGE [CN]; DE NONI ROBERTO [IT]


Application No.: US20100119619A1  Published: 13/May/2010

Title: AQUEOUS GEL HAVING AN ALPHA-HYDROXY ACID AND SUSPENDED PARTICULATES

Applicant/Assignee:

Application No.: 12/607553   Filing Date: 28/Oct/2009

Abstract:A personal care composition in the form of an aqueous gel may comprise an alpha-hydroxy acid, wherein the pH of the composition is less than about 4.5. The personal care composition comprises a gelling agent and an aqueous solvent. The personal care composition further comprises particulates and an effective amount of suspension agent to suspend the particulates. The personal care composition exhibits a consumer desired viscosity and translucency.

Priority: US20080109354P Applic. Date: 2008-10-29

Inventor: GRIFFITHS-BROPHY SUSAN ADAIR [US]; KUHLMAN DENNIS EUGENE [US]


Application No.: US20100120645A1  Published: 13/May/2010

Title: Fatty acid-free, foaming cosmetic composition and method of use

Applicant/Assignee: L'OREAL

Application No.: 12/587891   Filing Date: 14/Oct/2009

Abstract:Disclosed are cosmetic compositions containing a disodium lauryl sulfosuccinate and a hydrophilically modified urethane. Also disclosed are methods for treating a keratinous substrate, such as skin or hair, by applying the cosmetic compositions to the keratinous substrate to, e.g., cleanse the keratinous substrate or deposit a cosmetically acceptable ingredient thereupon.

Priority: US20080196293P Applic. Date: 2008-10-15

Inventor: FARES HANI [US]; CORNELL MARC [US]; RUSSELL MICHAEL [US]


Application No.: US20100120657A1  Published: 13/May/2010

Title: Reactive Polyorganosiloxanes Modified With Aromatic Substances

Applicant/Assignee: MOMENTIVE PERFORMANCE MATERIALS GMBH

Application No.: 12/531894   Filing Date: 19/Mar/2008

Abstract:The invention relates to polyorganosiloxanes modified with fragrances and having reactive groups, to a method for coating a substrate using the polyorganosiloxanes according to the invention, use of the polyorganosiloxanes according to the invention for releasing the fragrance, to a method for producing the polyorganosiloxanes according to the invention as well as to their use, for example, in detergents or laundry detergents, in care products, in surface treatment agents and in cosmetics.

Priority: DE200710012909 Applic. Date: 2007-03-19; WO2008EP53287 Applic. Date: 2008-03-19

Inventor: LANGE HORST [DE]; ROOS CHRISTOPHER [DE]; WAGNER ROLAND [DE]; KROPFGANS MARTIN [DE]


Application No.: US20100120669A1  Published: 13/May/2010

Title: THIADIAZOLE DERIVATIVES, INHIBITORS OF STEAROYL-COA DESATURASE

Applicant/Assignee:

Application No.: 12/528647   Filing Date: 26/Feb/2008

Abstract:The present invention relates to substituted thiadiazole compounds of the formula (I): and pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing them and their use in medicine. In particular, the invention relates to compounds for modulating SCD activity.

Priority: GB20070003906 Applic. Date: 2007-02-28; GB20070015654 Applic. Date: 2007-08-10; WO2008EP52276 Applic. Date: 2008-02-26

Inventor: BOUILLOT ANNE MARIE JEANNE [FR]; BOYER THIERRY [FR]; DAUGAN ALAIN CLAUDE-MARIE [FR]; DEAN ANTHONY WILLIAM [GB]; FILLMORE MARTIN CHRISTIAN [GB]; LAMOTTE YANN [FR]


Application No.: US20100120696A1  Published: 13/May/2010

Title: Peptides Having Activities of Epidermal Growth Factor and Its Uses

Applicant/Assignee: CAREGEN CO., LTD

Application No.: 12/444874   Filing Date: 08/Oct/2007

Abstract:The present invention relates to peptides comprising the amino acid sequence represented by the following formula 1 and having the activities of epidermal growth factor and their uses: Cys-Met-Tyr-Ile-Glu-Linker-Arg-Gly-Asp (1) The EGF-mimicking peptides of the present invention possess identical functions or activities to natural-occurring human EGF and are able to promote the generation of autocrine EGF in cells. In addition the peptides of the present invention are much higher stability and skin penetration potency than natural-occurring EGF. Therefore, the composition containing the peptide exhibits excellent treatment and prevention efficacies on diseases or conditions demanding EGF activities, and can be advantageously applied to pharmaceutical compositions, quasi-drugs and cosmetics.

Priority: KR20060098368 Applic. Date: 2006-10-10; WO2007KR04895 Applic. Date: 2007-10-08

Inventor: CHUNG YONG-JI [KR]; KIM YOUNG DEUG [KR]; KIM EUN MI [KR]; CHOI JUN YOUNG [KR]; SONG SANG SU [KR]


Application No.: US20100120705A1  Published: 13/May/2010

Title: COMPOSITIONS AND PRODUCTS CONTAINING S-EQUOL, AND METHODS FOR THEIR MAKING

Applicant/Assignee: AUSTRALIAN HEALTH & NUTRITION ASSOCIATION LIMITED CHILDREN'S HOSPITAL MEDICAL CENTER

Application No.: 12/558949   Filing Date: 14/Sep/2009

Abstract:A composition for use in making commercial food and skin products comprising S-equol or mixtures, including both a non-racemic mixture and a racemic mixture, of S-equol and R-equol. The composition can be used to make articles of commerce such as food supplements, pharmaceuticals, and medicaments. The compositions are useful in a method of delivering S-equol to a mammal to prevent or treat a disease or associated condition, including hormone-dependent diseases or conditions such as cardiovascular disease, lipid disorder, osteopenia, osteoporosis, liver disease, and acute ovarian estrogen deficiency. The S-equol enantiomer can be produced in a biological synthesis from the metabolism of an isoflavone by an organism.

Priority: US2008-167813 Applic. Date: 2008-07-03; US2003-625934 Applic. Date: 2003-07-24; US20020398270P Applic. Date: 2002-07-24

Inventor: SETCHELL KENNETH DAVID REGINALD [US]; COLE SIDNEY JOHN [AU]


Application No.: US20100120717A1  Published: 13/May/2010

Title: KINASE INHIBITORS

Applicant/Assignee:

Application No.: 12/444957   Filing Date: 08/Oct/2007

Abstract:Compounds are provided for use with kinases that comprise a compound selected from the group consisting of formula (I) wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture in comprising such compounds

methods and intermediates useful for making the compounds

and methods of using said compounds.

Priority: US2006-539857 Applic. Date: 2006-10-09; US20070912629P Applic. Date: 2007-04-18; WO2007US80714 Applic. Date: 2007-10-08

Inventor: BROWN JASON W [US]; DONG QING [US]; PARASELLI BHEEMA R [US]; STAFFORD JEFFREY A [US]; WALLACE MICHAEL B [US]; WIJESEKERA HASANTHI [US]


Application No.: US20100120749A1  Published: 13/May/2010

Title: TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS

Applicant/Assignee: GENKYO TEX SA

Application No.: 12/532567   Filing Date: 28/Mar/2008

Abstract:The present invention is related to tetrahydroindole derivatives of Formula (I), pharmaceutical composition thereof, methods of preparation thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase).

Priority: EP20070109561 Applic. Date: 2007-06-04; US20070908414P Applic. Date: 2007-03-28; WO2008EP53704 Applic. Date: 2008-03-28

Inventor: PAGE PATRICK [FR]; ORCHARD MIKE [GB]; FIORASO-CARTIER LAETICIA [FR]; MOTTIRONI BIANCA [CH]


Application No.: US20100120768A1  Published: 13/May/2010

Title: METHODS, KITS, AND COMPOSITIONS FOR GENERATING NEW HAIR FOLLICLES AND GROWING HAIR

Applicant/Assignee:

Application No.: 12/443122   Filing Date: 27/Sep/2007

Abstract:The invention features methods, kits, and compositions for generating new hair follicles and growing hair on a subject.

Priority: US20060847854P Applic. Date: 2006-09-28; WO2007US20842 Applic. Date: 2007-09-27

Inventor: STEINBERG DAVID [US]; POJASEK KEVIN [US]; PROUTY STEPHEN [US]; COTSARELIS GEORGE [US]; ITO MAYUMI [US]


Application No.: US20100121254A1  Published: 13/May/2010

Title: Method and apparatus for skin treatment

Applicant/Assignee:

Application No.: 12/583578   Filing Date: 21/Aug/2009

Abstract:Disclosed is a system and method for treatment of skin disorders. More particularly, the disclosed invention is directed toward the use of multiple light sources for treating skin with or without the use of a topical compositions or photomodulation enhancing agents. Dual light emitting diodes may, for example, be used at relatively low power (less than about 10 J/cm2) to photomodulate skin or living tissue to reduce wrinkles, fine lines, acne, acne bacteria, and other skin disorders.

Priority: US2006-332517 Applic. Date: 2006-01-17; US2005-119378 Applic. Date: 2005-05-02; US2001-933870 Applic. Date: 2001-08-22; US2001-819082 Applic. Date: 2001-02-15; US1998-203178 Applic. Date: 1998-11-30

Inventor: MCDANIEL DAVID H [US]


Application No.: US20100121256A1  Published: 13/May/2010

Title: Implantable and Refillable Drug Delivery Reservoir

Applicant/Assignee: MED-EL ELEKTROMEDIZINISCHE GERAETE GMBH

Application No.: 12/614552   Filing Date: 09/Nov/2009

Abstract:Implantable drug delivery apparatuses and methods are described. An input port septum receives a therapeutic drug. An implantable delivery catheter holds a volume of the therapeutic drug and includes a proximal end in fluid communication with the input port septum, a distal end including an output septum for removing fluid from the catheter, and a drug permeable surface for diffusion of the therapeutic drug into nearby tissue.

Priority: US20080112818P Applic. Date: 2008-11-10

Inventor: JOLLY CLAUDE [AT]; HESSLER ROLAND [AT]


Application No.: US20100124561A1  Published: 20/May/2010

Title: Anti-Aging Product

Applicant/Assignee:

Application No.: 12/273258   Filing Date: 18/Nov/2008

Abstract:The present invention is directed to an anti-aging product, a single use multi-chamber packaging and a method of using the anti-aging product for reducing and/or preventing age-related skin symptoms. More particularly, the present invention is directed to a single use multi-chamber packet that has at least two chambers or compartments each containing at least one portion of an anti-aging composition, wherein said portions can be combined prior to application to the skin for reducing and/or preventing age-related skin symptoms. In another embodiment, the present invention is directed to an anti-aging kit comprising at least two or more single use multi-chamber packets, each having at a different composition for reducing and/or preventing age-related skin symptoms.

Priority:

Inventor: STUDIN JOEL R [US]


Application No.: US20100126521A1  Published: 27/May/2010

Title: Personal Care Compositions Containing Skin Conditioning Agents

Applicant/Assignee:

Application No.: 12/338327   Filing Date: 18/Dec/2008

Abstract:Personal care compositions are provided that include an aqueous base composition and a volatile post foaming agent mixed with the base composition. The base composition comprises a lipophilic skin conditioning agent, a structuring agent, and a water soluble or water dispersible surface active agent.

Priority: US20070009152P Applic. Date: 2007-12-26

Inventor: KYTE III KENNETH EUGENE [US]


Application No.: US20100126727A1  Published: 27/May/2010

Title: IN SITU RECOVERY FROM A HYDROCARBON CONTAINING FORMATION

Applicant/Assignee: SHELL OIL COMPANY

Application No.: 12/329942   Filing Date: 08/Dec/2008

Abstract:An in situ process for treating a hydrocarbon containing formation is provided. The process may include providing heat from one or more heaters to at least a portion of the formation. The heat may be allowed to transfer from the one or more heaters to a part of the formation such that heat from the one or more heat sources pyrolyzes at least some hydrocarbons within the part. Hydrocarbons may be produced from the formation.

Priority: US2007-657442 Applic. Date: 2007-01-23; US2002-279288 Applic. Date: 2002-10-24; US20010334568P Applic. Date: 2001-10-24; US20010337136P Applic. Date: 2001-10-24; US20020374970P Applic. Date: 2002-04-24; US20020374995P Applic. Date: 2002-04-24

Inventor: VINEGAR HAROLD J [US]; SUMNU-DINDORUK MELLIHA DENIZ [US]; WELLINGTON SCOTT LEE [US]; MAHER KEVIN ALBERT [US]; KARANIKAS JOHN MICHAEL [US]; DE ROUFFIGNAC ERIC PIERRE [NL]; MESSIER MARGARET ANN [CA]; ROBERTS BRUCE EDMUNDS [CA]; CRANE STEVEN DEXTER [US]


Application No.: US20100129301A1  Published: 27/May/2010

Title: COSMETIC COMPOSITIONS

Applicant/Assignee:

Application No.: 12/624236   Filing Date: 23/Nov/2009

Abstract:A cosmetic composition comprises a) from about 0.1% to about 15% of an emulsifying crosslinked siloxane elastomer

b) from about 0.1% to about 10% of a noncrosslinked silicone emulsifier having a polyglycerin unit

c) from about 1% to about 50% of a solvent for the emulsifying crosslinked siloxane elastomer

d) from about 0.05% to about 10% of an amphiphilic active

and e) water.

Priority: US20080117264P Applic. Date: 2008-11-24

Inventor: TANAKA SHUHEI [JP]; YOSHIMI NAOHISA [JP]


Application No.: US20100129302A1  Published: 27/May/2010

Title: ANTIMICROBIAL COMPOSITION WITH LOW CYTOTOXICITY

Applicant/Assignee: OY GRANULA AB LTD

Application No.: 12/626072   Filing Date: 25/Nov/2009

Abstract:A composition includes at least one antimicrobial agent

a possible solvent system with either hydrophobic or hydrophilic nature, selected according to the target of usage

as well as possible surface active agent. The compound mixture is obtained by pulverizing wood or plant material and/or by extracting the possibly pulverized wood or plant material, so that the compound mixture contains at least two different polyphenolic compounds selected from the following group: lignans, stilbenes, juvabiones and flavonoids

the compound mixture further containing oligomers of the polyphenolic compounds, so that the compound mixture preferably has the following properties: the compound mixture has an antimicrobial effect in the composition

the cytotoxicity of the polyphenols contained in the compound mixture is at least 10 times lower with respect to BHT

the compound mixture does not irritate the skin in a so-called single patch test with contents of 0.1 wt %.

Priority: US20080117684P Applic. Date: 2008-11-25

Inventor: AHLNAES THOMAS [FI]


Application No.: US20100129304A1  Published: 27/May/2010

Title: METHOD FOR PREPARING A COMPOSITION COMPRISING A COMPOUND MIXTURE AND A CARRIER AGENT

Applicant/Assignee: OY GRANULA AB LTD

Application No.: 12/626063   Filing Date: 25/Nov/2009

Abstract:In a method for preparing a composition including a compound mixture and a carrier agent, the compound mixture is obtained by pulverizing the wood material and/or by extracting the wood material so that the compound mixture contains at least two different compounds, selected from a first specified group, at least one compound selected from a second specified group, the compound mixture is mixed with the carrier agent, the amount of the compound mixture is kept in a range of 0.1-5 wt % from the total weight of the composition, providing that the range is also such that the total cytotoxicity of compound mixture dissolved in ethanol, measured for a HaCat cell culture after 24 h incubation period, is lower than the cytotoxicity of 0.02-0.1 wt % butylated hydroxy toluene (BHT) dissolved in ethanol for a HaCat cell culture after 24 h incubation period.

Priority: US20080117702P Applic. Date: 2008-11-25

Inventor: AHLNAS THOMAS [FI]


Application No.: US20100129332A1  Published: 27/May/2010

Title: METHODS AND PHARMACEUTICAL COMPOSITIONS FOR HEALING WOUNDS

Applicant/Assignee:

Application No.: 12/693968   Filing Date: 26/Jan/2010

Abstract:A pharmaceutical composition and method for inducing or accelerating a healing process of a skin wound are described. The pharmaceutical composition contains, as an active ingredient, a therapeutically effective amount of at least one agent for modulating PKC production and/or activation, and a pharmaceutically acceptable carrier. The method is effected by administering the composition to a wound.

Priority: US2009-404622 Applic. Date: 2009-03-16; US2003-644775 Applic. Date: 2003-08-21; US2002-169801 Applic. Date: 2002-07-09; WO2001IL00675 Applic. Date: 2001-07-23; US2002-214228 Applic. Date: 2002-08-08; US2000-629970 Applic. Date: 2000-07-31

Inventor: TENNENBAUM TAMAR [IL]; SAMPSON SANFORD [IL]; KUROKI TOSHIO [JP]; ALT ADDY [IL]; SHEN SHLOMZION [IL]


Application No.: US20100129342A1  Published: 27/May/2010

Title: Human Growth and Differentiation Factor GDF-5

Applicant/Assignee:

Application No.: 12/374080   Filing Date: 17/Jul/2007

Abstract:This invention relates to the production and use of pharmaceutical growth factor compositions with novel characteristics, e.g. improved solubility and controlled release characteristics under physiological conditions. Said compositions of one or more precursor proteins of growth factors of the GDF family provoke morphogenic effects such as for example growth, differentiation, protection and regeneration of a variety of tissues and organs, e.g. bone, cartilage, tendons, ligaments, nerves and skin. The invention can be advantageously used for the healing of tissue-destructive injuries and for the prevention or therapy of degenerative disorders.

Priority: EP20060014928 Applic. Date: 2006-07-18; WO2007EP06331 Applic. Date: 2007-07-17

Inventor: POHL JENS [DE]; PLOEGER FRANK [DE]


Application No.: US20100129357A1  Published: 27/May/2010

Title: ANTIBODIES TO IL-6 AND USE THEREOF

Applicant/Assignee:

Application No.: 12/502581   Filing Date: 14/Jul/2009

Abstract:The present invention is directed to therapeutic methods using IL-6 antagonists such as an Ab1 antibody or antibody fragment having binding specificity for IL-6 to prevent or treat disease or to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level, reduced serum albumin level, elevated D-dimer or other cogulation cascade related protein(s), cachexia, fever, weakness and/or fatigue prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, and others.

Priority: US20080117861P Applic. Date: 2008-11-25; US20080117839P Applic. Date: 2008-11-25; US20080117811P Applic. Date: 2008-11-25

Inventor: GARCIA-MARTINEZ LEON [US]; JENSEN ANN ELISABETH CARVALHO [US]; OLSON KATIE [US]; DUTZAR BEN [US]; OJALA ETHAN [US]; KOVACEVICH BRIAN [US]; LATHAM JOHN [US]; SMITH JEFFREY T L [US]


Application No.: US20100130462A1  Published: 27/May/2010

Title: LANOLIN COMPOSITIONS AND METHODS FOR MAKING AND USING SAME

Applicant/Assignee:

Application No.: 12/596334   Filing Date: 18/Apr/2008

Abstract:A composition suitable for application to the skin comprising lanolin, an oil, an anti-oxidant, and a combination thereof. The composition is suitable for particular application to a human breast.

Priority: US20070913238P Applic. Date: 2007-04-20; US20070913490P Applic. Date: 2007-04-23; WO2008US60890 Applic. Date: 2008-04-18

Inventor: THOMAS SHERRY L [US]; MARSEGLIA LAURA [US]; HANSON STEPHEN F [US]; AMIRAN MOHSEN [US]


Application No.: US20100130605A1  Published: 27/May/2010

Title: Use of Derivatives of Sinapinic Acid and Compositions Comprising Such Derivatives

Applicant/Assignee: COGNIS IP MANAGEMENT GMBH

Application No.: 12/530037   Filing Date: 26/Feb/2008

Abstract:The present invention relates to substances which can be used as cosmetic ingredients, especially for skin whitening and as cosmetic agents against signs of ageing skin. The present invention also relates to the use of such substances for the manufacture of a medicament for the treatment of disorders related to the pigmentation of the skin. The invention furthermore relates to specific substances.

Priority: EP20070004523 Applic. Date: 2007-03-06; WO2008EP01492 Applic. Date: 2008-02-26

Inventor: MARKERT THOMAS [DE]; MOUSSOU PHILIPPE [FR]; DANOUX LOUIS [FR]; RATHJENS ANDREAS [FR]


Application No.: US20100130618A1  Published: 27/May/2010

Title: TREATMENT OF HUMAN DISEASE CONDITIONS AND DISORDERS USING VITAMIN K ANALOGUES AND DERIVATIVES

Applicant/Assignee: VIRIDIS BIOPHARMA PVT. LTD

Application No.: 12/452803   Filing Date: 21/Jul/2008

Abstract:The present invention is related to the therapeutic uses of vitamin K, its analogues and derivatives in a diverse array of disease conditions. Vitamin K improves blood perfusion and ameliorates hypoxia in prevention and treatment of conditions such as chronic venous insufficiency manifestations, post thrombotic syndrome, skin conditions related to melanization, hyperpigmentation, Paresthesiae, oedema, varicose veins, VTE and cramps. The invention also provides pharmaceutical compositions comprising vitamin K, its analogues, derivatives or vitamin K-like compounds either alone or in combination with one or more therapeutically effective active agents for the diseases/conditions of venous, nerves and lymph, that are encompassed by this invention.

Priority: IN2007MU01419 Applic. Date: 2007-07-24; WO2008IN00465 Applic. Date: 2008-07-21

Inventor: VAIDYA ASHOK B [IN]; MEHTA DILIP S [IN]; DE SOUZA ANSELM [IN]; VAIDYA RAMA A [IN]


Application No.: US20100130910A1  Published: 27/May/2010

Title: Patches and method for the transdermal delivery of a therapeutically effective amount of iron

Applicant/Assignee:

Application No.: 12/459183   Filing Date: 25/Jun/2009

Abstract:Embodiments of the invention provide patches for the transdermal delivery of iron-containing compositions to an individual suffering from an iron deficiency. Many embodiments provide an iontophoretic patch for the transdermal delivery of a therapeutically effective amount of iron. The patch comprises an electrode and a reservoir containing a composition comprising ionic iron for the delivery of the therapeutically effective amount of iron. Various embodiments provide methods of using embodiments of the iontophoretic patch for delivering a therapeutically effective amount of iron to an individual suffering from one more forms of iron deficiency including iron deficiency anemia. Such methods can be used for treating and/or preventing the iron deficiency. The amount of delivered iron can be adjusted depending upon various treatment parameters such as patient weight and type and amount of iron deficiency.

Priority: US20080075720P Applic. Date: 2008-06-25

Inventor: BERENSON RONALD J [US]


Application No.: US20100135942A1  Published: 03/Jun/2010

Title: Depigmenting keratin materials utilizing dithiolane compounds

Applicant/Assignee: L'OREAL

Application No.: 12/591714   Filing Date: 30/Nov/2009

Abstract:A cosmetic regime or regimen for depigmenting, lightening and/or bleaching keratin materials, especially the skin, entails topically applying thereon a cosmetic composition containing a dithiolane compound of formula (I): in which: Y is O, NR1 or S R1 is a hydrogen atom

a C1-C20 alkyl radical or an optionally substituted phenyl radical

R is a hydrogen atom

or a C1-C20 alkyl radical, or an optionally substituted phenyl radical, or a C1-C8 alkyl radical containing an optionally substituted phenyl substituent

n=0 or 1 or 2

and also the salts, chelates, solvates and optical isomers thereof.

Priority: FR20080058075 Applic. Date: 2008-11-28; US20080193507P Applic. Date: 2008-12-04

Inventor: MARAT XAVIER [FR]


Application No.: US20100136002A1  Published: 03/Jun/2010

Title: METHODS FOR TREATING AND PREVENTING MULTIPLE SCLEROSIS

Applicant/Assignee:

Application No.: 12/598525   Filing Date: 01/May/2008

Abstract:We have discovered that LRG-47 (also called p47 GTPase), plays a central role in the pathogenesis of multiple sclerosis, and that inhibition of LRG-47 activity by anti-LRG-47 antibodies or of LRG-47 expression by siRNA dramatically reduce the pathology and symptoms of multiple sclerosis. Certain embodiments of the invention are directed to the therapeutic use of anti-LRG-47 antibodies (mouse or rabbit or other antibodies that are humanized or human antibodies to LRG-47, preferably antibodies made against human LRG-47) or siRNA or antisense nucleotides that specifically hybridize with the gene or mRNA or cDNA encoding human LRG-47 to treat or prevent multiple sclerosis and other autoimmune diseases that are T-cell-mediated. Other embodiments are directed to methods for the diagnosis of multiple sclerosis or to determining the aggressiveness of multiple sclerosis by determining the amount of human LRG-47 or LRG-47 mRNA in a biological sample from the patient.

Priority: US20070915127P Applic. Date: 2007-05-01; WO2008US62158 Applic. Date: 2008-05-01

Inventor: YAN SHI DU [US]


Application No.: US20100136103A1  Published: 03/Jun/2010

Title: COSMETIC ANTI-AGEING SKIN CARE COMPOSITIONS

Applicant/Assignee: TUPPERWARE PRODUCTS S.A

Application No.: 12/599419   Filing Date: 08/May/2008

Abstract:The invention is directed to an anti ageing skin care composition, more in particular a cosmetic anti aging skin care composition. The anti ageing skin care composition of the invention comprise, in a physiologically acceptable medium, (i) at least one peptide from Laminin-1 that is able to promote synthesis of Laminin-5

(ii) at least one peptide capable of at least partially inhibiting neuronal exocytosis

and (iii) at least one tripeptide producing a rapid and strong stimulation of collagen synthesis. The compositions of the present invention are effective in reducing existing wrinkles and/or preventing the formation of new wrinkles.

Priority: EP20070107712 Applic. Date: 2007-05-08; WO2008NL50278 Applic. Date: 2008-05-08

Inventor: OTTE STEPHANUS CORNELIS MARIA [NL]; ESTRADA HEMANDEZ CLAUDIA AMALIA [MX]; WON ANNIS [AU]


Application No.: US20100136121A1  Published: 03/Jun/2010

Title: MEDICAMENTS

Applicant/Assignee: INNOVATA BIOMED LIMITED

Application No.: 12/683959   Filing Date: 07/Jan/2010

Abstract:There is described a bimodal pharmaceutical composition comprising effective amounts of a first active ingredient which substantially comprises a coarse fraction and a second active ingredient which substantially comprise a fine fraction characterized in that the coarse fraction possesses a greater mass median aerodynamic diameter than the fine fraction. There is also described a method of delivering a therapeutically effective amount of a substantially fine active ingredient to the lung of a patient by co-administration with a substantially coarse active ingredient.

Priority: GB20010002902 Applic. Date: 2001-02-06; GB20010009215 Applic. Date: 2001-04-12; US2006-511730 Applic. Date: 2006-08-29; US2003-467153 Applic. Date: 2003-12-08; WO2002GB00480 Applic. Date: 2002-02-05

Inventor: SANDERS MARK [GB]


Application No.: US20100136124A1  Published: 03/Jun/2010

Title: NANOPARTICLE-COATED CAPSULE FORMULATION FOR DERMAL DRUG DELIVERY

Applicant/Assignee: UNIVERSITY OF SOUTH AUSTRALIA

Application No.: 12/596679   Filing Date: 21/Apr/2008

Abstract:A method and formulation for the delivery of an active substance to the skin (epidermis, including the stratum corneum and viable epidermis, and dermis) of a subject. The formulation comprises oil-based or aqueous droplets comprising the active substance within a coating of nanoparticles, particularly silica nanoparticles. The active substance may be suitable for the treatment of a disease or condition which is localised, or at least partially localised, to the skin (eg skin cancer, psoriasis, eczema, infections including bacterial and fungal infections, acne, dermatitis, inflammation, and rheumatoid arthritis).

Priority: AU20070902112 Applic. Date: 2007-04-20; WO2008AU00555 Applic. Date: 2008-04-21

Inventor: PRESTIDGE CLIVE ALLAN [AU]; SIMOVIC SPOMENKA [AU]; ESKANDAR NASRIN GHOUCHI [AU]


Application No.: US20100137179A1  Published: 03/Jun/2010

Title: Mineral oil free polymerically stabilized make-up remover

Applicant/Assignee: L'OREAL

Application No.: 12/587892   Filing Date: 14/Oct/2009

Abstract:Disclosed are make-up removal compositions, comprising a mineral oil-free oil phase

a sodium salt of an acrylate copolymer

a stabilizing polymer

and a hydrophobic wetting agent, and methods of using the compositions to remove make-up from facial tissue or skin. The disclosed compositions exhibit a rheological profile that features a variable ("up and down" or "increasing and then decreasing") shear stress response to increasing shear rates, and which is believed to contribute to better performance than known make-up removal compositions tested.

Priority: US20080196309P Applic. Date: 2008-10-15

Inventor: RUSSELL MICHAEL [US]; CORNELL MARC [US]


Application No.: US20100137186A1  Published: 03/Jun/2010

Title: USE OF AN ACTIVE PRINCIPLE ORIGINATING FROM AMARANTH (AMARANTHUS) FOR PREPARING A COMPOSITION INTENDED TO ACTIVATE CELLULAR ENERGY AND TO PROTECT THE SKIN FROM OXIDATIVE DAMAGE

Applicant/Assignee: SOCIETE D'EXTRACTION DES PRINCIPES ACTIFS S.A. (ISP VINCIENCE)

Application No.: 12/597867   Filing Date: 27/Oct/2009

Abstract:Methods of administering in a cosmetic composition or a pharmaceutical composition, an effective amount of a peptide active principle originating from amaranth of the species Amaranthus hypochondriacus. The active principle is intended to activate cellular energy and to protect the skin from oxidativ damage, and the active principle may be used alone or in association with at least one other active principles. The active principle may also be used in a cosmetic treatment for protecting the skin and the appendages from external aggressions and to combat cutaneous aging.

Priority: FR20070003062 Applic. Date: 2007-04-27; WO2008FR00576 Applic. Date: 2008-04-23

Inventor: DAL FARRA CLAUDE [FR]; DOMLOGE NOUHA [FR]; BOTTO JEAN-MARIE [FR]


Application No.: US20100137190A1  Published: 03/Jun/2010

Title: LIQUID COMPOSITION FOR EXTERNAL APPLICATION AND PREPARATION FOR EXTERNAL APPLICATION FOR TREATMENT OF SKIN ULCER

Applicant/Assignee: CELLGENTECH, INC

Application No.: 12/293622   Filing Date: 22/Mar/2007

Abstract:An object of the present invention is to provide a liquid composition for external application and a preparation for external application which are excellent in healing effect on skin ulcers including intractable skin ulcers such as bedsore (decubitus), diabetic skin ulcer and ischemic skin ulcer. The liquid composition for external application of the present invention as means for the resolution is characterized by comprising at least G-CSF (a granulocyte colony stimulating factor) as an active ingredient and 0.001% to 5% of alginic acid. The preparation for external application for treatment of a skin ulcer of the present invention is characterized by comprising the liquid composition for external application of the present invention as a medicinal ingredient.

Priority: JP20060079614 Applic. Date: 2006-03-22; WO2007JP55883 Applic. Date: 2007-03-22

Inventor: JIMI SHIRO [JP]; SUZUMIYA JUNJI [JP]


Application No.: US20100137198A1  Published: 03/Jun/2010

Title: PHARMACEUTICAL COMPOSITION FOR TOPICAL APPLICATION

Applicant/Assignee: FOAMIX LTD

Application No.: 12/705219   Filing Date: 12/Feb/2010

Abstract:A pharmaceutical or cosmetic carrier or composition for topical application characterized by rheological properties which render the carrier or composition semi-solid at rest and a liquid upon application of shear forces thereto. The composition or carrier are prepared by mixing 1-25 percent of a solidifying agent and 75-99 percent of a hydrophobic solvent, by weight, wherein at least one of them has therapeutic or cosmetic benefits, in the presence or absence of a biologically active substance.

Priority: US2005-294318 Applic. Date: 2005-12-05; US2003-392071 Applic. Date: 2003-03-19; US2000-653267 Applic. Date: 2000-08-31; US20000216162P Applic. Date: 2000-07-03

Inventor: EINI MEIR [IL]; TAMARKIN DOV [IL]


Application No.: US20100137201A1  Published: 03/Jun/2010

Title: MEDICAMENTS

Applicant/Assignee: RENOVO LIMITED

Application No.: 12/306501   Filing Date: 29/Jun/2007

Abstract:There is provided the use of WNT5A, or a therapeutically effective fragment or derivative thereof, in the preparation of a medicament for use in the prevention, reduction or inhibition of scarring. There is also provided the use of WNT5A, or a therapeutically effective fragment or derivative thereof, in the preparation of a medicament for use in the prevention and/or treatment of a fibrotic disorder. Further aspects relate to methods by which scarring may be prevented, reduced or inhibited, and by which fibrotic disorders may be prevented and/or treated. Therapeutically effective amounts of WNT5A, or its fragments or derivatives, that may be used in the medicaments or methods of the invention are also provided.

Priority: GB20060013031 Applic. Date: 2006-06-30; WO2007GB02445 Applic. Date: 2007-06-29

Inventor: FERGUSON MARK W J [GB]; LAVERTY HUGH G [GB]; OCCLESTON NICHOLAS [GB]; O'KANE SHARON [GB]; NIELD KERRY [GB]; GOLDSPINK NICHOLAS [GB]


Application No.: US20100137429A1  Published: 03/Jun/2010

Title: COMPOSITION FOR TRANSDERMAL OR TRANSMUCOSAL ADMINISTRATION

Applicant/Assignee: FUJIMOTO CO., LTD

Application No.: 12/452239   Filing Date: 20/Jun/2008

Abstract:The present invention provides a composition for transdermal or transmucosal administration, which is useful as an anti-Alzheimer's drug, an antiparkinson drug, an antidepressant, a psychoactive drug, or a therapeutic agent for drug dependence. The composition for transdermal or transmucosal administration comprising an effective dose of a racemate or an optically acceptable substance of 1-(benzofuran-2-yl)-2-propylaminopentane or a pharmacologically acceptable salt thereof and a vehicle, which can be administered without an invasion of skin and mucous membrane, is an excellent agent serving as an anti-Alzheimer's drug, an antiparkinson drug, an antidepressant, a psychoactive drug or a therapeutic agent for drug dependence, which can allow its active ingredient in a sufficient effective amount to stably arrive, through the skin and mucous membrane, at a body or a brain and is free of disadvantages such as a reduction in an active component caused by a first pass effect in a liver, as well as pains, damages or infections.

Priority: JP20070163692 Applic. Date: 2007-06-21; WO2008JP61300 Applic. Date: 2008-06-20

Inventor: YONEDA FUMIO [JP]; OHDE HIRONORI [JP]; WATANABE MAYUMI [JP]; SUGIMOTO MIKIYO [JP]; KAMADA TAKAHIRO [JP]; HUKUMOTO MIZUE [JP]; TAKASE AZUSA [JP]; HOSHINO NAOYA [JP]


Application No.: US20100137443A1  Published: 03/Jun/2010

Title: Ibuprofen for Topical Administration

Applicant/Assignee: BIOCHEMICS, INC

Application No.: 12/557470   Filing Date: 10/Sep/2009

Abstract:Set forth herein is a preparation of ibuprofen (2-(4-isobutylphenyl)propionic acid) in the free acid form that is suitable for topical administration. The topical ibuprofen formulation is prepared by dissolving the free acid form of ibuprofen, or preparing a homogeneous suspension of the free acid form of ibuprofen, in the presence of a pharmaceutically acceptable solvent so as to produce a topical drug formulation compatible with the penetration of 2-(4-isobutylphenyl) propionic acid through the skin tissue. Topical formulations of ibuprofen can be based on a pharmaceutically acceptable solvent such as, e.g., a pyrrolidone solvent or dimethylacetamide.

Priority: US20080095672P Applic. Date: 2008-09-10

Inventor: CARTER STEPHEN G [US]; ZHU ZHEN [US]; PATEL KANU [US]; KOZWICH DIANE L [US]


Application No.: US20100138945A1  Published: 03/Jun/2010

Title: HUMANIZED ANTI-IL-6 ANTIBODIES

Applicant/Assignee: BIOATLA, LLC

Application No.: 12/617915   Filing Date: 13/Nov/2009

Abstract:The present invention relates to novel chimeric, humanized or CDR-grafted anti-IL-6 antibodies, including isolated nucleic acids that encode at least one such anti-IL-6 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof, including therapeutic compositions, methods and devices.

Priority: US20080114295P Applic. Date: 2008-11-13

Inventor: FREY GERHARD [US]; CHANG HWAI WEN [US]; SHORT JAY [US]


Application No.: US20100141689A1  Published: 10/Jun/2010

Title: ELECTRONIC SKIN READER

Applicant/Assignee: KENT DISPLAYS, INC

Application No.: 12/631133   Filing Date: 04/Dec/2009

Abstract:A portable electronic device includes a portable electronic device housing having a surface and a primary, light-emissive display. A display skin covers a portion of the surface of the portable electronic device housing. The display skin provides a secondary, light-reflective display. The display skin includes an optically active layer comprising electrooptical material. A first electrode layer is disposed on a first side of the optically active layer proximal the surface of the portable electronic device housing. A second electrode layer disposed on a second side of the optically active layer distal of the surface of the portable electronic device housing. Electronic circuitry selectively activates the optically active layer such that images including portions of a document are selectively displayed by the display skin. The display skin is capable of maintaining a display of a selectively displayed portion of the document while the primary display is in an unpowered state.

Priority: US20080200806P Applic. Date: 2008-12-04; US20090157661P Applic. Date: 2009-03-05

Inventor: JOHNSON ROGER LAVERNE [US]


Application No.: US20100143273A1  Published: 10/Jun/2010

Title: COSMETIC COMPOSITION COMPRISING AT LEAST ONE APROTIC HYDROCARBON-BASED VOLATILE SOLVENT

Applicant/Assignee:

Application No.: 12/516015   Filing Date: 20/Nov/2007

Abstract:The present application relates to a cosmetic composition comprising, in a physiologically acceptable medium, at least one aprotic hydrocarbon-based volatile solvent comprising no more than one branch, the volatility of said solvent being such that the amount evaporated in 30 minutes is between 4.1 mg/cm2 and 24 mg/cm2. This composition can be used as a product for caring for and/or making up keratin materials, in particular the skin, the lips and/or the integuments.

Priority: FR20060055058 Applic. Date: 2006-11-23; US20060872485P Applic. Date: 2006-12-04; WO2007EP62583 Applic. Date: 2007-11-20

Inventor: AUGUSTE FREDERIC [FR]; FOURON JEAN-YVES [FR]


Application No.: US20100143276A1  Published: 10/Jun/2010

Title: Ester solvents derived from 4-carboxy-2-pyrrolidinone formulated into UV-screening cosmetic compositions

Applicant/Assignee: L'OREAL

Application No.: 12/654032   Filing Date: 08/Dec/2009

Abstract:Stable UV-screening cosmetic compositions contain at least one ester solvent derived from 4-carboxy-2-pyrrolidinone, of formula (I): in which: R1 is a linear or branched C1-C20 alkyl radical, and R2 is a linear or branched C1-C20 alkyl radical optionally containing a C5-C6 ring member, the phenyl radical, the benzyl radical or the phenethyl radical, and at least one liquid fatty phase and at least one lipophilic UV-screening active agent, the at least one ester derivative constituting a solvent for the at least one active agent in the at least one liquid fatty phase and/or constituting an agent for improving the solubility of the at least one active agent in the at least one fatty phase.

Priority: FR20080058337 Applic. Date: 2008-12-08; US20080193647P Applic. Date: 2008-12-12

Inventor: RICHARD HERVE [FR]; MULLER BENOIT [FR]


Application No.: US20100143278A1  Published: 10/Jun/2010

Title: Low-residue deodorant or antiperspirant stick based on an oil-in-water emulsion

Applicant/Assignee:

Application No.: 12/622755   Filing Date: 20/Nov/2009

Abstract:Deodorant or antiperspirant sticks based on an oil-in-water dispersion for application to the skin.

Priority: DE200410036689 Applic. Date: 2004-07-28; US2005-192389 Applic. Date: 2005-07-28; US20040600688P Applic. Date: 2004-08-11

Inventor: BANOWSKI BERNHARD [DE]; WADLE ARMIN [DE]; CLAAS MARCUS [DE]


Application No.: US20100143279A1  Published: 10/Jun/2010

Title: COSMETIC/DERMATOLOGICAL COMPOSITIONS COMPRISING A DERIVATIVE OF GLUCOSE AND OF VITAMIN F AND A SPECIFIC SURFACTANT

Applicant/Assignee: L'OREAL

Application No.: 12/704806   Filing Date: 12/Feb/2010

Abstract:Topically applicable cosmetic/dermatological compositions suited for improving the condition of human keratin fibers, notably human hair, especially for reducing or stopping loss and/or inducing and/or stimulating growth and/or density thereof, contain a thus effective amount of (a) at least one derivative of glucose and of vitamin F, solubilized in a topically applicable, physiologically acceptable medium therefor which includes (b) at least one nonionic surfactant having a hydrophilic/lipophilic balance (HLB) of greater than 10, (c) at least one C1-C4 alcohol and (d) water.

Priority: FR20050050363 Applic. Date: 2005-02-08; US2006-349249 Applic. Date: 2006-02-08; US20050672070P Applic. Date: 2005-04-18

Inventor: MEZURE PATRICIA [FR]; DUBIEF CLAUDE [FR]


Application No.: US20100143285A1  Published: 10/Jun/2010

Title: Dermatological/pharmaceutical compositions comprising benzoyl peroxide, at least one naphthoic acid compound and at least one polyurethane polymer

Applicant/Assignee: GALDERMA RESEARCH & DEVELOPMENT, BIOT, FRANCE

Application No.: 12/453968   Filing Date: 28/May/2009

Abstract:Topically applicable, dermatological/pharmaceutical compositions contain, formulated into a physiologically acceptable medium, benzoyl peroxide, at least one naphthoic acid compound and at least one compound of the polyurethane polymer type or derivatives thereof, wherein the benzoyl peroxide and the at least one naphthoic acid compound are dispersed therein.

Priority: FR20060055138 Applic. Date: 2006-11-28; WO2007FR52412 Applic. Date: 2007-11-28

Inventor: MALLARD CLAIRE [FR]; AT EMMANUELLE [FR]


Application No.: US20100143347A1  Published: 10/Jun/2010

Title: TARGETING NCCA-ATP CHANNEL FOR ORGAN PROTECTION FOLLOWING ISCHEMIC EPISODE

Applicant/Assignee: THE UNIVERSITY OF MARYLAND, BALTIMORE

Application No.: 12/522444   Filing Date: 11/Jan/2008

Abstract:The present invention concerns protection of an organ or tissue following an ischemic episode In particular aspects, the invention concerns organ preservation for transplantation, angina pectoris, kidney reperfusion injury, and so forth In specific embodiments, the organ is subjected to an inhibitor of an NCCa-ATP channel that is regulated by SUR1 Exemplary inhibitors include sulfonylurea compounds, such as glibenclamide, for example

Priority: US20070880119P Applic. Date: 2007-01-12; US20070923378P Applic. Date: 2007-04-13; US20070952396P Applic. Date: 2007-07-27; US20070012613P Applic. Date: 2007-12-10; WO2008US50922 Applic. Date: 2008-01-11

Inventor: SIMARD J MARC [US]


Application No.: US20100143358A1  Published: 10/Jun/2010

Title: Use of Antibody Conjugates

Applicant/Assignee: THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS

Application No.: 12/523438   Filing Date: 22/Jan/2008

Abstract:Provided herein are methods for inducing growth arrest or apoptosis in cancer cells in a subject. Further provided are methods of inhibiting or treating metastasis of a cancer cell in a subject. The methods involve administering to the subject an antibody conjugate containing an antibody, variant thereof, or functional fragment thereof having binding specificity of the antibody as produced by the hybridoma having ATCC accession number PTA 2439 and a biologically active molecule. The antibody (e.g., mAb 3E10) variant or functional fragment thereof provides for the in vivo transduction of the conjugate to the nucleus of mammalian cells, where the conjugated biologically active molecule may exert its effect. In particular embodiments, the antibody conjugate comprises a single chain Fv fragment of an antibody having the binding specificity of mAb 3E10 produced by ATCC PTA 2439, conjugated to p53.

Priority: US20070897012P Applic. Date: 2007-01-22; WO2008US51734 Applic. Date: 2008-01-22

Inventor: WEISBART RICHARD H [US]


Application No.: US20100143421A1  Published: 10/Jun/2010

Title: Delivery Device

Applicant/Assignee:

Application No.: 12/296978   Filing Date: 10/Apr/2007

Abstract:A process for the production of water-containing silicone rubber device comprising the steps of mixing an external phase comprising an organopolysiloxane polymer having at least two reactive groups per molecule, a water in oil emulsifier and where required one or more active ingredients and/or optional additives

with an internal phase comprising water and optionally one or more active ingredients to form an emulsion

and subsequently introducing a cure package comprising a cure package comprising a suitable catalyst, which will be determined by the cure reaction between the polymer and where required a cross-linker, and which contains more than two reactive groups, designed to react with the reactive groups in the polymer in the presence of said catalyst in order to cure the external phase of the composition, thereby entrapping the water within the body of said water-containing silicone rubber device. The resulting product is preferably used fragrance delivery in applications selected from aromatherapy anti stress ball, aromatherapy pillow, deodorising shoe sole solid deodorising device for houses, external prosthesis, facial mask for delivery of actives.

Priority: GB20060007438 Applic. Date: 2006-04-13; WO2007EP53456 Applic. Date: 2007-04-10

Inventor: VAN REETH ISABELLE [BE]; CAPRASSE VIRGINIE [BE]; THOMAS XAVIER [BE]; LECOMTE JEAN-PAUL [BE]; COUREL BENEDICTE [BE]; SCHIROSI ESTERNIA [BE]


Application No.: US20100143424A1  Published: 10/Jun/2010

Title: CASEIN NANOPARTICLE

Applicant/Assignee: FUJIFILM CORPORATION

Application No.: 12/630575   Filing Date: 03/Dec/2009

Abstract:It is an object of the present invention to provide: a positively charged nanoparticle which can be produced without using surfactants or synthetic polymers, the size of which can be controlled, which is stable at acidic condition, and which contains an active substance therein

and a method for producing the same. The present invention provides a casein particle, wherein zeta potential is positive.

Priority: JP20080310530 Applic. Date: 2008-12-05

Inventor: KANAZAWA KATSUHIKO [JP]


Application No.: US20100143451A1  Published: 10/Jun/2010

Title: Composition for Improving Skin Condition and Appearance

Applicant/Assignee:

Application No.: 12/512368   Filing Date: 30/Jul/2009

Abstract:Disclosed is a cosmetic composition comprising prenylated isoflavonoid and a carrier, wherein the prenylated isoflavonoid is from about 0.0000001% to about 10%, preferably from 0.00001% to 1%, most preferably from 0.01% to 1%, by weight, based on the total weight of the composition. The active agent prenylated isoflavonoid induces a statistically significant upregulation of collagen 1A1 and elastin genes in normal human dermal fibroblasts. The composition is effective to stimulate the production of collagen and elastin and improve the appearance and condition of the skin.

Priority: US20080085114P Applic. Date: 2008-07-31

Inventor: GRUBER JAMES V [US]


Application No.: US20100144643A1  Published: 10/Jun/2010

Title: Polymeric Biosufactants

Applicant/Assignee:

Application No.: 12/227825   Filing Date: 31/May/2007

Abstract:The present invention is directed to biosurfactants that can self-assemble or auto-aggregate into polymeric micellar structures and their use in topically-applied dermatologic products. The invention relates in particular to polymeric acylated biosurfactants (PABs) conforming to the formula Acyl-AA-Term where Acyl is an 8- to 22-membered carbon chain, branched or unbranched, saturated or unsaturated, AA is a consecutive sequence of four to nine amino acid residues, where at least one, preferably at least two of the amino acid residues is charged, and Term is an acid C-terminus or an amide C-terminus. PABs of the present invention have low critical micelle concentrations (predominantly less than about 100 ppm) in an aqueous environment of Minimal Essential Media (MEM) and can lower the surface tension in the aqueous MEM environment to less about 50 dynes/cm2. They also have the ability to increase metabolic soluble proteins.

Priority: US20060809825P Applic. Date: 2006-06-01; WO2007US12799 Applic. Date: 2007-05-31

Inventor: OWEN DONALD [US]; FAN LILI [US]


Application No.: US20100144671A1  Published: 10/Jun/2010

Title: Compositions and Methods for Cancer Treatment

Applicant/Assignee: WOMEN AND INFANTS HOSPITAL OF RI, INC

Application No.: 11/885606   Filing Date: 03/Mar/2006

Abstract:Bromoacetoxycalcidiol (B3CD), which is structurally related to calcidiol, exhibits cytotoxic and apoptotic activity toward cancer cells, including highly aggressive neuroblastoma cells. A series of small molecules designed around the structure of B3CD is expected to have growth inhibitory and apoptogenic activities toward a wide range of malignancies. B3CD shows no apparent toxicity in vivo, indicating potential value as a chemotherapeutic agent which will be particularly useful in treating highly aggressive tumors.

Priority: US20050658627P Applic. Date: 2005-03-04; WO2006US07710 Applic. Date: 2006-03-03

Inventor: SWAMY NARASIMHA [US]; SUNDARESHA HEMA MALINI K [US]


Application No.: US20100144683A1  Published: 10/Jun/2010

Title: METHODS FOR GENERATING MAMMALIAN MODELS OF ATOPIC DISEASES, AND SCREENING FOR THEIR TREATMENT

Applicant/Assignee: ASSOCIATION POUR LA RECHERCHE A L'IGBMC (ARI)

Application No.: 12/307966   Filing Date: 24/Jul/2007

Abstract:The present invention concerns a method for generating a human atopic disease-like phenotype, preferably an atopic dermatitis (AD)-like phenotype in a mammal comprising administering to said mammal at least one compound selected in the group comprising the physiologically active vitamin D3 (1[alpha],25(OH)2D3) and agonistic analogs thereof. The present invention also concerns a method for treating and/or preventing an atopic disease in a patient in a patent comprising administrating to said patient an effective amount of at least one vitamin D3 antagonist.

Priority: EP20060291201 Applic. Date: 2006-07-24; US20060832864P Applic. Date: 2006-07-24; WO2007IB02102 Applic. Date: 2007-07-24

Inventor: CHAMBON PIERRE [FR]; METZGER DANIEL [FR]; LI MEI [FR]


Application No.: US20100144708A1  Published: 10/Jun/2010

Title: HETEROCYCLIC COMPOUNDS CONTAINING NITROGEN ATOMS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME FOR TREATMENT OF CANCER

Applicant/Assignee: KOREA RESEARCH INSTITITUTE OF BIOSCIENCE AND BIOTECHNOLOGY SEOUL PHARMA, CO., LTD

Application No.: 12/376889   Filing Date: 10/Aug/2007

Abstract:The present invention relates to new heterocyclic compounds containing nitrogen atoms or pharmaceutically acceptable salts thereof, a process for the preparation thereof, and a pharmaceutical composition comprising the same for treatment of cancer. The compounds according to the present invention induce DNA damage due to reactive oxygen species to activate c-abl and p53, induce RhoB to generate apoptosis, and induce cell death by down-regulating Bcl2 involved in cell survival, which is generated by dysregulated signals via the mitochondria pathway, thereby inhibiting tumor cell growth and inducing apoptosis. Accordingly, the composition according to the present invention can be used to treat cancer.

Priority: KR20060075827 Applic. Date: 2006-08-10; WO2007KR03861 Applic. Date: 2007-08-10

Inventor: HAN GYOON HEE [KR]; CHOI EUN HYUN [KR]; YANG JEE SUN [KR]; HONG SUNG HEE [KR]; KIM MYUNG SOOK [KR]; WON MI SUN [JP]; CHUNG KYUNG SOOK [KR]; KIM DONG MYUNG [KR]; YOO HYANG SOOK [KR]; KIM HWAN MOOK [KR]; PARK SONG KYU [KR]; LEE KI HO [KR]; LEE CHANG WOO [KR]; CHOI YOUN WOONG [KR]; JEONG YONG MI [KR]; MIN BYUNG GU [KR]


Application No.: US20100144883A1  Published: 10/Jun/2010

Title: TOPICALLY APPLICABLE COMPOSITIONS FOR THE TREATMENT OF KERATINIZATION DISORDERS

Applicant/Assignee: GALDERMA RESEARCH & DEVELOPMENT, BIOT, FRANCE

Application No.: 12/652417   Filing Date: 05/Jan/2010

Abstract:Topical compositions containing from 0.01% to 0.09% by weight of adapalene or salts thereof are useful for the treatment or prevention of keratinization disorders, particularly acne, and additionally contain at least one gelling agent selected from among carbomers, polysaccharides, cellulose and its derivatives, copolymers of acrylate and of alkyl acrylate, copolymers of acrylamide and of sodium acrylamido-2-methylpropanesulfonate, and xanthan gum.

Priority: WO2008EP58775 Applic. Date: 2008-07-07; US20070929652P Applic. Date: 2007-07-06

Inventor: DOUTREMEPUICH JEAN-DANIEL [FR]


Application No.: US20100145257A1  Published: 10/Jun/2010

Title: METHOD, APPARATUS, AND KIT FOR ONYCHOMYCOSIS TREATMENT

Applicant/Assignee: POWER PAPER, LTD

Application No.: 12/632277   Filing Date: 07/Dec/2009

Abstract:Methods, apparatus, and kits for onychomycosis treatment are presented. In one embodiment, a kit for treatment includes an anti-fungal agent, in a composition, and an electrically powered patch. Exemplary embodiments of the patch include a first electrode, a power source having a first and second terminal, a second electrode coupled to the second terminal of the power source, and a base member supporting the first electrode, the second electrode, and the power source. Embodiments include those where the first and second electrode and power source are printed on the base member. Anti-fungal agents may be unionized while the composition includes an ionizing agent. Home use may be practiced, as embodiments include those in which the voltage or current of the power source cannot be adjusted by a user. Exemplary methods include the selection of a nail or diseased area to which treatment is desired and administering the kit as described.

Priority: US2004-890297 Applic. Date: 2004-07-14; US20030486973P Applic. Date: 2003-07-14

Inventor: NITZAN ZVI [IL]; TAMARKIN DOV [IL]; MAVOR DANIELA [IL]; HAREL NURIT [IL]; EMANUEL NOAM [IL]


Application No.: US20100150829A1  Published: 17/Jun/2010

Title: Antibodies to IL-6 and use thereof

Applicant/Assignee:

Application No.: 12/624778   Filing Date: 24/Nov/2009

Abstract:The present invention is directed to therapeutic methods using IL-6 antagonists such as an Ab1 antibody or antibody fragment having binding specificity for IL-6 to prevent or treat disease or to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level, reduced serum albumin level, elevated D-dimer or other coagulation cascade related protein(s), cachexia, fever, weakness and/or fatigue prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, and others.

Priority: US2009-502581 Applic. Date: 2009-07-14; US2009-399156 Applic. Date: 2009-03-06; US2009-391717 Applic. Date: 2009-02-24; US2009-366567 Applic. Date: 2009-02-05; US20080117839P Applic. Date: 2008-11-25; US20080117861P Applic. Date: 2008-11-25; US20080117811P Applic. Date: 2008-11-25

Inventor: GARCIA-MARTINEZ LEON [US]; JENSEN ANNE ELISABETH CARVALHO [US]; OLSON KATIE [US]; DUTZAR BEN [US]; LATHAM JOHN [US]; KOVACEVICH BRIAN [US]; SMITH JEFFREY T L [US]; LITTON MARK [US]; SCHATZMAN RANDALL [US]


Application No.: US20100150853A1  Published: 17/Jun/2010

Title: Artificially coloring the skin with a carotene compound, a xanthophyll compound and a lipophilic green dye composition

Applicant/Assignee: L'OREAL

Application No.: 12/591778   Filing Date: 01/Dec/2009

Abstract:A method for artificially coloring the skin entails topical application thereon of a composition containing, formulated into a physiologically acceptable medium: a) at least one compound of the carotene type, b) at least one compound of the xanthophyll type, c) at least one lipophilic green dye

the composition advantageously includes a mixture of dyes including: a) at least one compound of the carotene type, b) at least astaxanthin, c) at least one lipophilic green dye.

Priority: FR20080058152 Applic. Date: 2008-12-01; US20080193580P Applic. Date: 2008-12-08

Inventor: CASSIN GUILLAUME [FR]; POURHAMIDI SAYEH [FR]; ELGUIDJ IRENE [FR]


Application No.: US20100150869A1  Published: 17/Jun/2010

Title: USE OF TELLURIUM COMPOUNDS FOR TREATMENT OF BASAL CELL CARCINOMA AND/OR ACTINIC KERATOSIS

Applicant/Assignee: BIOMAS LTD

Application No.: 12/517222   Filing Date: 02/Jun/2009

Abstract:Methods for treating skin conditions such as basal cell carcinoma and/or actinic keratosis are provided, which are effected by administering a pharmaceutically effective amount of a tellurium-containing compound. A pharmaceutical composition for treatment of skin conditions such as basal cell carcinoma an/or actinic keratosis is also provided.

Priority: US20050716923P Applic. Date: 2005-09-15; WO2006IL01080 Applic. Date: 2006-09-14

Inventor: SREDNI BENJAMIN [IL]; ALBECK MICHAEL [IL]


Application No.: US20100150908A1  Published: 17/Jun/2010

Title: Affinity matured CRIg variants

Applicant/Assignee:

Application No.: 12/387794   Filing Date: 06/May/2009

Abstract:The present invention concerns affinity matured CRIg variants. In particular, the invention concerns CRIg variants having increased binding affinity to C3b and retaining selective binding to C3b over C3.

Priority: US20080189653P Applic. Date: 2008-08-20; US20080050888P Applic. Date: 2008-05-06

Inventor: SIDHU SACHDEV S [CA]; LI BING [US]; CAMPAGNE MENNO VAN LOOKEREN [US]; WIESMANN CHRISTIAN [US]


Application No.: US20100150940A1  Published: 17/Jun/2010

Title: ANTI-IGF ANTIBODIES

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: 12/636195   Filing Date: 11/Dec/2009

Abstract:Antibody molecules, in particular fully human antibodies that bind to human IGF-1 and cross-react with IGF-2 such that binding of IGF-1 and IGF-2 to the IGF-1 receptor is prevented and IGF-1 receptor-mediated signaling is inhibited. The antibodies do not bind to insulin and thus do not affect the mitogenic properties of insulin that are mediated by its binding to the insulin receptors. The antibodies are useful for the treatment of hyperproliferative diseases, in particular cancer.

Priority: EP20080171554 Applic. Date: 2008-12-12

Inventor: ADAM PAUL [AT]; BORGES ERIC [AT]


Application No.: US20100150975A1  Published: 17/Jun/2010

Title: Structured Composition Comprising an Encapsulated Active

Applicant/Assignee:

Application No.: 12/581941   Filing Date: 20/Oct/2009

Abstract:A structured liquid composition having a liquid matrix having water and a fibrous network structurant, the fibrous network structurant having a non-polymeric crystalline hydroxyl-functional materials

a bacterial cellulose network

and mixtures thereof

and an encapsulated active. The encapsulated active is suspended within the liquid matrix of the structured liquid composition such that the encapsulated actives do not undesirably sink, float, or collect in any discrete portion of the composition. Further, the structured liquid composition can be in the form of a raw material such as an encapsulated active slurry, in the form of an additive such as a laundry additive, and as a consumer end product. In one embodiment, the encapsulated active is a perfume microcapsule.

Priority: US20080106723P Applic. Date: 2008-10-20

Inventor: DIHORA JITEN ODHAVJI [US]; JAFFER SHAFFIQ AMIN [US]; RADOMYSELSKI ANNA VADIMOVNA [US]; VINSON PHILLIP KYLE [US]


Application No.: US20100150989A1  Published: 17/Jun/2010

Title: SUBSTRATES PROVIDING MULTIPLE RELEASES OF ACTIVE AGENTS

Applicant/Assignee:

Application No.: 12/336243   Filing Date: 16/Dec/2008

Abstract:The present disclosure comprises a polymeric substrate that provides multiple releases of active agents. A substrate for multiple phase delivery of active agents is provided having a first polymer matrix layer having a first active agent disposed therein, a second polymer matrix layer having a second active agent disposed therein, and a coacervate layer disposed between the first polymer matrix layer and the second polymer matrix layer. Selected first and second active agents are included in the first and second polymer matrices such that as the first and second polymer matrices dissolve, the active agents are released. Multiple phase active agent release is achieved by constructing multiple layers of a polymer matrix containing an active agents formed with polymers having different solubility characteristics or with active agents at different concentration levels.

Priority:

Inventor: HOFFMAN DOUGLAS ROBERT [US]; SMILTNEEK ANDREA JO [US]; CARNEY SARA ANN [US]; WENZEL SCOTT W [US]; KOENIG DAVID WILLIAM [US]; SEIDLING JEFFERY RICHARD [US]


Application No.: US20100150994A1  Published: 17/Jun/2010

Title: AMPHIPHILIC ENTITY NANOPARTICLES

Applicant/Assignee: ANTERIOS, INC

Application No.: 12/517154   Filing Date: 30/Nov/2007

Abstract:The present invention provides nanoparticle compositions comprising AE nanoparticles. The present invention provides AE nanoparticles comprising one or more amphiphilic entities and pharmaceutical compositions comprising AE nanoparticles. The present invention provides methods of manufacturing AE nanoparticles. The present invention provides methods of delivering a biologically active agent to a subject by administering AE nanoparticles containing a biologically active agent to a subject.

Priority: US20060872198P Applic. Date: 2006-12-01; WO2007US86018 Applic. Date: 2007-11-30

Inventor: KOTYLA TIMOTHY [US]


Application No.: US20100151002A1  Published: 17/Jun/2010

Title: Guggulphospholipid Methods and Compositions

Applicant/Assignee: JINA PHARMACEUTICALS, INC

Application No.: 12/513654   Filing Date: 06/Nov/2007

Abstract:The present invention relates to the methods for preparing synthetic guggulphospholipids, their fatty acid analogues and other bioactive molecules. The present invention relates to E-guggulsterone and Z-guggulsterone or mixture of E- and Z-guggulsterones. The present invention also provides a novel method for the preparation of E-guggulsterol and Z-guggulsterol or mixture of E- and Z-guggulsterols from a mixture of E- and Z-guggulsterones. The present invention further relates to guggulphospholipids and other bioactive molecules incorporated into complexes such as liposomes, complexes, emulsions, vesicles, micelles, and mixed micelles, which can include other active agents, such as hydrophobic or hydrophilic drugs for use, e.g., in treatment of human and animal diseases.

Priority: US20060856952P Applic. Date: 2006-11-06; WO2007US83832 Applic. Date: 2007-11-06

Inventor: AHMAD MOGHIS U [US]; ALI SHOUKATH M [US]; AHMAD ATEEQ [US]; SHEIKH SAIFUDDIN [US]; AHMAD IMRAN [US]


Application No.: US20100152119A1  Published: 17/Jun/2010

Title: PHARMACEUTICAL AND/OR COSMETIC COMPOSITION CONTAINING PEPTIDES

Applicant/Assignee: SOCIETE D'EXTRACTION DES PRINCIPES ACTIFIS SA (VINCIENCE)

Application No.: 12/446951   Filing Date: 26/Oct/2007

Abstract:The present invention concerns the use of peptide fragments of the protein SLC24A5 as active agents designed to induce, increase, or restore the synthesis of melanin in the melanocytes of the epidermis or of the pilar bulb, alone or in association with at least one other active agent, in a cosmetic composition or for the preparation of a pharmaceutical or particularly dermatological composition. The invention is also related to any composition containing the active agents.

Priority: FR20060009415 Applic. Date: 2006-10-26; WO2007FR01774 Applic. Date: 2007-10-26

Inventor: DAL FARRA CLAUDE [FR]; DOMLOGE NOUHA [FR]; BOTTO JEAN-MARIE [FR]


Application No.: US20100152167A1  Published: 17/Jun/2010

Title: PYRIMIDINE DERIVATIVES

Applicant/Assignee: BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG BOEHRINGER INGELHEIM PHARMACEUTICALS, INC

Application No.: 12/711364   Filing Date: 24/Feb/2010

Abstract:The present invention relates to trisubstituted pyrimidines of formula (I) wherein 0Ra to Re are defined as in claim 1, which are suitable for the treatment of illnesses characterised by excessive or abnormal cell proliferation, the use thereof for preparing a pharmaceutical composition with the abovementioned properties, and processes for the preparation thereof.

Priority: US2005-313380 Applic. Date: 2005-12-21; US2002-271763 Applic. Date: 2002-10-16; US20010330145P Applic. Date: 2001-10-17

Inventor: DAHMANN GEORG [DE]; HIMMELSBACH FRANK [DE]; KRIST BERND [DE]; LENTER MARTIN [DE]; PAUTSCH ALEXANDER [DE]; SCHNAPP GISELA [DE]; STEEGMAIER MARTIN [DE]; WITTNEBEN HELMUT [DE]; PROKOPOWICZ ANTHONY S [US]; SPEVAK WALTER [AT]; SCHOOP ANDREAS [DE]; STEURER STEFFEN [AT]


Application No.: US20100152687A1  Published: 17/Jun/2010

Title: Feminine undergarment

Applicant/Assignee:

Application No.: 12/654241   Filing Date: 15/Dec/2009

Abstract:An undergarment comprises a strapless, coreless web sized and configured between an anterior end and a posterior end to cover, in use, at least the vulva of an adult female wearer. The undergarment is pre-adherent to the wearer, e.g., having pre-applied adhesive or pre-applied suction material on the body side of the web, suitable for contact with human skin and sufficiently adherent to removably hold the undergarment in place during use. In another aspect, a feminine undergarment comprises such pre-adherent strapless, coreless web with a removable protective cover over at least the adhesive. In another aspect, a package of feminine undergarments comprises outer packaging containing at least multiple of such feminine undergarments and optionally inner packaging for each of the undergarments individually.

Priority: US20080138343P Applic. Date: 2008-12-17

Inventor: CARLOZZI ANTONELLA F [US]


Application No.: US20100152691A1  Published: 17/Jun/2010

Title: LIQUID SURFACTANT COMPOSITIONS THAT ADHERE TO SURFACES AND SOLIDIFY AND SWELL IN THE PRESENCE OF WATER AND ARTICLES USING THE SAME

Applicant/Assignee:

Application No.: 12/336262   Filing Date: 16/Dec/2008

Abstract:A liquid surfactant composition includes at least one anionic surfactant and at least one cationic surfactant. The combination of surfactants is formulated to provide a liquid composition that swells in the presence of water or body fluids, becomes a moldable solid in the presence of an excess of water, and adheres to surfaces. In addition, the liquid surfactant composition may be incorporated into or onto a substrate, such as an absorbent substrate, a fabric or cloth substrate, a tissue substrate, or a protective garment substrate.

Priority:

Inventor: SEIDLING JEFFERY RICHARD [US]; WENZEL SCOTT W [US]; KOENIG DAVID WILLIAM [US]


Application No.: US20100154143A1  Published: 24/Jun/2010

Title: COSMETIC COMPOSITION COMPRISING AT LEAST ONE ORTHO-DIPHENOL, METAL SALT, HYDROGEN PEROXIDE, (BI)CARBONATE AND SURFACE-ACTIVE AGENT, AND DYEING METHOD THEREWITH

Applicant/Assignee:

Application No.: 12/637251   Filing Date: 14/Dec/2009

Abstract:The disclosure relates to a method for dyeing keratinous fibers by applying to said fibers i) at least one entity chosen from ortho-diphenol and derivatives thereof, ii) at least one metal salt, iii) hydrogen peroxide or at least one system which generates hydrogen peroxide, iv) at least one (bi)carbonate and v) at least one surface-active agent chosen from anionic and nonionic surface-active agents. The disclosure also relates to a composition comprising i) at least one entity chosen from ortho-diphenol and derivatives thereof, ii) at least one metal salt, iii) hydrogen peroxide or at least one system which generates hydrogen peroxide, iv) at least one (bi)carbonate and v) at least one surface-active agent chosen from anionic and nonionic surface-active agents. The disclosure also relates to a multicompartment device comprising from 2 to 5 compartments comprising from 2 to 5 compositions in which the ingredients i) at least one entity chosen from ortho-diphenol and derivatives thereof, ii) at least one metal salt, iii) hydrogen peroxide or at least one system which generates hydrogen peroxide, iv) at least one (bi)carbonate, and v) at least one surface-active agent chosen from anionic and nonionic surface-active agents are distributed, said compositions being aqueous or pulverulent, with one at least of these compositions being aqueous.

Priority: FR20080058555 Applic. Date: 2008-12-12; US20080141400P Applic. Date: 2008-12-30

Inventor: GUERIN FREDERIC [FR]; GOURLAOUEN LUC [FR]


Application No.: US20100158828A1  Published: 24/Jun/2010

Title: Topical Compositions Containing CIS-6-Nonenol and its Derivatives and Methods for Treating Skin

Applicant/Assignee: AVON PRODUCTS, INC

Application No.: 12/342197   Filing Date: 23/Dec/2008

Abstract:Cosmetic compositions comprising cis-6-nonenol and methods of using such compositions to impart anti-aging benefits to the skin are disclosed. Cis-6-nonenol is believed to have modulatory activity against at least one biochemical pathway implicated in skin aging.

Priority:

Inventor: PTCHELINTSEV DMITRI S [US]; HWANG CHENG SHINE [US]


Application No.: US20100158830A1  Published: 24/Jun/2010

Title: Multiphase Personal Care Composition With Enhanced Deposition

Applicant/Assignee:

Application No.: 12/510880   Filing Date: 28/Jul/2009

Abstract:A multiphase personal care composition that comprises a structured surfactant phase and an oil continuous benefit phase. The structured surfactant phase comprises from about 5% to about 30% of a mixture of lathering surfactants, a lamellar inducing agent and a cationic polymer. The oil continuous benefit phase comprises a hydrocarbon based benefit material and a low HLB emulsifier. The low HLB emulsifier comprises an unsaturated monoglyceryl ester having from about 14 to about 30 carbon atoms. The oil continuous benefit phase comprises a ratio of said hydrocarbon based benefit materials to said low HLB emulsifier comprising from about 30:1 to about 200:1.

Priority: US20080084146P Applic. Date: 2008-07-28

Inventor: WEI KARL SHIQING [US]; STELLA QING [US]


Application No.: US20100158832A1  Published: 24/Jun/2010

Title: COSMETIC COMPOSITION COMPRISING A SUPRAMOLECULAR POLYMER AND METHOD FOR MAKING UP THE SKIN AND/OR LIPS EMPLOYING A COMPOSITION COMPRISNG A SUPRAMOLECULAR POLYMER

Applicant/Assignee:

Application No.: 12/624741   Filing Date: 24/Nov/2009

Abstract:The present disclosure relates to a method for making up the skin and/or lips, wherein a cosmetic makeup composition comprising, in a cosmetically acceptable medium, at least one polyalkene-based supramolecular polymer is applied. The disclosure also relates to a cosmetic composition for making up the skin and/or lips, comprising, in a cosmetically acceptable medium, at least one polyalkene-based supramolecular polymer and at least one coloring material.

Priority: FR20080057939 Applic. Date: 2008-11-24; US20080119207P Applic. Date: 2008-12-02

Inventor: CHODOROWSKI-KIMMES SANDRINE [FR]; ARNAUD PRASCAL [FR]; BARBA CLAUDIA [FR]


Application No.: US20100158842A1  Published: 24/Jun/2010

Title: NATURAL SKIN WHITENER: 4-HYDROXY-OXINDOLE-3-ACETIC ACID

Applicant/Assignee: SPECTRUM DYNAMICS LLC

Application No.: 12/576570   Filing Date: 09/Oct/2009

Abstract:A cosmetic and dermatological composition comprises 2, 3-dihydro-4-hydroxy-2-oxo-1-H-indole-3-acetic acid (4-hydroxy-1-oxindole-3-acetic acid) as an active ingredient for use as a melanin inhibitor and as an anti-tyrosinase enzyme inhibitor. This composition is excellent as a skin whitening agent. Since it also has potent antioxidant and anti-irritant activities it is useful in a cosmetic composition for improving hyperpigmentation disorders of the skin.

Priority: US20080195697P Applic. Date: 2008-10-09

Inventor: WILLE JR JOHN JACOB [US]


Application No.: US20100159035A1  Published: 24/Jun/2010

Title: KIT FOR TREATING SKIN INFECTION

Applicant/Assignee:

Application No.: 12/296280   Filing Date: 10/Apr/2007

Abstract:The invention provides a therapeutic composition, simultaneously containing (1) at least one polar solvent, selected from the group of a short-chain mono-alcohol and a diol

(2) between about 2% and about 25% of at least two keratolytic agents

and (3) a therapeutically safe and effective concentration of a antifungal agent It further provides a kit, consisting of an occlusive device and a therapeutic composition, useful for treatment of fungal skin infection.

Priority: US2006-219484 Applic. Date: 2006-04-04; WO2007IL00437 Applic. Date: 2007-04-10

Inventor: SHEMER AVNER [IL]


Application No.: US20100159045A1  Published: 24/Jun/2010

Title: COSMETIC USE OF ACTIVE AGENTS FOR STIMULATING THE EXPRESSION OF FN3K AND/OR FN3K RP TO IMPROVE THE SKIN'S BARRIER FUNCTION

Applicant/Assignee: CHANEL PARFUMS BEAUTE

Application No.: 12/664128   Filing Date: 13/May/2008

Abstract:A cosmetic process for caring for human skin, intended for preventing or combating the cutaneous signs resulting from non-pathological impairment of the barrier function, includes the topical application to the skin of a composition containing at least one active agent for stimulating the expression of FN3K and/or FN3K RP. The use of this active agent for preventing or combating the cutaneous signs resulting from non-pathological impairment of the barrier function is also disclosed.

Priority: US20070943120P Applic. Date: 2007-06-11; WO2008EP55862 Applic. Date: 2008-05-13

Inventor: LASSERRE CHRISTELLE [US]; FEDOROVA ELENA [US]; MAESTRO YANNICK [FR]


Application No.: US20100160208A1  Published: 24/Jun/2010

Title: Pharmaceutical composition

Applicant/Assignee: ANTISENSE PHARMA GMBH

Application No.: 12/585086   Filing Date: 02/Sep/2009

Abstract:The invention concerns a pharmaceutical composition comprising at least one stimulator of the immune cell functions and at least one substance inhibiting the cell proliferation and/or inducing cell death. In a preferred embodiment the stimulator of the function of the immune system and/or the immune cells are antagonists of TGF-beta selected from the group of oligonucleotides hybridizing with an area of the messenger RNA and or DNA encoding TGF-beta and the at least one substance inhibiting cell proliferation and/or inducing cell death is selected from the group of temozolomide, nitrosoureas, Vinca alkaloids, antagonists of the purine and pyrimidines bases, cytoststatic active antibiotics, caphthotecine derivatives, anti estrogens, anti-androgens and analogs of gonadotropin releasing hormone.

Priority: EP20030029367 Applic. Date: 2003-12-19; US2004-581547 Applic. Date: 2004-12-20; WO2004EP53604 Applic. Date: 2004-12-20; US20040541771P Applic. Date: 2004-02-05

Inventor: SCHLINGENSIEPEN KARL-HERMANN [DE]; SCHLINENSIEPEN REIMAR [DE]


Application No.: US20100160213A1  Published: 24/Jun/2010

Title: ANTIMICROBIAL AND ANTICANCER LIPOPEPTIDES

Applicant/Assignee: YEDA RESEARCH & DEVELOPMENT CO. LTD

Application No.: 12/685202   Filing Date: 11/Jan/2010

Abstract:The invention provides lipophilic conjugates comprising a peptide coupled to a fatty acid, the peptide comprising at least two positively charged amino acid residues, said peptide after conjugation to the fatty acid possessing antibacterial, antifungal, and/or anticancer activity higher than prior to conjugation. The lipophilic conjugates are suitable for treatment of infections caused by pathogenic organisms such as bacteria and fungi. The lipophilic conjugates are also suitable for sanitation, as disinfectants, or for food preservation.

Priority: US2006-560727 Applic. Date: 2006-10-10; WO2004IL00544 Applic. Date: 2004-06-18; US20030479465P Applic. Date: 2003-06-19

Inventor: SHAI YECHIEL [IL]; AVRAHAMI DORIT [IL]


Application No.: US20100160245A1  Published: 24/Jun/2010

Title: Quercetin-Containing Compositions

Applicant/Assignee: QUERCEGEN PHARMA LLC

Application No.: 12/639212   Filing Date: 16/Dec/2009

Abstract:This invention relates to a composition containing quercetin, vitamin B3, and vitamin C. Also disclosed is a method of using the composition for enhancing physical or mental performance or treating various diseases or disorders.

Priority: US2007-778234 Applic. Date: 2007-07-16; US20060807601P Applic. Date: 2006-07-17; US20060807694P Applic. Date: 2006-07-18; US20070900626P Applic. Date: 2007-02-08; US20070911747P Applic. Date: 2007-04-13; US20070913164P Applic. Date: 2007-04-20

Inventor: LINES THOMAS CHRISTIAN [US]


Application No.: US20100160251A1  Published: 24/Jun/2010

Title: IMIDAZO COMPOUNDS

Applicant/Assignee:

Application No.: 12/296311   Filing Date: 05/Apr/2007

Abstract:The present invention relates to the use of at least one lactose-derived C-glycoside of general formula (I): as an agent for protecting and/or stimulating the activity and/or the proliferation of gamma-delta T lymphocyte cells ([gamma][delta]T cells) in a composition containing a cosmetically or pharmaceutically acceptable medium. The composition will find applications for promoting skin tissue repair, for reequilibrating epidermal proliferation and differentiation disorders which appear with lack of sleep, and for improving the appearance of the head of hair and limiting hair loss.

Priority: FR20060051271 Applic. Date: 2006-04-07; WO2007EP53386 Applic. Date: 2007-04-05

Inventor: BRENTON LIONEL [FR]


Application No.: US20100160453A1  Published: 24/Jun/2010

Title: High alcohol content foaming compositions

Applicant/Assignee: DEB WORLDWIDE HEALTHCARE INC

Application No.: 12/659063   Filing Date: 24/Feb/2010

Abstract:This invention relates to a "high lower alcohol content" (>40% v/v of a C1-4 alcohol) liquid composition able to be either dispensed as a stable foam with the use of non-propellant foam dispensing devices from non-pressurized containers or as an alcohol gel composition which does not use thickener and gelling agents that leave undesirable deposits or a sticky after-feel and that has a final viscosity less than 4,000 cps. The liquid compositions comprise an alcohol, C1-4 (>40% v/v), a fluorosurfactant of at least 0.001% by weight to prepare a foamable composition or from 0-2.0% to prepare a gel-like composition of a final viscosity less than 4,000 cps, 0-10% w/w of additional minor components added to obtain the desired performance (a foamable composition or a gel-like composition with a viscosity less than 4,000 cps), and the balance being purified water. The compositions may include emulsifier-emollients and mosturizers, secondary surfactants, foam stabilizers, fragrances, antimicrobial agents, other type of medicinal ingredients, and the like ingredients or additives or combinations thereof commonly added to alcohol gels or foams, aerosol compositions or to toiletries, cosmetics, pharmaceuticals and the like.

Priority: US2006-507626 Applic. Date: 2006-08-22; US2004-952474 Applic. Date: 2004-09-29; US20030506172P Applic. Date: 2003-09-29; US20040591601P Applic. Date: 2004-07-28

Inventor: KOIVISTO BRUCE MICHAEL [CA]; DE CASTRO MARIA TERESA FERNANDEZ [CA]


Application No.: US20100161029A1  Published: 24/Jun/2010

Title: Emulsifiers for Multiple Emulsions

Applicant/Assignee:

Application No.: 10/555477   Filing Date: 07/May/2004

Abstract:The present invention relates to a stable multiple water-in-oil-in-water emulsion comprising: A multiple water-in-oil-in-water emulsion composition comprising: (1) A discontinuous phase, wherein that discontinuous phase is an internal water-in-oil emulsion comprising a) a water discontinuous phase, b) an oil continuous phase, c) a polyisobutenyl succinic anhydride-derived emulsifier(s) and/or a polyisobutylene derived emulsifier(s) d) optionally a co-emulsifier and e) optionally thickeners for the discontinuous phase a)

and (2) A continuous phase, wherein that continuous phase is an external aqueous phase comprising: a) water b) an oil-in-water emulsifier and c) optionally thickeners for the external aqueous phase resulting in a stable water-in-oil-in-water multiple emulsion. The multiple emulsions are useful for personal care products.

Priority: US20030468439P Applic. Date: 2003-05-07; WO2004US14336 Applic. Date: 2004-05-07

Inventor: FILIPPINI BRIAN B [US]; HUANG NAI Z [US]; CAREY JEFFREY M [US]; MULLAY JOHN J [US]


Application No.: US20100166252A1  Published: 01/Jul/2010

Title: METHOD AND APPARATUS FOR DETERMINING BLOOD OXYGENATION USING A MOBILE COMMUNICATION DEVICE

Applicant/Assignee: MOTOROLA, INC

Application No.: 12/347400   Filing Date: 31/Dec/2008

Abstract:A method (300) and apparatus (110) that determines blood oxygenation using a mobile communication device is disclosed. The method can include capturing (320) a plurality of images of skin using an array of pixels in a camera on a portable electronic device. The method can include comparing (330) image characteristics corresponding to the plurality of captured images at a first wavelength with image characteristics corresponding to the plurality of captured images at a second wavelength, the second wavelength being substantially distinct from the first wavelength. The method can include determining (340) blood oxygen level based on comparing the image characteristics.

Priority:

Inventor: AHMED IMTIAZ AHMED [US]; FARSHI JASMIN [US]; JONNALAGADDA KRISHNA [US]; SCHULER FRANCESCA [US]


Application No.: US20100166674A1  Published: 01/Jul/2010

Title: TRANSDERMAL DELIVERY RATE CONTROL USING AMORPHOUS PHARMACEUTICAL COMPOSITIONS

Applicant/Assignee: ACRUX DDS PTY LTD

Application No.: 12/642301   Filing Date: 18/Dec/2009

Abstract:A pharmaceutical composition for transdermal delivery comprising one or more physiologically active agents

one or more dermal penetration enhancers

and a volatile pharmaceutically acceptable carrier comprising a volatile solvent

and wherein the physiologically active agent and dermal penetration enhancer form an amorphous deposit upon evaporation of the volatile carrier, said amorphous deposit forming a reservoir within the stratum corneum

and (A) wherein the composition has a release rate profile of physiologically active agent so as to provide a ratio of the maximum concentration (Cmax) to the average concentration (Cavg) for the physiologically active agent over the dosage interval within the range of 1 to 10.

Priority: US2004-004926 Applic. Date: 2004-12-07; WO2003AU00787 Applic. Date: 2003-06-24; US20020391081P Applic. Date: 2002-06-25

Inventor: MORGAN TIMOTHY MATTHIAS [AU]; WILKINS NINA FRANCES [AU]; KLOSE KATHRYN TACI-JANE [AU]; FINNIN BARRIE CHARLES [AU]; REED BARRY LEONARD [AU]


Application No.: US20100166681A1  Published: 01/Jul/2010

Title: Anhydrous Multiphase Gel System

Applicant/Assignee:

Application No.: 11/989968   Filing Date: 04/Aug/2006

Abstract:An anhydrous multiphase gel system consisting of an outer lipid matrix and an inner phase gelled by means of a polymer is described, which can be obtained by a) Melting the lipid phase with the formation of a liquid lipid phase, b) Mixing and homogenizing polymers or polymer blends capable of swelling with the formation of a polymer phase to be dispersed, c) Combining the polymer phase with the liquid lipid phase and homogenizing the phases, and d) Cold stirring the phase mixture until a solid gel-like mixed structure of the entire system is formed. The anhydrous multiphase gel system is particularly suitable for taking up difficultly soluble active substances in high concentration and for providing topical and transdermal applications. The described system is called an EDRS, "Entrapped Drug Reservoir System".

Priority: DE200510037844 Applic. Date: 2005-08-04; WO2006DE01410 Applic. Date: 2006-08-04

Inventor: FRANKE PATRICK [DE]


Application No.: US20100166687A1  Published: 01/Jul/2010

Title: COSMETIC LIGHT PROTECTION AGENT

Applicant/Assignee: COTY PRESTIGE LANCASTER GROUP GMBH

Application No.: 12/529324   Filing Date: 29/Feb/2008

Abstract:The invention relates to a cosmetic light-protective agent for wavelengths of from 250 to 1400 nm, containing at least methylene bis-benzotriazolyl tetramethylbutylphenol as UVA filter

at least one UVB filter

sea buckthorn oil with a refractive index of from 1.4 to 1.59 and a solid with a d50 of from 3 to 50 [mu]m, selected among citrine, topaz, amethyst, ruby, glass with a refractive index of from 1.500 to 1.599 and mixtures thereof

at least one infrared-absorbing glass with a d50 of from 5 to 50 [mu]m

a free-radical scavenger, and cosmetic adjuvants and/or excipients and optionally further cosmetic active substances. The agent shows an unexpectedly high light absorption and largely prevents skin damage caused by light of 250-1400 nm in wavelength.

Priority: DE200710010861 Applic. Date: 2007-03-01; WO2008EP52507 Applic. Date: 2008-02-29

Inventor: GOLZ-BERNER KARIN [MC]; MITON SANDRA [FR]; ZASTROW LEONHARD [MC]


Application No.: US20100166814A1  Published: 01/Jul/2010

Title: Cosmetic Composition Containing At Least Two Osmolytes With A Moisturizing Or Antiaging Effect

Applicant/Assignee: LVMH RECHERCHE

Application No.: 12/644067   Filing Date: 22/Dec/2009

Abstract:The present invention relates to a cosmetic composition, which comprises a combination of at least two osmolytes chosen from the group comprising taurine or a derivative thereof, inositol, betaine and trehalose. This composition is intended for restoring, maintaining or reinforcing the moisturization of the skin and/or for protecting it against different types of stress and/or for preventing or retarding the appearance of the signs of aging of the skin, or for attenuating the effects thereof, or alternatively for promoting cell or tissue longevity.

Priority: FR20080059083 Applic. Date: 2008-12-24

Inventor: DUMAS MARC C M [FR]; KRZYCH VALERIE A S [FR]; PELLE DE QUERAL DELPHINE [FR]; HEUSELE CATHERINE [FR]


Application No.: US20100166836A1  Published: 01/Jul/2010

Title: Transdermal Therapeutic System for Volatile and/or Thermo-Labile Substances

Applicant/Assignee:

Application No.: 12/160641   Filing Date: 16/Dec/2006

Abstract:The present invention relates to a transdermal therapeutic system comprising at least one readily volatile and/or thermolabile active ingredient and/or auxiliary, which can be produced by laminating at least three components onto one another, namely a polymeric matrix layer, a likewise polymeric acceptor layer that absorbs the active ingredient and/or auxiliary at an increased rate, and a donor layer comprising, at the point of production, the volatile and/or thermolabile active ingredient and/or auxiliary. The system according to the invention is characterized in that, during or shortly after the lamination process, the donor layer combines with the acceptor layer as a result of migration of the readily volatile and/or thermolabile substances.

Priority: DE200610001536 Applic. Date: 2006-01-12; DE200610026060 Applic. Date: 2006-06-03; WO2006EP12149 Applic. Date: 2006-12-16

Inventor: JUNG TOBIAS [DE]; HORSTMANN MICHAEL [DE]; DZEKAN HORST [DE]


Application No.: US20100166844A1  Published: 01/Jul/2010

Title: POLYMER PARTICLE DISPERSION, COMPOSITION CONTAINING THE SAME AND COSMETIC TREATMENT METHOD

Applicant/Assignee:

Application No.: 12/527641   Filing Date: 12/Feb/2008

Abstract:The present patent application relates to novel dispersions of particles of polymer stabilized at the surface in a nonaqueous medium, in which dispersions the polymer comprises mainly hydrophilic cationic monomers. Another subject-matter of the invention is a cosmetic or pharmaceutical composition comprising the said dispersion in a cosmetically or pharmaceutically acceptable medium. The invention also relates to a method for the cosmetic treatment of keratinous substances employing the said composition.

Priority: FR20070053336 Applic. Date: 2007-02-19; US20070904175P Applic. Date: 2007-03-01; WO2008FR50213 Applic. Date: 2008-02-12

Inventor: MOUGIN NATHALLE [FR]; JEGOU GWENAELLE [FR]


Application No.: US20100166852A1  Published: 01/Jul/2010

Title: Cream gels comprising at least one retinoid and benzoyl peroxide

Applicant/Assignee: GALDERMA RESEARCH & DEVELOPMENT

Application No.: 12/457788   Filing Date: 22/Jun/2009

Abstract:The invention relates to a composition in the form of a cream gel comprising, in a physiologically acceptable medium, at least one dispersed retinoid and dispersed benzoyl peroxide, to its process of preparation and to its use in cosmetics and in dermatology.

Priority: FR20060055784 Applic. Date: 2006-12-21; WO2007FR52613 Applic. Date: 2007-12-21

Inventor: MALLARD CLAIRE [FR]; LOUIS FABIENNE [FR]; AT EMMANUELLE [FR]


Application No.: US20100166854A1  Published: 01/Jul/2010

Title: ELECTROSPUN MATRICES FOR DELIVERY OF HYDROPHILIC AND LIPOPHILIC COMPOUNDS

Applicant/Assignee: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY

Application No.: 12/513125   Filing Date: 25/Oct/2007

Abstract:A method of forming electrospun fiber mats from a plurality of different biodegradable polymeric fibers is provided, in which a plurality of up to six different biodegradable polymer solutions are electrospun together by a method comprising the steps of providing a plurality of up to six different biodegradable polymer solutions each containing at least one biologically or pharmaceutically active material and each in communication with a needle for electrospinning a biodegradable polymer fiber from the solution, and pumping each solution through its respective needle into an electric field under conditions effective to produce uncontrolled charged jet streams of the polymer solutions directed at a grounded rotating mandrel, thereby forming fiber threads of the biologically or pharmaceutically active compounds and polymers in the solutions that are deposited on the mandrel to form an electrospun non-woven fiber mat, wherein the needles are positioned for co-deposition of the fiber threads from the polymer solution streams together on the mandrel to form a fiber mat.

Priority: US20060863517P Applic. Date: 2006-10-30; WO2007US82459 Applic. Date: 2007-10-25

Inventor: MICHNIAK-KOHN BOZENA B [US]; THAKUR RASHMI A [US]; FLOREK CHARLES A [US]; KOHN JOACHIM [US]


Application No.: US20100167936A1  Published: 01/Jul/2010

Title: USE OF ASCORBIC ACID DERIVATIVES FOR THE FUNCTIONALIZATION OF MATRICES

Applicant/Assignee:

Application No.: 12/377008   Filing Date: 27/Jun/2007

Abstract:The invention relates to the use of at least one ascorbic acid derivative for the functionalisation of matrices, and to specific ascorbic acid derivatives and processes for the preparation thereof.

Priority: DE200610037724 Applic. Date: 2006-08-11; WO2007EP05672 Applic. Date: 2007-06-27

Inventor: RUDOLPH THOMAS [DE]; BUEHLE PHILIPP [DE]; BUCHHOLZ HERWIG [DE]


Application No.: US20100167997A1  Published: 01/Jul/2010

Title: METHOD FOR STIMULATION COLLAGEN SYNTHESIS AND/OR KGF EXPRESSION

Applicant/Assignee: ATYR PHARMA, INC

Application No.: 11/815307   Filing Date: 24/Jan/2006

Abstract:The present invention relates to a method for stimulating collagen synthesis and/or KGF expression, and more particularly, to a method for stimulating collagen synthesis and/or KGF expression using the AIMP1 or its fragment. The AIMP1 or its fragment can be effectively used for the stimulation of collagen synthesis and/or KGF expression in a subject in need thereof, the treatment of skin aging in the subject, the treatment of the flaccid and/or wrinkled skin in the subject, the promoting the smoothing and/or firming of the skin in the subject, the treatment of adverse cutaneous effects of menopause in the subject, and the treatment of adverse effects of menopause on the collagen.

Priority: WO2005KR00300 Applic. Date: 2005-02-01; WO2006KR00275 Applic. Date: 2006-01-24

Inventor: KIM SUNG-HOON [KR]


Application No.: US20100168005A1  Published: 01/Jul/2010

Title: Pyridin-3-yl derivatives as immunomodulating agents

Applicant/Assignee: ACTELION PHARMACEUTICALS LTD

Application No.: 12/310763   Filing Date: 06/Sep/2007

Abstract:The invention relates to pyridin-3-yl derivatives of Formula (I) wherein R1, R2, R3, R4, R5

R6 and A are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.

Priority: WO2006IB53187 Applic. Date: 2006-09-08; WO2007IB53593 Applic. Date: 2007-09-06

Inventor: BOLLI MARTIN [CH]; LEHMANN DAVID [CH]; MATHYS BORIS [CH]; MUELLER CLAUS [DE]; NAYLER OLIVER [CH]; STEINER BEAT [CH]


Application No.: US20100168077A1  Published: 01/Jul/2010

Title: Novel Pyridine Derivatives, Processes for Preparing Them, Pharmaceutical Compositions Thereof

Applicant/Assignee: UCB PHARMA, S.A

Application No.: 12/594313   Filing Date: 31/Mar/2008

Abstract:The present invention concerns 2-amino pyridine derivatives of formula 1 processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.

Priority: GB20070006649 Applic. Date: 2007-04-04; EP20070010008 Applic. Date: 2007-05-19; WO2008EP02525 Applic. Date: 2008-03-31

Inventor: HANNAH DUNCAN [GB]


Application No.: US20100172851A1  Published: 08/Jul/2010

Title: Hydroxy-oligocarboxylic esters: effects on nerve and use for cutaneous and mucocutaneous organs or sites

Applicant/Assignee:

Application No.: 12/726522   Filing Date: 18/Mar/2010

Abstract:A composition and method for producing a beneficial effect on a subject's nerve associated with at least one of a cosmetic condition, a dermatological indication and a dental indication and another condition. The composition comprises a hydroxy-oligocarboxylic ester and is formulated for topical administration of the product to a subject to produce the beneficial effect. The method includes topically applying to the subject in a region where the beneficial effect is desired a hydroxy-oligocarboxylic ester in an amount effective to produce the beneficial effect.

Priority: US2006-548945 Applic. Date: 2006-10-12; US20050727419P Applic. Date: 2005-10-17; US20060759525P Applic. Date: 2006-01-17

Inventor: YU RUEY J [US]; VAN SCOTT EUGENE J [US]


Application No.: US20100172943A1  Published: 08/Jul/2010

Title: PEPTIDE NANOPARTICLES AND USES THEREFOR

Applicant/Assignee: ANTERIOS, INC

Application No.: 12/517149   Filing Date: 30/Nov/2007

Abstract:The present invention provides nanoparticle compositions including one or more peptides. The present invention achieves transdermal delivery of such peptides without the need for peptide modification, or for use of chemical or mechanical abrasion or disruption of skin.

Priority: US20060872206P Applic. Date: 2006-12-01; WO2007US86040 Applic. Date: 2007-11-30

Inventor: EDELSON JONATHAN [US]; KOTYLA TIMOTHY [US]


Application No.: US20100172960A1  Published: 08/Jul/2010

Title: PRO-DRUGS OF NSAIAS WITH VERY HIGH SKIN AND MEMBRANES PENETRATION RATES AND THEIR NEW MEDICINAL USES

Applicant/Assignee:

Application No.: 12/663262   Filing Date: 04/Jun/2007

Abstract:The novel positively charged pro-drugs of NSAIAs in the general formulas (1, 2a, 2b, 2c, or 2d) "Structure 1, 2a, 2b, 2c, or 2d" were designed and synthesized. The compounds of the general formulas (1, 2a, 2b, 2c, or 2d) "Structure 1, 2a, 2b, 2c, or 2d" indicated above can be prepared from metal salts, organic base salts, or immobilized base salts of NSAIAs with suitable halide compounds. The positively charged amino groups in the pro-drugs in this invention largely increase the solubility of the drugs in water and will bond to the negative charge on the phosphate head group of membrane. Thus, the local concentration of the outside of the membrane or skin will be very high and will facilitate the passage of these pro-drugs from a region of high concentration to a region of low concentration. This bonding will disturb the membrane a little bit and may make some room for the lipophilic portion of the pro-drug. When the molecules of membrane move, the membrane may "crack" a little bit due to the bonding of the pro-drug. This will let the pro-drug insert into the membrane. At pH 7.4, only about 99% of the amino group is protonated. When the amino group is not protonated, the bonding between the amino group of the pro-drug and the phosphate head group of the membrane will disassociate, and the pro-drug will enter the membrane completely. When the amino group of the pro-drug flips to the other side of the membrane and thus becomes protonated, then the pro-drug is pulled into the cytosol, a semi-liquid concentrated aqueous solution or suspension. These pro-drugs can be used for treating and preventing diabetes (type I or/and type II), abnormal blood glucose and lipid levels, stroke, heart attack, and other heart and vascular diseases Alzheimer's diseases, Parkinson's diseases and other neurodegenerative diseases, psoriasis, discoid lupus erythematosus, systemic lupus erythematosus (SLE), autoimmune hepatitis, multiple sclerosis (MS), and other autoimmune diseases, amyotrophic lateral sclerosis (ALS), oculopharyngeal muscular dystrophy (OPMD), and other muscle disorders, inflamed hemorrhoids, cryptitis, other inflammatory conditions of the anorectum, and pruritus ani, prostatitis, prostatocystitis, varicose veins, autoimmune liver inflammation, autoimmune kidney inflammation, vein inflammation and other inflammations, skin cancers, breast cancer, colon-rectum cancer, oral cancer, and other cancers, scars, abnormal vascular skin lesions, birthmarks, moles (nevi), skin tags, aging spots (liver spots), and other skin disorders. These pro-drugs can be administered transdermally without the help of skin penetration enhancers.

Priority: WO2007IB52090 Applic. Date: 2007-06-04

Inventor: YU CHONGXI [US]; XU LINA [CN]


Application No.: US20100172964A1  Published: 08/Jul/2010

Title: VESICLE USEFUL FOR EXTERNAL PREPARATION FOR SKIN, AND EXTERNAL PREPARATION FOR SKIN COMPRISING THE VESICLE

Applicant/Assignee: POLA CHEMICAL INDUSTRIES INC

Application No.: 12/601481   Filing Date: 10/Apr/2008

Abstract:Disclosed is a technique for allowing an active ingredient as an agent for improving or maintaining the dermal environment to reach a dermis. Specifically disclosed is a vesicle comprising the following components 1) to 3): 1) an [alpha],[epsilon]-bis([gamma]-N-(C10-30) acylglutamyl) lysine and/or a salt thereof

2) ceramide and/or a derivative thereof

and 3) one or more selected from a glycerin fatty acid ester, a polyglycerin fatty acid ester and a pyroglutamic acid glycerin fatty acid ester. The acyl group in the [alpha],[epsilon]-bis([gamma]-N-(C10-30) acylglutamyl) lysine is preferably a lauroyl group. The ceramide or the derivative thereof is preferably ceramide type-2 or ceramide type-3. The vesicle can encapsulate an active ingredient. The vesicle can be contained in an external preparation for the skin.

Priority: JP20070141345 Applic. Date: 2007-05-29; WO2008JP57081 Applic. Date: 2008-04-10

Inventor: AKATSUKA HIDETAKA [JP]; IMAMURA HITOSHI [JP]; ISHIHARA YASUYUKI [JP]


Application No.: US20100172993A1  Published: 08/Jul/2010

Title: PARTICLES FOR DELIVERY OF ACTIVE INGREDIENTS, PROCESS OF MAKING AND COMPOSITIONS THEREOF

Applicant/Assignee:

Application No.: 12/377185   Filing Date: 10/Aug/2007

Abstract:The present invention discloses compositions having particles comprising, inorganic element

one or more active ingredient and optionally a release rate modulating agent, suitable for the delivery of active ingredients to human and animal tissues. The particles are nanoparticles or microparticles or mixtures thereof, made preferably by sol-gel method. The compositions are useful for application to the topical or mucosal surfaces preferably in the form of creams, gels, lotions, dry powders, spray, foam and other suitable forms.

Priority: IN2006MU01276 Applic. Date: 2006-08-11; IN2007MU00666 Applic. Date: 2007-04-03; WO2007IN00340 Applic. Date: 2007-08-10

Inventor: SINGH AMARJIT [IN]; SINGH SARABJIT [IN]; SINGH PARAMJIT [IN]; JAIN RAJESH [IN]


Application No.: US20100173003A1  Published: 08/Jul/2010

Title: COMPOSITION AND METHOD FOR ENCAPSULATING BENEFIT AGENTS

Applicant/Assignee: AMCOL INTERNATIONAL

Application No.: 12/601686   Filing Date: 27/May/2008

Abstract:A benefit agent encapsulated in a particulate-based encapsulant, and a method of manufacturing the encapsulated benefit agent, are disclosed.

Priority: US20070939988P Applic. Date: 2007-05-24; WO2008US64884 Applic. Date: 2008-05-27

Inventor: SENGUPTA ASHOKE K [US]; KOTLOSKI DAVE [US]; LOSACCO VINCENT J [US]; MCGREGOR DAVID [US]


Application No.: US20100173007A1  Published: 08/Jul/2010

Title: COMPOSITIONS AND METHODS FOR TREATING SKIN CONDITIONS IN MAMMALS

Applicant/Assignee:

Application No.: 12/725986   Filing Date: 17/Mar/2010

Abstract:A topical composition for treating skin diseases is provided. The composition comprises calendula, tea tree oil, eucalyptus oil, grape seed oil, and Aloe Vera. In some embodiment, the composition may also include beeswax, vegetable oil, vitamin E, rosemary oil, or shea butter or combinations thereof to further enhance its beneficial effects.

Priority: US2007-961333 Applic. Date: 2007-12-20

Inventor: DILEVA ROSE MARIE [US]


Application No.: US20100173021A1  Published: 08/Jul/2010

Title: Topical Product formulations containing strontium for reducing skin irritation

Applicant/Assignee: COSMEDERM TECHNOLOGIES, INC

Application No.: 12/654563   Filing Date: 23/Dec/2009

Abstract:Topical formulations containing aqueous-soluble divalent strontium cation in a suitable topical keratinized skin formulation vehicle, and methods of using these formulations to inhibit skin irritation in keratinized skin, are disclosed.

Priority: US2007-979154 Applic. Date: 2007-10-31; US2001-992491 Applic. Date: 2001-11-21; US2001-871576 Applic. Date: 2001-05-31; US1998-149886 Applic. Date: 1998-09-08; US1996-666978 Applic. Date: 1996-06-20; US1994-362100 Applic. Date: 1994-12-21

Inventor: HAHN GARY S [US]; THUESON DAVID O [US]


Application No.: US20100173910A1  Published: 08/Jul/2010

Title: TRIAMINOPYRIMIDINE CYCLOBUTENEDIONE DERIVATIVES USED AS PHOSPHATASE CDC25 INHIBITORS

Applicant/Assignee: IPDRN PHSTMS D.S.S

Application No.: 12/668999   Filing Date: 10/Jul/2008

Abstract:The present invention relates to triaminopyrimidine derivatives of formula (I) where Y, R3, W, R4a, R5a, R4b, R5b, n and m are variable. These compounds have CDC25 phosphatase-inhibiting activity and can therefore be used as drugs in diseases in which CDC25 phosphatases are involved. The invention also relates to pharmaceutical compositions containing said products and methods of using the drug.

Priority: FR20070005094 Applic. Date: 2007-07-13; WO2008FR01006 Applic. Date: 2008-07-10

Inventor: LIBERATORE ANNE-MARIE [FR]; PONS DOMINIQUE [FR]; BIGG DENNIS [FR]; PREVOST GREGORIE [FR]; BREZAK PANNETIER MARIE-CHRISTINE [FR]


Application No.: US20100174915A1  Published: 08/Jul/2010

Title: TURNOVER CONTROLLER

Applicant/Assignee:

Application No.: 12/602491   Filing Date: 29/May/2008

Abstract:This disclosure solves the problem of data security of transactions and turnovers in all distribution levels, including monitoring by the appropriate government institutions, in order to prevent tax avoidance, VAT fraud, smuggling, bootlegging, diversion of original goods from the distribution system and infiltration into the distribution system of counterfeited and original goods without payment of customs, tax and excise duties.

Priority: RS20070023720 Applic. Date: 2007-05-30; WO2008RS00013 Applic. Date: 2008-05-29

Inventor: PROKIN MILAN [RS]


Application No.: US20100178260A1  Published: 15/Jul/2010

Title: COMPOSITION COMPRISING A RETINOID, AN ADENOSINE-BASED NONPHOSPHATED COMPOUND, AND A SEMICRYSTALLINE POLYMER

Applicant/Assignee: L'OREAL

Application No.: 12/687225   Filing Date: 14/Jan/2010

Abstract:Composition containing, in a physiologically acceptable medium, at least one retinoid or a derivative thereof, one adenosine-based nonphosphated compound, and one semicrystalline polymer with one or more crystallizable side chain(s). Use for preventing and/or treating the cutaneous signs of ageing.

Priority: FR20090050238 Applic. Date: 2009-01-15; US20090149346P Applic. Date: 2009-02-03

Inventor: RAVAUX DANIELLE [FR]; MORENO ANGELES FONOLLA [FR]


Application No.: US20100178261A1  Published: 15/Jul/2010

Title: Cationic Cassia Derivatives and Applications Therefor

Applicant/Assignee:

Application No.: 12/732659   Filing Date: 26/Mar/2010

Abstract:This invention relates to cationically derivatized polycalactomannans obtained from cassia tora and cassia obtusifolia and to their use in personal care, household care, and institutional care compositions.

Priority: US2008-254437 Applic. Date: 2008-10-20; US2007-843920 Applic. Date: 2007-08-23; US2004-874296 Applic. Date: 2004-06-18; US20030479793P Applic. Date: 2003-06-19

Inventor: LEPILLEUR CAROLE A [US]


Application No.: US20100178323A1  Published: 15/Jul/2010

Title: Dermal Delivery Device

Applicant/Assignee:

Application No.: 12/687489   Filing Date: 14/Jan/2010

Abstract:A transdermal drug delivery device is disclosed. Over an extended wear period, the device causes cumulative moderate irritation plus significant irritation of less than 5% and/or achieves a meaningful degree of detachment over a seven day period of less than 20%.

Priority: WO2008US69618 Applic. Date: 2008-07-10; WO2008US69622 Applic. Date: 2008-07-10; US20070948757P Applic. Date: 2007-07-10; US20070948759P Applic. Date: 2007-07-10

Inventor: KYDONIEUS AGIS [US]; CONWAY ROBERT G [US]; ROSSI THOMAS M [US]


Application No.: US20100179469A1  Published: 15/Jul/2010

Title: Organic Light Emitting Diode Phototherapy Lighting System

Applicant/Assignee: PLEXTRONICS, INC

Application No.: 12/652359   Filing Date: 05/Jan/2010

Abstract:A lighting system includes a plurality of organic light emitting diode (OLED) devices. By selecting the plurality of OLED devices, or by selectively controlling the plurality of OLED devices, the color characteristics of the lighting system can be tuned. The lifespan of the lighting system can be improved.

Priority: US20090142403P Applic. Date: 2009-01-05; US20090167352P Applic. Date: 2009-04-07

Inventor: HAMMOND TROY [US]; NAIK SUJIT [US]; PATTISON LISA [US]


Application No.: US20100183519A1  Published: 22/Jul/2010

Title: Topical Poloxamer Formulations for Enhancing Microvascular Flow: Compositions and Uses Thereof

Applicant/Assignee: UNIVERSITY OF VIRGINIA PATENT FOUNDATION

Application No.: 12/663583   Filing Date: 06/Jun/2008

Abstract:This invention relates to therapeutic compositions comprising a surface active copolymer, such as poloxamer-188, in an amount effective to enhance microvascular blood flow and/or inflammation in injured skin or other tissue, and methods of using the therapeutic compositions of the invention to inhibit decreased blood flow associated with an injury, disease, or disorder.

Priority: US20070933902P Applic. Date: 2007-06-08; WO2008US66094 Applic. Date: 2008-06-06

Inventor: KATZ ADAM J [US]; RODEHEAVER GEORGE T [US]


Application No.: US20100183527A1  Published: 22/Jul/2010

Title: Cosmetic Compositions Comprising Sclareolide and Hesperidin Methyl Chalcone

Applicant/Assignee: COGNIS IP MANAGEMENT GMBH

Application No.: 12/665836   Filing Date: 11/Jun/2008

Abstract:The present invention relates to cosmetic compositions comprising sclareolide and hesperidin methyl chalcone (HMC), which can be used especially for the tanning of skin and/or the darkening of hair and/or preventing of greying of hair. The present invention also relates to the use of agents for these purposes.

Priority: EP20070012049 Applic. Date: 2007-06-20; WO2008EP04641 Applic. Date: 2008-06-11

Inventor: MOSER PHILIPPE [FR]; MOUSSOU PHILIPPE [FR]; DANOUX LOUIS [FR]; FREIS OLGA [FR]


Application No.: US20100183528A1  Published: 22/Jul/2010

Title: ACNE TREATMENT POWDER FOUNDATION

Applicant/Assignee: HARMONY LABORATORIES, INC

Application No.: 12/639851   Filing Date: 16/Dec/2009

Abstract:Dry powder foundation formulations that include a sustained-release salicylic acid composition, an effective, buffering amount of one or more salicylate ions, and one or more of zinc and titanium oxides, and pigments or colorants, are disclosed. The formulations provide both acne treatment and prevention, and sunblock protection. The formulation can also include other sunblocking or sunscreen agents to prevent photoaging and sunburn, such as avobenzone, and 3-benzophenone, and other cosmetically-acceptable active agents and excipients.

Priority: US20080138436P Applic. Date: 2008-12-17

Inventor: MALONEY JOHN D [US]; BARGER KATHERINE NATALIE [US]


Application No.: US20100183529A1  Published: 22/Jul/2010

Title: Cosmetic compositions comprising photostabilized dibenzoylmethane compounds and 2-pyrrolidinone-4- carboxy esters

Applicant/Assignee: L'OREAL

Application No.: 12/654031   Filing Date: 08/Dec/2009

Abstract:Photostable cosmetic compositions contain, formulated into a cosmetically acceptable vehicle, at least one UV-screening system that includes: (a) at least one dibenzoylmethane compound, and (b) at least one 2-pyrrolidinone-4-carboxy ester compound having the following formula (I): in which: R1 is a linear or branched C1-C20 alkyl radical, and R2 is a linear or branched C1-C20 alkyl radical which optionally includes a C5-C6 ring member, the phenyl radical, the benzyl radical or the phenethyl radical.

Priority: FR20080058335 Applic. Date: 2008-12-08; US20080193646P Applic. Date: 2008-12-12

Inventor: RICHARD HERVE [FR]; MARAT XAVIER [FR]


Application No.: US20100183539A1  Published: 22/Jul/2010

Title: Personal Care Compositions of Sulfonated Estolides and Other Derivatives of Fatty Acids and Uses Thereof

Applicant/Assignee:

Application No.: 12/506930   Filing Date: 21/Jul/2009

Abstract:Formulations of personal care compositions and personal care concentrate compositions containing sulfo-estolides are described. Personal care compositions of the present technology include liquid hand soaps, bath and shower washes, shampoos, 2-in-1 or 3-in-1 shampoos, antidandruff shampoo, facial cleaners, among others.

Priority: WO2009US31608 Applic. Date: 2009-01-21

Inventor: BERNHARDT RANDAL J [US]; DADO GREGORY P [US]; SAJIC BRANKO [US]; SHAPIRO IRENE [US]


Application No.: US20100183688A1  Published: 22/Jul/2010

Title: Delivery System and Method of Manufacturing the Same

Applicant/Assignee: AMCOL INTERNATIONAL CORPORATION

Application No.: 12/373769   Filing Date: 23/Jul/2007

Abstract:A microparticle delivery system for an active compound which includes an active compound loaded onto polymeric microparticles, wherein the loaded microparticles are encased by a matrix material comprising about 68% to about 99%, by weight, of the microparticle delivery system. Compositions containing the microparticle delivery system, and methods of manufacturing the microparticle delivery system, also are disclosed.

Priority: US20060832880P Applic. Date: 2006-07-24; WO2007US16516 Applic. Date: 2007-07-23

Inventor: LIU LIMIN [US]; SPINDLER RALPH [US]; URBANEC STEPHEN J [US]; VAKILI-TAHAMI GHOLAM-REZA [US]; SENGUPTA ASHOKE K [US]; CURETON KEVIN [US]


Application No.: US20100183699A1  Published: 22/Jul/2010

Title: COMPOSITIONS AND METHODS TO CROSS LINK POLYMER FIBERS

Applicant/Assignee:

Application No.: 12/691020   Filing Date: 21/Jan/2010

Abstract:Novel compositions comprising genipin for cross-linking polymer fibers, are provided. In aspects of the invention the compositions further comprise a solvent system, wherein said solvent system comprises alcohol solvent and water. The genipin-based compositions are useful in methods for promoting the stabilization of fibers in an aqueous environment, and in tissue engineering. The novel genipin-based composition is also useful in methods of treating dermatological conditions.

Priority: US20090117997P Applic. Date: 2009-01-21

Inventor: WAN WANKEI [CA]; MEKHAIL MINA [CA]


Application No.: US20100184637A1  Published: 22/Jul/2010

Title: PHARMACEUTICAL AND/OR COSMETIC COMPOSITION CONTAINING AN ACTIVE ANTIOXYDANT PRINCIPLE AND CELL ENERGY ACTIVATOR

Applicant/Assignee: SOCIETE D'EXTRACTION DES PRINCIPES ACTIFS S.A. (ISP VINCIENCE)

Application No.: 12/597862   Filing Date: 27/Oct/2009

Abstract:A cosmetic or pharmaceutical composition, and particularly dermatological composition, comprising, in a physiologically adapted medium, as active principle, polypeptides or peptides, and methods of administering a composition capable of increasing cell energy and to protect the skin from oxidative damage. Also, a cosmetic treatment procedure aimed at protecting the skin and the skin appendages from external aggressions and to combat skin aging.

Priority: FR20070003063 Applic. Date: 2007-04-27; WO2008FR00575 Applic. Date: 2008-04-23

Inventor: DAL FARRA CLAUDE [FR]; DOMLOGE NOUHA [FR]; BOTTO JEAN-MARIE [FR]


Application No.: US20100184667A1  Published: 22/Jul/2010

Title: MODIFIED PLASMINOGEN ACTIVATOR INHIBITOR TYPE-1 MOLECULE AND METHODS BASED THEREON

Applicant/Assignee: THE UNIVERSITY OF TOLEDO

Application No.: 12/597686   Filing Date: 24/Apr/2008

Abstract:The present invention relates to a modified plasminogen activator inhibitor type-1 (PAI-1) molecule that displays CN an increased in vivo half-life of the active form of PAI-1, but is deficient in one or more functional activities as compared to the wild-type PAI-1 protein. The modified PAI-1 molecule that displays an increased half-life further displays at least one of the following funtional characteristics: (i) decreased binding activity to at least one of the following molecules: urokinase plasminogen activator (uPA), tissue plasminogen activator (tPA) and vitronectin (Vn)

and (ii) decreased specific activity against at least one of the following molecules: uPA, tPA and Vn. The invention further relates to pharmaceutical compositions comprising modified PAI-1 molecules and methods of using these pharmaceutical compositions for treatment.

Priority: US20070926797P Applic. Date: 2007-04-27; WO2008US05272 Applic. Date: 2008-04-24

Inventor: JANKUN JERZY [US]; SKRZYPCZAK-JANKUN EWA [US]; SELMAN STEVEN H [US]


Application No.: US20100184733A1  Published: 22/Jul/2010

Title: SKIN TREATMENT COMPOSITION

Applicant/Assignee: EVONIK GOLDSCHMIDT GMBH

Application No.: 12/445365   Filing Date: 19/Mar/2010

Abstract:The invention discloses skin treatment compositions consisting essentially of a mixture of ceramides, cholesterol, free fatty acids-the mixture being able to mimic skin identical lamellar structures-and nonionic emulsifiers. These compositions are liquid and pumpable at room temperature which means that they can be incorporated easily into cosmetic formulations with no need for heating. Furthermore, the skin treatment compositions allow the stable inclusion of long-chain ceramides into oil-in-water emulsions as well as into water-in-oil emulsions. Inclusion of short chain ceramides that can act as dermatological regulators did not affect the lamellar lipid organization. The skin treatment compositions are claimed as well as their use in cosmetic and dermatological formulations.

Priority: WO2006EP09919 Applic. Date: 2006-10-13

Inventor: KOREVAAR CORNELIS GERRIT NIJS [NL]; FARWICK MIKE [DE]; MEYER JUERGEN [DE]; LERSCH PETER [DE]; REIDICK WILMA [DE]; WEITEMEYER CHRISTIAN [DE]


Application No.: US20100184818A1  Published: 22/Jul/2010

Title: PHOTOSENSITIZERS FOR TARGETED PHOTODYNAMIC THERAPY

Applicant/Assignee: THE GENERAL HOSPITAL CORPORATION LYNNTECH, INC

Application No.: 12/598007   Filing Date: 15/Apr/2008

Abstract:The present invention provides photosensitizer compounds based on functionalized fullerenes useful in targeted photodynamic therapy (PDT), and methods of use thereof.

Priority: US20070927365P Applic. Date: 2007-05-02; WO2008US04865 Applic. Date: 2008-04-15

Inventor: WHARTON JOHN TIMOTHY [US]; GALI HARIPRASAD [US]; HAMBLIN MICHAEL R [US]; MROZ PAWEL [US]


Application No.: US20100184842A1  Published: 22/Jul/2010

Title: Ultraconserved Regions Encoding ncRNAs

Applicant/Assignee: THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION

Application No.: 12/672014   Filing Date: 04/Aug/2008

Abstract:Described herein are methods for differentiate human cancers comprising using one or more transcribed ultraconserved regions (T-UCR) expression profiles where the association between the genomic location of UCRs and the analyzed cancer-related genomic elements is highly statistically significant and comparable to that reported for miRNAs.

Priority: US20070963329P Applic. Date: 2007-08-03; WO2008US72081 Applic. Date: 2008-08-04

Inventor: CROCE CARLO M [US]


Application No.: US20100184849A1  Published: 22/Jul/2010

Title: UREA OLIGOMERS, THEIR PREPARATION PROCESS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Applicant/Assignee: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQU

Application No.: 12/716602   Filing Date: 03/Mar/2010

Abstract:A method for treating a cytotoxic disease by administrating compounds having a general formula X-(A)n-Y, wherein: n varies between 6 and 20

X denotes a hydrogen atom, an RaCO, RaOCO, RaNHCO or RaSO2 group, Ra being an alkyl, alkenyl, alkynyl, aryl, aralkyl, heteroaryl group, the groups being substituted or not, on condition that X is different from H when n is equal to 6

A denotes either a group having formula (I) or (II), wherein Ri is a hydrogen atom, an amino acid side chain, an alkyl, alkenyl, alkynyl, aryl, aralkyl or heteroaryl group, said groups being substituted or not, i being an integer of between 1 and n

Y is an NRbRc, Rb and Rc group having the same meaning as given earlier for Ra.

Priority: FR20010012659 Applic. Date: 2001-10-02; US2004-491549 Applic. Date: 2004-10-12; WO2002FR03355 Applic. Date: 2002-10-02

Inventor: GUICHARD GILLES FRANCOIS ROGER [FR]; BRIAND JEAN-PAUL [FR]; SEMETEY VINCENT [FR]; NEUBERG PATRICK [LU]


Application No.: US20100184867A1  Published: 22/Jul/2010

Title: USE OF ACTIVE AGENTS FOR STIMULATING THE EXPRESSION OF FN3K AND/OR FN3K RP FOR COMBATING AGEING OF THE SKIN

Applicant/Assignee: CHANEL PARFUMS BEAUTE

Application No.: 12/664124   Filing Date: 13/May/2008

Abstract:A cosmetic process for caring for human skin, which is intended for preventing and/or combating at least one sign of ageing of the skin or the 'orange peel' appearance of the skin, includes the topical application to the skin of a composition containing at least one active agent for stimulating the expression of FN3K and/or FN3K RP. The use of this active agent for preventing and/or combating at least one sign of ageing of the skin or the 'orange peel' appearance of the skin associated with cellulite is also disclosed.

Priority: US20070943101P Applic. Date: 2007-06-11; WO2008EP55861 Applic. Date: 2008-05-13

Inventor: LASSERRE CHRISTELLE [US]; FEDOROVA ELENA [US]; MAESTRO YANNICK [FR]


Application No.: US20100185224A1  Published: 22/Jul/2010

Title: SKIN-PIERCING DEVICE FOR TREATMENT OF ACNE

Applicant/Assignee:

Application No.: 12/067883   Filing Date: 03/Jan/2008

Abstract:The invention features a skin-piercing device having a piercing element and the use thereof of treating acne.

Priority: US20060860703P Applic. Date: 2006-11-22; US20070896536P Applic. Date: 2007-03-23; WO2008US50105 Applic. Date: 2008-01-03

Inventor: WU JEFFREY M [US]; GILLESPIE RONALD J [US]; HULL JR RAYMOND J [US]; MCDONOUGH JUSTIN E [US]; MCLAUGHLIN ROBERT A [US]; WNEK NICHOLAS M [US]


Application No.: US20100187263A1  Published: 29/Jul/2010

Title: Foamable Composition Containing Alcohol

Applicant/Assignee: THE CLOROX COMPANY

Application No.: 12/753430   Filing Date: 02/Apr/2010

Abstract:This invention relates to compositions containing lower (C1-C4) alcohol and a polymeric fluorosurfactant formulated for being dispensed as a foam product. More particularly, the invention relates to improved compositions formulated with polymeric fluorosurfactants with pendant perfluoroalkyl side chains of a fully fluorinated chain length of C1-C7. The compositions also relate to use for personal care, such as skin sanitizing and cleansing.

Priority: US2006-466657 Applic. Date: 2006-08-23

Inventor: LESTAGE DAVID [US]; SCHEUING DAVID R [US]; CUMBERLAND SCOTT L [US]; TEMPLIN GRANT [US]


Application No.: US20100189611A1  Published: 29/Jul/2010

Title: Foamable Composition Containing Alcohol

Applicant/Assignee: THE CLOROX COMPANY

Application No.: 12/753498   Filing Date: 02/Apr/2010

Abstract:This invention relates to compositions containing lower (C1-C4) alcohol and a polymeric fluorosurfactant formulated for being dispensed as a foam product. More particularly, the invention relates to improved compositions formulated with polymeric fluorosurfactants with pendant perfluoroalkyl side chains of a fully fluorinated chain length of C1-C7. The compositions also relate to use for personal care, such as skin sanitizing and cleansing.

Priority: US2006-466657 Applic. Date: 2006-08-23

Inventor: LESTAGE DAVID [US]; SCHEUING DAVID R [US]; CUMBERLAND SCOTT L [US]; TEMPLIN GRANT [US]


Application No.: US20100189662A1  Published: 29/Jul/2010

Title: DMS (derma membrane structure) in Foam Creams

Applicant/Assignee: NEUBOURG SKIN CARE GMBH & CO. KG

Application No.: 12/664732   Filing Date: 19/Jun/2008

Abstract:The invention relates to a foam formulation comprising an emulsion, comprising an oil phase and a water phase, the oil phase comprising at least one membrane-forming substance forming a lamellar membrane in the foam formulation.

Priority: EP20070110571 Applic. Date: 2007-06-19; WO2008EP57791 Applic. Date: 2008-06-19

Inventor: NEUBOURG THOMAS [DE]


Application No.: US20100189669A1  Published: 29/Jul/2010

Title: Regulation of Mammalian Keratinous Tissue Using Skin and/or Hair Care Actives

Applicant/Assignee:

Application No.: 12/692826   Filing Date: 25/Jan/2010

Abstract:Personal care compositions containing an active selected from the group consisting of phlorogine, phlorgine BG, deoxyArbutin, sucrose dilaurate, bakuchiol, pyrenoine, millet, arlatone dioic acid, cinnamic acid, ferulic acid, achromaxyl, methyl nicotinamide, oil soluble licorice extract, folic acid, undecylenic acid, zinc undecylenate, L-tryptophan, thiamine HCl, hexylresorcinol, lipidami red vine, dragosine, methyl gentisate, inositol, symdiol 68, laminaine, their salts, their derivatives, their precursors, and/or combinations thereof. Methods for regulating the condition of mammalian keratinous tissue by topically applying the personal care compositions are also provided.

Priority: US20090148081P Applic. Date: 2009-01-29

Inventor: HAKOZAKI TOMOHIRO [US]


Application No.: US20100189761A1  Published: 29/Jul/2010

Title: Methods for Prevention and/or Treatment of Capsular Contracture

Applicant/Assignee: J&E SOLUTIONS, LLC

Application No.: 12/617502   Filing Date: 12/Nov/2009

Abstract:Methods for prevention or treatment of capsular contracture following surgical implants and other fibrosis related conditions comprising applying a topical composition comprising a pharmaceutically acceptable keratolytic, a pharmaceutically acceptable protein denaturant, a hydrating agent, and combinations thereof are disclosed.

Priority: US20090146778P Applic. Date: 2009-01-23; US20090183150P Applic. Date: 2009-06-02

Inventor: FRIEDMAN JEANNE V [US]; RASKIN ELSA M [US]


Application No.: US20100189793A1  Published: 29/Jul/2010

Title: ELECTROPHORETIC TRANSDERMAL DELIVERY SYSTEM

Applicant/Assignee: ACINO AG FRIEDRICH-ALEXANDER-UNIVERSITAT ERLANGEN-NUMBERG

Application No.: 12/646780   Filing Date: 23/Dec/2009

Abstract:A transdermal delivery system (TDS) for administering at least one active agent through the skin. The system has a first electrode, a second electrode, and a matrix located between the first and second electrodes. The TDS contains at least one active agent which is either alkaline or acidic. The system is configured such that when applying a voltage to the electrodes, the pH of the matrix, in the case of an alkaline active agent, does not exceed the pH of the active agent and, in case of an acidic active agent, does not fall below the pH of the active agent.

Priority: DE200710029139 Applic. Date: 2007-06-25; WO2008DE01070 Applic. Date: 2008-06-25

Inventor: MEYER ELISABETH [DE]; SCHRODER BRITTA [DE]; ZOGLMEIER CHRISTINE [DE]; NICKEL ULRICH [DE]


Application No.: US20100189794A1  Published: 29/Jul/2010

Title: NUCLEIC ACID HYDROGEL VIA ROLLING CIRCLE AMPLIFICATION

Applicant/Assignee: CORNELL UNIVERSITY

Application No.: 12/652707   Filing Date: 05/Jan/2010

Abstract:Methods and compositions are provided for producing nucleic acid-based compositions. Methods include enzyme catalyzed or nucleic acid polymer conjugation. Compositions include nucleic acid-containing hydrogels which can be elongated via rolling circle amplification. The hydrogels can encapsulate bioactive agents for drug delivery.

Priority: US20090204385P Applic. Date: 2009-01-05

Inventor: LUO DAN [US]; LEE JONG BUM [US]; FUNABASHI HISAKAGE [JP]


Application No.: US20100189809A1  Published: 29/Jul/2010

Title: Foamable Compositions Containing Alcohol

Applicant/Assignee: THE CLOROX COMPANY

Application No.: 12/753469   Filing Date: 02/Apr/2010

Abstract:This invention relates to compositions containing lower (C1-C4) alcohol and a polymeric fluorosurfactant formulated for being dispensed as a foam product. More particularly, the invention relates to improved compositions formulated with polymeric fluorosurfactants with pendant perfluoroalkyl side chains of a fully fluorinated chain length of C1-C7. The compositions also relate to use for personal care, such as skin sanitizing and cleansing.

Priority: US2006-466675 Applic. Date: 2006-08-23

Inventor: LESTAGE DAVID [US]; SCHEUING DAVID R [US]; CUMBERLAND SCOTT L [US]; TEMPLIN GRANT [US]


Application No.: US20100189821A1  Published: 29/Jul/2010

Title: COMPOSITION OF SKIN EXTERNAL APPLICATION CONTAINING GINSENG BERRY EXTRACTS

Applicant/Assignee:

Application No.: 12/602421   Filing Date: 30/May/2008

Abstract:Disclosed herein is a. skin external composition containing ginseng berry extract. More specifically, disclosed is a skin external composition, which contains, as an active ingredient, ginseng berry extract having the specific components and compositions, among the above-ground parts of ginseng, and thus promotes the production of collagen in the skin, shows an MMP-I inhibitory effect and, at the same time, has skin-aging inhibitory and wrinkle-reducing effects, resulting from antioxidant effects and DNA damage-protecting effects. Also disclosed is a skin external composition, which contains, as an active ingredient, ginseng berry extract, which has a skin whitening effect resulting from the effects of inhibiting melanin production and reducing pigmentation caused by UV radiation, the effects of relieving dry skin symptoms and atopic symptoms by inducing and maintaining the normal differentiation of skin keratinocytes, the effect of relieving acne and skin troubles by the regulation of sebum secretion and an anti-inflammatory effect, and makes complexion ruddy through the improvement of peripheral blood circulation to make the skin clean and clear. Also disclosed is a food composition for reducing and preventing obesity, which contains, as an active ingredient, ginseng berry extract, which increases the expression of a carnitine palmitoyl transterase-1 (CPT-I) gene, serves to transport fatty acids into mitochondria in fatty acid oxidation and promotes fat oxidation.

Priority: KR20070053097 Applic. Date: 2007-05-31; WO2008KR03069 Applic. Date: 2008-05-30

Inventor: PARK CHAN WOONG [KR]; YEOM MYEONG HOON [KR]; LEE JIN YOUNG [KR]; JEON HEE YOUNG [KR]; LEE SANG JUN [KR]; CHO NAM HOON [KR]; LEE DONG SUNG [KR]


Application No.: US20100190675A1  Published: 29/Jul/2010

Title: Personal Care Article For Sequentially Dispensing Compositions With Variable Concentrations Of Hydrophobic Benefit Materials

Applicant/Assignee:

Application No.: 12/478624   Filing Date: 04/Jun/2009

Abstract:The personal care article comprises a single chamber package and a personal care product. The package comprises a dispensing orifice, a first zone, a second zone and a third zone that are located proximal, medial and distal to the dispensing orifice. The personal care product comprises a first, a second and a third personal care composition with a first, second, and third concentration of hydrophobic benefit material. The first, second, and third personal care compositions are substantially within the first, second and third zones. The personal care product comprises a second concentration that is greater than the first and third concentration of hydrophobic benefit material. The personal care product is sequentially dispensed, such that, the first personal care composition is capable of being substantially dispensed prior to the second and third personal care compositions and the second is capable of being substantially dispensed prior to the third personal care composition.

Priority: US2009-361492 Applic. Date: 2009-01-28

Inventor: CETTI JONATHAN ROBERT [US]; PUTMAN CHRISTOPHER DEAN [US]; FARRIS RICHARD DUFFY [US]; WEI KARL SHIQING [US]; ABSHER SARAH NOELLE [US]


Application No.: US20100190740A1  Published: 29/Jul/2010

Title: OIL-IN-WATER EMULSION

Applicant/Assignee: L'OREAL

Application No.: 12/637803   Filing Date: 15/Dec/2009

Abstract:The present invention relates to a composition in the form of an emulsion of the oil-in-water type formed of oily globules which are each provided with a lamellar liquid crystal coating and which are dispersed in an aqueous phase, wherein it has a pH ranging from 3 to 5.5 and in that it contains at least one lipophilic surface-active agent with an HLB ranging from 2 to 5, at least one hydrophilic surface-active agent with an HLB ranging from 8 to 12 and at least one amphiphilic compound of ionic nature at a pH ranging from 3 to 5.5.

Priority: FR20080058755 Applic. Date: 2008-12-18; US20080139734P Applic. Date: 2008-12-22

Inventor: L ALLORET FLORENCE [FR]; SIMONNET JEAN-THIERRY [FR]


Application No.: US20100190759A1  Published: 29/Jul/2010

Title: NK 1 ANTAGONISTS

Applicant/Assignee: OPKO HEALTH, INC

Application No.: 12/750420   Filing Date: 30/Mar/2010

Abstract:A compound having the general structure shown in Formula I: or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NK1 receptors, for example various physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.

Priority: US2005-172289 Applic. Date: 2005-06-30; US20040584502P Applic. Date: 2004-07-01

Inventor: PALANI ANANDAN [US]; HUANG XIANHAI [US]; XIAO DONG [US]; PALIWAL SUNIL [US]; TSUI HON-CHUNG [US]; WROBLESKI MICHELLE LACI [US]; RAO ASHWIN U [US]; WANG CHENG [US]; SHAH SAPNA S [US]; SHIH NENG-YANG [US]


Application No.: US20100190806A1  Published: 29/Jul/2010

Title: SUBSTITUTED 6-ANILINOPURINE DERIVATIVES AS INHIBITORS OF CYTOKININ OXIDASE/DEHYDROGENASE AND PREPARATIONS CONTAINING THESE DERIVATIVES

Applicant/Assignee:

Application No.: 12/666189   Filing Date: 02/Jul/2008

Abstract:The invention relates to substituted 6-anilinopurine derivatives of the general formula I, wherein R denotes one to five substituents independently selected from the group consisting of hydrogen, halogen, hydroxyl, amino, alkyloxy and alkyl group, and R2 denotes amino, halogen, nitro, thio, alkylthio or alkyl group for use as inhibitors of cytokinin oxidase/dehydrogenase. The invention also relates to the compositions containing these derivatives.

Priority: CZ20070000453 Applic. Date: 2007-07-04; WO2008CZ00074 Applic. Date: 2008-07-02

Inventor: SPICHAL LUKAS [CZ]; GEMROTOVA MARKETA [CZ]; ZATLOUKAL MAREK [CZ]; FREBORTOVA JITKA [CZ]; GALUSZKA PETR [CZ]; WERNER TOMAS [DE]; SCHMULLING THOMAS [DE]; DOLEZAL KAREL [CZ]; STRNAD MIROSLAV [CZ]


Application No.: US20100190816A1  Published: 29/Jul/2010

Title: KINASE INHIBITORS

Applicant/Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Application No.: 12/708304   Filing Date: 18/Feb/2010

Abstract:Compounds, pharmaceutical compositions, kits and methods are provided for use with kinases that comprise a compound selected from the group consisting of: wherein the variables are as defined herein.

Priority: US2006-539857 Applic. Date: 2006-10-09; US20050724619P Applic. Date: 2005-10-07

Inventor: DONG QING [US]; PARASELLI BHEEMA R [US]; SCORAH NICHOLAS [US]; WALLACE MICHAEL B [US]; STAFFORD JEFFREY A [US]


Application No.: US20100190849A1  Published: 29/Jul/2010

Title: Novel Clerodanes and Methods for Repelling Arthropods

Applicant/Assignee:

Application No.: 12/708726   Filing Date: 19/Feb/2010

Abstract:A method for repelling arthropods involving treating a subject or an object with an arthropod repelling composition containing an arthropod repelling effective amount of at least one clerodane of the formula in which R1 is H, halogen, formyl, a straight chain or branched C1-4 saturated alkyl, a straight chain or branched C2-4 unsaturated alkyl, or an aryl containing 6-10 carbon atoms in the ring skeleton thereof, wherein R1 is unsubstituted or substituted with one or more substituents, which are the same or different, selected from the group consisting of oxo (-O), OR2, CO2R2, and OC(O)R2, wherein R2 is H, a straight chain or branched C1-30 saturated alkyl, a straight chain or branched C2-30 unsaturated alkyl, or an aryl comprising 6-10 carbon atoms in the ring skeleton thereof

wherein R2 is unsubstituted or substituted with one or more substituents selected from the group consisting of halogen, amino, hydroxyl, oxo (-O), thio, cyano and nitro

optionally a carrier, optionally an arthropod repellant, and optionally an insecticide. Preferably the compound is 13,14,15,16-tetranorclerod-3-en-12-al (callicarpenal), 13,14,15,16-tetranorclerod-3-en-12-ol, 13,14,15,16-tetranorclerod-3-en-12-oic acid, [beta]-epoxycallicarpenal, [alpha]-epoxycallicarpenal, or mixtures thereof. Also a compound of the above formula. Also an arthropod repellant composition containing an arthropod repelling effective amount of at least one of the compounds of the above formula and a carrier. The present invention does not involve the use of any compound isolated from Callicarpa species other than callicarpenal, intermedeol, or spathulenol.

Priority: US2006-374866 Applic. Date: 2006-03-14

Inventor: CANTRELL CHARLES L [US]; KLUN JEROME A [US]; DUKE STEPHEN O [US]


Application No.: US20100190851A1  Published: 29/Jul/2010

Title: Use of Entacapone in cosmetic, dermatological and pharmaceutical compositions

Applicant/Assignee:

Application No.: 12/523577   Filing Date: 16/Jan/2008

Abstract:A compound of formula (I), a salt of this compound or an isomeric or polymorphic form thereof can be used for the preparation of a cosmetic or dermatological composition, which is useful for the treatment or prophylaxis of itching or skin ageing caused by a combination of intrinsic and extrinsic factors.

Priority: EP20070100668 Applic. Date: 2007-01-17; WO2008EP50438 Applic. Date: 2008-01-16

Inventor: KRANICH REMO [DE]; AYDT EWALD M [DE]; BOCK DANIEL [DE]; WOLFF GERHARD [US]


Application No.: US20100190855A1  Published: 29/Jul/2010

Title: ORGANIC COMPOUNDS

Applicant/Assignee: NABRIVA THERAPEUTICS AG

Application No.: 12/668690   Filing Date: 11/Jul/2008

Abstract:A compound of formula (I) wherein Y is oxygen or sulfur, and X1, X2 and X3 are independently of each other hydrogen, halogen, hydroxy or linear or branched (C1-6)-alkoxy, or hydroxy-(C1-6)alkyl or (C1-6)alkoxy-(C1-6)alkyl, mono- or dihalogenated (C1-6)-alkyl, amino(C1-6)-alkyl, hydroxy(C1-6)-alkyl, with one of the two provisos that: (1) at least of X1, X2 and X3 is other than hydrogen, and (2) X2 is other than hydroxy, when X1 and X3 are hydrogen.

Priority: EP20070450123 Applic. Date: 2007-07-13; WO2008AT00255 Applic. Date: 2008-07-11

Inventor: THIRRING KLAUS [AT]; HEILMAYER WERNER [AT]


Application No.: US20100191171A1  Published: 29/Jul/2010

Title: Iontophoresis device

Applicant/Assignee: LG HOUSEHOLD & HEALTH CARE LTD

Application No.: 12/310584   Filing Date: 29/Aug/2007

Abstract:The iontophoresis device according to the exemplary embodiment of the present invention may concentrate care skin to where liver spots and freckles exist, and may be compact, portable, and convenient. An iontophoresis device according to an exemplary embodiment of the present invention may include: a housing providing an inner space

a battery installed in the housing for supplying power

a control circuit for controlling a current output from the battery

a first contact portion electrically connected with the battery and contacting the skin

a second contact portion electrically connected with the battery and disposed to the housing

and an operation portion for turning the power on and off.

Priority: KR20060083057 Applic. Date: 2006-08-30; KR20060118999 Applic. Date: 2006-11-29; KR20070068180 Applic. Date: 2007-07-06; KR20070085302 Applic. Date: 2007-08-24; WO2007KR04158 Applic. Date: 2007-08-29

Inventor: PARK HYEON-WOO [KR]


Application No.: US20100191314A1  Published: 29/Jul/2010

Title: Temperature controlled facial mask with area-specific treatments

Applicant/Assignee:

Application No.: 12/321757   Filing Date: 23/Jan/2009

Abstract:A temperature controlled cosmetic treatment facial mask with area-specific treatments of the present invention includes a substantially planar mask body which is formed with cut-outs for a person's eyes, nose, and mouth. The mask may include a number of large and small area treatment zones in combination with asymmetrical treatment zones suitable for treatment of specific and localized skin conditions. The treatments zones are coated with skin treatments, such as compounds, lotions, gels, and the like as are known in the facial treatment, cosmetics, spa and medical industry. The mask may include a self-heating or cooling substrate to provide temperature control to the face mask and each mask may include heating areas, cooling areas, or both. A system is also provided that includes an imaging device that feeds its output to a central computer system having an image analyzer, CPU, memory and Look Up Table, and face map for determining specific treatment requirements for the particular patient. An output from the central computer system is provided to a treatment deposition device which deposits various treatments onto an intermediate membrane layer to generate a custom temperature controlled facial mask with area-specific treatments for that particular patient.

Priority:

Inventor: YOUNG DANIEL L [US]


Application No.: US20100196266A1  Published: 05/Aug/2010

Title: Humanized Anti-HLA-DR Antibodies

Applicant/Assignee: IMMUNOMEDICS, INC

Application No.: 12/754140   Filing Date: 05/Apr/2010

Abstract:The present invention concerns compositions and methods of use of humanized anti-HLA-DR antibodies. In preferred embodiments, the antibodies induce apoptosis and inhibit proliferation of lymphoma cells without inducing CDC or ADCC. In more preferred embodiments, the humanized anti-HLA-DR antibodies bind to the same epitope of HLA-DR as, or compete for binding to HLA-DR with, a murine L243 antibody. Most preferably, the humanized anti-HLA-DR antibody exhibits a higher affinity for HLA-DR than the parental murine antibody. The humanized HLA-DR antibody is of use for therapy of various diseases such as cancer, autoimmune disease or immune dysregulatory function, and is of particular use for therapy of B cell lymphomas and leukemias. In most preferred embodiments, the humanized anti-HLA-DR antibody is capable of inducing at least partial remission of lymphomas that are resistant to other B cell antibodies, such as rituximab.

Priority: US2009-556718 Applic. Date: 2009-09-10; US2006-368296 Applic. Date: 2006-03-03; US20050657695P Applic. Date: 2005-03-03; US20090166809P Applic. Date: 2009-04-06; US20090168715P Applic. Date: 2009-04-13

Inventor: GOLDENBERG DAVID M [US]; HANSEN HANS J [US]; CHANG CHIEN-HSING [US]


Application No.: US20100196267A1  Published: 05/Aug/2010

Title: Humanized L243 Antibodies

Applicant/Assignee: IMMUNOMEDICS, INC

Application No.: 12/556718   Filing Date: 10/Sep/2009

Abstract:Humanized antibodies are provided that specifically bind HLA-DR. The antibodies recognize the epitope recognized by the murine monoclonal antibody L243. Processes for preparing such antibodies, pharmaceutical compositions containing such antibodies, and clinical therapeutic and diagnostic, as well as research-related uses for such antibodies, are provided.

Priority: US2006-368296 Applic. Date: 2006-03-03; US20050657695P Applic. Date: 2005-03-03

Inventor: GOLDENBERG DAVID M [US]; HANSEN HANS J [US]; QU ZHENGXING [US]; CHANG CHIEN-HSING [US]


Application No.: US20100196290A1  Published: 05/Aug/2010

Title: COMPOSITIONS COMPRISING BETULONIC ACID

Applicant/Assignee: VALTION TEKNILLINEN TUTKIMUSKESKUS

Application No.: 12/303665   Filing Date: 06/Jun/2007

Abstract:The invention relates to compositions of cosmetic and pharmaceutical industries comprising betulonic acid for humans and animals, and further, to the use of betulonic acid in compositions of cosmetic and pharmaceutical industries. The invention is also directed to compositions containing, besides betulonic acid, optionally other compounds derived from betulin.

Priority: FI20060005388 Applic. Date: 2006-06-07; WO2007FI50333 Applic. Date: 2007-06-06

Inventor: YLI-KAUHALUOMA JARI [FI]; KOSKIMIES SALME [FI]; ALAKURTTI SAMI [FI]; BERGSTROEM PIA [FI]; AHLNAES THOMAS [FI]; MEINANDER KRISTIAN [FI]; TAMMELA PAEIVI [FI]


Application No.: US20100196293A1  Published: 05/Aug/2010

Title: USE OF AN ACTIVE PRINCIPLE ORIGINATING FROM FLAX IN A COMPOSITION INTENDED TO REINFORCE THE BARRIER FUNCTION OF THE SKIN AND TO PROTECT THE SKIN AND THE APPENDAGES AGAINST EXTERNAL AGGRESSIONS

Applicant/Assignee: SOCIETE D'EXTRACTION DES PRINCIPES ACTIFS S.A. (VINCIENCE)

Application No.: 12/724082   Filing Date: 15/Mar/2010

Abstract:The present invention concerns the use, in a cosmetic composition, of an effective quantity of active principle originating from flax (genus Linum) to reinforce the barrier function of the skin and to protect the skin and the appendages against external aggressions. The active principle originates from the hydrolysis of flax proteins and contains principally polypeptides or peptides. The invention likewise relates to the use, in a cosmetic composition, of a peptidic hydrolysate of flax as active principle capable of activating HMG-CoA reductase. The invention likewise relates to the use of a peptidic hydrolysate of flax as active principle capable of activating transglutaminase. The active principle can likewise be used to prepare pharmaceutical compositions intended to prevent or combat against the pathologies linked to alterations to the barrier function, such as certain hypersensitivies, irritations of the skin and reactive skins, or atopic dermatitis.

Priority: FR20070005295 Applic. Date: 2007-07-20; US2010-669836 Applic. Date: 2010-01-20; WO2008FR01072 Applic. Date: 2008-07-21

Inventor: DAL FARRA CLAUDE [FR]; DOMLOGE NOUHA [FR]; BOTTO JEAN-MARIE [FR]


Application No.: US20100196315A1  Published: 05/Aug/2010

Title: IL-12/p40 BINDING PROTEINS

Applicant/Assignee: ABBOTT LABORATORIES

Application No.: 12/763048   Filing Date: 19/Apr/2010

Abstract:The present invention encompasses IL-12p40 binding proteins, particularly antibodies that bind human interleukin-12 (hIL-12) and/or human IL-23 (hIL-23). Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Preferred antibodies have high affinity for hIL-12 and/or hIL-23 and neutralize h IL-12 and/or hIL-23 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and/or hIL-23 and for inhibiting hIL-12 and/or hIL-23 activity, e.g., in a human subject suffering from a disorder in which hIL-12 and/or hIL-23 activity is detrimental.

Priority: US2006-478096 Applic. Date: 2006-06-29; US20050695679P Applic. Date: 2005-06-30

Inventor: LACY SUSAN E [US]; FUNG EMMA [US]; BELK JONATHAN P [US]; DIXON RICHARD W [US]; ROGUSKA MICHAEL [US]; HINTON PAUL R [US]; KUMAR SHANKAR [US]


Application No.: US20100196395A1  Published: 05/Aug/2010

Title: ANTI-IGF ANTIBODIES

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: 12/665373   Filing Date: 19/Jun/2008

Abstract:Antibody molecules, in particular fully human antibodies that bind to human IGF-1 and cross-react with IGF-2 such that binding of IGF-1 and IGF-2 to the IGF-1 receptor is prevented and IGF-1 receptor-mediated signaling is inhibited. The antibodies do not bind to insulin and thus do not affect the mitogenic properties of insulin that are mediated by its binding to the insulin receptors. The antibodies are useful for the treatment of hyperproliferative diseases, in particular cancer.

Priority: EP20070110587 Applic. Date: 2007-06-19; WO2008EP57789 Applic. Date: 2008-06-19

Inventor: ADAM PAUL [AT]; OSTERMANN ELINBORG [AT]


Application No.: US20100196406A1  Published: 05/Aug/2010

Title: AGENTS FOR THE TREATMENT OF INFLAMMATORY DISEASES AND METHODS OF USING SAME

Applicant/Assignee: RAPPAPORT FAMILY INSTITUTE FOR RESEARCH IN THE MEDICAL SCIENCES

Application No.: 12/602771   Filing Date: 04/Jun/2008

Abstract:A method of treating an autoimmune disease such as Multiple Sclerosis is disclosed. The method comprises administering to a subject a therapeutically effective amount of CXCL11. Polypeptides and pharmaceutical compositions for treating same are also disclosed.

Priority: US20070924866P Applic. Date: 2007-06-04; WO2008IL00757 Applic. Date: 2008-06-04

Inventor: KARIN NATHAN [IL]; ZOHAR YANIV [IL]; WILDBAUM GIZI [IL]


Application No.: US20100196478A1  Published: 05/Aug/2010

Title: PROTEIN MATRIX MATERIALS, DEVICES AND METHODS OF MAKING AND USING THEREOF

Applicant/Assignee: GEL-DEL TECHNOLOGIES, INC

Application No.: 12/700896   Filing Date: 05/Feb/2010

Abstract:The present invention relates to protein matrix materials and devices and the methods of making and using protein matrix materials and devices. More specifically the present invention relates to protein matrix materials and devices that may be utilized for various medical applications including, but not limited to, drug delivery devices for the controlled release of pharmacologically active agents, encapsulated or coated stent devices, vessels, tubular grafts, vascular grafts, wound healing devices including protein matrix suture material and meshes, skin/bone/tissue grafts, biocompatible electricity conducting matrices, clear protein matrices, protein matrix adhesion prevention barriers, cell scaffolding and other biocompatible protein matrix devices. Furthermore, the present invention relates to protein matrix materials and devices made by forming a film comprising one or more biodegradable protein materials, one or more biocompatible solvents and optionally one or more pharmacologically active agents. The film is then partially dried, rolled or otherwise shaped, and then compressed to form the desired protein matrix device.

Priority: US2001-796170 Applic. Date: 2001-02-28; US1998-160421 Applic. Date: 1998-09-25

Inventor: MASTERS DAVID B [US]


Application No.: US20100196484A1  Published: 05/Aug/2010

Title: Use of expanded amorphous mineral particles for increasing the tenacity of a fragrance, scenting composition and method for treating body odours

Applicant/Assignee: L'OREAL

Application No.: 12/620236   Filing Date: 17/Nov/2009

Abstract:The subject-matter of the invention is a cosmetic method for scenting a human keratinous substance which consists in applying, to the said substance, a scenting composition comprising, in a cosmetically acceptable medium, at least 0.3% by weight of at least one scenting substance and at least particles of an expanded amorphous mineral material and in particular of an expanded amorphous mineral material resulting from at least one volcanic rock and more particularly expanded perlite particles. Another subject-matter of the present invention is a cosmetic method for treating human body odours, in particular axillary odours, which consists in applying, to the surface of the skin, an effective amount of the said composition. The invention relates to specific scenting compositions comprising, in a cosmetically acceptable medium: a) at least 0.3% by weight, with respect to the total weight of the composition, of a scenting substance

b) at least the said particles.

Priority: FR20080057790 Applic. Date: 2008-11-17; US20080116802P Applic. Date: 2008-11-21

Inventor: AUBRUN ODILE [FR]; CASSIER MATTHIEU [FR]


Application No.: US20100197734A1  Published: 05/Aug/2010

Title: PLEUROMUTILIN DERIVATIVES AND THEIR USE AS ANTIMICROBIALS

Applicant/Assignee: NABRIVA THERAPEUTICS AG

Application No.: 12/668769   Filing Date: 11/Jul/2008

Abstract:A compound of formula (I) or of formula (II) wherein X is oxygen or sulfur, and Y is a residue of pipecolic acid or a residue of an amino acid, preferably a naturally occurring amino acid.

Priority: EP20070450124 Applic. Date: 2007-07-13; WO2008AT00254 Applic. Date: 2008-07-11

Inventor: THIRRING KLAUS [AT]; HEILMAYER WERNER [AT]


Application No.: US20100197805A1  Published: 05/Aug/2010

Title: COMPOSITION FOR IMPROVING THE SURFACE APPEARANCE OF THE SKIN

Applicant/Assignee: L'OREAL

Application No.: 12/694345   Filing Date: 27/Jan/2010

Abstract:The present invention relates to a cosmetic composition in the form of a paste, containing, in a physiologically acceptable medium, at least 10% by weight, relative to its total weight, of filler(s), at least one silicone polyamide block copolymer (PSPA) and at least one wax having a starting melting point of greater than or equal to 50 DEG C. The present invention also relates to a cosmetic treatment method for improving the surface appearance of the skin, and in particular for reducing the visible and/or tactile irregularities of the skin, for instance the cutaneous microrelief, comprising at least the application of at least one composition as defined above to skin exhibiting said irregularities.

Priority: FR20090050491 Applic. Date: 2009-01-27; US20090152976P Applic. Date: 2009-02-17

Inventor: CASSIN GUILLAUME [FR]


Application No.: US20100197809A1  Published: 05/Aug/2010

Title: SKIN SOLUTION AND PREPARATION METHOD THEREOF

Applicant/Assignee:

Application No.: 12/365527   Filing Date: 04/Feb/2009

Abstract:A skin solution for transporting molecules with high molecular weight to the skin, and/or moisturizing the epidermal tissues of the skin, and/or alternating the membrane permeability of the skin, and/or softening any type of callus, corns, nail folds or dry skin and facilitating the removal of the same. A method for preparing the skin solution, the solution being sprayable to form tiny droplets to be readily absorbed by the skin.

Priority:

Inventor: ORTIZ ALVARO ERNESTO [US]


Application No.: US20100202987A1  Published: 12/Aug/2010

Title: PREPARATION FOR IMPROVING THE PROTECTION OF HUMAN CELLS, ESPECIALLY CELLS OF THE HUMAN SKIN, FROM THE HARMFUL INFLUENCES OF OXIDATIVE NOXAE AND UV RADIATION

Applicant/Assignee:

Application No.: 12/668675   Filing Date: 01/May/2008

Abstract:The invention relates to topical preparations for improving the protection of the mitochondria of human skin cells from the deleterious influences of oxidative noxae and UV irradiation, said preparations being characterised by a content in proteins that are capable of permeating the mitochondrial membrane. The invention also relates to a corresponding cosmetic method for treating human skin.

Priority: DE200710033067 Applic. Date: 2007-07-13; WO2008US05587 Applic. Date: 2008-05-01

Inventor: KRUTMANN JEAN [DE]; HAENDELER JUDITH [DE]


Application No.: US20100203004A1  Published: 12/Aug/2010

Title: COSMETIC COMPOSITION CONTAINING A TENSIONING AGENT AND AN ACRYLIC POLYMER

Applicant/Assignee: L'OREAL

Application No.: 12/676541   Filing Date: 28/Oct/2008

Abstract:The invention relates to a cosmetic composition comprising, in a physiologically acceptable medium, a skin-tensioning agent and an acrylic polymer containing a group of phosphorylcholine type. The invention also relates to a cosmetic skincare process, more particularly for facial skin, in particular wrinkled skin, comprising the application of the composition to the skin.

Priority: WO2008EP64612 Applic. Date: 2008-10-28; FR20070058725 Applic. Date: 2007-10-31

Inventor: SIMONNET JEAN-THIERRY [FR]; CASSIN GUILLAUME [FR]


Application No.: US20100203094A1  Published: 12/Aug/2010

Title: COMBINATION OF A MICROORGANISM AND A PHYTOSPHINGOSINE DERIVATIVE, COMPOSITION, METHODS OF USE

Applicant/Assignee: L'OREAL

Application No.: 12/685697   Filing Date: 12/Jan/2010

Abstract:At least one phytosphingosine salicylate derivative and at least one lysate of at least one microorganism of the genus Bifidobacterium. Composition, combination. Use, including cosmetic use for reinforcing the repair and regeneration capacity of an epithelium, especially an epidermis, in particular an aged epidermis.

Priority: FR20090050143 Applic. Date: 2009-01-12; US20090146319P Applic. Date: 2009-01-22

Inventor: AMAR DAVID [FR]; BERNARD BRUNO [FR]; BERNARD DOMINIQUE [FR]; CASTIEL ISABELLE [FR]


Application No.: US20100203122A1  Published: 12/Aug/2010

Title: Delivery System for Remote Treatment of an Animal

Applicant/Assignee:

Application No.: 12/447877   Filing Date: 31/Oct/2007

Abstract:A remote treatment delivery system comprising a substantially non-skin piercing dosage projectile containing a biologically active agent and a transdermal carrier.

Priority: US20060855745P Applic. Date: 2006-11-01; WO2007AU01651 Applic. Date: 2007-10-31

Inventor: WEYER GRANT [AU]; TRICKEY SIMON ROBERT SANFORD [ZA]; ROSE TIMOTHY DONALD [AU]


Application No.: US20100203158A1  Published: 12/Aug/2010

Title: ANTISEPTIC COMPOSITIONS AND USES THEREOF

Applicant/Assignee: RAMOT AT TEL AVIV UNIVERSITY LTD

Application No.: 12/703853   Filing Date: 11/Feb/2010

Abstract:Antiseptic compositions and kits containing a source of silver ions and menthol, which act in synergy such that a concentration of silver ions in the composition is substantially reduced, are disclosed. Further disclosed are uses of the antiseptic compositions as disinfectants and in the treatment of wounds.

Priority: US20090151539P Applic. Date: 2009-02-11

Inventor: HADAR NOA [IL]; FREEMAN AMIHAY [IL]


Application No.: US20100203175A1  Published: 12/Aug/2010

Title: DEGLYCATION OF AGEs

Applicant/Assignee: BASF BEAUTY CARE SOLUTIONS FRANCE S.A.S

Application No.: 12/668061   Filing Date: 09/Jul/2008

Abstract:The invention relates to the use, as an active ingredient, of at least one substance that promotes the deglycation of AGEs for preparing a composition, especially for limiting the presence of AGEs in a tissue. The invention particularly relates to the use of such a substance for preparing a composition intended to prevent and/or combat a reduction in flexibility and/or plasticity and/or elasticity and/or functionality of a tissue, and/or to prevent and/or combat the ageing of a tissue, by promoting the deglycation of AGEs in the tissue, said tissue preferably being the skin, or the tissue wall of a blood vessel or of an organ.

Priority: FR20070056350 Applic. Date: 2007-07-09; WO2008EP58955 Applic. Date: 2008-07-09

Inventor: ABDUL-MALAK NABIL [FR]; ALTOBELLI CECILE [FR]; PERRIER ERIC [FR]


Application No.: US20100203638A1  Published: 12/Aug/2010

Title: Method of Producing High-Density Cultured Tissue and High-Density Cultured Tissue

Applicant/Assignee: SCHOOL JURIDICAL PERSON KITASATO GAKUEN

Application No.: 11/884308   Filing Date: 14/Feb/2006

Abstract:It is intended to provide a method comprising providing a mesh member and a liquid flow controlling member in a channel, in which a cell culture liquid containing an extracellular matrix component and animal cells of one or more types are cultured under circulation, so that the liquid flow-controlling member is located in contact with or close to the back face of the mesh member with respect to the liquid flow, and thus collecting the polymerized extracellular matrices and the animal cells at a high density on the surface of the mesh member. According to this method, an artificial tissue similar to a biological tissue, in which cells are collected at a high density, can be quickly constructed by a simple procedure.

Priority: JP20050038261 Applic. Date: 2005-02-15; WO2006JP302561 Applic. Date: 2006-02-14

Inventor: ADACHI EIJIRO [JP]; OHASHI SHIHOKA [JP]; HIRAI KAZUYA [JP]


Application No.: US20100204211A1  Published: 12/Aug/2010

Title: MEDICAMENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: 12/645151   Filing Date: 22/Dec/2009

Abstract:The present invention relates to the use of indolinones of general formula substituted in the 6 position, wherein R1 to R5 and X are defined as in claim 1, the isomers and the salts thereof, particularly the physiologically acceptable salts thereof, as a medicament for the prevention or treatment of specific fibrotic diseases.

Priority: EP20040030770 Applic. Date: 2004-12-24; US2005-275223 Applic. Date: 2005-12-20

Inventor: PARK JOHN EDWARD [DE]; ROTH GERALD JUERGEN [DE]; HECKEL ARMIN [DE]; CHAUDHARY NVEED [GB]; BRANDL TRIXI [CH]; DAHMANN GEORG [DE]; GRAUERT MATTHIAS [DE]


Application No.: US20100204227A1  Published: 12/Aug/2010

Title: ISOINDOLINE COMPOUNDS AND METHODS OF THEIR USE

Applicant/Assignee:

Application No.: 12/608953   Filing Date: 29/Oct/2009

Abstract:Provided herein are isoindoline compounds, pharmaceutical compositions comprising one or more of such compounds, and methods of their use for treating, preventing, or managing various diseases.

Priority: US20080109475P Applic. Date: 2008-10-29

Inventor: MULLER GEORGE W [US]; RUCHELMAN ALEXANDER L [US]


Application No.: US20100204262A1  Published: 12/Aug/2010

Title: CATIONIC PHARMACEUTICALLY ACTIVE INGREDIENT CONTAINING COMPOSITION, AND METHODS FOR MANUFACTURING AND USING

Applicant/Assignee:

Application No.: 12/701367   Filing Date: 05/Feb/2010

Abstract:A cationic pharmaceutically active ingredient containing composition is provided. The composition includes a cationic pharmaceutically active ingredient, a hydrophobic polymer/hydrophilic polymer adduct comprising a poly(vinylpyrrolidone/alkylene) polymer and a polymer comprising carboxylic acid groups, hydroxyl groups, or a mixture of carboxylic acid groups and hydroxyl groups, a compatibilizing amount of a long chain organic acid having a carbon chain of at least 8 carbon atoms, and at least about 50 wt. % water.

Priority: US20090150673P Applic. Date: 2009-02-06

Inventor: ROSZELL JAMES A [US]; ZHANG JIE [US]


Application No.: US20100204632A1  Published: 12/Aug/2010

Title: PERMEABLE PRESSURE SENSITIVE ADHESIVE

Applicant/Assignee:

Application No.: 12/452513   Filing Date: 17/Jun/2008

Abstract:The present invention relates to a pressure sensitive, hot melt processable adhesive composition comprising a polar plasticising oil and a polar polyethylene copolymer, and a layered adhesive construct and a medical device comprising the adhesive composition according to the invention.

Priority: DK20070001003 Applic. Date: 2007-07-06; WO2008DK50146 Applic. Date: 2008-06-17

Inventor: LYKKE MADS [DK]; TOFTKAER ASTRID [DK]; BUUS HASSE [DK]; KONGEBO TOM [DK]


Application No.: US20100209361A1  Published: 19/Aug/2010

Title: HIGHLY CATIONIC COPOLYMERS BASED ON QUATERNIZED NITROGEN-CONTAINING MONOMERS

Applicant/Assignee: BASF SE

Application No.: 12/669315   Filing Date: 01/Jul/2008

Abstract:The present invention relates to a copolymer with high cationic charge based on quaternized nitrogen-containing monomers, to cosmetic or pharmaceutical compositions which comprise at least one such copolymer, and to further uses of these copolymers.

Priority: EP20070112639 Applic. Date: 2007-07-17; WO2008EP58439 Applic. Date: 2008-07-01

Inventor: MEIER NICOLE [DE]; CASTRO IVETTE GARCIA [DE]; WOOD CLAUDIA [DE]; STAUB JESSICA [DE]


Application No.: US20100209364A1  Published: 19/Aug/2010

Title: Emulsified Composition

Applicant/Assignee: ROHTO PHARMACEUTICAL CO., LTD

Application No.: 12/669744   Filing Date: 17/Jul/2008

Abstract:An emulsified composition comprises (A) petrolatum, (B) lecithin, (C) glycerin, (D) water and (E) a water-soluble polymer, wherein the content of the petrolatum (A) is 10 to 30 wt % relative to 100 wt % of the emulsified composition, and an internal phase of the emulsified composition has an average particle diameter of not more than 800 nm as measured by a dynamic light scattering method based on the dynamic light scattering theory.

Priority: JP20070190216 Applic. Date: 2007-07-20; WO2008JP62912 Applic. Date: 2008-07-17

Inventor: ABE MASAMICHI [JP]; ISHIKAWA TAKASHI [JP]; KATANO TAKASHI [JP]; MARUKAWA JUNKO [JP]; KASUGA SHINYA [JP]


Application No.: US20100209494A1  Published: 19/Aug/2010

Title: Liposomes and Uses Thereof

Applicant/Assignee: SYNVOLUX IP B.V

Application No.: 12/717447   Filing Date: 04/Mar/2010

Abstract:The invention relates to the field of molecular medicine and pharmacology. More specifically, it relates to liposomes and their use as delivery vehicle for therapeutic compounds. Provided is a liposome comprising at least one lipid bilayer enclosing an interior compartment, wherein said lipid bilayer comprises at least one synthetic pyridinium-derived amphiphile, for instance a Saint-molecule.

Priority: EP20070115897 Applic. Date: 2007-09-07; WO2008NL50587 Applic. Date: 2008-09-05

Inventor: KAMPS JOHANNES ADRIANUS ANTONIUS MARIA [NL]; MOLEMA GRIETJE [NL]; RUITERS MARCEL HERMAN JOSEF [NL]; ADRIAN JOANNA EWA [NL]


Application No.: US20100209544A1  Published: 19/Aug/2010

Title: BOTANICAL EXTRACTS FROM OIL PALM VEGETATION LIQUOR FOR COSMECEUTICAL APPLICATIONS

Applicant/Assignee:

Application No.: 12/595612   Filing Date: 14/Apr/2008

Abstract:A cosmeceutical composition comprising phenolic compounds, fruit acids and sugars. extracted from the vegetation liquor of the palm oil milling process has been suggested. This composition is rich in antioxidants, and significantly improves skin health, including preventing aging of the skin.

Priority: MY20070000568 Applic. Date: 2007-04-12; WO2008MY00030 Applic. Date: 2008-04-14

Inventor: SAMBANTHMURTHI RAVIGADEVI [MY]; TAN YEW AI [MY]; MANICKAM KALYANA SUNDRAM [MY]; WAHID MOHD BASRI BIN [MY]


Application No.: US20100210499A1  Published: 19/Aug/2010

Title: SKIN AND HAND CLEANING COMPOSITIONS WITH HYDROPHILIC EMOLLIENTS

Applicant/Assignee: EVONIK STOCKHAUSEN GMBH

Application No.: 12/595531   Filing Date: 22/Apr/2008

Abstract:The invention relates to skin cleansers/hand cleaners, particularly coarse hand cleaners, containing at least 0.1 wt. % of at least one hydrophilic emollient having an HLB value of >=10. Said skin cleansers/ hand cleaners especially contain, relative to the entire composition of the cleanser/cleaner, a.) at least 0.1 wt. % of at least one hydrophilic emollient, preferably a polyol ester, b.) 2 to 40 wt. % of at least one surfactant selected from among the group comprising fatty alcohol ethoxylates, fatty alcohol ether sulfates, and salts of sulfated and/or sulfonated fatty acids, c.) 30 to 90 wt. % of water, d.) 0 to 30 wt. % of one or more cleaning promoters selected from among the group comprising polyols, polyether, polyphosphates, and phosphates, e.) 0 to 30 wt. % of one or more abrasive agents, f.) 0 to 1.0 wt. % of propoxylated fatty alcohols, g.) one or more optional viscosity-forming agents, h.) other optional cosmetic auxiliary agents, additives, and/or active substances, the total of components a.) to h.) amounting to 100 wt. %.

Priority: DE200710022693 Applic. Date: 2007-05-11; WO2008EP54834 Applic. Date: 2008-04-22

Inventor: ALLEF PETRA [DE]; KLOTZBACH VOLKER [DE]; VEEGER MARCEL [DE]


Application No.: US20100210994A1  Published: 19/Aug/2010

Title: DELIVERY OF THERAPEUTICALLY/DERMATOLOGICALLY ACTIVE SPECIES INTO THE SKIN VIA ELECTROPORATION

Applicant/Assignee: GALDERMA RESEARCH & DEVELOPMENT

Application No.: 12/541376   Filing Date: 14/Aug/2009

Abstract:A regime or regimen for treating a skin disease, disorder or condition afflicting a patient in need thereof includes forming at least one micropore to a predetermined depth through a surface of the afflicted skin of such patient

positioning at least a first electrode on the surface of the afflicted skin electrically coupled to the at least one micropore and a second electrode on the surface of the afflicted skin spaced apart from the first electrode

applying an electrical voltage from the first and second electrodes to produce a desired electroporation in the skin, and further including the step of delivering a biologically active species to the afflicted skin at the at least two micropores formed therein, wherein the biologically active species is therapeutically/dermatologically active against the skin disease, disorder or condition.

Priority: WO2008EP52081 Applic. Date: 2008-02-20; US20070902088P Applic. Date: 2007-02-20

Inventor: ZARIF LEILA [FR]


Application No.: US20100215575A1  Published: 26/Aug/2010

Title: Systemic Administration of Chlorotoxin Agents for the Diagnosis and Treatment of Tumors

Applicant/Assignee: TRANSMOLECULAR, INC

Application No.: 12/682692   Filing Date: 10/Oct/2008

Abstract:The present invention is directed to methods and compositions for the treatment and diagnosis of neoplastic tumors. The inventive methods generally include systemic (e.g., intravenous) administration of a chloroxotoxin agent that may or may not be labeled.

Priority: US20070979714P Applic. Date: 2007-10-12; WO2008US79547 Applic. Date: 2008-10-10

Inventor: O'NEILL ALISON [US]; JACOBY DOUGLAS B [US]


Application No.: US20100215595A1  Published: 26/Aug/2010

Title: Personal Care Compositions Containing Silicone-Organic Gels From Polyalkyloxlene Crosslinked Silicone Elastomers

Applicant/Assignee:

Application No.: 12/680269   Filing Date: 26/Sep/2008

Abstract:Silicone organic gels and ge! paste compositions are disclosed containing a silicone organic elastomer in a carrier fluid. The silicone organic elastomer is a reaction product of a linear or branched organohydrogensiioxane, an [alpha], [omega]-unsaturated poly[upsilon]xyalkylene, and a hydrosilylation catalyst. The silicone organic elastomer is particularly useful to gel organic carrier fluids. The gels and gels pastes also provide enhanced compatibility with many personal and health care actives.

Priority: US20070975318P Applic. Date: 2007-09-26; WO2008US77791 Applic. Date: 2008-09-26

Inventor: KENNAN JOHN JOSEPH [US]; MESSNER KATHRYN ELIZABETH [US]; VAN REETH ISABELLE [CN]; GARAUD JEAN-LUC [FR]


Application No.: US20100215596A1  Published: 26/Aug/2010

Title: Aqueous Meta-Stable Oil-in-Water Emulsions

Applicant/Assignee: COGNIS IP MANAGEMENT GMBH

Application No.: 12/681727   Filing Date: 25/Sep/2008

Abstract:Disclosed are aqueous o/w emulsions with the ability to invert into w/o emulsions by introduction of mechanical energy, comprising (a) oil components, (b) w/o emulsifiers, (c) cationic surfactants, (d) actives, and (e) cationic-compatible stabilisers. The emulsions are useful for making cosmetic or pharmaceutical compositions, particularly sprayable sun care emulsions.

Priority: EP20070019441 Applic. Date: 2007-10-04; WO2008EP08122 Applic. Date: 2008-09-25

Inventor: AMELA CONESA CRISTINA [ES]; DOMINGO MARTA [ES]; BEUCHE MARC [FR]


Application No.: US20100215634A1  Published: 26/Aug/2010

Title: VISFATIN THERAPEUTIC AGENTS FOR THE TREATMENT OF ACNE AND OTHER CONDITIONS

Applicant/Assignee:

Application No.: 12/652798   Filing Date: 06/Jan/2010

Abstract:The present disclosure relates to compositions and methods for treating acne and other conditions. In particular, the compositions and methods are useful for the treatment of sebum associated conditions.

Priority: US20090208386P Applic. Date: 2009-02-24; US20090261453P Applic. Date: 2009-11-16

Inventor: TENNENBAUM TAMAR [IL]; BRAIMAN-WIKSMAN LIORA [IL]; MANDIL-LEVIN REVITAL [IL]


Application No.: US20100215643A1  Published: 26/Aug/2010

Title: ANTI-INFECTIVE FUNCTIONALIZED SURFACES AND METHODS OF MAKING SAME

Applicant/Assignee: ORTHOBOND CORP

Application No.: 12/712031   Filing Date: 24/Feb/2010

Abstract:Devices are provided which are functionalized to include surface regions having anti-infective agents. Methods are provided for functionalizing various material surfaces to include active surface regions for binding anti-infective agents. Methods are provided by which anti-infective moieties or agents are bonded to functionalized surfaces.

Priority: US20090155324P Applic. Date: 2009-02-25

Inventor: CLEVENGER RANDELL [US]; SCHWARTZ JEFFREY [US]


Application No.: US20100215701A1  Published: 26/Aug/2010

Title: COSMETIC COMPOSITION COMPRISING A FINE POWDER

Applicant/Assignee: ARKEMA FRANCE

Application No.: 12/595672   Filing Date: 14/Apr/2008

Abstract:The present invention relates to cosmetic compositions used in the care and make-up field. This composition mainly comprising a continuous aqueous phase, a fatty phase and a fine and porous pulverulent copolyamide powder phase, is in the form of creamy, liquid or gelled compositions. This is in particular an emulsion, but it may also be a two-phase formulation or composition in which the fatty phase and aqueous phase are separate. The invention more particularly relates to cosmetic care and/or make-up compositions having a continuous aqueous phase in the case of an oil-in-water emulsion.

Priority: FR20070054431 Applic. Date: 2007-04-12; WO2008FR50662 Applic. Date: 2008-04-14

Inventor: LOYEN KARINE [FR]


Application No.: US20100215702A1  Published: 26/Aug/2010

Title: MICROPARTICLES COMPRISING PCL AND USES THEREOF

Applicant/Assignee: AQTIS IP BV

Application No.: 12/670518   Filing Date: 23/Jul/2008

Abstract:The invention relates to a process for preparing PCL-comprising microparticles, to microparticles obtainable by said process, to gel hence obtained and to several uses of the gel such as for the preparation of a medicament for treating a skin abnormality or disfigurement, and/or for controlling bladder function and/or controlling gastric reflux and/or for treating erectile dysfunction and/or for treating vocal cords. The gel may also be used for cosmetic applications.

Priority: EP20070135251 Applic. Date: 2007-07-26; US20070952056P Applic. Date: 2007-07-26; WO2008NL50506 Applic. Date: 2008-07-23

Inventor: SUPER HENDERIKUS [NL]; MIJNEN PAUL WILLEM [NL]; ZIJLSTRA PIETER GERARD [NL]; GRIJPMA DIRK WYBE [NL]


Application No.: US20100215708A1  Published: 26/Aug/2010

Title: COATING OF DEVICES WITH EFFECTOR COMPOUNDS

Applicant/Assignee:

Application No.: 12/306794   Filing Date: 28/Jun/2007

Abstract:This invention is directed to substrates, materials and devices coated with a gel, foam, film, particle or composition comprising a polymei solvent and effector compounds attached thereto, processes of producing the same, and methods of use thereof, of in, inter-alia, biological applications, including preventing infection and the treatment of various diseases.

Priority: US20060817075P Applic. Date: 2006-06-29; WO2007US15052 Applic. Date: 2007-06-28

Inventor: ZUMBUEHL ANDREAS [CH]; KOHANE DANIAL S [US]; DA SILVA FERREIRA LINO [PT]; LANGER ROBERT S [US]; FINK GERALD R [US]


Application No.: US20100215726A1  Published: 26/Aug/2010

Title: Compositions for Diminishing the Appearance of Wrinkles

Applicant/Assignee:

Application No.: 12/392949   Filing Date: 25/Feb/2009

Abstract:Topical skin care compositions are provided for the improvement of the appearance of the skin, namely of the skin comprising the face, surrounding the eyes, mouth, and hands, as well as the skin of the body. The skin care compositions include synergistic combinations of active peptide ingredients that are specially formulated to enhance the natural appearance of the face, hands, and/or body. Specifically, the synergistic skin care compositions may be applied to one or more of the skin surrounding the eyes, mouth, nose, forehead, ears, neck, hands, feed, and overall body to give the skin thereof a cleaner, smoother and more wrinkle free appearance.

Priority:

Inventor: ROTH PETER THOMAS [US]


Application No.: US20100216165A1  Published: 26/Aug/2010

Title: USE OF SOLUBLE FORMS OF THE DESMOGLEIN I PROTEIN FOR THE PURPOSES OF SCREENING FOR ANTI-AGEING ACTIVE AGENTS

Applicant/Assignee: L'OREAL

Application No.: 12/687601   Filing Date: 14/Jan/2010

Abstract:The invention relates to the use of one or more complexed or noncomplexed, soluble peptide form(s) of Desmoglein I, as a marker for evaluating the effectiveness of active agents and/or of treatments, in particular anti-ageing active agents and/or treatments, with regard to an epidermis.

Priority: FR20090050159 Applic. Date: 2009-01-13; US20090202078P Applic. Date: 2009-01-27

Inventor: DONOVAN MARK [FR]; SIMONETTI LUCIE [FR]; BERNARD DOMINIQUE [FR]


Application No.: US20100216689A1  Published: 26/Aug/2010

Title: CYTOTOXIC T CELL ACTIVATOR COMPRISING EP4 AGONIST

Applicant/Assignee: ONO PHARMACEUTICAL CO., LTD NATIONAL UNIVERSITY CORPORATION, HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE

Application No.: 12/599194   Filing Date: 07/May/2008

Abstract:Disclosed is a substance which has a low molecular weight, can be applied in a simpler manner, and has an immunopotentiating activity against cancer and/or a microorganism-mediated infectious disease. An EP4 agonist exhibits an immunopotentiating activity through the activation of a cytotoxic T cell, and is therefore useful for the prevention and/or treatment of cancer or a microorganism-mediated infection disease.

Priority: JP20070123119 Applic. Date: 2007-05-08; WO2008JP58464 Applic. Date: 2008-05-07

Inventor: TAKIGAWA MASAHIRO [JP]; SEO NAOHIRO [JP]; KABASHIMA KENJI [JP]; MARUYAMA TAKAYUKI [JP]; KANAJI TOSHIYA [JP]


Application No.: US20100216707A1  Published: 26/Aug/2010

Title: COSMETIC USE OF APOLIPOPROTEIN D TYPE PROTEINS

Applicant/Assignee: L'OREAL

Application No.: 12/602246   Filing Date: 20/Jun/2008

Abstract:The subject of the present invention is the use, in particular the cosmetic and/or therapeutic use, of the apolipoprotein D, of polypeptides derived from this protein or of analogues thereof, of a nucleic sequence encoding such a polypeptide or of an agent modulating the activity or of the expression of such a polypeptide, in particular for stimulating terminal epithelial differentiation. The invention also relates to the use of the protein apolipoprotein D, of polypeptides derived from this protein or of analogues thereof, or of a nucleic sequence encoding such a polypeptide as a marker for evaluating the state of the epidermis.

Priority: FR20070055976 Applic. Date: 2007-06-22; US20070952262P Applic. Date: 2007-07-27; WO2008IB52440 Applic. Date: 2008-06-20

Inventor: BERNARD DOMINIQUE [FR]; CASTIEL ISABELLE [FR]; SIMONETTI LUCIE [FR]


Application No.: US20100216753A1  Published: 26/Aug/2010

Title: CONTROLLED RELEASE OF DRUGS INTO/THROUGH THE SKIN

Applicant/Assignee: GALDERMA S.A

Application No.: 12/714739   Filing Date: 01/Mar/2010

Abstract:The slow and sustained, controlled release of a drug into and through the skin includes topically applying onto the skin of an individual in need of such treatment, a composition containing at least one solubilized drug, at least one film-forming silicone, and at least one volatile solvent.

Priority: US2007-000187 Applic. Date: 2007-12-10; WO2006EP05831 Applic. Date: 2006-05-22; US20050689282P Applic. Date: 2005-06-10

Inventor: ANDRES PHILIPPE [FR]; MALLARD CLAIRE [FR]


Application No.: US20100216880A1  Published: 26/Aug/2010

Title: TRANSDERMAL COMPOSITIONS FOR ANTICHOLINERGIC AGENTS

Applicant/Assignee:

Application No.: 12/614216   Filing Date: 06/Nov/2009

Abstract:The present invention relates generally to compositions or formulations for transdermal or transmucosal administration of anticholinergic agents such as oxybutynin. The invention utilizes a novel delivery vehicle and is a substantially malodorous-free and irritation free transdermal formulation which is substantially free of long chain fatty alcohols, long-chain fatty acids, and long-chain fatty esters. A method is disclosed for treating a subject for urinary incontinence with these formulations while reducing the incidences of peak concentrations of drug and undesirable side effects associated with oral anticholinergics.

Priority: WO2000EP07533 Applic. Date: 2000-08-03; US2004-798111 Applic. Date: 2004-03-10; US20030510613P Applic. Date: 2003-10-10; US20030453604P Applic. Date: 2003-03-11

Inventor: CARRARA DARIO NORBERTO R [CH]; GRENIER ARNAUD [FR]


Application No.: US20100216888A1  Published: 26/Aug/2010

Title: LIQUID COMPOSITIONS CONTAINING SOLUBILIZED BENZOYL PEROXIDE, MEANS FOR APPLYING SAME AND METHODS OF TREATMENT USING SAME

Applicant/Assignee:

Application No.: 12/773322   Filing Date: 04/May/2010

Abstract:Liquid medicaments incorporate about 1.0-3.0% active benzoyl peroxide (BP) by weight in substantially fully solubilized form, while being substantially free of acetone and other harsh, dermatologically undesirable solvents. The novel compositions are produced by (a) creating an emulsion or slurry of BP in an emollient, topically acceptable ester, and (b) dissolving the emulsion or slurry in absolute alcohol. The medicaments may be used in the treatment of BP-responsive skin conditions in mammals, e.g., acne vulgaris or rosacea. The novel medicaments may be dispensed directly to the affected skin area through the use of an applicator device comprising a fluid reservoir associated with a foam applicator tip, or via a spray dispenser, atomizer or pump spray.

Priority: US2007-820949 Applic. Date: 2007-06-21

Inventor: BLACKMAN STEVEN T [US]


Application No.: US20100217176A1  Published: 26/Aug/2010

Title: METERED GEL DISPENSER

Applicant/Assignee:

Application No.: 12/775053   Filing Date: 06/May/2010

Abstract:The invention relates to a dermal flowable-composition dispenser that includes a body for retaining a supply of the composition, an application portion having an application surface, and a conduit connecting the supply chamber with the application surface for facilitating the reproducible delivery of a predetermined dose of the composition to the application surface. The application surface includes a concave application surface and a front side having an upper rim enclosing the application surface and forming a depression that has a volume that is greater than or equal to the volume of the predetermine dose. Also, the application surface is configured and dimensioned such it can receive the patient's skin to allow for removal of the predetermined dose of the composition, and wherein the concave application surface is shaped such that the entire application surface contacts the patient's skin when the application surface is pressed thereagainst.

Priority: WO2008US83196 Applic. Date: 2008-11-12; US20070987233P Applic. Date: 2007-11-12

Inventor: CARRARA R DARIO NORBERTO [CH]; GRENIER ARNAUD [FR]; KRAUS HOLGER [CH]; SADOWSKI PETER L [US]; GREENHALGH PAUL [GB]; YOUNG MATTHEW [GB]; REBER DOMINIC [GB]; MURPHY MARTIN [GB]


Application No.: US20100221179A1  Published: 02/Sep/2010

Title: IL-1 Binding Proteins

Applicant/Assignee: ABBOTT LABORATORIES

Application No.: 12/696314   Filing Date: 29/Jan/2010

Abstract:The present invention encompasses IL-1[alpha] binding proteins. Specifically, the invention relates to antibodies that are chimeric, CDR grafted and humanized antibodies. Antibodies of the invention have high affinity for IL-1[alpha] and neutralize IL-1[alpha] activity. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. Method of making and method of using the antibodies of the invention are also provided. The antibodies, or antibody portions, of the invention are useful for detecting IL-1[alpha] and for inhibiting IL-1[alpha] activity, e.g., in a human subject suffering from a disorder in which IL-1[alpha] activity is detrimental.

Priority: US20090206250P Applic. Date: 2009-01-29

Inventor: HSIEH CHUNG-MING [US]; WU CHENGBIN [US]


Application No.: US20100221194A1  Published: 02/Sep/2010

Title: TOPICAL FOAM COMPOSITION

Applicant/Assignee:

Application No.: 12/711337   Filing Date: 24/Feb/2010

Abstract:The present invention relates to a novel oil in water emulsion aerosol foam composition containing an active agent for the treatment of various chronic and acute skin conditions, particularly acne and psoriasis

and processes for preparing the emulsion aerosol foam compositions. In particular, the present invention relates to oil in water emulsion aerosol foam compositions containing a retinoid in the oil phase.

Priority: US20100292403P Applic. Date: 2010-01-05; US20090202403P Applic. Date: 2009-02-25

Inventor: LOUPENOK LEON [AU]


Application No.: US20100221195A1  Published: 02/Sep/2010

Title: SUBSTANTIALLY NON-AQUEOUS FOAMABLE PETROLATUM BASED PHARMACEUTICAL AND COSMETIC COMPOSITIONS AND THEIR USES

Applicant/Assignee: FOAMIX LTD

Application No.: 12/778591   Filing Date: 12/May/2010

Abstract:The present invention relates to stable substantially non-aqueous, non-alcoholic, non-silicone, foamable carrier compositions comprising petrolatum or mixtures thereof, at least one foam agent, at least one propellant, and with and without the addition of an active agent. The formulations may contain a solvent substantially miscible therein. The present invention further provides a method of treating, alleviating or preventing a disorder of mammalian subject in need thereof, comprising administering the above-mentioned compositions to an afflicted target site of said mammalian subject.

Priority: US2008-025547 Applic. Date: 2008-02-04; US2007-940290 Applic. Date: 2007-11-14; US20070899176P Applic. Date: 2007-02-02; US20070915859P Applic. Date: 2007-05-03; US20060858747P Applic. Date: 2006-11-14

Inventor: TAMARKIN DOV [IL]; FRIEDMAN DORON [IL]; ZIV ENBAL [IL]; EINI MEIR [IL]; BERMAN TAL [IL]; DANZIGER JORGE [IL]; KEYNAN RITA [IL]; SCHUZ DAVID [IL]


Application No.: US20100221294A1  Published: 02/Sep/2010

Title: Use of Non-Straight Fiber Dispersed in a Composition and Compositions Thereof

Applicant/Assignee: AVONE PRODUCTS ,INC

Application No.: 12/089616   Filing Date: 14/Dec/2006

Abstract:Compositions and methods for enhancing, lengthening, volumizing, or concealment of keratinous surfaces or tissue. The compositions comprise non-straight fibers useful for formulating cosmetics, personal care products, and pharmaceutical compositions which are comfortable, durable, and overcome smudging, smearing, flaking, and detachment from keratinous surfaces, thereby resulting in an aesthetically pleasing appearance.

Priority: US20050754936P Applic. Date: 2005-12-29; WO2006US47764 Applic. Date: 2006-12-14

Inventor: KUREK JOHN S [US]; ZHENG TAO [US]; GLYNN JR JOHN R [US]; PAHLICK HAROLD E [US]


Application No.: US20100221295A1  Published: 02/Sep/2010

Title: COSMETIC USE OF WHEY PROTEIN MICELLES

Applicant/Assignee:

Application No.: 12/294447   Filing Date: 26/Mar/2007

Abstract:The present invention relates to use of whey protein micelles as a cosmetic agent or abrasive agents, and in particular to the use of such micelles in cosmetic compositions as well as to a method for obtaining such compositions.

Priority: EP20060006299 Applic. Date: 2006-03-27; WO2007EP52889 Applic. Date: 2007-03-26

Inventor: BOVETTO LIONEL JEAN RENE [CH]; SCHMITT CHRISTOPHE JOSEPH ETIENNE [CH]


Application No.: US20100221299A1  Published: 02/Sep/2010

Title: THERAPEUTIC STEM CELL NUTRIENT COMPOSITION AND USES THEREOF

Applicant/Assignee:

Application No.: 12/778246   Filing Date: 12/May/2010

Abstract:The present invention relates to a composition and uses thereof for treatment of damaged tissue comprising at least one essential amino acid in L form and at least one essential lipid

wherein the composition is administered to a mammal suffering from severe tissue damage. The invention further relates to a composition and uses thereof comprising the mixture of one or more free L-amino acids in which the molar ratio of the free L-amino acids corresponds to the molar ratio of amino components in a mammalian tissue protein

and at least one essential lipid.

Priority: US2005-212530 Applic. Date: 2005-08-26; US2000-639859 Applic. Date: 2000-08-16; US19990149338P Applic. Date: 1999-08-17

Inventor: GIRSH LEONARD S [US]


Application No.: US20100221364A1  Published: 02/Sep/2010

Title: COMPOSITIONS AND METHODS OF INDUCING HAIR GROWTH UTILIZING COTINUS COGGYGRIA

Applicant/Assignee:

Application No.: 12/718101   Filing Date: 05/Mar/2010

Abstract:This application relates to compositions and methods for inducing hair growth and improving hair quality utilizing extracts of Cotinus coggygria in an amount effective to induce hair growth when applied topically to an area of the skin on which hair growth is desired.

Priority: US2007-952399 Applic. Date: 2007-12-07; US20060869770P Applic. Date: 2006-12-13

Inventor: BRUNING ELIZABETH [US]; STONE VIOLETTA IOTSOVA [US]; ZHAO RENBIN [US]


Application No.: US20100222757A1  Published: 02/Sep/2010

Title: Hydrophobic Surface Coated Material for use in Absorbent Articles

Applicant/Assignee:

Application No.: 12/691929   Filing Date: 22/Jan/2010

Abstract:An improved barrier member for an absorbent article that includes a nonwoven treated with a hydrophobic surface coating. The hydrophobic surface coating includes a non-aqueous, solventless, multicomponent silicone composition. The hydrophobic surface coating may be substantially free of aminosilicones.

Priority: US20090156090P Applic. Date: 2009-02-27

Inventor: TEE JR JOHANNSON JIMMY [US]; CATALAN KEMAL VATANSEVER [US]


Application No.: US20100226892A1  Published: 09/Sep/2010

Title: USE OF PROBIOTIC MICROORGANISMS TO LIMIT SKIN IRRITATION

Applicant/Assignee: L'OREAL NESTEC SA

Application No.: 12/717438   Filing Date: 04/Mar/2010

Abstract:Disclosed are methods directed to the cosmetic use of an effective amount of at least one probiotic microorganism especially from the genus Lactobacillus sp. and/or Bifidobacterium sp., of a fraction thereof and/or of a metabolite thereof, as an active agent for limiting, preventing or treating skin irritation and/or irritative skin disorders.

Priority: FR20090051362 Applic. Date: 2009-03-04; US20090202627P Applic. Date: 2009-03-19

Inventor: GUENICHE AUDREY [FR]


Application No.: US20100226943A1  Published: 09/Sep/2010

Title: SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL

Applicant/Assignee: UNIVERSITY OF FLORIDA

Application No.: 12/550870   Filing Date: 31/Aug/2009

Abstract:Disclosed herein is an article that includes a first plurality of spaced features. The spaced features are arranged in a plurality of groupings

the groupings of features include repeat units

the spaced features within a grouping are spaced apart at an average distance of about 1 nanometer to about 500 micrometers

each feature having a surface that is substantially parallel to a surface on a neighboring feature

each feature being separated from its neighboring feature

the groupings of features being arranged with respect to one another so as to define a tortuous pathway. The plurality of spaced features provide the article with an engineered roughness index of about 5 to about 20.

Priority: US2006-567103 Applic. Date: 2006-12-05; US2005-202532 Applic. Date: 2005-08-12; US2004-780424 Applic. Date: 2004-02-17

Inventor: BRENNAN ANTHONY B [US]; LONG CHRISTOPHER JAMES [US]; BAGAN JOSEPH W [US]; SCHUMACHER JAMES FREDERICK [US]; SPIECKER MARK M [US]


Application No.: US20100226949A1  Published: 09/Sep/2010

Title: INSECT REPELLENT AND ATTRACTANTS

Applicant/Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Application No.: 12/398164   Filing Date: 04/Mar/2009

Abstract:The disclosure provides compounds useful as insect repellents and compositions comprising such repellents. The disclosure further provides insect traps.

Priority:

Inventor: RAY ANANDASANKAR [US]; TURNER STEPHANIE LYNN [US]


Application No.: US20100226963A1  Published: 09/Sep/2010

Title: BI-FUNCTIONAL CO-POLYMER USE FOR OPTHALMIC AND OTHER TOPICAL AND LOCAL APPLICATIONS

Applicant/Assignee: EYEON PARTICLE SCIENCES LLC

Application No.: 12/708329   Filing Date: 18/Feb/2010

Abstract:The invention contemplates a copolymer which is a graft or block copolymer useful to change wettability and surface characteristics of biological surfaces. Methods for use of these formulations and coatings to change wettability and sterically stabilize, and lubricate biological surfaces in a subject, for example, in the treatment of dry eye syndrome, and to prevent adherence of unwanted proteins, for example in the treatment of contact lens intolerance, are provided.

Priority: US20090153416P Applic. Date: 2009-02-18

Inventor: COOPER EUGENE R [US]; KLEINMAN DAVID M [US]; LOXLEY ANDREW [US]; MITCHNICK MARK [US]


Application No.: US20100226972A1  Published: 09/Sep/2010

Title: TRANSDERMAL PAIN GEL

Applicant/Assignee:

Application No.: 12/718417   Filing Date: 05/Mar/2010

Abstract:A transdermal gel including a complementary array of medicinal components has beneficial effects for pain relief in muscular and connective tissues. The medicinal components include active ingredients having a synergistic effect for permitting musculoskeletal movement by countering the symptoms of musculoskeletal pain and being non-narcotic for avoiding dependency, and are combined in a liposomal base with a wetting agent to form a gel consistency suitable for skin application. The transdermal gel allows topical application of greater quantities and concentrations of the active ingredients than could safely be obtained via conventional oral administration.

Priority: US20090158161P Applic. Date: 2009-03-06

Inventor: LUTZ GEORGE W [US]


Application No.: US20100226982A1  Published: 09/Sep/2010

Title: Stabilized Active Ingredient Composition

Applicant/Assignee: DR. SUWELACK SKIN & HEALTH CARE AG

Application No.: 12/377613   Filing Date: 16/Aug/2007

Abstract:The invention relates to a stabilized active ingredient composition comprising at least one carrier material and at least one active ingredient present in stabilized form, and at least one agent for forming the active ingredient from the stabilized form upon addition of an aqueous phase to the composition, wherein the composition is obtained by freeze drying, a process for producing the composition as well as the use of the composition.

Priority: DE200610038629 Applic. Date: 2006-08-17; WO2007EP58543 Applic. Date: 2007-08-16

Inventor: MALESSA RALF [DE]


Application No.: US20100227002A1  Published: 09/Sep/2010

Title: ANTIOXIDANT COMPOSITIONS COMPRISING EXTRACTS OF MYRTLE AND ROSEMARY

Applicant/Assignee: NURAGING BIOTECH S.R.L

Application No.: 12/376363   Filing Date: 24/Jul/2007

Abstract:The invention relates to a composition based on extracts of myrtle and rosemary which has been found to synergistically increase the protection of cells against pathophysiological conditions characterised and partly caused by overproduction of free radicals and to counteract the oxidative stress caused by excessive production of said free radicals, as well as for preventing and/or treating related pathologies, including apoptosis.

Priority: IT2006RM00427 Applic. Date: 2006-08-04; WO2007EP57605 Applic. Date: 2007-07-24

Inventor: CARTA ANGELICO [IT]


Application No.: US20100227010A1  Published: 09/Sep/2010

Title: PESTICIDAL COMPOSITIONS AND METHODS OF USE THEREOF

Applicant/Assignee: ECOBLEND, LLC

Application No.: 12/698489   Filing Date: 02/Feb/2010

Abstract:A pest-combating composition including sodium lauryl sulfate and one or more of C6-12 fatty acids, preferably lauric and/or capric and/or caprylic acid, soy methyl ester, and 2-undecanone, and methods of combating pests utilizing same, are disclosed. The compositions can include a carrier oil such as silicon oil, soy methyl ester, or a vegetable oil, and can be in the form of an emulsion. The composition may be constituted as a spray composition, an aerosol, a lotion, a paste, or another compositional form. Pests that may be usefully combated with such composition include flying insects, including flies, mosquitoes, and wasps, ants, including arthropods such as fire ants, ticks, fleas, cockroaches, silver fish, thrips, gnats, aphids, Japanese beetles, and agricultural and horticultural arthropods and insects including beetles (potato and bean), flea beetles, fleahoppers, squash bugs, slugs, leaf hoppers, harlequin bugs, milk weed bugs, spiders, mites, lice, rodents, and deer.

Priority: US20090149114P Applic. Date: 2009-02-02

Inventor: JONES ALLEN [US]


Application No.: US20100227011A1  Published: 09/Sep/2010

Title: REGULATION OF MAMMALIAN KERATINOUS TISSUE USING PERSONAL-CARE COMPOSITIONS COMPRISING A TURMERONE COMPOUND

Applicant/Assignee:

Application No.: 12/709769   Filing Date: 22/Feb/2010

Abstract:Personal-care compositions for improving keratinous tissue conditions, particularly skin lightening, comprising a turmerone compound, a safe and effective amount of at least one additional skin and/or hair care active, and a dermatologically acceptable carrier are provided. Suitable additional skin and/or hair care actives are a sugar amine, a vitamin B3 compound, a retinoid, a peptide, a hexamidine, a sunscreen, a water-soluble vitamin, an oil-soluble vitamin, an additional skin lightener, and combinations thereof. Methods for regulating the condition of mammalian keratinous tissue and for lighening skin by topically applying the personal-care compositions are also provided.

Priority: US20090154941P Applic. Date: 2009-02-24

Inventor: KUHLMAN DENNIS EUGENE [US]; MISHRA RAJESH KANT [US]


Application No.: US20100228180A1  Published: 09/Sep/2010

Title: Power Source Electrode Treatment Device

Applicant/Assignee: POWER PAPER LTD

Application No.: 12/223178   Filing Date: 25/Jan/2007

Abstract:The present invention provides a powered treatment device comprising at least one power source for supplying electrical energy to the device, and wherein at least one component of the power source is also configured as a power source treatment device electrode to facilitate electrical contact with a body region. In an embodiment wherein one component of the power source is configured as a power source treatment device electrode, the powered treatment device may further comprise at least one non-power source device electrode of opposite polarity from the power source treatment device electrode, wherein the at least one non-power source device electrode is electrically coupled to the at least one power source to facilitate electrical contact with a body area.

Priority: US20060762137P Applic. Date: 2006-01-26; WO2007IL00093 Applic. Date: 2007-01-25

Inventor: JAYES DALIA [IL]; MOSHKOVICH MORDECHAY [IL]; NITZAN ZVI [IL]


Application No.: US20100228181A1  Published: 09/Sep/2010

Title: USE OF GREEN LIGHT TO ACTIVATE L-AMINO ACID OXIDASE

Applicant/Assignee: L'OREAL

Application No.: 12/668689   Filing Date: 16/Jul/2008

Abstract:The present invention relates more specifically to the use of a source of green light for activating L-amino acid oxidase in the presence of at least one substrate of this enzyme in order to stimulate the energy metabolism of the cells of the skin, to stimulate their replacement and thus to improve the appearance of the skin and hair, in particular to prevent and/or treat cutaneous signs of ageing of the skin and hair. The invention also relates to a composition comprising at least one substrate of the enzyme and at least one substrate capable of emitting green light, to a kit comprising a green light device and the composition comprising at least one substrate of the said enzyme and to a cosmetic method employing the compositions or kits according to the invention.

Priority: FR20070056506 Applic. Date: 2007-07-16; US20070982455P Applic. Date: 2007-10-25; WO2008FR51333 Applic. Date: 2008-07-16

Inventor: LABOUREAU JULIEN [FR]; NGUYEN QUANG LAN [FR]


Application No.: US20100231385A1  Published: 16/Sep/2010

Title: Hand Washing Compliance Detection System

Applicant/Assignee:

Application No.: 12/772583   Filing Date: 03/May/2010

Abstract:Systems and methods are provided for monitoring use of hand washing agents to determine compliance with hand hygiene guidelines. A hand washing agent is provided with a detectable, volatile compound, such as odors, which is then rubbed onto a subject's hands using the subject's hand washing technique. After the hand washing event, the subject's hand is then exposed to an detector (such as a badge), which includes a sensor capable of detecting the volatile compound, and an indicator that communicates detection of the volatile compound, indicating use of the hand washing agent and hand hygiene compliance.

Priority: US2007-760100 Applic. Date: 2007-06-08

Inventor: MELKER RICHARD J [US]; GRAVENSTEIN NIKOLAUS [US]; DENNIS DONN M [US]; BATICH CHRISTOPHER D [US]


Application No.: US20100233079A1  Published: 16/Sep/2010

Title: Dual Variable Domain Immunoglobulins and Uses Thereof

Applicant/Assignee: ABBOTT LABORATORIES

Application No.: 12/631483   Filing Date: 04/Dec/2009

Abstract:The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.

Priority: US20080200877P Applic. Date: 2008-12-04; US20090212071P Applic. Date: 2009-04-07

Inventor: JAKOB CLARISSA G [US]; WU CHENGBIN [US]; WALTER KARL A [US]; GHAYUR TARIQ [US]


Application No.: US20100233109A1  Published: 16/Sep/2010

Title: METHOD AND THERAPEUTIC/COSMETIC TOPICAL COMPOSITIONS FOR THE TREATMENT OF ROSACEA AND SKIN ERYTHEMA USING A1-ADRENOCEPTOR AGONISTS

Applicant/Assignee: VICEPT THERAPEUTICS, INC

Application No.: 12/788746   Filing Date: 27/May/2010

Abstract:The present invention is directed to the treatment of skin erythema as exhibited in rosacea and other conditions characterized by increased erythema (redness) of the skin. These conditions exhibit dilation of blood vessels due to a cutaneous vascular hyper-reactivity. In particular, the present invention is directed to a novel composition and method for the treatment of skin erythema using [alpha]1-adrenergic receptor ([alpha]1-adrenoceptor) agonists incorporated into cosmetic, pharmacological or dermatological compositions for topical application to the skin.

Priority: US2004-763807 Applic. Date: 2004-01-22

Inventor: SHANLER STUART D [US]; ONDO ANDREW [US]


Application No.: US20100233110A1  Published: 16/Sep/2010

Title: Powder Compositions Containing Edible Grains

Applicant/Assignee:

Application No.: 12/403922   Filing Date: 13/Mar/2009

Abstract:A powder composition comprising a particulate phase containing a plurality of edible grains.

Priority:

Inventor: COHEN KENNETH [CA]; SINGH DAVID [CA]


Application No.: US20100233153A1  Published: 16/Sep/2010

Title: NOVEL GENE DISRUPTIONS, COMPOSITIONS AND THE METHODS RELATING THERETO

Applicant/Assignee: GENENTECH, INC LEXICON PHARMACEUTICALS, INC

Application No.: 12/375662   Filing Date: 01/Oct/2007

Abstract:The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising disruptions in PRO1105, PRO1279 or PRO1783 genes. Such in vivo studies and characterizations may provide valuable identification and discovery of therapeutics and/or treatments useful in the prevention, amelioration or correction of diseases or dysfunctions associated with gene disruptions such as neurological disorders

cardiovascular, endothelial or angiogenic disorders

eye abnormalities

immunological disorders

oncological disorders

bone metabolic abnormalities or disorders

lipid metabolic disorders

or developmental abnormalities.

Priority: US20060865777P Applic. Date: 2006-11-14; WO2007US80102 Applic. Date: 2007-10-01

Inventor: BORROMEO MARK DOMINIC [US]; CUNNINGHAM JAIME-JO [US]; DESAUVAGE FREDERICK [US]; FILVAROFF ELLEN [US]; KLAMER MARK ALAN [US]; MINZE LAURIE JEANETTE [US]; PAYNE BOBBY JOE [US]; RANGEL CAROLINA [US]; SHI ZHENG-ZHENG [US]; VOGEL PETER [US]


Application No.: US20100233219A1  Published: 16/Sep/2010

Title: INORGANIC NANOPARTICLE COMPROMISING AN ACTIVE SUBSTANCE IMMOBILIZED ON THE SURFACE AND A POLYMER

Applicant/Assignee: FUJIFILM CORPORATION

Application No.: 12/293392   Filing Date: 30/Mar/2007

Abstract:An object of the present invention is to provide highly safe nanoparticles which can be used simultaneously for imaging, hyperthermia and DDS and have high drug incorporation ratio. The present invention provides a nanoparticle which comprises an inorganic nanoparticle of 1 to 500 nm in average particle size having an active substance immobilized on the surface and a polymer.

Priority: JP20060093480 Applic. Date: 2006-03-30; WO2007JP57719 Applic. Date: 2007-03-30

Inventor: AIMI MAKIKO [JP]; NEMORI RYOICHI [JP]; KOJIMA MASAYOSHI [JP]


Application No.: US20100233247A1  Published: 16/Sep/2010

Title: Dressing Material Comprising Active Substances

Applicant/Assignee:

Application No.: 11/991810   Filing Date: 01/Aug/2006

Abstract:The present invention relates to a dressing material comprising a support material and at least one active substance from in each case Arnica montana, Rhus toxicodendron and Ruta graveolens. The invention further relates to a medicament comprising this dressing material and to the use of this dressing material for producing a medicament for the treatment of disorders or impairments of the musculoskeletal system. The dressing material is preferably employed in this connection as tape dressing.

Priority: EP20050019854 Applic. Date: 2005-09-13; WO2006EP64887 Applic. Date: 2006-08-01

Inventor: HOHMANN SABINE [DE]


Application No.: US20100233279A1  Published: 16/Sep/2010

Title: Compositions And Methods Comprising Analogues Of Radicicol A

Applicant/Assignee:

Application No.: 12/663079   Filing Date: 05/Jun/2008

Abstract:Disclosed are novel analogues of the natural product radicicol A of formulae I, .Ia, pi, Ha, lib and HI, pharmaceutical compositions comprising the compounds. The compounds of the invention are kinase and phosphatase inhibitors and find utility in the treatment or prevention of kinase and phosphatase-mediated disorders. Also provided are uses and methods for the treatment or prevention of kinase- and phosphatase-mediated disorders and synthetic processes for the preparation of the compounds.

Priority: US20070933171P Applic. Date: 2007-06-05; WO2008IB02497 Applic. Date: 2008-06-05

Inventor: WINSSINGER NICOLAS [FR]; BARLUENGA SOFIA [FR]


Application No.: US20100234304A1  Published: 16/Sep/2010

Title: BETA SHEET TAPES RIBBONS IN TISSUE ENGINEERING

Applicant/Assignee: UNIVERSITY OF LEEDS

Application No.: 12/729046   Filing Date: 22/Mar/2010

Abstract:There is described a material comprising tapes, ribbons, fibrils or fibres characterized in that each of the ribbons, fibrils or fibres have an antiparallel arrangement of peptides in a [beta]-sheet tape-like substructure.

Priority: GB20020016286 Applic. Date: 2002-07-15; US2005-521628 Applic. Date: 2005-09-08; WO2003GB03016 Applic. Date: 2003-07-15

Inventor: BODEN NEVILLE [GB]; AGGELI AMALIA [GB]; INGHAM EILEEN [GB]; KIRKHAM JENNIFER [GB]


Application No.: US20100234383A1  Published: 16/Sep/2010

Title: TREATING, PREVENTING OR AMELIORATING A HYPERPROLIFERATIVE DISEASE/DISORDER

Applicant/Assignee:

Application No.: 12/723911   Filing Date: 15/Mar/2010

Abstract:The invention provides a method for treating, preventing or ameliorating a hyperproliferative disease and/or disorder such as cancer (e.g. leukemia) in a mammal comprising administering a therapeutically effective amount of one or more compounds selected from the group consisting of compounds of Formula (I), quinolones and fluoroquinolones

or a pharmaceutically acceptable salt thereof to said mammal: wherein R1 comprises a structural moiety represented by X-C(O)-CH-NH (X=O or S). The invention also provides a combination therapy method using such compounds in combination with other cancer fighting chemicals. The invention exhibits merits such as none or minimal side effect associated with chemotherapy.

Priority: US20090159832P Applic. Date: 2009-03-13

Inventor: KLOPMAN GILLES [US]


Application No.: US20100234385A1  Published: 16/Sep/2010

Title: Compsition Containing Biopterin and Method for Using The Same

Applicant/Assignee: KANEKA CORPORATION

Application No.: 12/225307   Filing Date: 15/Mar/2007

Abstract:It is thought that applications and use of tetrahydrobiopterin (BH4), which is used as a pharmaceutical, will expand due to its superior efficacy. However, in addition to BH4 being extremely expensive, since it is unstable with respect to oxidation, applications other than pharmaceuticals are considered to be difficult. Further, it is difficult for BH4 to permeate through a blood-brain barrier, so that BH4 concentrations in the brain tend not to increase under the present conditions. Biopterins are oxidized form of BH4, stable to oxidation, easy to handle, and can be produced inexpensively. The inventors found that administration of biopterin can be expected to demonstrate effects equal to or greater than those of administration of BH4. On the basis of the result, it was first clarified that administration of a composition containing biopterin causes increase in BH4 concentration in the body (especially BH4 concentration in the brain, which is difficult to be increased by BH4 administration) to demonstrate sufficient actions.

Priority: JP20060076180 Applic. Date: 2006-03-20; WO2007JP55184 Applic. Date: 2007-03-15

Inventor: HASEGAWA HIROYUKI [JP]; SAWABE KEIKO [JP]; SHIMIZU ICHIRO [JP]; IKENAKA YASUHIRO [JP]


Application No.: US20100234474A1  Published: 16/Sep/2010

Title: Method and Composition for Evenly Applying Water Soluble Actives

Applicant/Assignee: CONOPCO, INC., D/B/A UNILEVER

Application No.: 12/402238   Filing Date: 11/Mar/2009

Abstract:A method and composition for evenly applying water soluble actives is described. The method includes applying a composition with a HIPE to skin and generating a film having a hydrophilic surface so that composition and active can be evenly applied.

Priority:

Inventor: LOU ANJING [US]; QIU QIANG [US]


Application No.: US20100234704A1  Published: 16/Sep/2010

Title: Non-Invasive Polarimetric Apparatus and Method for Analyte Sensing in Birefringent Media

Applicant/Assignee: UNIVERSITY OF TOLEDO

Application No.: 12/741289   Filing Date: 07/Nov/2008

Abstract:A noninvasive polarimetric apparatus used to measure levels of a substance in a sample in the presence of dynamically changing sample birefringence is provided. A polarization system generates multiple states of polarized light which interact with the sample. An analyzer system receives a signal from the sample and generates a secondary signal. This signal is detected and then processed to measure levels of a substance in a sample that may be have time varying birefringent components.

Priority: US20070002195P Applic. Date: 2007-11-07; US20070005120P Applic. Date: 2007-12-03; WO2008US82742 Applic. Date: 2008-11-07

Inventor: CAMERON BRENT D [US]


Application No.: US20100234828A1  Published: 16/Sep/2010

Title: Methods and Compositions for Facilitating Arterial Access

Applicant/Assignee:

Application No.: 12/712636   Filing Date: 25/Feb/2010

Abstract:Provided are methods and compositions for locally increasing arterial diameter and providing local anesthesia in a subject. The methods include applying to a skin site of the subject a topical composition that includes a vasodilation agent and an anesthetic agent in a manner sufficient for locally increasing arterial diameter and providing local anesthesia in the subject. In some embodiments, the method includes inserting a cannula into an artery at the skin site of the subject. Also provided are topical compositions that find use in performing the subject methods.

Priority: US20090159358P Applic. Date: 2009-03-11

Inventor: BOYLE ANDREW [US]; MAJURE DAVID [US]


Application No.: US20100239510A1  Published: 23/Sep/2010

Title: SKIN-CARE COMPOSITION COMPRISING DILL EXTRACT

Applicant/Assignee:

Application No.: 12/691471   Filing Date: 21/Jan/2010

Abstract:A skin-care composition may comprise a dill extract, a safe and effective amount of a peptide, a safe and effective amount of a hydrating skin active, and a dermatologically acceptable carrier. The skin-care composition may further comprise a safe and effective amount of an acute skin-care active. Further, a method of producing a chronic skin-firming benefit and, optionally, an acute skin-tightening sensation, said method comprising the step of topically applying to the skin of a mammal in need of such treatment, a safe and effective amount of the skin-care composition.

Priority: US20090146543P Applic. Date: 2009-01-22

Inventor: HA ROBERT BAO KIM [US]; OSBORNE ROSEMARIE [US]; SZCZEPANIAK RICHARD JOHN [US]


Application No.: US20100239514A1  Published: 23/Sep/2010

Title: COMPOSITIONS AND METHODS FOR USE ON ARTIFICIALLY COLORED HAIR

Applicant/Assignee: L:OREAL

Application No.: 12/679588   Filing Date: 16/Oct/2008

Abstract:The present invention provides a cosmetic composition comprising at least one saccharide-siloxane copolymer, a cosmetically-acceptable medium, and optionally, at least one auxiliary agent chosen from a nonionic agent and a cationic agent, wherein the pH of the composition is up to about 5.8. The present invention also provides for a method of using said composition for enhancing color protection of artificially colored hair while providing color vibrancy, excellent conditioning, natural feel and brilliant shine.

Priority: US20070981274P Applic. Date: 2007-10-19; WO2008US80141 Applic. Date: 2008-10-16

Inventor: PREM PADMAJA [US]; SULEIMAN AZIZA [US]; HUYNH MARIE [US]; CERVANTES FREDERIC [US]


Application No.: US20100239522A1  Published: 23/Sep/2010

Title: CHEMOTHERAPEUTIC FOR INDUCING AN MSH2-DEPENDENT APOPTOTIC PATHWAY

Applicant/Assignee:

Application No.: 12/711306   Filing Date: 24/Feb/2010

Abstract:A method of treating cancer in a subject in need thereof comprises administering said subject reserpine, yohimbine, an analog thereof, or a pharmaceutically acceptable salt or prodrug thereof, in an amount effective to treat the cancer. Compounds and compositions useful for carrying out the method are also described.

Priority: WO2008US09979 Applic. Date: 2008-08-22; US20070957761P Applic. Date: 2007-08-24

Inventor: SALSBURY JR FREDDIE R [US]; SCARPINATO KARIN D [US]; KING S BRUCE [US]


Application No.: US20100239633A1  Published: 23/Sep/2010

Title: IMMUNOGLOBULIN CONSTANT REGION FC RECEPTOR BINDING AGENTS

Applicant/Assignee: UNIVERSITY OF MARYLAND BALTIMORE

Application No.: 12/602609   Filing Date: 30/May/2008

Abstract:IVIG replacement compounds are derived from recombinant and/or biochemical creation of immunologically active biomimetic(s). These replacement compounds are then screened in vitro to assess each replacements compound's efficiency at modulating immune function. Particular replacement compounds are selected for further in vivo validation and dosage/administration optimization. Finally, the replacement compounds are used to treat a wide range of diseases, including inflammatory and autoimmune diseases.

Priority: US20070941644P Applic. Date: 2007-06-01; US20070015127P Applic. Date: 2007-12-19; US20070015547P Applic. Date: 2007-12-20; WO2008US65428 Applic. Date: 2008-05-30

Inventor: STROME SCOTT E [US]; SCHULZE DAN H [US]; BLOCK DAVID S [US]


Application No.: US20100239654A1  Published: 23/Sep/2010

Title: VESICULAR PHOSPHOLIPID GELS COMPRISING PROTEINACEOUS SUBSTANCES

Applicant/Assignee:

Application No.: 12/692416   Filing Date: 22/Jan/2010

Abstract:The present invention relates to a pharmaceutical composition for sustained release of a pharmaceutically active compound, the composition comprising a vesicular phospholipid gel. More particularly, the invention relates to a pharmaceutical composition comprising at least one proteinaceous substance as the pharmaceutically active compound in encapsulated form, the at least one proteinaceous substance being a biologically active protein, peptide or polypeptide. Furthermore, the present invention relates to a method for the production of said pharmaceutical composition comprising dual asymmetric centrifugation and to the use of said pharmaceutical composition for immunotherapy and/or for stimulating selective tissue regeneration in the treatment of surgical defects in the course of surgical interventions.

Priority: EP20090151127 Applic. Date: 2009-01-22

Inventor: WINTER GERHARD [DE]


Application No.: US20100239687A1  Published: 23/Sep/2010

Title: USES OF RARE EARTH ELEMENTS FOR SLIMMING

Applicant/Assignee: TAEWUNG ELS, INC

Application No.: 12/599812   Filing Date: 09/May/2008

Abstract:Disclosed is a use of rare earth element selected from the group consisting of lanthanum (La), cerium (Ce), praseodymium (Pr), neodymium (Nd), promethium (Pm), samarium (Sm), europium (Eu), gadolinium (Gd), terbium (Tb), dysprosium (Dy), holmium (Ho), erbium (Er), thulium (Tm), ytterbium (Yb), lutetium (Lu), scandium (Sc) and yttrium (Y), and a mixture thereof, or a salt or an oxide, for promoting lipidolysis, anti-cellulite, enhancing skin firmness, or for slimming.

Priority: KR20070046248 Applic. Date: 2007-05-11; WO2008KR02635 Applic. Date: 2008-05-09

Inventor: KIM SANG KOOK [KR]; JUNG HYUK [KR]


Application No.: US20100240592A1  Published: 23/Sep/2010

Title: TEMPLATE-FIXED PEPTIDOMIMETICS WITH ANTIMICROBIAL ACTIVITY

Applicant/Assignee: POLYPHOR LTD UNIVERSITAET ZUERICH

Application No.: 12/161065   Filing Date: 15/Jan/2007

Abstract:Template-fixed [beta]-hairpin peptidomimetics of the general formula (I) wherein Z is a template-fixed chain of 12 [alpha]-amino acid residues which, depending on their positions in the chain (counted starting from the N-terminal amino acid) are Gly, or Pro, or of certain types which, as the remaining Symbols in the above formula, are defined in the description and the claims, and salts thereof, have the property to selectively inhibit the growth of or to kill microorganisms such as Pseudomonas aeruginosa. They can be used as disinfectants for foodstuffs, cosmetics, medicaments or other nutrient-containing materials, or as medicaments to treat or prevent infections. These [beta]-hairpin peptidomimetics can be manufactured by processes which are based on a mixed solid- and Solution phase synthetic strategy.

Priority: WO2006CH00036 Applic. Date: 2006-01-16; WO2007CH00017 Applic. Date: 2007-01-15

Inventor: DEMARCO STEVEN J [CH]; VRIJBLOED WIM [CH]; DIAS RICARDO [CH]; ROBINSON JOHN ANTHONY [CH]; SRINIVAS NITYAKALYANA [CH]; GOMBERT FRANK [DE]; OBRECHT DANIEL [CH]


Application No.: US20100240658A1  Published: 23/Sep/2010

Title: Oxadiazole Derivatives

Applicant/Assignee: MERCK SERONO SA

Application No.: 12/675235   Filing Date: 01/Oct/2008

Abstract:The invention relates to compounds of formula I: wherein R1, R2, Ra, Rb, W, Q and S have the meanings given in claim 16. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis.

Priority: EP20070117921 Applic. Date: 2007-10-04; US20070998254P Applic. Date: 2007-10-09; WO2008EP63180 Applic. Date: 2008-10-01

Inventor: QUATTROPANI ANNA [CH]; MONTAGNE CYRIL [FR]; SAUER WOLFGANG [CH]; CROSIGNANI STEFANO [FR]; BOMBRUN AGNES [CH]; MUZERELLE MATHILDE [FR]; DORBAIS JEROME [FR]; MARIN DELPHINE [FR]; GONZALEZ JEROME [FR]; GERBER PATRICK [CH]


Application No.: US20100240724A1  Published: 23/Sep/2010

Title: Edible Film

Applicant/Assignee: C.L. PHARM

Application No.: 12/680720   Filing Date: 25/Sep/2008

Abstract:The present invention relates to an edible film composition comprising a waxy starch hydrolysate, a modified starch and a water-soluble polymer, and an edible film comprising the same. The present edible film may not only have an excellent film forming property, solubility and feeling in the oral cavity, but also be easily prepared at low cost, and thus be usefully used as an oral cleanser or a bad breath remover for oral cleansing, and a soluble formulation on tongue for uptake of drug in the oral cavity.

Priority: KR20070099559 Applic. Date: 2007-10-03; KR20080093403 Applic. Date: 2008-09-23; WO2008KR05698 Applic. Date: 2008-09-25

Inventor: CHANG SEOK HOON [KR]; JUNG KYOUNG TAE [KR]


Application No.: US20100240746A1  Published: 23/Sep/2010

Title: STEREOISOMERS OF TRICYCLODECAN-9-YL-XANTHOGENATE

Applicant/Assignee: LUMAVITA AG

Application No.: 12/666282   Filing Date: 03/Jul/2008

Abstract:Provided herein are optically active stereoisomers of tricylclodecan-9-yl xanthogenate, processes of preparation, and pharmaceutical compositions thereof. Also provided are methods of their use for treating, preventing, or ameliorating one or more symptoms of a disease caused by a virus.

Priority: US20070958370P Applic. Date: 2007-07-03; WO2008EP05460 Applic. Date: 2008-07-03

Inventor: TOMIOKA MIYUKI [CH]; HASEGAWA KO [JP]


Application No.: US20100240754A1  Published: 23/Sep/2010

Title: UNSATURATED FATTY AMINO ACID DERIVATIVES AND USE THEREOF IN DERMAL COSMETOLOGY

Applicant/Assignee: PIERRE FABRE DEMO-COSMETIQUE

Application No.: 12/523231   Filing Date: 16/Jan/2008

Abstract:The present invention relates to drugs consisting of unsaturated fatty amino-acid derivatives of the general formula (I), and to their pharmaceutically acceptable acid addition salts, in which: X is oxygen or NH, Rn are independently hydrogen or a (C1-C6)alkyl optionally substituted by halogen

R1 is hydrogen, fluorine, chlorine or bromine, or a CF3 or CHF2 or a (C1-C6)alkyl, (C1-C6)alkenyl or (C1-C6)alkynyl, optionally substituted by one or more halogen atoms

R is hydrogen or a (C1-C6)alkyl or (C3-C6)cycloalkyl optionally substituted by one or more halogen atoms

Ra and Rb are independently hydrogen (C1-C6)alkyl or (C1-C6)acyl, and Ra and Rb a hydrocarbonated cycle containing 4 to 6 carbon atoms

and n is an integer between 2 and 14.

Priority: FR20070000291 Applic. Date: 2007-01-16; FR20070053864 Applic. Date: 2007-03-15; WO2008EP50471 Applic. Date: 2008-01-16

Inventor: TARROUX ROGER [FR]; CHARVERON MARIE [FR]; DAUNES-MARION SYLVIE [FR]; FRISON NATACHA [FR]; FOLLEAS BENOIT [FR]; BRAYER JEAN-LOUIS [FR]


Application No.: US20100240755A1  Published: 23/Sep/2010

Title: THERAPEUTIC AND COSMETIC COMPOSITIONS FOR TREATMENT OF SKIN

Applicant/Assignee:

Application No.: 12/408341   Filing Date: 20/Mar/2009

Abstract:The present invention is directed to a skin cream containing L-glutathione and methyl sulfone in combination with perfluorodecalin and various vitamins such as Vitamin D and C. The cream can be used to treat cancerous and precancerous diseases found in or on the skin.

Priority:

Inventor: PEREZ THOMAS [US]


Application No.: US20100240774A1  Published: 23/Sep/2010

Title: USE OF HYDROPHOBIN POLYPEPTIDES AS PENETRATION ENHANCERS

Applicant/Assignee: BASF SE

Application No.: 12/721973   Filing Date: 11/Mar/2010

Abstract:The present invention relates to the use of hydrophobin polypeptides as penetration intensifiers.

Priority: EP20070116363 Applic. Date: 2007-09-13; EP20070121650 Applic. Date: 2007-11-27; WO2008EP60870 Applic. Date: 2008-08-20

Inventor: SUBKOWSKI THOMAS [DE]; KAROS MARVIN [DE]; BARG HEIKO [DE]; BOLLSCHWEILER CLAUS [DE]


Application No.: US20100241059A1  Published: 23/Sep/2010

Title: METHOD AND PORTABLE DEVICE FOR TREATING SKIN DISORDERS

Applicant/Assignee: SKINTREET, LLC

Application No.: 12/739659   Filing Date: 23/Oct/2008

Abstract:A device for treating a skin condition is provided. The device comprises a delivery system for administering a composition to the skin disorder. The delivery system includes an electrode for delivering a composition to the skin of a person and a counter electrode. The device also includes a drainage system which includes a channel for removing material from a person's skin and a pump in communication with the channel The device further includes a control system for powering and controlling the electrode system.

Priority: US20070000135P Applic. Date: 2007-10-24; WO2008US80977 Applic. Date: 2008-10-23

Inventor: PRUSHINSKAYA MARINA [US]; KAPLAN LEONID [US]


Application No.: US20100242198A1  Published: 30/Sep/2010

Title: Cleansing and Personal Care Article

Applicant/Assignee:

Application No.: 12/599273   Filing Date: 07/May/2008

Abstract:A single- or multiple-use cleansing or personal care article comprising (i) a flexible, three-dimensional, water-absorbent substrate material comprising a cavity for accepting an electronic device within a waterproof housing, wherein the water-absorbent substrate is comprised of a web of substantially water-insoluble fibers and (ii) an electronic device within a waterproof housing comprised of one or more of a light-emitting device, a sound-emitting device, or an electromechanical vibrating device or a waterproof metered dispenser and either or both of (iii) a pourable soap impregnated into the water-absorbent material in an amount sufficient to produce foam in water having a di- or trivalent cationic salts present at a concentration of at least about 120 mg/L and/or (iv)

a solid anhydrous composition having a melting point of from about 450 C to about 550 C said anhydrous composition comprising a haircare or skincare active ingredient.

Priority: US20070924271P Applic. Date: 2007-05-07; WO2008US05811 Applic. Date: 2008-05-07

Inventor: POPOVSKY MICHAEL [US]


Application No.: US20100247449A1  Published: 30/Sep/2010

Title: FOAMABLE COMPOSITION ESSENTIALLY FREE OF PHARMACEUTICALLY ACTIVE INGREDIENTS FOR THE TREATMENT OF HUMAN SKIN

Applicant/Assignee: INTENDIS GMBH

Application No.: 12/646013   Filing Date: 23/Dec/2009

Abstract:The present invention related to the use of a pharmaceutical composition which is essentially free of pharmaceutically active ingredients for the treatment of human skin, especially in the treatment of rosacea, acne, atopic dermatitis, contact dermatitis, perioral dermatitis, psoriasis or neurodermitis, as well as for prophylactic and/or cosmetic purposes.

Priority: EP20080022333 Applic. Date: 2008-12-23

Inventor: GRAUPE KLAUS [DE]; STAEDTLER GERALD [DE]


Application No.: US20100247460A1  Published: 30/Sep/2010

Title: Silicone Organic Elastomer Gels From Organopolysiloxane Resins

Applicant/Assignee:

Application No.: 12/680212   Filing Date: 22/Sep/2008

Abstract:Gel compositions are disclosed comprising a silicone elastomer from the reaction of an SiH containing organopolysiloxane resin and an organic compound having at least two aliphatic unsaturated groups in its molecule.

Priority: US20070975365P Applic. Date: 2007-09-26; WO2008US77167 Applic. Date: 2008-09-22

Inventor: LIN SHAOW BURN [US]; STARK-KASLEY LORI ANN [US]


Application No.: US20100247466A1  Published: 30/Sep/2010

Title: COSMETIC COMPOSITION FORMING AFTER APPLICATION A SUPRAMOLECULAR POLYMER

Applicant/Assignee: L'OREAL

Application No.: 12/796005   Filing Date: 08/Jun/2010

Abstract:The present invention relates to a care, and/or treatment, and/or make-up cosmetic composition for keratin materials, comprising, in a physiologically acceptable medium, an efficient amount of at least one linear, branched or cyclic polymer, or dendrimer, comprising: a -POL- polymeric backbone comprising at least two repeating patterns, and at least two binding groups (A), attached on the polymeric backbone and adapted to create H links with one or more partner binding groups, of an identical or different chemical nature, each coupling of two binding groups involving at least three H links.

Priority: FR20010007476 Applic. Date: 2001-06-07; US2003-479716 Applic. Date: 2003-12-05; WO2002FR01966 Applic. Date: 2002-06-07

Inventor: MOUGIN NATHALIE [FR]; LIVOREIL AUDE [FR]; MONDET JEAN [FR]


Application No.: US20100247544A1  Published: 30/Sep/2010

Title: Compositions and Methods for Promoting the Healing of Tissue of Multicellular Organisms

Applicant/Assignee:

Application No.: 12/690081   Filing Date: 19/Jan/2010

Abstract:Compositions are provided for promoting healing of tissue of a vertebrate organism. The compositions can be for internal administration of a therapeutically effective amount of pharmacologically active, protease inhibiting, aqueous media soluble polysulfonated materials in salt form and associated with a secondary material to reduce one or more of inflammation, bacterial proliferation, proteolytic activity, and cancerous cell growth. The compositions may additionally or alternatively be cross-linked so as to alter the solubility of these pharmacologically active salts or slow dissolution by providing biodegradable cross-linkers. Compositions for healing the tissue of a multicellular organism are provided that can include a polysulfonated material in a liquid mixture, as solid particles or constructs that may or may not biodegrade or deliver a pharmacologically relevant value. Some of the compositions are also provided for inclusion into a device for preventing infection, reducing inflammation, and preserving the activity of a protein or protein drug.

Priority: US2008-162990 Applic. Date: 2008-07-31; WO2007US02780 Applic. Date: 2007-01-31; US20060764033P Applic. Date: 2006-01-31

Inventor: VACHON DAVID JOHN [US]


Application No.: US20100247587A1  Published: 30/Sep/2010

Title: PIGMENTATION-REGULATING COMPOUNDS

Applicant/Assignee: LIPOTEC, S.A

Application No.: 12/440707   Filing Date: 11/Apr/2008

Abstract:The present invention relates to compounds of general formula (I): wherein X is selected from the group consisting of O or S and R is a linear or branched, saturated or unsaturated aliphatic group with from 2 to 23 carbon atoms (C2 to C23), or a cyclic group, and which can contain substituents selected from the group consisting of hydroxy, alkoxy, amino, carboxyl, cyano, nitro, alkylsulfonyl or halogen atoms, a method of obtaining them, cosmetic or pharmaceutical compositions containing them and the use thereof for treating, caring for and/or cleaning skin, hair and/or nails, preferably those conditions, disorders or pathologies of the skin, hair and/or nails which require regulating melanogenesis.

Priority: ES20070001663 Applic. Date: 2007-06-15; US20080037085P Applic. Date: 2008-03-17; WO2008ES00230 Applic. Date: 2008-04-11

Inventor: CEBRIAN PUCHE JUAN [ES]; MESSEGUER PEYPOCH ANGEL [ES]; FERRER MONTIEL ANTONIO [ES]; ALMINANA DOMENECH NURIA [ES]; CARRENO SERRAIMA CRISTINA [ES]


Application No.: US20100247689A1  Published: 30/Sep/2010

Title: Agent containing fat (oil), which contains onion extract, the production and use thereof for caring, preventing or treating damaged skin tissue, especially scarred tissue

Applicant/Assignee: MERZ PHARMA GMBH & CO. KGAA

Application No.: 12/802250   Filing Date: 02/Jun/2010

Abstract:The invention relates to a novel agent containing fat (oil), which contains onion extract, in addition to the production and use thereof for caring, preventing or treating damaged skin tissue, such as after operations, biopsies, wounds, burns and other accidents, and especially scarred tissue, stretch marks, degenerative skin conditions and others. The agent is characterised in that the base thereof is based on oil, which can be used to produce, for example, cream, lotion, fluid, massage, or balm based products which contain fail (oil). Surprisingly, the onion extract, which contains water, alcohol or water-alcohol, can be integrated into a base containing oil without the effectiveness thereof being reduced or a phase separation being produced. The effectiveness thereof could be proved when the medical application thereof was monitored.

Priority: DE20011032003 Applic. Date: 2001-07-03; US2003-481773 Applic. Date: 2003-12-22; WO2002EP07216 Applic. Date: 2002-07-01

Inventor: PASPALEEVA-KUEHN VALENTINA [DE]; BEUTLER ROLF D [DE]; SCHATSCHNEIDER SIMONE [DE]; HEBERER MARTINA [DE]


Application No.: US20100249156A1  Published: 30/Sep/2010

Title: ANTIVIRAL TOPICAL FORMULATIONS IN THE FORM OF A BIO-ADHESIVE GEL

Applicant/Assignee:

Application No.: 12/676311   Filing Date: 03/Sep/2008

Abstract:The invention relates to topical formulations in the form of a bioadhesive hydrophilic gel comprising acyclovir as active ingredient, Sodium hyaluronate and an acrylic polymer. Said formulations improve the local administration of acyclovir in the treatment of herpes infections, because they possess good properties of adherence to the mucosa and high resistance to physiological removal mechanisms.

Priority: IT2007MI01724 Applic. Date: 2007-09-05; WO2008IB02280 Applic. Date: 2008-09-03

Inventor: CARAMELLA CARLA MARCELLA [IT]; ROSSI SILVIA [IT]; SANDRI GIUSEPPINA [IT]; GENNARI GIOVANNI [IT]


Application No.: US20100249220A1  Published: 30/Sep/2010

Title: COUMERMYCIN/NOVOBICIN-REGULATED GENE EXPRESSION SYSTEM

Applicant/Assignee: NATIONAL RESEARCH COUNCIL OF CANADA

Application No.: 12/771457   Filing Date: 30/Apr/2010

Abstract:A chimeric transactivator comprises a transcription activation domain, a repressor protein DNA binding domain and the bacterial DNA gyrase B subunit. A target gene is operatively linked to operator DNA sequences recognized by the repressor binding domain. The addition of the antibiotic coumermycin results in a coumermycin-switched dimerization of the transactivator, which then binds to operator DNA sequences and activates transcription of the target gene. The addition of novobiocin switches off expression of the target gene by abolishing coumermycin-induced dimerization of the transactivator.

Priority: US2004-559411 Applic. Date: 2004-06-09; WO2004CA00854 Applic. Date: 2004-06-09; US20030477055P Applic. Date: 2003-06-10

Inventor: ZHAO HUI-FEN [CA]; SHEN SHI-HSIANG [CA]


Application No.: US20100249244A1  Published: 30/Sep/2010

Title: METHODS AND COMPOSITIONS FOR TREATING DERMATOLOGICAL DISEASES AND CONDITIONS

Applicant/Assignee:

Application No.: 12/751728   Filing Date: 31/Mar/2010

Abstract:The presently claimed and disclosed inventive concept(s) contemplates compositions comprising compounds, in particular dihydroeugenol (DHE) and/or isoeugenol (IE) and/or ethyl vanillin (EV) or salts, esters, ethers, or derivatives thereof, and methods for topically or systemically delivering them for treatment against inflammation-related and other dermatological conditions such as described herein. These DHE and/or IE and/or EV or salts, esters, ethers or derivatives thereof also are delivered to a measurable extent transepidermally or transdermally. In one of its method aspects, this presently claimed and disclosed inventive concept(s) is directed to a method for treating a patient with a dermatological disease or condition by topically administering to said patient a pharmaceutical or cosmetic composition comprising a pharmaceutically or cosmetically acceptable topical carrier and an effective dermatological disease, disorder or condition-treating amount of a formulation of DHE and/or IE and/or EV, or salts, esters, ethers, or derivatives thereof. In particular, the presently claimed and disclosed inventive concept(s) is directed to a method of using a composition comprising one or more of DHE and/or IE and/or EV or salts, esters, ethers, or derivatives for treating dermatologic diseases, disorders or conditions, aging effects related to decreasing production of collagen, elastin, or hyaluronic acid, or to hyperpigmentation. The formulations may further contain cinnamaldehyde.

Priority: WO2008US79534 Applic. Date: 2008-10-10

Inventor: FULLER BRYAN B [US]


Application No.: US20100249247A1  Published: 30/Sep/2010

Title: ANTIMICROBIAL COMPOSITIONS

Applicant/Assignee:

Application No.: 12/414843   Filing Date: 31/Mar/2009

Abstract:An antimicrobial composition for use as a disinfectant or a preservative. The disinfectant may be used in disinfecting and cleaning surfaces. The preservative is particularly useful in personal care and cosmetic products, and pharmaceuticals. The composition includes a base component and an alkyl mono propylene glycol ether, an alkyl mono glycerol ether, or a combination of these ethers. The base component may be water, alcohol, lotion, cream, shampoo, soap, cosmetic color agent, hair conditioner, lip balm, and face, eye or lip make up, ointment.

Priority:

Inventor: ANDREWS JEFFREY FALLIN [US]; COOK WILLIAM GERARD [US]


Application No.: US20100254920A1  Published: 07/Oct/2010

Title: Aqueous photoprotective compositions comprising hydrophilic metal oxide nanopigments and vinylpyrrolidone homopolymers

Applicant/Assignee: L'OREAL

Application No.: 11/653392   Filing Date: 16/Jan/2007

Abstract:Stable, reduced whitening photoprotective compositions contain: a) at least one aqueous phase, b) at least hydrophilic metal oxide nanoparticles, and c) at least one vinylpyrrolidone homopolymer, formulated into d) a topically applicable, physiologically acceptable medium therefor.

Priority: FR20040007828 Applic. Date: 2004-07-13; WO2005EP07368 Applic. Date: 2005-06-20; US20040600781P Applic. Date: 2004-08-12

Inventor: L ALLORET FLORENCE [FR]; SIMONNET JEAN-THIERRY [FR]


Application No.: US20100254923A1  Published: 07/Oct/2010

Title: COMPOSITION AND PROCESS FOR PROTECTING CELLULAR TARGETS FROM AGING AND PHOTODAMAGE

Applicant/Assignee: L'OREAL

Application No.: 12/754192   Filing Date: 05/Apr/2010

Abstract:The present invention is directed to a composition and process for protecting cellular targets from UV rays and free radical-induced damage by applying onto skin a composition containing: (a) at least one antioxidant chosen from 4-hydroxybenzylidene malonate derivatives and 4-hydroxycinnamate derivatives

(b) at least one extract of the plant Cassia alata

and (c) at least one sunscreen active.

Priority: US20090166978P Applic. Date: 2009-04-06

Inventor: GALDI ANGELIKE [US]; FOLTIS PETER [US]; SHAH ANIL [US]


Application No.: US20100254969A1  Published: 07/Oct/2010

Title: Cosmetic Composition For Exfoliating Skin Keratin

Applicant/Assignee: AMOREPACIFIC CORPORATION

Application No.: 11/720281   Filing Date: 28/Nov/2006

Abstract:The present invention relates to a cosmetic composition containing enzymes, and more particularly to a cosmetic composition, which contains, as active ingredients, 1) papain, and 2) at least one selected from the group consisting of theanine and N-acetyl glucosamine, and thus functions to control the skin turnover cycle and promote the exfoliation of skin keratin.

Priority: KR20060070765 Applic. Date: 2006-07-27; WO2006KR05055 Applic. Date: 2006-11-28

Inventor: BAIK SEUNG JAE [KR]; KANG BEUNG YOUNG [KR]; KIM EUN JOO [KR]


Application No.: US20100255003A1  Published: 07/Oct/2010

Title: Immune Disease Medicament Comprising a Modulator of the Binding Between a Heparin Bindin Domain of Thrombospondin-1 and a Beta1 Integrin

Applicant/Assignee: HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT YISSUM RESEARCH DEVELOPMENT OF THE HEBREW UNIVERSITY OF JERUSALEM

Application No.: 11/922607   Filing Date: 20/Jun/2006

Abstract:An article of manufacture comprising packaging material and a pharmaceutical composition is disclosed, the article of manufacture being identified in print in or on the packaging material for treatment of an immunity-related disease in a subject in need thereof. The pharmaceutical composition comprises a pharmaceutically acceptable carrier and, as an active ingredient, a compound being capable of modulating an interaction between a heparin-binding domain of a thrombospondin and a receptor of the heparin-binding domain.

Priority: US20050691848P Applic. Date: 2005-06-20; WO2006IL00712 Applic. Date: 2006-06-20

Inventor: MEVORACH DROR [IL]; KRISPIN ALON [IL]; BLEDI YANIV [IL]; LINIAL MICHAL [IL]


Application No.: US20100255024A1  Published: 07/Oct/2010

Title: COMPOSITION FOR INHIBITION OF TRANSPLANT REJECTION CONTAINING THE PHELLINUS LINTEUS MYCELLIA EXTRACT AS AN ACTIVE INGREDIENT

Applicant/Assignee: HANKOOK PHARM. CO., INC

Application No.: 12/740015   Filing Date: 27/Apr/2010

Abstract:Disclosed is a composition for the inhibition of transplant rejection and the prevention and treatment of skin diseases, comprising a Phellinus sp. mycelial extract as an active ingredient. The Phellinus sp. mycelial extract significantly suppresses the production of antibodies to transplants without side effects, such as weight change. Based on natural material, the composition is non-toxic and harmless to the human body and thus can be used as an immunosuppressant for organ transplantation. Also, it stops oozing from sores and is applicable to the prevention and treatment of skin diseases, including atopy, allergic reactions, decubitus ulcers, and smallpox.

Priority: WO2007KR06355 Applic. Date: 2007-12-07

Inventor: HAN MAN WOO [KR]; YOO JAE KUK [KR]; HUR CHANG-UK [KR]; KIM HWAN-CHUL [KR]; KIM JIN PYO [KR]


Application No.: US20100255052A1  Published: 07/Oct/2010

Title: INTEGRATED IMPLANT SYSTEM (IIS) BIOCOMPATIBLE, BIODEGRADABLE AND BIOACTIVE, COMPRISING A BIOCOMPATIBLE STERILE POROUS POLYMERIC MATRIX AND A GEL, INTEGRATING IN SITU THE TRIDIMENSIONAL MATRIX STRUCTURE

Applicant/Assignee:

Application No.: 12/303714   Filing Date: 07/Jun/2007

Abstract:The present invention refers to an Integrated Implant System constituted as a gel-matrix-cells integrated system, that allows providing implants in a brief time period, for covering a great skin extension to be treated, with a successful acceptance in patients with burns, chronic damage or wound skin, needing of a skin grafting.

Priority: CL20060001397 Applic. Date: 2006-06-07; WO2007EP05060 Applic. Date: 2007-06-07

Inventor: YOUNG ANZE MANUEL EDUARDO [CL]; ACEVEDO GUTIERREZ CRISTIAN ANDRES [CL]; ALBORNOZ MARQUEZ FERNANDO ANTONIO [CL]; WEINSTEIN OPPENHEIMER CAROLINE RUTH [CL]; ACEITUNO ALVAREZ ALEXIS ROOBINS [CL]; BROWN GONZALEZ DONALD IRVING [CL]; TAPIA MURUA SERGIO MIGUEL [CL]


Application No.: US20100255069A1  Published: 07/Oct/2010

Title: COMPOSITIONS AND METHODS FOR TREATING ANGIOGENESIS-RELATED DISEASES, WOUNDS AND COSMETIC USE OF COMPONENTS OF ANGELICA SINENSIS, AND METHODS OF PREPARATION THEREOF

Applicant/Assignee: SUNNY BIODISCOVERY, INC

Application No.: 12/758863   Filing Date: 13/Apr/2010

Abstract:Compositions and methods for treating angiogenesis-related diseases and for skin care in mammals is disclosed that includes, as an active pharmaceutical agent, an effective amount of purified extract from Angelica sinensis, or a fraction or a lyophilizate thereof, or one or more active component contained in said extract.

Priority: US2004-948590 Applic. Date: 2004-09-24

Inventor: ZHAO HUI [US]; BOJANOWSKI KRZYSZTOF [US]; ARIA FARIBA [US]; MORTEZAEI REZA [US]


Application No.: US20100255072A1  Published: 07/Oct/2010

Title: DERMAL DELIVERY DEVICE WITH IN SITU SEAL

Applicant/Assignee:

Application No.: 12/668322   Filing Date: 10/Jul/2008

Abstract:This invention relates to a transdermal drug delivery device that comprises an active ingredient (Al) layer, having a skin contacting surface and a non-skin contacting surface and comprising a volatile component, a release liner impermeable to the volatile component adjacent the skin contacting surface of the Al layer having a pe[pi]meter that extends beyond the perimeter of the Al layer in all directions, and an overlay comprising a pressure sensitive adhesive (PSA) that does not absorb the volatile component adjacent the non-skin contacting surface of the Al layer having a pe[pi]meter of which extends beyond the penmeter of the Al layer in all directions, wherein the release liner and the PSA of the overlay are in contact with and adhered to each other around the pe[pi]meter of the Al layer to form a seal that reduces or prevents volatile component loss.

Priority: US20070948757P Applic. Date: 2007-07-10; WO2008US69618 Applic. Date: 2008-07-10

Inventor: KYDONIEUS AGIS [US]; CONWAY ROBERT G [US]; ROSSI THOMAS M [US]


Application No.: US20100255076A1  Published: 07/Oct/2010

Title: COMPOSITION AND METHOD FOR DERMAL REGENERATION

Applicant/Assignee: ULTRACEUTICALS R & D PTY LTD

Application No.: 12/681391   Filing Date: 03/Oct/2008

Abstract:The present invention relates to glucommannan oligosaccharides and polysaccharides that possess one or more properties selected from skin regeneration, wound healing and skin augmentation. More particularly, the invention relates to the use of glucomannan oligosaccharides and polysaccharides for one or more of skin regeneration, wound healing and skin augmentation agents in a mammal. The invention also relates to a pharmaceutical formulation for treating skin of a subject comprising an active component comprising glucomannan in a suitable diluent, excipient or physical form such as dermal scaffold or sponge, the active component being capable of promoting an accumulation of fibroblasts in the skin and stimulating production of collagen in the skin.

Priority: AU20070905441 Applic. Date: 2007-10-04; WO2008AU01474 Applic. Date: 2008-10-03

Inventor: HEBER GEOFFREY [AU]; STAMFORD NICHOLAS PATRICK JOHN [AU]


Application No.: US20100255079A1  Published: 07/Oct/2010

Title: Systems and methods for skin rejuvenation

Applicant/Assignee: SESVALIA USA, LLC

Application No.: 12/798416   Filing Date: 02/Apr/2010

Abstract:Systems and methods for skin rejuvenation are disclosed herein. In an embodiment, a skin rejuvenation system includes a unit dose of a booster product that includes active ingredients of ferulic acid and phloretin

a unit dose of at least one exfoliating product that includes active ingredients of ferulic acid and phloretin in combination with fruit acids or alpha hydroxyacids

and a unit dose of a nano-additive product for enhancing penetration of the active ingredients. A method for skin rejuvenation includes applying topically, to a skin surface to be treated, a booster product including active ingredients of ferulic acid and phloretin

applying topically, to the skin surface, at least one exfoliating product including active ingredients of ferulic acid and phloretin in combination with one of fruit acids or alpha hydroxyacids

and applying topically, to the skin surface, a nano-additive product for enhancing penetration of the active ingredients.

Priority: US20090166192P Applic. Date: 2009-04-02; US20090166165P Applic. Date: 2009-04-02

Inventor: SANMIGUEL GABRIEL SERRANO [US]; NUNEZ JUAN MANUEL SERRANO [ES]; ZAMORA JOAQUIN MELENDEZ [ES]


Application No.: US20100255107A1  Published: 07/Oct/2010

Title: COMPOSITION EXHIBITING ENHANCED FORMULATION STABILITY AND DELIVERY OF TOPICAL ACTIVE INGREDIENTS

Applicant/Assignee: SOL-GEL TECHNOLOGIES LTD

Application No.: 12/818924   Filing Date: 18/Jun/2010

Abstract:A therapeutic, cosmetic or cosmeceutic composition for topical application, capable of stabilizing an active ingredient and delivering the active ingredient, comprising a plurality of microcapsules having a core-shell structure. The microcapsules have a diameter of approximately 0.1 to 100 micron. The core of each microcapsule includes at least one active ingredient, and is encapsulated within a microcapsular shell. The shell is comprised of at least one inorganic polymer obtained by a sol-gel process, and the shell protects the active ingredient before topical application and is designed to release the active ingredient from the microcapsules following application. The composition is useful in encapsulating active ingredients, such as benzoyl peroxide, that are unstable in other formulation, or are irritating to the skin.

Priority: US2001-983229 Applic. Date: 2001-10-23; WO2001IL00370 Applic. Date: 2001-04-20; US20000198749P Applic. Date: 2000-04-21

Inventor: LAPIDOT NOA [IL]; MAGDASSI SHLOMO [IL]; AVNIR DAVID [IL]; ROTTMAN CLAUDIO [IL]; GANS ORIT [IL]; SERI-LEVY ALON [IL]


Application No.: US20100255514A1  Published: 07/Oct/2010

Title: TUMOR CELL-DERIVED MICROVESICLES

Applicant/Assignee: THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY

Application No.: 12/759378   Filing Date: 13/Apr/2010

Abstract:The present invention relates to a method for diagnosis of cancer and for monitoring the progression of cancer and/or the therapeutic efficacy of an anti-cancer treatment in a sample of a subject by detecting oncogenic and cancer related proteins in microvesicles, and to the use of an agent blocking exchange of microvesicles for treating cancer.

Priority: WO2008CA01441 Applic. Date: 2008-08-08; US20070935505P Applic. Date: 2007-08-16

Inventor: RAK JANUSZ [CA]; AL-NEDAWI KHALID [CA]; MEEHAN BRIAN [CA]; GUHA ABHIJIT [CA]


Application No.: US20100256064A1  Published: 07/Oct/2010

Title: DELIVERY DEVICE AND METHOD

Applicant/Assignee:

Application No.: 12/680118   Filing Date: 29/Sep/2008

Abstract:A microprotrusion array for use in transport of a material across a biological barrier, wherein said array comprises a plurality of microprotusions composed of a swellable polymer composition.

Priority: GB20070018996 Applic. Date: 2007-09-28; GB20080015654 Applic. Date: 2008-08-28; WO2008GB03280 Applic. Date: 2008-09-29

Inventor: WOOLFSON DAVID A [GB]; MORROW DESMOND IAN JOHN [GB]; MORRISSEY ANTHONY [IE]; DONNELLY RYAN F [GB]; MCCARRON PAUL A [GB]


Application No.: US20100256129A1  Published: 07/Oct/2010

Title: SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) AND USES THEREOF

Applicant/Assignee:

Application No.: 12/734993   Filing Date: 12/Dec/2008

Abstract:Provided herein are compounds of formulae I to II that bind to androgen receptors and/or modulate activity of androgen receptors

and to methods for making and using such compounds. Also provided are compositions including such compounds and methods for making and using such compositions.

Priority: US20070008731P Applic. Date: 2007-12-21; WO2008US13657 Applic. Date: 2008-12-12

Inventor: ZHI LIN [US]


Application No.: US20100256228A1  Published: 07/Oct/2010

Title: External Composition For Skin Containing Manassantin B as Active Ingredient and the Use Thereof For Skin Whitening

Applicant/Assignee: AMOREPACIFIC CORPORATION

Application No.: 12/515151   Filing Date: 02/Nov/2007

Abstract:Disclosed herein are an external composition for skin, which contains, as an active ingredient, manassantin B extracted from Saururus chinensis Baill, and the use thereof for skin whitening. More particularly, disclosed are an external composition for skin, which contains, as an active ingredient, manassantin B, which inhibits the transfer of melanosomes, thus providing a skin-whitening effect without influencing the melanin synthesis function of the melanocytes, ad well as the use thereof for skin whitening.

Priority: KR20060113662 Applic. Date: 2006-11-17; WO2007KR05523 Applic. Date: 2007-11-02

Inventor: CHANG HUI KYOUNG [KR]; KIM DAE GUN [KR]; YEOM MYEONG HOON [KR]; CHOI HYUN JUNG [KR]; JOO KYUNG MI [KR]; HWANG JAE SUNG [KR]; AHN SOO MI [KR]


Application No.: US20100256346A1  Published: 07/Oct/2010

Title: Anti-Tumor Agent and Immunostimulating Agent

Applicant/Assignee:

Application No.: 12/087180   Filing Date: 25/Dec/2006

Abstract:To provide a pharmaceutical composition comprising a ceramide-related substance having little adverse side effects as an active ingredient by using a raw material that is highly safe to a human body and is inexpensive. A pharmaceutical composition comprising at least one sphingoglycolipid derivative that is produced from a beer waste and is represented by the formula below as an active ingredient: wherein R3 represents H or OH

R4 is as defined by (a) or (b): (a) when R3 is H, R4 represents (CH2)13CH3 or (CH2)6CH-CHCH2CH-CH(CH2)4CH3

and (b) when R3 is OH, R4 represents (CH2)yCH3 (where Y represents an integer of 13 to 21) or (CH2)z1CH-CH(CH2)Z2CH3 (where Z1 and Z2 independently represent 0 or a natural number, provided that Z1+Z2=19).

Priority: JP20050376609 Applic. Date: 2005-12-27; WO2006JP325817 Applic. Date: 2006-12-25

Inventor: OKU HIROSUKE [JP]; IWASAKI HIRONORI [JP]; TAKARA KENSAKU [JP]; WATANABE HISAMI [JP]; MATSUZAKI GORO [JP]; ISHIKAWA TAKAHIRO [JP]; TAKEUCHI KOUJI [JP]; TAIRA AKIRA [JP]


Application No.: US20100256671A1  Published: 07/Oct/2010

Title: Tissue sealant for use in noncompressible hemorrhage

Applicant/Assignee: BIOMEDICA MANAGEMENT CORPORATION

Application No.: 12/419734   Filing Date: 07/Apr/2009

Abstract:ClotFoam is an hemostatic agent designed for non-compressible hemorrhage. It can be applied outside the operating room through a mixing needle and/or a spray injection method following abdominal, chest, extremities or other intracavitary severe trauma to promote hemostasis, or it can be used in the operating room for laparoscopic procedures or other surgical procedures in which compression is not possible or recommended. Its crosslinking technology generates an adhesive three-dimensional polymeric network or scaffold that carries a fibrin sealant required for hemostasis. When mixed, Clotfoam produces a foam that spreads throughout a body cavity reaching the lacerated tissue to seal tissue and promote the coagulation cascade. The viscoelastic attachment properties of the foam as well as the rapid formation of a fibrin clot that ensure that the sealant remains at the site of application without being washed away by blood or displaced by movement of the target tissue .

Priority:

Inventor: FALUS GEORGE [US]


Application No.: US20100260668A1  Published: 14/Oct/2010

Title: Dual Variable Domain Immunoglobulins and Uses Thereof

Applicant/Assignee: ABBOTT LABORATORIES

Application No.: 12/605094   Filing Date: 23/Oct/2009

Abstract:The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.

Priority: US2009-431460 Applic. Date: 2009-04-28; US20080125834P Applic. Date: 2008-04-29; US20080134283P Applic. Date: 2008-07-08; US20080197191P Applic. Date: 2008-10-23; US20080199009P Applic. Date: 2008-11-12

Inventor: GHAYUR TARIQ [US]; MORGAN-LAPPE SUSAN E [US]; REILLY EDWARD B [US]; KINGSBURY GILLIAN A [US]; PHILLIPS ANDREW [US]; WANG JIEYI [US]; BELL RANDY L [US]; NORVELL SUZANNE M [US]; LI YINGCHUN [US]; LIU JUNJIAN [US]; YING HUA [US]; LIU ZHIHONG [US]


Application No.: US20100260687A1  Published: 14/Oct/2010

Title: PERSONAL CARE COMPOSITIONS INCLUDING POLYURETHANE DISPERSIONS

Applicant/Assignee:

Application No.: 12/679735   Filing Date: 23/Sep/2008

Abstract:Personal care compositions comprising a high solid aqueous polyurethane dispersion, substantially free of organic solvent and tertiary amines, are described.

Priority: US20070974646P Applic. Date: 2007-09-24; WO2008US77341 Applic. Date: 2008-09-23

Inventor: YU WEI H [US]; JORDAN SUSAN L [US]; LI WING K [US]; BHATTACHARJEE DEBKUMAR [US]


Application No.: US20100260697A1  Published: 14/Oct/2010

Title: Composition Containing An Extract of the Fruit of Schisandra Chinensis and Process for Producing Same

Applicant/Assignee: COGNIS FRANCE S.A.S

Application No.: 12/823332   Filing Date: 25/Jun/2010

Abstract:A composition including (a) an extract from the fruit of Schisandra chinensis

and (b) at least one auxiliary and/or additive is provided. A composition also provided includes (a) a component selected from the group of an extract of the fruit of Schisandra chinensis, schizandrin, deoxyschizandrin, schisandrin C, gomisin A, gomisin N, pregomisin, and nordihydroguaiaretic acid

and (b) at least one auxiliary and/or additive. A process for producing an extract from the fruit of Schisandra chinensis is also provided, and includes the steps of (a) extracting of the fruit of Schisandra chinensis with a solvent selected from the group consisting of water, alcohols, esters, hydrocarbons, ketones, halogenated hydrocarbons and supercritical fluids to obtain a mixture comprising the extract and the solvent

and, (b) removing the solvent from the mixture.

Priority: EP20030292802 Applic. Date: 2003-11-07; US2006-578344 Applic. Date: 2006-05-05; WO2004EP12278 Applic. Date: 2004-10-29

Inventor: HENRY FLORENCE [FR]; DANOUX LOUIS [FR]; PAULY GILLES [FR]


Application No.: US20100260698A1  Published: 14/Oct/2010

Title: Anhydrous Antiperspirant Compositions with Improved Active Substance Release

Applicant/Assignee:

Application No.: 12/823484   Filing Date: 25/Jun/2010

Abstract:Antiperspirant compositions for personal body care, ready-made as a stick, soft solid, cream, gel, suspension, solution or impregnated on a substrate, containing at least one antiperspirant active substance, at least one oil, liquid under normal conditions, as a carrier, 0-3 wt. % by weight of free water, based on weight of the composition, and at least one organosiloxane oxyalkylene copolymer.

Priority: DE200710063352 Applic. Date: 2007-12-28; WO2008IB03974 Applic. Date: 2008-12-22

Inventor: GALANTE CHERYL [US]; BANOWSKI BERNHARD [DE]; BUSE NADINE [DE]


Application No.: US20100260699A1  Published: 14/Oct/2010

Title: Transparent Antiperspirant Gels

Applicant/Assignee:

Application No.: 12/823272   Filing Date: 25/Jun/2010

Abstract:Transparent antiperspirant compositions in the form of a water-in-oil emulsion containing a balanced mixture of selected oil components and emulsifiers, thereby improving the antiperspirant effect of the compositions.

Priority: DE200710063351 Applic. Date: 2007-12-28; WO2008EP68194 Applic. Date: 2008-12-22

Inventor: BANOWSKI BERNHARD [DE]; CLAAS MARCUS [DE]; BUSE NADINE [DE]


Application No.: US20100260700A1  Published: 14/Oct/2010

Title: COSMETIC METHOD USING A COMPOSITION COMPRISING A SILOXANE RESIN AND A MINERAL FILLER

Applicant/Assignee: L'OREAL

Application No.: 12/746428   Filing Date: 05/Dec/2008

Abstract:The invention relates to a cosmetic method for making up and/or caring for keratinous substances, in particular the skin, comprising the application, to said keratinous substances, of a cosmetic composition comprising a siloxane resin and an inorganic filler. The invention relates in particular to compositions for caring for or making up said keratinous substances.

Priority: US20070992357P Applic. Date: 2007-12-05; WO2008FR52235 Applic. Date: 2008-12-05

Inventor: DOP FLORENCE [FR]


Application No.: US20100260701A1  Published: 14/Oct/2010

Title: COSMETIC METHOD USING A COMPOSITION COMPRISING A SILOXANE RESIN AND A VOLATILE HYDROCARBON-BASED SOLVENT

Applicant/Assignee: L'OREAL

Application No.: 12/746454   Filing Date: 05/Dec/2008

Abstract:The invention relates to a cosmetic method for making up and/or caring for keratinous substances, in particular the skin, comprising the application, to said keratinous substances, of a cosmetic composition comprising a siloxane resin and a volatile hydrocarbon solvent. The invention relates in particular to compositions for caring for or making up said keratinous substances.

Priority: US20070992357P Applic. Date: 2007-12-05; WO2008FR52236 Applic. Date: 2008-12-05

Inventor: DOP FLORENCE [FR]


Application No.: US20100260703A1  Published: 14/Oct/2010

Title: INJECTABLE BIODEGRADABLE POLYMER COMPOSITIONS FOR SOFT TISSUE REPAIR AND AUGMENTATION

Applicant/Assignee:

Application No.: 12/678492   Filing Date: 05/Oct/2008

Abstract:Methods for soft tissue repair and/or augmentation using injectable, biodegradable polymers are described herein. In one embodiment, the polymer compositions are liquid or pastes at room temperature. In a preferred embodiment, the polymer composition contains liquid or pasty hydroxy fatty acid-based copolyesters, polyester-anhydrides, or combinations thereof. The viscosity of the polymers increases upon contact with bodily fluid to form a solid or semisolid implant suitable for soft tissue repair and/or augmentation. In another embodiment, the polymer composition contains particles of a polymer stereocomplex. One or more active agents may be incorporated into the polymer compositions. Suitable classes of active agents include local anesthetics, anti-inflammatory agents, antibiotics, analgesics, growth factors and agents that induce and/or enhance growth of tissue within the filled cavity or control the growth of a certain type of tissue, and combinations thereof. The polymer compositions may also contain one or more additives or excipients that modify the physical and/or mechanical properties of the polymer. The polymer compositions are typically administered by injection. The injectable polymers can be used for a variety of soft tissue repair and augmentation procedures.

Priority: US20070977991P Applic. Date: 2007-10-05; WO2008IL01320 Applic. Date: 2008-10-05

Inventor: YANKELSON LIOR [IL]; DOMB ABRAHAM J [IL]


Application No.: US20100260823A1  Published: 14/Oct/2010

Title: PREPARATION WITH MARINE COLLAGEN FOR PROTEASE INHIBITION

Applicant/Assignee: LOHMANN & RAUSCHER GMBH & CO KG

Application No.: 12/377407   Filing Date: 28/Jul/2007

Abstract:The invention relates to pharmaceutical preparations made from marine collagens for inhibiting matrix metalloproteases and the use of a marine collagen for production of a pharmaceutical preparation for inhibiting matrix metalloproteases.

Priority: DE200610038252 Applic. Date: 2006-08-16; WO2007EP06694 Applic. Date: 2007-07-28

Inventor: ALUPEI CORNELIU IULIAN [DE]; RUTH PETER [DE]; WILHELMS TIM AXEL [DE]; ROHRER CHRISTIAN [AT]


Application No.: US20100260835A1  Published: 14/Oct/2010

Title: PHARMACEUTICAL COMPOSITION

Applicant/Assignee:

Application No.: 12/666505   Filing Date: 26/Jun/2008

Abstract:A pharmaceutical composition comprising a moulded body of a polymer matrix, said polymer matrix comprising at least one polyaphron dispersion and at least one pharmaceutically active agent dispersed therein.

Priority: GB20070012389 Applic. Date: 2007-06-26; WO2008GB02212 Applic. Date: 2008-06-26

Inventor: WHEELER DEREK ALFRED [GB]; STEELE DAVID FRASER [GB]


Application No.: US20100261629A1  Published: 14/Oct/2010

Title: Benefit agent containing delivery particles

Applicant/Assignee: APPLETON PAPERS INC

Application No.: 12/384685   Filing Date: 08/Apr/2009

Abstract:The present invention relates to benefit agent containing delivery particles, compositions comprising said particles, and processes for making and using the aforementioned particles and compositions. When employed in compositions, for example, compositions for cleaning, fabric care, or coating onto various substrates, textiles or surfaces, such particles increase the efficiency of benefit agent delivery, thereby allowing reduced amounts of benefit agents to be employed. In addition to allowing the amount of benefit agent to be reduced, such particles allow a broad range of benefit agents to be employed.

Priority:

Inventor: SMETS JOHAN [BE]; SANDS PEGGY DOROTHY [US]; GUINEBRETIERE SANDRA JACQUELINE [US]; PINTENS AN [BE]; DIHORA JITEN ODHAVJI [US]


Application No.: US20100261658A1  Published: 14/Oct/2010

Title: PEPTIDE FOR ACTIVATING AQUAPORIN SYNTHESIS

Applicant/Assignee:

Application No.: 12/808266   Filing Date: 17/Dec/2008

Abstract:The present invention concerns a peptide of the general formula (I): R1-(AA)nX1-X2-X3-Pro-X4-X5-X7-(AA)p-R2, capable of activating the synthesis of proteins of the family of aquaporins. The present invention also concerns a cosmetic, nutraceutical or pharmaceutical composition, comprising a peptide of general formula (I) as active principle. The invention also relates to the use of this new active principle in a cosmetic or nutraceutical composition, intended to improve the moisturizing and the barrier function of the epidermis and intended to stimulate cutaneous regeneration. The invention also relates to the use of this new active principle to realize a pharmaceutical composition, and in particular a dermatological composition, intended to regulate and/or stimulate the activity of the aquaporins and to thus treat the pathological dryness of the skin or mucosa. The invention also relates to a method of cosmetic treatment intended to prevent or combat against dryness of the skin and mucosa, and the manifestations of cutaneous ageing.

Priority: FR20070008977 Applic. Date: 2007-12-21; WO2008FR01759 Applic. Date: 2008-12-17

Inventor: DAL FARRA CLAUDE [US]; DOMLOGE NOUHA [FR]; BOTTO JEAN-MARIE [FR]


Application No.: US20100261772A1  Published: 14/Oct/2010

Title: Cycloalkylidene Compounds As Selective Estrogen Receptor Modulators

Applicant/Assignee:

Application No.: 12/785788   Filing Date: 24/May/2010

Abstract:The present invention relates to compounds of formula (I) with a variety of therapeutic uses, more particularly the substituted cyclic alkylidene compounds are useful for selective estrogen receptor modulation.

Priority: US2007-915436 Applic. Date: 2007-11-26; WO2006US20185 Applic. Date: 2006-05-24; US20050684433P Applic. Date: 2005-05-25

Inventor: FANG JING [US]; HEYER DENNIS [US]; KATAMREDDY SUBBA REDDY [US]; BATCHELOR KENNETH WILLIAM [US]; CALDWELL RICHARD DANA [US]


Application No.: US20100261778A1  Published: 14/Oct/2010

Title: Tumor Suppressor Killin

Applicant/Assignee:

Application No.: 12/543213   Filing Date: 18/Aug/2009

Abstract:The present invention relates to a new tumor suppressor, designated Killin. Also described are diagnostic and therapeutic uses of the Killin protein and the killin gene, alone or in combination with traditional cancer therapies.

Priority: US2006-519193 Applic. Date: 2006-09-11; US20050716691P Applic. Date: 2005-09-13

Inventor: LIANG PENG [US]; CHO YONG-JIG [US]


Application No.: US20100262090A1  Published: 14/Oct/2010

Title: WOUND CARE ARTICLE FOR EXTRACTION AND CONTROL OF WOUND FLUIDS

Applicant/Assignee:

Application No.: 12/443989   Filing Date: 28/Sep/2007

Abstract:The subject of the invention is a wound care article for extraction and control of wound fluids, comprising at least one first fluid-absorbing structure (1

10

36), which is surrounded by a liquid-permeable, first enclosure (2), and a liquid-permeable, second enclosure (3) comprising two enclosing surfaces (13.1, 13.2). The wound care article is thus characterized in that the first enclosure (2) is covered or supported on at least one of its flat sides (4.1, 4.2) by at least one fluid-absorbing material layer (6.1, 6.2

6.3), which is arranged (FIG. 1a) between the first enclosure (2) and one of the enclosing surfaces (13.1, 13.2) of the second enclosure (3).

Priority: DE200610047041 Applic. Date: 2006-10-02; WO2007EP60304 Applic. Date: 2007-09-28

Inventor: RIESINGER BIRGIT [DE]


Application No.: US20100266510A1  Published: 21/Oct/2010

Title: Foamable Vehicle and Pharmaceutical Compositions Thereof

Applicant/Assignee: FOAMIX LTD

Application No.: 12/767511   Filing Date: 26/Apr/2010

Abstract:A hygroscopic pharmaceutical composition includes at least one hygroscopic substance at a concentration sufficient to provide an Aw value of at least 0.9 and an antiinfective agent. A foamble pharmaceutical carrier includes about 50% to about 98% of a polar solvent selected from the group consisting of a polyol and PEG

0% to about 48% of a secondary polar solvent

about 0.2% to about 5% by weight of a surface-active agent

about 0.01% to about 5% by weight of at least one polymeric agent

and a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.

Priority: US2006-430599 Applic. Date: 2006-05-09; US2004-835505 Applic. Date: 2004-04-28; US20030492385P Applic. Date: 2003-08-04; US20030530015P Applic. Date: 2003-12-16; US20050679020P Applic. Date: 2005-05-09; US20060784793P Applic. Date: 2006-03-21

Inventor: TAMARKIN DOV [IL]; FRIEDMAN DORON [IL]; EINI MEIR [IL]; BESONOV ALEX [IL]


Application No.: US20100266512A1  Published: 21/Oct/2010

Title: CROSSLINKED HYALURONIC ACID IN EMULSION

Applicant/Assignee: EVONIK GOLDSCHMIDT GMBH

Application No.: 12/809809   Filing Date: 10/Dec/2008

Abstract:The present invention relates to methods of producing crosslinked hyaluronic acid microbeads, as well as the produced microbeads, said method comprising the steps of: (a) providing an aqueous alkaline solution comprising hyaluronic acid, or a salt thereof

(b) forming microdroplets having a desired size from the mixed solution of step (a) in an organic or oil phase to form a water in organic or water in oil (VWO) emulsion, wherein the amount of oil phase used is of from 20 to less than 50% by weight based on the sum of oil phase and water

(c) adding a solution comprising a crosslinking agent to the emulsion, whereby the reaction of hyaluronic acid with the crosslinking agent takes place to provide crosslinked hyaluronic acid microbeads

and (d) optionally working up the dispersion of crosslinked hyaluronic acid microbeads obtained in step (c).

Priority: EP20070150176 Applic. Date: 2007-12-19; US20070015261P Applic. Date: 2007-12-20; WO2008EP67172 Applic. Date: 2008-12-10

Inventor: WENK HANS HENNING [DE]; FARWICK MIKE [DE]; NATTLAND SANDRA [DE]; MACZKIEWITZ URSULA [DE]; MOELHOLM MALLE BIRGITTE [DK]


Application No.: US20100266523A1  Published: 21/Oct/2010

Title: COMPOSITIONS CONTAINING FLAVANOID POLYPHENOL DERIVATIVES, AND APPLICATIONS THEREOF IN CONTROLLING DISEASES AND AGEING OF LIVING ORGANISMS

Applicant/Assignee:

Application No.: 12/734678   Filing Date: 17/Nov/2008

Abstract:The invention relates to compositions of polyphenol derivatives, characterised in that said polyphenols contain monomers, oligomers or polymers of units of the formula (I), wherein said units are characterised by the simultaneous presence of a phloroglucinol-type core (core A) and of a catechol-type core (core B) bonded together by a segment of 3 carbons such as C, said derivatives being over-activated in terms of nucleophilic power by the alkylation of at least one phenol function of each constituent monomer unit, and stabilised by the esterification of all the others with mixtures of fatty acids in proportions representing those of vegetable oils mainly consisting of AGI. These compositions can particularly be used in cosmetics, nutrition and therapy.

Priority: FR20070008021 Applic. Date: 2007-11-15; WO2008IB54814 Applic. Date: 2008-11-17

Inventor: VERCAUTEREN JOSEPH [FR]


Application No.: US20100266531A1  Published: 21/Oct/2010

Title: IL-17 BINDING PROTEINS

Applicant/Assignee: ABBOTT LABORATORIES

Application No.: 12/718841   Filing Date: 05/Mar/2010

Abstract:Proteins that bind IL-17 and/or IL-17F are described along with there use in composition and methods for treating, preventing, and diagnosing IL-17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions.

Priority: US20090209272P Applic. Date: 2009-03-05

Inventor: HSIEH CHUNG-MING [US]; HUGUNIN MARGARET [US]; MURTAZA ANWAR [US]; MCRAE BRADFORD L [US]; KUTSKOVA YULIYA [US]; MEMMOTT JOHN E [US]; PEREZ JENNIFER M [US]; ZHONG SUJU [US]; TARCSA EDIT [US]; CLABBERS ANCA [US]; WALLACE CRAIG [US]; BRYANT SHAUGHN H [US]; LEDDY MARY R [US]


Application No.: US20100266535A1  Published: 21/Oct/2010

Title: Compounds Having CRTH2 Antagonist Activity

Applicant/Assignee: OXAGEN LIMITED

Application No.: 12/828800   Filing Date: 01/Jul/2010

Abstract:Compounds of general formula (II) wherein W is chloro or fluoro

R1 is phenyl optionally substituted with one or more substituents, selected from halo, -CN, -C1-C6 alkyl, -SOR3, -SO2R3, -SO2N(R2)2, -N(R2)2, -NR2C(O)R3, -CO2R2, -CONR2R3, -NO2, -OR2, -SR2, -O(CH2)pOR2, or -O(CH2)pO(CH2)qOR2 wherein each R2 is independently hydrogen, -C1-C6 alkyl, -C3-C8 cycloalkyl, aryl or heteroaryl

each R3 is independently, -C1-C6 alkyl, -C3-C8 cycloalkyl, aryl or heteroaryl

p and q are each independently an integer from 1 to 3

and R4 is hydrogen, C1-C6 alkyl, C1-C6 alkyl substituted with aryl, aryl, (CH2)mOC(-O)C1-C6alkyl, ((CH2)mO)nCH2CH2X, (CH2)mN(R5)2 or CH((CH2)mO(C-O)R6)2

m is 1 or 2

n is 1-4

X is OR5 or N(R5)2

R5 is hydrogen or methyl

and R6 is C1-C18 alkyl

and their pharmaceutically acceptable salts, hydrates, solvates, complexes or prodrugs are useful in orally administrable compositions for the treatment of allergic diseases such as asthma, allergic rhinitis and atopic dermatitis.

Priority: GB20080000874 Applic. Date: 2008-01-18; GB20080020526 Applic. Date: 2008-11-10; US2009-625497 Applic. Date: 2009-11-24; US2009-356822 Applic. Date: 2009-01-21

Inventor: ARMER RICHARD EDWARD [GB]; PETTIPHER ERIC ROY [GB]; WHITTAKER MARK [GB]; WYNNE GRAHAM MICHAEL [GB]; VILE JULIA [GB]; SCHROER FRANK [GB]


Application No.: US20100266621A1  Published: 21/Oct/2010

Title: METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS WITH PSORALEN DERIVATIVES

Applicant/Assignee: DUKE UNIVERSITY IMMUNOLIGHT, LLC

Application No.: 12/763404   Filing Date: 20/Apr/2010

Abstract:Psoralen compounds of Formula (I): wherein (N+ Aryl) is a member selected from the group consisting of nitrogen containing aromatic heterocycles of formulae (i)-(iii): wherein Z is a group of formula: wherein R is C1-C30 hydrocarbyl, which may be linear, branched or cyclic and contains from 1 to 15 carbon-carbon double bonds, which may be conjugated or unconjugated with one another or may include an aryl ring, and may contain one or more substituents

R1 is hydrogen, aryl, heteroaryl, alkyl, cycloalkyl, heterocyclyl, alkenyl, alkynyl, alkene-aryl, alkene-heteroaryl, alkene-heterocyclyl, alkene-cycloalkyl, fused cycloalkylaryl, fused cycloalkylheteroaryl, fused heterocyclylaryl, fused heterocyclyheteroaryl, alkylene-fused cycloalkylaryl, alkylene-fused cycloalkylheteroaryl, alkylene-fused heterocyclylaryl, alkylene-fused heterocyclyheteroaryl

n is an integer from 1 to 8 and X is a pharmaceutically acceptable counter ion

and their use in methods for the treatment of a cell proliferation disorder in a subject, pharmaceutical compositions containing the psoralen derivatives, a kit for performing the method, and a method for causing an autovaccine effect in a subject using the method.

Priority: US20090171158P Applic. Date: 2009-04-21

Inventor: TOONE ERIC [US]; GOODEN DAVID [US]; VO-DINH TUAN [US]; BOURKE JR FREDERIC A [US]


Application No.: US20100266647A1  Published: 21/Oct/2010

Title: Optical Blurring Pigment Composition Suitable for Use in Cosmetics

Applicant/Assignee: AVON PRODUCTS, INC

Application No.: 12/744061   Filing Date: 14/Nov/2008

Abstract:Compositions comprising a gel system made from a combination of a fractal network of nanoparticles and translucent macroscopic particles, titanium dioxide and other color pigments is disclosed. The compositions are capable of forming an effective film on the biological surface such as skin to blurring fine lines and wrinkles while retaining a natural look of the skin as a consequence of synergy between the fractal particles, the macroscopic particles, titanium dioxide and color pigments. Also disclosed methods for their use.

Priority: US20070016971P Applic. Date: 2007-12-27; WO2008US83508 Applic. Date: 2008-11-14

Inventor: DINGLEY AJAY G [US]; FAIR MICHAEL J [US]; GLYNN JR JOHN R [US]; SANDSTROM GIOVANA A [US]


Application No.: US20100266649A1  Published: 21/Oct/2010

Title: Gel Technology Suitable for Use in Cosmetic Compositions

Applicant/Assignee: AVON PRODUCTS, INC

Application No.: 12/747469   Filing Date: 19/Nov/2008

Abstract:A gel system comprising a fractal network of nanoparticles and macroscopic particles is disclosed. The gel system is capable of forming an "optical gel" effective to blurrfine lines and wrinkles as a consequence of the size domain differences between the fractal particles and the macroscopic particles. Cosmetic compositions comprising such gels and methods for their use are also disclosed.

Priority: US20070016967P Applic. Date: 2007-12-27; WO2008US84017 Applic. Date: 2008-11-19

Inventor: MAITRA PRITHWIRAJ [US]; BROWN STEVEN E [US]; GLYNN JR JOHN R [US]; ROTHOUSE JASON [US]; BRAHMS JOHN C [US]; FAIR MICHAEL J [US]


Application No.: US20100266650A1  Published: 21/Oct/2010

Title: METHOD OF COSMETIC CARE STIMULATING MITOCHONDRIAL ACONITASE

Applicant/Assignee: LVMH RECHERCHE

Application No.: 12/751710   Filing Date: 31/Mar/2010

Abstract:The invention relates to the use of a plant extract as a cosmetic agent. This extract is obtained from a plant belonging to the genus Citrus, or from hybrids derived from the crossing of plant species, at least one of which belongs to the genus Citrus, as a cosmetic active agent. The invention makes it possible to prevent or retard the appearance of the signs of ageing of the skin or to attenuate the effects thereof and/or to improve or restore the radiance of the skin complexion.

Priority: FR20090052072 Applic. Date: 2009-03-31

Inventor: NIZARD CARINE [FR]; MOREAU MARIELLE [FR]; ARCHAMBAULT JEAN-CHRISTOPHE [FR]


Application No.: US20100267603A1  Published: 21/Oct/2010

Title: Detergent Compositions for Cleaning and Fabric Care

Applicant/Assignee:

Application No.: 12/827249   Filing Date: 30/Jun/2010

Abstract:Detergent compositions comprising selected deposition polymers for improved deposition of fabric care benefit agents, such as organosilicones, polyolefin dispersions, polymer latexes, microencapsulated fabric care actives, onto fabrics through the laundering operation.

Priority: US2007-818473 Applic. Date: 2007-06-14; US20060815241P Applic. Date: 2006-06-20

Inventor: PANANDIKER RAJAN KESHAV [US]; SIVIK MARK ROBERT [US]; MCCHAIN ROBERT JOE [US]; BUESCHER SUSAN EILEEN [US]; ROTHGEB TIMOTHY MICHAEL [US]; SHEETS CONNIE LYNN [US]; KINDEL PAUL FRANCIS [US]


Application No.: US20100267606A1  Published: 21/Oct/2010

Title: FRAGRANCING COMPOSITION COMPRISING AN AMPHIPHILIC COPOLYMER OF 2 ACRYLAMIDOMETHYLPROPANE-SULPHONIC ACID AND OPTIONALLY A CELLULOSE ALKYL ETHER AND/OR AN ALKYLCELLULOSE ALKYL ETHER

Applicant/Assignee: L'OREAL

Application No.: 12/676166   Filing Date: 08/Sep/2008

Abstract:The invention relates to a fragrancing composition comprising, in a cosmetically acceptable medium: a) at least 1% by weight relative to the total weight of the composition of at least one fragrancing substance

b) at least one volatile alcohol and/or one volatile silicone oil

c) at least one crosslinked or uncrosslinked amphiphilic copolymer of partially or completely neutralized 2-acrylamidomethylpropanesulphonic acid (AMPS) monomer (A) and at least one hydrophobic monomer (B) d) optionally at least a cellulose alkyl ether and/or an alkylcellulose alkyl ether, the alkyl radicals being linear or branched saturated C1-C4 alkyl radicals

and e) optionally water. The invention also relates to a method of fragrancing human keratinous substances and especially the skin, lips and integuments, comprising the application to the keratinous substances of the composition defined previously.

Priority: FR20070058577 Applic. Date: 2007-10-25; FR20070058579 Applic. Date: 2007-10-25; US20070996206P Applic. Date: 2007-11-06; US20070996208P Applic. Date: 2007-11-06; WO2008EP61872 Applic. Date: 2008-09-08

Inventor: TABARIE FREDERIQUE [FR]; PICARD-LESBOUEYRIES ELISABETH [FR]


Application No.: US20100267633A1  Published: 21/Oct/2010

Title: N-(4-Oxo-3,4-Dihydroquinazolin-2Yl) Butanamides as Androgen Receptor Modulators

Applicant/Assignee:

Application No.: 11/992446   Filing Date: 22/Sep/2006

Abstract:The invention relates to substituted N-(4-oxo-3,4-dihydroquinazolin-2-yl)butanamid derivatives which modulate androgen receptors to treat conditions such as: osteoporosis, peridontal disease, bone fracture, frailty, and sarcopenia.

Priority: US20050720587P Applic. Date: 2005-09-26; WO2006US37273 Applic. Date: 2006-09-22

Inventor: HANNEY BARBARA [US]; KIM YUNTAE [US]; MITCHELL HELEN J [US]; MUSSELMAN JEFFREY D [US]; PERKINS JAMES J [US]


Application No.: US20100267642A1  Published: 21/Oct/2010

Title: USE OF COMPLEX FORMS OF CALMODULIN-LIKE SKIN PROTEIN CLSP

Applicant/Assignee: L'OREAL

Application No.: 12/686672   Filing Date: 13/Jan/2010

Abstract:The present invention relates to the use of a complex form of calmodulin-like skin protein (CLSP), of polypeptides derived from this protein or of analogues thereof, as a marker for evaluating a state of an epithelium. The invention also relates to the use of these complex forms for the purposes of screening for biological or chemical compounds capable of modulating a biological activity of said complex forms and/or for preparing and/or improving a pluristratified cell model.

Priority: FR20090050162 Applic. Date: 2009-01-13; US20090202077P Applic. Date: 2009-01-27

Inventor: DONOVAN MARK [FR]; BERNARD DOMINIQUE [FR]


Application No.: US20100267659A1  Published: 21/Oct/2010

Title: EXTRACT OBTAINED FROM ORCHIDACEAE PLANTS, METHOD FOR PRODUCING THE EXTRACT, AND EXTERNAL AGENT FOR SKIN COMPRISING THE EXTRACT

Applicant/Assignee: NICHIREI BIOSCIENCES INC

Application No.: 12/681043   Filing Date: 27/Mar/2009

Abstract:This invention relates to an extract obtained from a plant of the genus Odontoglossum of the family Orchidaceae, or from a plant derived from a hybrid plant of the genus Odontoglossum and the genus Cochlioda, to a method for preparing the extract, and to an external agent for skin comprising the extract.

Priority: JP20080129943 Applic. Date: 2008-05-16; WO2009JP56360 Applic. Date: 2009-03-27

Inventor: SASAKI AKIKO [JP]; KAWAGUCHI MASAKAZU [JP]; HIMONO AYAKA [JP]


Application No.: US20100267663A1  Published: 21/Oct/2010

Title: A COMPOSITION FOR CICATRISATION PROCESSES IN THE TREATMENT OF HYPERTROPHIC SCARS AND FOR IMPROVING THE BIOMECHANICAL PROPERTIES OF THE CUTIS

Applicant/Assignee:

Application No.: 12/743011   Filing Date: 30/Oct/2008

Abstract:This invention concerns a composition for pharmaceutical and/or cosmetic and/or in the form of medical device, in particular for the prevention and treatment of hypertrophic scars and/or cheloids, to inhibit any fibrosclerotic process and to improve the biomechanical properties of the skin and to obstruct retraction to cicatrisation of the skin, as it contains, as an active ingredient, at least one of the active principles chosen between fucose (and/or Fucose rich polysaccharides-FROPs), Dimethyl sulfone and acetyl glucosamine.

Priority: IT2007BS00178 Applic. Date: 2007-11-15; WO2008IT00675 Applic. Date: 2008-10-30

Inventor: DE PAOLI AMBROSI GIANFRANCO [IT]


Application No.: US20100267678A1  Published: 21/Oct/2010

Title: FLUX-ENABLING COMPOSITIONS AND METHODS FOR DERMAL DELIVERY OF DRUGS

Applicant/Assignee: ZARS PHARMA, INC

Application No.: 12/761540   Filing Date: 16/Apr/2010

Abstract:The present invention is drawn to adhesive solidifying formulations, methods of drug delivery, and solidified layers for dermal delivery of a drug. The formulation can include a drug, a solvent vehicle, and a solidifying agent. The solvent vehicle can include a volatile solvent system comprising at least one volatile solvent, and a non-volatile solvent system comprising at least one non-volatile solvent, wherein at least one non-volatile solvent is a flux-enabling non-volatile solvent(s) capable of facilitating the delivery of the drug at therapeutically effective rates over a sustained period of time. The formulation can have a viscosity suitable for application to a skin surface prior to evaporation of the volatile solvents system. When applied to the skin, the formulation can form a solidified layer after at least a portion of the volatile solvent system is evaporated.

Priority: US2006-640437 Applic. Date: 2006-12-14; US2005-146917 Applic. Date: 2005-06-06; US20050750637P Applic. Date: 2005-12-14; US20050750523P Applic. Date: 2005-12-14; US20050750652P Applic. Date: 2005-12-14; US20060795091P Applic. Date: 2006-04-25; US20040577536P Applic. Date: 2004-06-07

Inventor: ZHANG JIE [US]; WARNER KEVIN S [US]; SHARMA SANJAY [US]


Application No.: US20100267683A1  Published: 21/Oct/2010

Title: PHARMACEUTICAL COMPOSITION COMPRISING PEROXIDED OIL AND CHOLESTEROL AND USES THEREOF IN MEDICAL FIELD

Applicant/Assignee:

Application No.: 12/741955   Filing Date: 06/Nov/2008

Abstract:The present invention concerns a pharmaceutical composition comprising peroxided oil and cholesterol to be used in medical field, for example, in the treatment of tumours, viral diseases, ulcers and dermatitis.

Priority: IT2007RM00582 Applic. Date: 2007-11-08; WO2008IT00693 Applic. Date: 2008-11-06

Inventor: CARRATELLI MAURO [IT]


Application No.: US20100267711A1  Published: 21/Oct/2010

Title: METHOD OF ENHANCING CELLULAR PRODUCTION OF MOLECULAR CHAPERONE, HYDROXYLAMINE DERIVATIVES USEFUL FOR ENHANCING THE CHAPERONE PRODUCTION AND THE PREPARATION THEREOF

Applicant/Assignee: CYTRX CORPORATION

Application No.: 12/823823   Filing Date: 25/Jun/2010

Abstract:A method of increasing expression of a molecular chaperon by a cell and/or enhancing the activity of a molecular chaperon in cells is provided. The method comprises treating a cell that is exposed to a physiological stress which induces expression of a molecular chaperon by the cell with an effective amount of a certain hydroxylamine derivative to increase the stress. Alternatively, an hydroxylamine derivative can be administrated to a cell before it is exposed to a physiological stress which induces expression of a molecular chaperon by the cell. Preferably, the cell to which an hydroxylamine derivative is administered is an eukaryotic cell. The hydroxylamine derivative corresponds to the formulae (I) or (II). The invention also provides novel hydroxylamine derivatives falling within the scope of the formulae (I) and (II) as well as pharmaceutical and/or cosmetical compositions comprising the said compounds.

Priority: HU19950003141 Applic. Date: 1995-11-02; HU19960003919 Applic. Date: 1996-02-09; HU19960029820 Applic. Date: 1996-10-04; US2003-618162 Applic. Date: 2003-07-10; US1999-860582 Applic. Date: 1999-12-07; WO1996HU00064 Applic. Date: 1996-11-01

Inventor: VIGH LASZLO [HU]; NAGY PETER LITERATI [HU]; SZILBEREKY JENO [HU]; UEROEGDI LASZLO [HU]; JEDNAKOVITS ANDREA [HU]; JASZLITS LASZLO [HU]; BIRO KATALIN [HU]; MARVANYOS EDE [HU]; BARABAS MIHALY [HU]; HEGEDUES ERZSEBET [HU]; KORANYI LASZLO [HU]; KUERTHY MARIA [HU]; BALOGH GABOR [HU]; HORVATH IBOLYA [HU]; TOEROEK ZSOLT [HU]; UDVARDY EVA [HU]; DORMAN GYOERGY [HU]; MEDZIHRADSZKY DENES [HU]; MEZES BEA [HU]; KOVACS ESZTER [HU]; DUDA ERNO [HU]; FARKAS BEATRIX [HU]; GLATZ ATTILA [HU]


Application No.: US20100271470A1  Published: 28/Oct/2010

Title: METHOD AND APARRATUS FOR CHARACTERIZING A PERSON'S SKIN IMPERFECTIONS

Applicant/Assignee: LVMH RECHERCHE

Application No.: 12/762853   Filing Date: 19/Apr/2010

Abstract:A method of characterizing a person's skin imperfections uses a digital color image-taking device to take at least one digital image of an area of skin including at least one imperfection to be characterized. An apparatus for characterizing the imperfections of the skin and a method for measuring the effectiveness of a treatment for skin imperfections use an active cosmetic, dermatological or pharmaceutical agent and further measure the effectiveness of a staining method aiming to attenuate or mask skin imperfections.

Priority: FR20090052660 Applic. Date: 2009-04-23

Inventor: STEPHAN SANDRINE [FR]; PELLE DE QUERAL DELPHINE [FR]


Application No.: US20100272333A1  Published: 28/Oct/2010

Title: METHOD AND APPARATUS FOR CHARACTERIZING PIGMENT SPOTS

Applicant/Assignee: LVMH RECHERCHE

Application No.: 12/763656   Filing Date: 20/Apr/2010

Abstract:A method involving filters of an extracted plane from a digital image of an area of skin to obtain a first ripple image and a second roughness image, from which appropriate computation devices are used to calculate different types of gray levels to characterize a pigment spot, notably with regard to the uniformity or disparity of the spot. A method measures the effectiveness of a cutaneous pigment spot treatment by an active pigmenting or depigmenting agent.

Priority: FR20090052662 Applic. Date: 2009-04-23

Inventor: STEPHAN SANDRINE [FR]; PELLE DE QUERAL DELPHINE [FR]


Application No.: US20100272652A1  Published: 28/Oct/2010

Title: DETERMINATION OF TRACERS WITHIN SUBJECTS

Applicant/Assignee: SEVENTH SENSE BIOSYSTEMS, INC

Application No.: 12/748316   Filing Date: 26/Mar/2010

Abstract:The present invention generally relates to the use of tracers, for example, to track a substance that has been administered to a subject. A tracer may be separate from the substance to be administered, or in some cases, the tracer and the substance are chemically bonded to each other. When administered to a subject (e.g., ingested), the tracer and the substance to be administered may be absorbed and/or metabolized by the subject, and the pharmacokinetic activity of the tracer within the subject may be related to the pharmacokinetic activity of the substance. Thus, by following the pharmacokinetic activity of the tracer, the pharmacokinetic activity of the substance may be determined. The tracer itself may be determined within a subject using any suitable method, depending on the tracer. As an example, the tracer may be determined by administering an indicator able to interact with the tracer. For instance, the indicator may be applied to the skin of the subject, and the indicator may give a different visual appearance based on the concentration of the tracer, or otherwise exhibit a determinable change in a property of the indicator. Other aspects of the invention are generally directed to methods of making or using tracers, methods of promoting the making or use of such tracers, kits involving such tracers, and the like.

Priority: US20090163733P Applic. Date: 2009-03-26

Inventor: LEVINSON DOUGLAS A [US]


Application No.: US20100272657A1  Published: 28/Oct/2010

Title: ENHANCED EFFICIENCY OF SUNSCREEN COMPOSITIONS

Applicant/Assignee: AKZO NOBEL CHEMICALS INTERNATIONAL B.V SCHERING-PLOUGH HEALTHCARE PRODUCTS, INC

Application No.: 12/628916   Filing Date: 01/Dec/2009

Abstract:Compositions comprising UV blocking agents, a film forming polymer containing acid groups and a neutralizing agent

compositions and methods for increasing the SPF of a composition by neutralizing at least a portion of the acid groups of the film forming agent with the neutralizing agent.

Priority: US20090172916P Applic. Date: 2009-04-27

Inventor: HE QIWEI [US]; PHILBIN MICHAEL TIMOTHY [US]; MARTINO GARY THEODORE [US]; MEYER THOMAS A [US]; BEASLEY DONATHAN G [US]; WAGNER JR JOHN H [US]


Application No.: US20100272658A1  Published: 28/Oct/2010

Title: ENHANCED EFFICIENCY OF SUNSCREEN COMPOSITIONS

Applicant/Assignee: AKZO NOBEL CHEMICALS INTERNATIONAL B.V SCHERING-PLOUGH HEALTHCARE PRODUCTS, INC

Application No.: 12/628924   Filing Date: 01/Dec/2009

Abstract:Compositions comprising UV blocking agents, a film forming polymer containing acid groups and a neutralizing agent

compositions and methods for increasing the SPF of a composition by neutralizing at least a portion of the acid groups of the film forming agent with the neutralizing agent.

Priority: US20090172916P Applic. Date: 2009-04-27

Inventor: HE QIWEI [US]; PHILBIN MICHAEL TIMOTHY [US]; MARTINO GARY THEODORE [US]; MEYER THOMAS A [US]; BEASLEY DONATHAN G [US]; WAGNER JR JOHN H [US]


Application No.: US20100272660A1  Published: 28/Oct/2010

Title: COSMETIC OR PHARMACEUTICAL COMPOSITION COMPRISING A POLYCONDENSATE, THE SAID POLYCONDENSATE AND METHOD OF COSMETIC TREATMENT

Applicant/Assignee:

Application No.: 12/681473   Filing Date: 02/Oct/2008

Abstract:The present application relates to a cosmetic or pharmaceutical composition comprising a polycondensate capable of being obtained by the reaction of the following monomers alone: of 10 to 30% by weight, relative to the total weight of the polycondensate, of one or more polyols comprising 3 to 6 hydroxyl groups

of 30 to 80% by weight, relative to the total weight of the polycondensate, of one or more linear, branched and/or cyclic, saturated or unsaturated, non-aromatic monocarboxylic acids comprising 6 to 32 carbon atoms

of 1 to 40% by weight, relative to the total weight of the polycondensate, of one or more polycarboxylic acids and/or cyclic anhydrides of such a polycarboxylic acid and/or lactones comprising at least one COOH group

and optionally of 0.1 to 15% by weight, relative to the total weight of the polycondensate, of one or more silicones having a hydroxyl and/or carboxyl functional group. The application also relates to a method of cosmetic treatment using the said composition, and the polycondensate thus defined.

Priority: FR20070058057 Applic. Date: 2007-10-04; US20070984739P Applic. Date: 2007-11-02; WO2008FR51782 Applic. Date: 2008-10-02

Inventor: MALLE GERARD [FR]


Application No.: US20100272662A1  Published: 28/Oct/2010

Title: COSMETIC COMPOSITION CONTAINING AN ADENIUM OBESUM EXTRACT, USE THEREOF AND METHOD FOR COSMETIC CARE INCLUDING THE USE THEREOF

Applicant/Assignee: LVMH RECHERCHE

Application No.: 12/599591   Filing Date: 07/May/2008

Abstract:The invention relates to a cosmetic composition. This cosmetic composition comprises an extract of Adenium obesum, and at least one cosmetically acceptable excipient. This composition can be used to strengthen the cutaneous barrier, to reinforce the cohesion of the dermal-epidermal junction, to prevent or delay the effects of skin aging, or else to provide a protective, corrective, restructuring, hydrating or moisturizing effect.

Priority: FR20070055042 Applic. Date: 2007-05-11; WO2008FR50811 Applic. Date: 2008-05-07

Inventor: BONTE FREDERIC [FR]; DUMAS MARCH [FR]; ARCHAMBAULT JEAN-CHRISTOPHE [FR]


Application No.: US20100272765A1  Published: 28/Oct/2010

Title: Stable emulsion and process for preparing the same

Applicant/Assignee: AKZO NOBEL N.V

Application No.: 12/811955   Filing Date: 08/Jan/2009

Abstract:The invention relates to a stable emulsion comprising (a) an oil

(b) water

(c) a surfactant

and (d) solid particulate material, wherein an emulsion comprising the oil, water, and the surfactant has a transitional phase inversion point, wherein the stable emulsion contains droplets having a d50 value of below 1 [mu]m, and wherein the shelf life time of an emulsion comprising compounds (a) to (d) is longer than the shelf life time of emulsions containing only compounds (a) to (c).

Priority: EP20080100273 Applic. Date: 2008-01-09; US20080022699P Applic. Date: 2008-01-22; WO2009EP50185 Applic. Date: 2009-01-08

Inventor: HO O BOEN [NL]; BALTUSSEN JOZEF JOHANNES MARIA [NL]


Application No.: US20100272834A1  Published: 28/Oct/2010

Title: Freeze-Dried Molded Article Containing Magnesium Ascorbyl Phosphate

Applicant/Assignee: DR. SUWELACK SKIN & HEALTH CARE AG

Application No.: 12/763632   Filing Date: 20/Apr/2010

Abstract:The invention relates to freeze-dried molded articles containing magnesium ascorbyl phosphate and alginate as well as optionally one or more active substances and/or auxiliary substances. Furthermore, the invention relates to methods for manufacturing these freeze-dried molded articles, the combination of such freeze-dried molded articles in kit-of-parts arrangements together with aqueous solutions, as well as the use of the freeze-dried molded articles and the kit-of-parts combinations for pharmaceutical and cosmetic application.

Priority: EP20090158475 Applic. Date: 2009-04-22

Inventor: MALESSA RALF [DE]


Application No.: US20100272839A1  Published: 28/Oct/2010

Title: TREATMENT OF FATTY SCALP WITH A LYSATE OF BIFIDOBACTERIUM SPECIES

Applicant/Assignee: L'OREAL

Application No.: 12/607142   Filing Date: 28/Oct/2009

Abstract:The present invention treats a fatty dandruff state of the scalp with a lysate of at least one microorganism of the genus Bifidobacterium species and/or a fraction thereof.

Priority: FR20080057333 Applic. Date: 2008-10-28; US20080111426P Applic. Date: 2008-11-05

Inventor: GUENICHE AUDREY [FR]; BERNARD DOMINIQUE [FR]; CASTIEL ISABELLE [FR]


Application No.: US20100273729A1  Published: 28/Oct/2010

Title: Compositions Comprising Compounds Of Natural Origin For Damaged Skin

Applicant/Assignee: BIOSPECTRUM, INC

Application No.: 12/093233   Filing Date: 17/Dec/2007

Abstract:The present invention relates to a skin-protecting composition for the damaged skin, comprising glycyrrhizin, quercetin, rosmarinic acid, madecassic acid, chamazulene, bicalein and emodin. The composition of the present invention has all of excellent antioxidant, anti-inflammatory, wound-healing and moisturizing effects, thereby being widely used in medicine, cosmetic material or the like for the purpose of protecting the easily infectable, damaged and dried skin.

Priority: KR20060128500 Applic. Date: 2006-12-15; WO2007KR06604 Applic. Date: 2007-12-17

Inventor: PARK DEOK HOON [KR]; LEE JONG SUNG [KR]; JUNG KWANG SUN [KR]


Application No.: US20100273736A1  Published: 28/Oct/2010

Title: COSMETIC COMPOSITION COMPRISING GLYCOGEN FOR SKIN APPLICATION WITH VELVET EFFECT

Applicant/Assignee: AZIENDE CHIM. RIUN. ANG. FRANC. A.C.R.A.F. S.P.A

Application No.: 12/746878   Filing Date: 21/Jan/2009

Abstract:This invention relates to a cosmetic composition for skin application having a velvet effect on the skin comprising, as the cosmetic active ingredient, a glycogen having less than 1,000 ppm of nitrogen and less than 1% by weight of reducing sugars, in at least one cosmetically-acceptable vehicle.

Priority: EP20080425060 Applic. Date: 2008-02-01; WO2009EP50632 Applic. Date: 2009-01-21

Inventor: MARCHITTO LEONARDO [IT]; RAGNI LORELLA [IT]; MARIOTTI FRANCESCA [IT]


Application No.: US20100273747A1  Published: 28/Oct/2010

Title: Freeze-Dried Composition of Active Substances

Applicant/Assignee: DR. SUWELACK SKIN & HEALTH CARE AG

Application No.: 12/763605   Filing Date: 20/Apr/2010

Abstract:The invention relates to freeze-dried molded articles, containing >=50% by wt. of one or more active substances, and >15% by wt. of one or more scaffold-forming agents, with proteins being excepted, as well as optionally one or more auxiliary substances, in each case based on the total composition of the freeze-dried molded article, whose 1% by wt. solution or suspension in water, at 20 DEG C., has a pH value <7. Furthermore, the invention relates to methods for manufacturing these freeze-dried molded articles, the combination of such freeze-dried molded articles in kit-of-parts arrangements together with aqueous solutions, as well as the use of the freeze-dried molded articles and the kit-of-parts combinations for pharmaceutical and cosmetic application.

Priority: EP20090158473 Applic. Date: 2009-04-22

Inventor: MALESSA RALF [DE]; ELSINGHORST CLAUDIA [DE]; KUHLMANN FABIAN [DE]; WAGNER UWE [DE]


Application No.: US20100273800A1  Published: 28/Oct/2010

Title: PYRROLOTRIAZINE DERIVATIVES USEFUL FOR TREATING CANCER THROUGH INHIBITION OF AURORA KINASE

Applicant/Assignee:

Application No.: 12/679787   Filing Date: 22/Sep/2008

Abstract:This invention relates to novel compounds and processes for their preparation, methods of treating diseases, particularly Cancer, comprising administering said compounds, and methods of making pharmaceutical compositions for the treatment or prevention of disorders, particularly Cancer.

Priority: US20070995147P Applic. Date: 2007-09-25; WO2008US77211 Applic. Date: 2008-09-22

Inventor: MAGNUSON STEVEN [US]; WICKENS PHILIP [CA]; ZHANG ZHONGHUA [US]; QI NING [US]; MA XIN [US]


Application No.: US20100273882A1  Published: 28/Oct/2010

Title: METHOD FOR THE TREATMENT OF ACNE USING COMPOSITIONS COMPRISING 0.3% BY WEIGHT OF 6-[3-(1-ADAMANTYL)-4-METHOXYPHENYL]-2-NAPHTHOIC ACID

Applicant/Assignee: GALDERMA RESEARCH & DEVELOPMENT

Application No.: 12/772861   Filing Date: 03/May/2010

Abstract:Dermatological disorders having an inflammatory or proliferative component, notably common acne, are treated with topically applicable pharmaceutical compositions containing about 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthanoic acid (adapalene) or salt thereof, formulated into pharmaceutically acceptable media therefor, advantageously formulated into topically applicable gels, preferably aqueous gels, creams, lotions or solutions.

Priority: FR20020003070 Applic. Date: 2002-03-12; US2006-494693 Applic. Date: 2006-07-28; US2004-937612 Applic. Date: 2004-09-10; WO2003EP03246 Applic. Date: 2003-03-12; US20020370223P Applic. Date: 2002-04-08

Inventor: GRAEBER MICHAEL [US]; CZERNIELEWSKI JANUSZ [FR]


Application No.: US20100273895A1  Published: 28/Oct/2010

Title: FORMULATIONS OF CANNABIDIOL AND PRODRUGS OF CANNABIDIOL AND METHODS OF USING THE SAME

Applicant/Assignee: ALLTRANZ INC

Application No.: 12/769519   Filing Date: 28/Apr/2010

Abstract:Described herein are pharmaceutical compositions comprising a cannabinoid, such as cannabidiol or a cannabidiol prodrug, which is metabolized to cannabidiol, and a penetration enhancer. Also described herein are methods of using the same. One embodiment described herein relates to the transdermal or topical administration of pharmaceutical compositions comprising a cannabinoid, such as cannabidiol or a cannabidiol prodrug, and a penetration enhancer to a person in need thereof.

Priority: US20090173469P Applic. Date: 2009-04-28

Inventor: STINCHCOMB AUDRA LYNN [US]; BANKS STAN LEE [US]


Application No.: US20100278725A1  Published: 04/Nov/2010

Title: METHODS AND DEVICES FOR LYMPHATIC TARGETING

Applicant/Assignee:

Application No.: 12/063614   Filing Date: 14/Aug/2006

Abstract:The present invention is directed to an implantable device comprising a biocompatible and biodegradable matrix impregnated with a bioactive complex suitable for selectively targeting the lymphatic system, wherein the bioactive complex comprises one or more particle forming materials and one or more bioactive agents. The invention is further directed to methods of using and the process of preparing, the implantable device.

Priority: US20050707534P Applic. Date: 2005-08-12; WO2006CA01321 Applic. Date: 2006-08-14

Inventor: LIU JIANG [CA]; JOHNSTON MICHAEL RICHARD [CA]; WU XIAO YU [CA]


Application No.: US20100278755A1  Published: 04/Nov/2010

Title: COMPOSITION CONTAINING P-MENTHANE-3, 8-DIOL AND ITS USE AS INSECT REPELLANT

Applicant/Assignee:

Application No.: 12/677714   Filing Date: 12/Sep/2008

Abstract:An economical and simple method of producing para-menthane-3,8-diol in relatively high yield is disclosed. The product is useful as a repellent against noxious insects and other arthropods.

Priority: GB20070017782 Applic. Date: 2007-09-13; GB20080005561 Applic. Date: 2008-03-27; WO2008GB03113 Applic. Date: 2008-09-12

Inventor: DELL IAN THOMAS [GB]


Application No.: US20100278756A1  Published: 04/Nov/2010

Title: Peptides having activities of insulin like growth factor-1 and their uses

Applicant/Assignee: CAREGEN CO., LTD

Application No.: 12/659546   Filing Date: 12/Mar/2010

Abstract:The present invention relates to a peptide having the activity of insulin like growth factor-1 (IGF-1) and derived from IGF-1, a composition for improving skin conditions or treating a periodontal disease comprising the peptide. The IGF-1 mimicking peptides of this invention have identical functions or actions to natural-occurring IGF-1 and much better stability and skin permeation than natural-occurring IGF-1. In these connections, the composition comprising the peptides of this invention can exhibit excellent efficacies on the treatment, prevention and improvement of diseases or conditions demanding IGF-1 activities. In addition, the peptides of this invention can be advantageously applied to pharmaceutical compositions, quasi-drugs and cosmetics.

Priority: KR20060021099 Applic. Date: 2006-03-06; US2008-224788 Applic. Date: 2008-09-05; WO2007KR01086 Applic. Date: 2007-03-06

Inventor: CHUNG YONG JI [KR]; KIM YOUNG DEUG [KR]; KIM EUN MI [KR]


Application No.: US20100278759A1  Published: 04/Nov/2010

Title: Topical Therapeutic Delivery System

Applicant/Assignee:

Application No.: 12/223790   Filing Date: 08/Feb/2007

Abstract:The present invention relates to an oil-in-water emulsion topical delivery system comprising an oil phase

an aqueous phase

phenoxyethanol

an effective exfoliatingamount of a hydrophobic hydroxycarboxylic acid

a non-ionic emulsifier having an HLB of from about 7 to about 10

and at least one skin-supporting ordermatopharmaceutically active agent.

Priority: US20060771016P Applic. Date: 2006-02-08; WO2007US03427 Applic. Date: 2007-02-08

Inventor: MURAD HOWARD [US]


Application No.: US20100278764A1  Published: 04/Nov/2010

Title: COSMETIC AND/OR PHARMACEUTICAL COMPOSITION COMPRISING AT LEAST ONE COPOLYMER COMPRISING AT LEAST ONE IONIZABLE GROUP, AND COSMETIC TREATMENT PROCESS

Applicant/Assignee: L'OREAL S.A

Application No.: 12/833461   Filing Date: 09/Jul/2010

Abstract:Disclosed herein is a cosmetic and/or pharmaceutical composition comprising, in a physiologically acceptable medium, at least one (co)polymer comprising a polymer backbone and at least one junction group linked to the polymer backbone and capable of establishing H bonds with at least one partner junction group, each pairing of a junction group involving at least 3H bonds, wherein the at least one (co)polymer comprises at least one ionizable group. Also disclosed herein is a cosmetic treatment process comprising applying the composition to keratin materials.

Priority: FR20050053909 Applic. Date: 2005-12-16; US2006-640420 Applic. Date: 2006-12-18; US20050754183P Applic. Date: 2005-12-28

Inventor: MOUGIN NATHALIE [FR]; CHODOROWSKI-KIMMES SANDRINE [FR]; SCHULTZE XAVIER [FR]


Application No.: US20100278765A1  Published: 04/Nov/2010

Title: REGULATION OF MAMMALIAN KERATINOUS TISSUE USING HEXAMIDINE COMPOSITIONS

Applicant/Assignee:

Application No.: 12/835244   Filing Date: 13/Jul/2010

Abstract:The present invention relates to methods for regulating the condition of mammalian keratinous tissue wherein the methods each comprise the step of topically applying to the keratinous tissue of a mammal needing such treatment, a safe and effective amount of a skin care composition comprising: a) a safe and effective amount of a hexamidine compound selected from the group consisting of hexamidine, its salts, and derivatives

b) a safe and effective amount of one or more skin care active selected from the group consisting of sugar amine, vitamin B3, retinoid, peptide, phytosterol, butylated hydroxytoluene and butylated hydroxyanisole, their derivatives, and combinations thereof

and c) a dermatologically acceptable carrier for the hexamidine and the skin care active. In additional embodiments, the above composition is suitable for preventing, retarding, and/or treating dark under-eye circles, puffy eyes, sagging, sallowness as well as spider vessels and/or red blotchiness of skin, promoting skin desquamation, exfoliation, and/or turnover, regulating and/or reducing pore size appearance, preventing/retarding tanning, regulating oily/shiny appearance, preventing, retarding, and/or treating hyperpigmentation in mammalian skin, preventing, retarding, and/or treating itchiness of mammalian skin, preventing, retarding, and/or treating dryness of skin, preventing, retarding, and/or treating fine lines and wrinkles, preventing, retarding, and/or treating skin atrophy of mammalian skin, softening and/or smoothing lips, hair and nails of a mammal, and preventing, retarding, and/or treating the appearance of cellulite in mammalian skin.

Priority: US2004-780267 Applic. Date: 2004-02-17; US2003-379252 Applic. Date: 2003-03-04

Inventor: BISSETT DONALD LYNN [US]


Application No.: US20100278793A1  Published: 04/Nov/2010

Title: TREATMENT OF GREASY SKIN WITH A BACTERIAL LYSTATE

Applicant/Assignee: L'OREAL

Application No.: 12/607170   Filing Date: 28/Oct/2009

Abstract:The present invention relates to the cosmetic treatment of greasy skin and/or skin that tends to be greasy with a lysate of at least one microorganism of the genus Bifidobacterium species and/or a fraction thereof, as an active.

Priority: FR20080057336 Applic. Date: 2008-10-28; US20080111432P Applic. Date: 2008-11-05

Inventor: GUENICHE AUDREY [FR]; CASTIEL ISABELLE [FR]; BERNARD DOMINIQUE [FR]


Application No.: US20100278883A1  Published: 04/Nov/2010

Title: USE OF AMPHIPHILIC SELF-ASSEMBLING PROTEINS FOR FORMULATING POORLY WATER-SOLUBLE EFFECT SUBSTANCES

Applicant/Assignee: BASF SE

Application No.: 12/161364   Filing Date: 19/Jan/2007

Abstract:The invention relates to the use of amphiphilic self-assembling proteins for formulating poorly water-soluble effect substances.

Priority: EP20060100671 Applic. Date: 2006-01-20; WO2007EP50541 Applic. Date: 2007-01-19

Inventor: LIEBMANN BURGHARD [DE]; FEHR MARCUS [DE]; HUEMMERICH DANIEL [DE]; MARTIN INGRID [DE]; BRANDS MARIO [DE]; PTOCK ARNE [DE]; SCHEIBEL THOMAS [DE]


Application No.: US20100278886A1  Published: 04/Nov/2010

Title: PERSONAL CARE DISSOLVABLE FILMS

Applicant/Assignee:

Application No.: 12/665273   Filing Date: 26/Jun/2008

Abstract:Personal care dissolvable films comprising a water soluble film forming agent, cosmetically acceptable plasticizer, and detackifying agent are described, along with methods of using the same.

Priority: US20070947114P Applic. Date: 2007-06-29; WO2008US68379 Applic. Date: 2008-06-26

Inventor: YU WEI HONG [US]; DROVEISKAYA TATIANA V [US]; JORDAN SUSAN L [US]


Application No.: US20100278948A1  Published: 04/Nov/2010

Title: USE OF A COSMETIC COMPOSITION FOR THE CARE OF FATTY SKIN

Applicant/Assignee: LABORATORIES CLARINS

Application No.: 12/444343   Filing Date: 05/Oct/2007

Abstract:The present invention relates to the use of chrysin in a cosmetic composition for the care of fatty skin. The present invention also relates to a cosmetic treatment method for the prophylaxis or therapy of fatty skin that comprises the application onto the skin of a chrysin-containing cosmetic composition.

Priority: FR20060008785 Applic. Date: 2006-10-06; WO2007FR01628 Applic. Date: 2007-10-05

Inventor: COURTIN OLIVIER [FR]


Application No.: US20100279946A1  Published: 04/Nov/2010

Title: USE OF AN ACTIVE PRINCIPLE FROM FLAX FOR USE IN A COMPOSITION FOR ACTIVATING CYTOCHROME C

Applicant/Assignee: SOCIETE D'EXTRACTION DES PRINCIPES ACTIFS S.A. (VINCIENCE)

Application No.: 12/669836   Filing Date: 21/Jul/2008

Abstract:The present invention concerns the use, in a cosmetic composition, of an effective quantity of active principle originating from flax (genus Linum) to activate cytochrome c and to stimulate the functions of the mitochondria. The active principle originates from the hydrolysis of flax proteins and contains principally polypeptides or peptides. It can be used alone or in association with at least one other active principle. The invention further relates to a method of cosmetic treatment intended to protect the skin and the appendages from external aggressions and to combat against cutaneous ageing.

Priority: FR20070005295 Applic. Date: 2007-07-20; WO2008FR01072 Applic. Date: 2008-07-21

Inventor: DAL FARRA CLAUDE [FR]; DOMLOGE NOUHA [FR]; BOTTO JEAN-MARIE [FR]


Application No.: US20100280013A1  Published: 04/Nov/2010

Title: CARBINOL DERIVATIVES HAVING HETEROCYCLIC LINKER

Applicant/Assignee: KOWA COMPANY, LTD

Application No.: 12/769104   Filing Date: 28/Apr/2010

Abstract:[Object] It is to provide a novel LXR[beta] agonist useful as a preventative and/or therapeutic agent for atherosclerosis

arteriosclerosis such as those resulting from diabetes

dyslipidemia

hypercholesterolemia

lipid-related diseases

inflammatory diseases that are caused by inflammatory cytokines

skin diseases such as allergic skin diseases

diabetes

or Alzheimer's disease. [Solving Means] A carbinol compound represented by the following general formula (I) or salt thereof, or their solvate: (wherein, each V and W independently show N or C-R7

each X and Y independently show CH2, C-O, SO2, etc

Z shows CH or N

each R1, R2 and R7 independently show a hydrogen atom, C1-8 alkyl group, etc.

R3 shows C1-8 alkyl group

R4 shows an optionally substituted C6-10 aryl group or an optionally substituted 5- to 11-membered heterocyclic group

R5 and R6 show a hydrogen atom, etc.

L shows a C1-8 alkyl chain optionally substituted with an oxo group, etc.

and n shows any integer of 0 to 2.)

Priority: US20090173690P Applic. Date: 2009-04-29

Inventor: KOURA MINORU [JP]; SUMIDA HISASHI [JP]; KUROBUCHI SAYAKA [JP]; MATSUDA TAKAYUKI [JP]; WATANABE YUICHIRO [JP]; ENOMOTO TAKASHI [JP]; SHIBUYA KIMIYUKI [JP]; KUROBUCHI SUMIKO [JP]


Application No.: US20100280432A1  Published: 04/Nov/2010

Title: BIOSYNCHRONOUS TRANSDERMAL DRUG DELIVERY

Applicant/Assignee: CHRONO THERAPEUTICS, INC

Application No.: 12/835693   Filing Date: 13/Jul/2010

Abstract:Systems and methods for treating diseases, addictions and disorders in humans and animals involving synchronizing and tailoring the administration of drug compounds with the body's natural circadian rhythms, in order to counteract symptoms when they are likely to be at their worst. Automated and pre programmable transdermal drug administration system are used. This system can also utilize a pump or pressurized reservoir, and/or a system for removing depleted carrier solution, or other modulated dispensing actuator, in conjunction with micro-fabricated structures commonly referred to as Micro-needles, or heat, or iontophoresis, sonophoresis, or a wide range of chemical permeation enhancers.

Priority: US2005-162525 Applic. Date: 2005-09-13; US20040609418P Applic. Date: 2004-09-13; US2005-162517 Applic. Date: 2005-09-13

Inventor: DIPIERRO GUY [US]; GIANNOS STEVEN A [US]


Application No.: US20100280489A1  Published: 04/Nov/2010

Title: WASTE MANAGEMENT SYSTEM

Applicant/Assignee:

Application No.: 12/669876   Filing Date: 22/Jul/2008

Abstract:A waste management system includes a waste transport device and a waste collection device. The waste management system may include a securement device for maintaining the position of the waste transport device following insertion. The waste transport device may include a modular medication delivery apparatus with a disposable delivery device for delivering medication to the patient following insertion of the waste transport device.

Priority: WO2007US81120 Applic. Date: 2007-10-11; US20070951229P Applic. Date: 2007-07-22; US20070951228P Applic. Date: 2007-07-22; WO2008US70781 Applic. Date: 2008-07-22

Inventor: NISHTALA VASU [US]; KLINE JEFFREY FRANCIS [US]; BRACKEN RONALD L [US]


Application No.: US20100284938A1  Published: 11/Nov/2010

Title: PENETRATING PHARMACEUTICAL FOAM

Applicant/Assignee: FOAMIX LTD

Application No.: 12/752718   Filing Date: 01/Apr/2010

Abstract:The invention relates to an alcohol-free cosmetic or pharmaceutical foam composition comprising water, a hydrophobic solvent, a surface-active agent, a gelling agent, an active component selected from the group of urea, hydroxy acid and a therapeutic enhancer and a propellant. The foam further comprises active agents and excipients with therapeutic properties having enhanced skin penetration.

Priority: IL20020152486 Applic. Date: 2002-10-25; US2004-922358 Applic. Date: 2004-08-20; WO2003IB05527 Applic. Date: 2003-10-24; US2004-911367 Applic. Date: 2004-08-04; US20030497648P Applic. Date: 2003-08-25; US20020429546P Applic. Date: 2002-11-29; US20030492385P Applic. Date: 2003-08-04

Inventor: TAMARKIN DOV [IL]; FRIEDMAN DORON [IL]; EINI MEIR [IL]


Application No.: US20100285077A1  Published: 11/Nov/2010

Title: COSMETIC COMPOSITION COMPRISING HYDROXYMETHIONINE AND 3-AMINOPROPANESULFONIC ACID

Applicant/Assignee:

Application No.: 12/733557   Filing Date: 11/Sep/2008

Abstract:The present invention relates to cosmetic compositions comprising an association of hydroxymethionine and 3-aminopropanesulfonic acid, and a cosmetic method for the skin. These compositions are intended to prevent and/or treat the signs of the cutaneous ageing such as the sagging of the cutaneous and subcutaneous tissue, the loss of cutaneous elasticity and atony of the texture of the skin, the loss of firmness and tonicity, dermal atrophy and loss of density, wrinkle, little wrinkle, crack.

Priority: FR20070057616 Applic. Date: 2007-09-14; WO2008IB53667 Applic. Date: 2008-09-11

Inventor: LINTNER KARL [FR]; MAS CHAMBERLIN CLAIRE [FR]


Application No.: US20100285136A1  Published: 11/Nov/2010

Title: SYSTEM COMPRISING BACTERIOPHAGES AND PARTICLES THAT CONTAIN ACTIVE SUBSTANCES

Applicant/Assignee: BAYER TECHNOLOGY SERVICES GMBH

Application No.: 12/672096   Filing Date: 01/Aug/2008

Abstract:The present invention concerns a system, comprising bacteriophages and particles comprising active agents, in which a first additional peptide is fused to proteins of the bacteriophage, the first additional peptide adheres to the surface of the particle and furthermore a second additional peptide is fused to proteins of the bacteriophage. The second additional peptide can adhere on substrate surfaces. The present invention furthermore concerns the use of the system for delayed release of active agents and also a method for production of the system. The present invention furthermore concerns a method for the selection of phage species from a combinatorial phage population.

Priority: DE200710036866 Applic. Date: 2007-08-06; WO2008EP06336 Applic. Date: 2008-08-01

Inventor: EIDEN STEFANIE [DE]; EBLE AXEL [DE]; WEISS MARTIN [DE]; DUFF DANIEL GORDON [DE]; BORK OLAF [NZ]; EGGER HOLGER [DE]; BUDDE BASTIAN [DE]; PLUG SASCHA [DE]


Application No.: US20100285149A1  Published: 11/Nov/2010

Title: NOVEL TETRAHYDROPYRIDOTHIOPHENES

Applicant/Assignee:

Application No.: 12/377475   Filing Date: 15/Aug/2007

Abstract:Compounds of a certain formula I, in which Ra and Rb have the meanings indicated in the description, are novel effective compounds with anti-proliferative and apoptosis inducing activity.

Priority: EP20060119034 Applic. Date: 2006-08-16; WO2007EP58432 Applic. Date: 2007-08-15

Inventor: PEKARI KLAUS [DE]; SCHMIDT MATHIAS [DE]; ZIMMERMANN ASTRID [DE]; GEKELER VOLKER [DE]; BECKERS THOMAS [DE]; BAER THOMAS [DE]


Application No.: US20100286037A1  Published: 11/Nov/2010

Title: PHARMACEUTICAL AND/OR COSMETIC COMPOSITION CONTAINING ACTIVE-PRINCIPLE ACTIVATORS OF ACONITASE

Applicant/Assignee: SOCIETE D'EXTRACTION DES PRINCPES ACTIFS S.A. (VIN

Application No.: 12/597873   Filing Date: 27/Oct/2009

Abstract:The present invention relates to a cosmetic or pharmaceutical, and in particular dermatological, composition comprising, in a physiologically suitable medium, active ingredients capable of activating aconitase. These active ingredients may be polypeptides or peptides, used alone or in combination with at least one other active ingredient. The invention also relates to the use of a cosmetic composition which protects mitochondria. The invention also relates to a cosmetic treatment process for protecting the skin and the appendages against external attacks and for combating skin ageing.

Priority: FR20070003053 Applic. Date: 2007-04-27; WO2008FR00572 Applic. Date: 2008-04-23

Inventor: DAL FARRA CLAUDE [FR]; DOMLOGE NOUHA [FR]; BOTTO JEAN-MARIE [FR]


Application No.: US20100286056A1  Published: 11/Nov/2010

Title: COMPOSITIONS FOR REDUCING OXIDATIVE STRESS AND USES THEREOF

Applicant/Assignee:

Application No.: 12/742812   Filing Date: 19/Nov/2008

Abstract:The present invention relates to the use of one or more tripeptides selected from the group consisting of NLys-Pro-ValC, NLys-Pro-ThrC and NpGLu-His-ProC for the reduction of oxidative stress. The above tripeptides are particularly useful for the treatment of a disease or damage caused by oxidative stress

such as vitiligo, scleroderma, necrosis, or erythema

furthermore, a disease or damage of the hair, like premature hair loss or premature formation of grey hair. Furthermore the invention relates the cosmetic use of the above tripeptides, in particular against skin aging. Further the invention relates cosmetic compositions containing at least one of said tripeptides.

Priority: EP20070022401 Applic. Date: 2007-11-19; WO2008EP65841 Applic. Date: 2008-11-19

Inventor: BOEHM MARKUS [DE]


Application No.: US20100286285A1  Published: 11/Nov/2010

Title: Pharmaceutical composition comprising oleaginous ointments and vitamin D or its derivatives in the solubilized state

Applicant/Assignee: GALDERMA RESEARCH & DEVELOPMENT

Application No.: 11/984392   Filing Date: 16/Nov/2007

Abstract:The present invention relates to an anhydrous pharmaceutical composition for use in the treatment of psoriasis and other skin disorders, characterized in that it comprises an oleaginous ointment and, as active ingredient, a compound chosen from vitamin D and its derivatives, said active agent being in a solubilized form in said composition.

Priority: FR20050004889 Applic. Date: 2005-05-16; WO2006FR00971 Applic. Date: 2006-04-28

Inventor: BARTHEZ NATHALIE [FR]; ORSONI SANDRINE [FR]; FREDON LAURENT [FR]


Application No.: US20100287625A1  Published: 11/Nov/2010

Title: VEGF VARIANTS

Applicant/Assignee: UNIVERSITE DE LIEGE

Application No.: 12/161470   Filing Date: 18/Jan/2007

Abstract:This invention relates to a Vascular Endothelial Growth Factor (VEGF) polypeptide, which polypeptide lacks an amino acid sequence encoded by exon 5 of the VEGF gene. This variant of VEGF is capable of eliciting activities associated with VEGF whilst showing resistance to proteolytic degradation. The invention provides uses of this protein and nucleic acid sequences from the encoding genes in the diagnosis, prevention and treatment of disease.

Priority: GB20060001098 Applic. Date: 2006-01-19; EP20060255087 Applic. Date: 2006-10-02; WO2007IB00586 Applic. Date: 2007-01-18

Inventor: COLIGE ALAIN [BE]; MINEUR PIERRE [BE]; LAMBERT CHARLES [BE]


Application No.: US20100291045A1  Published: 18/Nov/2010

Title: DYNAMIC VIBRATIONAL METHOD AND DEVICE FOR VOCAL FOLD TISSUE GROWTH

Applicant/Assignee: UNIVERSITY OF DELAWARE

Application No.: 12/781305   Filing Date: 17/May/2010

Abstract:Dynamic vibrational methods and devices for inducing differentiation of stem cells into vocal fold fibroblast-like cells or for generating vocal fold-like tissue from cultured cells. Also provided are matrices providing sustained release of growth factors, and bioreactors generating and delivering a high frequency vibration with in-plane shear stress to cultured cells.

Priority: US20090178717P Applic. Date: 2009-05-15

Inventor: JIA XINQIAO [US]; JIA MINGDE [US]; JHA AMIT K [US]; FARRAN ALEXANDRA J E [US]; TONG ZHIXIANG [US]


Application No.: US20100291049A1  Published: 18/Nov/2010

Title: ANTI-WRINKLE AGENT

Applicant/Assignee: KABUSHIKI KAISHA YAKULT HONSHA

Application No.: 12/377523   Filing Date: 29/Aug/2007

Abstract:The invention provides an anti-wrinkle agent which has an excellent effect of inhibiting the formation of wrinkles and excellent safeness. The anti-wrinkle agent contains, as an active ingredient, a culture supernatant of a lactic acid bacterium belonging to Streptococcus thermophilus.

Priority: JP20060233095 Applic. Date: 2006-08-30; WO2007JP00927 Applic. Date: 2007-08-29

Inventor: IZAWA NAOKI [JP]; IIZUKA RYOKO [JP]; SONE TOSHIRO [JP]; CHIBA KATSUYOSHI [JP]


Application No.: US20100291154A1  Published: 18/Nov/2010

Title: COMPOSITION FOR INHIBITION OF TRANSPLANT REJECTION CONTAINING THE CORDYCEPS MYCELLIA EXTRACT AS AN ACTIVE INGREDIENT

Applicant/Assignee: HANKOOK PHARM. CO., INC

Application No.: 12/740139   Filing Date: 28/Apr/2010

Abstract:Disclosed is a composition for the inhibition of transplant rejection and the prevention and treatment of skin diseases, comprising a cordyceps mycellia extract as an active ingredient. The cordyceps mycellia extract significantly suppresses the production of antibodies to transplants without side effects, such as weight change. Based on natural material, the composition is non-toxic and harmless to the human body and thus can be used as an immunosuppressant for organ transplantation. Also, it stops oozing from sores and is useful in the prevention and treatment of skin diseases, including atopy, allergic reactions, decubitus ulcers, pemphigus and smallpox.

Priority: WO2007KR06356 Applic. Date: 2007-12-07

Inventor: HAN MAN WOO [KR]; YOO JAE KUK [KR]; HUR CHANG-UK [KR]; KIM HWAN-CHUL [KR]; KIM JIN PYO [KR]


Application No.: US20100291160A1  Published: 18/Nov/2010

Title: PHARMACEUTICAL SYSTEM FOR TRANS-MEMBRANE DELIVERY

Applicant/Assignee:

Application No.: 12/779017   Filing Date: 12/May/2010

Abstract:Non-invasive drug delivery systems useful for the absorption of therapeutically active agents through the epithelial membrane are described. The non-invasive drug delivery system delivers a therapeutic active agent with an ionizable, or ionized, metal, transition metal or metal-containing vehicle. The non-invasive drug delivery system may also have a pH adjustable vehicle which facilitates the absorption of the therapeutic agents by altering the pH of the non-invasive drug delivery system at the site of administration. Also disclosed is a method for the pH "sweeping" of the administered therapeutic active agent to provide a consistent and reproducible absorption of the active agent. Certain formulations utilize low doses of active agents without altering the active agents from their current or previous form.

Priority: US20090177753P Applic. Date: 2009-05-13; US20090243338P Applic. Date: 2009-09-17

Inventor: CARVER DAVID R [US]; FOHRMAN TROY G [US]; REYNOLDS SEAN WILLIAM [US]


Application No.: US20100291185A1  Published: 18/Nov/2010

Title: THERITOL PHOSPHATES, SALTS THEREOF AND METHODS OF USE

Applicant/Assignee: SUNNY BIODISCOVERY, INC

Application No.: 12/620138   Filing Date: 17/Nov/2009

Abstract:This application discloses compositions containing synthetic threitol phosphates, in particular threitol monophosphate, threitol-bis-phosphate, threitol diphosphate, and/or threitol triphosphate. The threitol phosphates are useful in treating wounds, for cosmetic applications, and for bone and periodontal regeneration.

Priority: WO2008US63634 Applic. Date: 2008-05-15; US20070930573P Applic. Date: 2007-05-17

Inventor: ZHAO HUI [US]; BOJANOWSKI KRZYSZTOF [US]; ARIA FARIBA [US]; MORTEZAEI REZA [US]


Application No.: US20100291249A1  Published: 18/Nov/2010

Title: Pomegranate-derived Products for the Treatment of Skin Sores and Lesions

Applicant/Assignee: ORI SOFTWARE

Application No.: 12/676957   Filing Date: 07/Sep/2008

Abstract:A method of treating skin sores is described, using medical compositions derived from pomegranate fruit. Methods for preparing such medical compositions are also described, including pomegranate seed oil extract, pomegranate inflorescence and peel extracts, and pomegranate peel powder.

Priority: IL20070185775 Applic. Date: 2007-09-06; WO2008IL01203 Applic. Date: 2008-09-07

Inventor: KLEIN MORDECHAI [IL]


Application No.: US20100292139A1  Published: 18/Nov/2010

Title: TOPICAL DRUG DELIVERY USING PHOSPHATIDYLCHOLINE

Applicant/Assignee:

Application No.: 12/830857   Filing Date: 06/Jul/2010

Abstract:The present invention relates to compositions and methods for transdermal drug delivery comprising formulating a phosphatidylcholine carrier composition containing the drug and applying the composition to the skin.

Priority: US2003-448632 Applic. Date: 2003-05-30; US20020384597P Applic. Date: 2002-05-31

Inventor: PERRICONE NICHOLAS V [US]


Application No.: US20100292159A1  Published: 18/Nov/2010

Title: METHOD OF TREATMENT OR PROPHYLAXIS OF INFLAMMATORY PAIN

Applicant/Assignee: UNIVERSITY OF QUEENSLAND

Application No.: 12/294035   Filing Date: 20/Mar/2007

Abstract:This invention discloses the use of angiotensin II receptor 2 (AT2 receptor) antagonists for the treatment, prophylaxis, reversal and/or symptomatic relief of inflammatory pain, including hyperalgesia, thermal or mechanical allodynia, in vertebrate animals and particularly in human subjects. The AT2 receptor antagonists may be provided alone or in combination with other compounds such as those that are useful in the control of inflammatory conditions.

Priority: AU20060901413 Applic. Date: 2006-03-20; WO2007AU00339 Applic. Date: 2007-03-20

Inventor: SMITH MAREE THERESE [AU]


Application No.: US20100292193A1  Published: 18/Nov/2010

Title: RADIOPROTECTIVE DRUGS

Applicant/Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

Application No.: 12/757786   Filing Date: 09/Apr/2010

Abstract:Drugs and their compositions useful in preventing and treating negative side effects associated with radiation exposure or clinical radiotherapy are disclosed. More specifically, new compounds that can be administered systemically to patients exposed to radiation or undergoing radiotherapy and methods of using these formulations are disclosed.

Priority: US20090168541P Applic. Date: 2009-04-10

Inventor: MCBRIDE WILLIAM H [US]; KIM KWANGHEE [US]; DAMOISEAUX ROBERT D [US]; NORRIS ANDREW J [US]


Application No.: US20100292316A1  Published: 18/Nov/2010

Title: IMPROVED THERAPEUTIC METHODS AND COMPOSITIONS COMPRISING CHROMAN RING COMPOUNDS

Applicant/Assignee: RESEARCH DEVELOPMENT FOUNDATION

Application No.: 12/669145   Filing Date: 09/Jul/2008

Abstract:The instant invention concerns chroman ring derivative compounds such as vitamin E derivatives and methods for their use. In certain aspects, methods for treating subjects comprising Arg, JNK, p73, NOXA or FOXO1 positive cancers are provided. In still further aspects, methods for treating cell proliferative disease such as cancer by administration of a chroman ring compound in conjunction with a P13 or Akt kinase inhibitor are described.

Priority: US20070950508P Applic. Date: 2007-07-18; WO2008US69512 Applic. Date: 2008-07-09

Inventor: SANDERS BOB G [US]; KLINE KIMBERLY [US]


Application No.: US20100297015A1  Published: 25/Nov/2010

Title: CANCER BIOMARKER AND USES THEREOF

Applicant/Assignee:

Application No.: 12/762305   Filing Date: 17/Apr/2010

Abstract:A method of determining the cancer status of a subject, comprising the steps of (a) providing a sample of material obtained from a subject

(b) determining the level GTPCH in the sample

and (c) comparing the level determined in (b) with one or more reference values.

Priority: GB20070020334 Applic. Date: 2007-10-17; WO2008GB03497 Applic. Date: 2008-10-16

Inventor: CAI SHIJIE [GB]


Application No.: US20100297028A1  Published: 25/Nov/2010

Title: MEDICAMENT COMBINATIONS FOR THE TREATMENT OF RESPIRATORY DISEASES

Applicant/Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH

Application No.: 12/848364   Filing Date: 02/Aug/2010

Abstract:The present invention relates to new medicament combinations which contain in addition to one or more, preferably one compound of general formula 1 wherein A, B, R1, X, n and m may have the meanings given in the claims and in the specification, at least one other active substance 2, processes for preparing them and their use as pharmaceutical compositions.

Priority: EP20060110009 Applic. Date: 2006-02-16; US2007-675932 Applic. Date: 2007-02-16

Inventor: KONETZKI INGO [DE]; BOUYSSOU THIERRY [DE]; PESTEL SABINE [DE]; SCHNAPP ANDREAS [DE]


Application No.: US20100297040A1  Published: 25/Nov/2010

Title: Cellular age advantage

Applicant/Assignee:

Application No.: 12/662168   Filing Date: 02/Apr/2010

Abstract:In recent years the demand for cosmetic compositions and cosmetic methods for improving the appearance and condition of skin has grown enormously

consumers are seeking topical skin care products that help treat or delay the signs of natural (chronoaging) and environmental aging. The present invention relates to topical compositions for application to human skin and to their use in improving the condition and appearance of skin. It is based on the premise that effective treatment of normal skin conditions due to natural or environmental aging, such as wrinkles, lines, sagging, hyperpigmentation and age spots, and/or of sensitive, dry, rough, flaky, red, itchy, irritated skin may be obtained through the application of cosmetic compositions to the skin which comprise a combination of collagen stimulators, phytoestrogens, plant derived anti-inflammatory agents, fatty acid, antioxidants.

Priority: US20090216697P Applic. Date: 2009-05-20

Inventor: KEEFE CANDACE ROSE [US]


Application No.: US20100297041A1  Published: 25/Nov/2010

Title: STABLE DISPERSIONS OF SOLID PARTICLES IN A HYDROPHOBIC SOLVENT AND METHODS OF PREPARING THE SAME

Applicant/Assignee: THE PROCTER & GAMBLE COMPANY

Application No.: 12/681952   Filing Date: 20/Nov/2008

Abstract:A method of dispersing a solid particles in a hydrophobic solvent is disclosed. The method utilizes an acrylate copolymer containing long siloxane chains to provide stable dispersions of solid particles in hydrophobic solvents having a solubility parameter of about 8 or less, such as a silicone fluid.

Priority: KR20070059174 Applic. Date: 2007-06-15; KR20080014672 Applic. Date: 2008-02-19; WO2008US84215 Applic. Date: 2008-11-20

Inventor: SMITH STEVEN DARYL [US]; VATTER MICHAEL LEE [US]; DOYLE KEVIN LEE [US]


Application No.: US20100297045A1  Published: 25/Nov/2010

Title: EFFECT PIGMENTS BASED ON ARTIFICIALLY PRODUCED SUBSTRATES WITH A NARROW SIZE DISTRIBUTION

Applicant/Assignee:

Application No.: 12/864146   Filing Date: 25/Nov/2008

Abstract:The invention relates to effect pigments comprising artificial platelet-shaped substrates which have at least one optically active coating, where the effect pigments have a volume-averaged cumulative undersize distribution curve with the characteristic numbers D10, D50 and D90, said cumulative undersize distribution curve having a span [Delta]D of 0.7-1.4, and the span [Delta]D being calculated in accordance with formula (I): [Delta]D=(D90-D10)/D50 (I), and the average thickness of the artificial platelet-shaped substrates being 500 nm to 2000 nm.

Priority: EP20080003114 Applic. Date: 2008-02-20; WO2008EP09993 Applic. Date: 2008-11-25

Inventor: KAUPP GUENTER [DE]; SCHMIDT ULRICH [DE]; SCHUMACHER DIRK [DE]; SCHNEIDER RALPH [DE]


Application No.: US20100297046A1  Published: 25/Nov/2010

Title: Compositions and Methods Related to Fructosamine-3-Kinase Inhibitors

Applicant/Assignee: DYNAMIS THERAPEUTICS, INC

Application No.: 12/294182   Filing Date: 30/Mar/2007

Abstract:The invention relates to compounds and methods for inhibiting production and function of 3-deoxyglucosone and other alpha-dicarbonyl sugars in skin, by way of fructosamine-3-kinase inhibition, thereby treating or prevention various diseases, disorders or conditions. Additionally, the invention relates to treatment of various diseases, disorders or conditions associated with or mediated by oxidative stress since 3DG induces ROS and AGEs, which are associated with the inflammatory response caused by oxidative stress.

Priority: US20060788430P Applic. Date: 2006-03-31; WO2007US08209 Applic. Date: 2007-03-30

Inventor: SCHWARTZ MICHAEL [US]; KAPPLER FRANCIS [US]; SU BANGYING [US]


Application No.: US20100297047A1  Published: 25/Nov/2010

Title: ESTERS OF GLYCEROL AND THEIR USES IN COSMETIC AND PHARMACEUTICAL APPLICATIONS

Applicant/Assignee: BIOPHIL ITALIA S.P.A

Application No.: 12/740009   Filing Date: 28/Oct/2008

Abstract:The invention provides mixtures of tri-, di-, and mono-glycerides obtained by esterification of fatty acids from vegetal oils such as olive oil with glycerine, their production process and their use in cosmetic and pharmaceutical preparations, in particular as vehicle or solubiliser for active ingredients.

Priority: IT2007MI02081 Applic. Date: 2007-10-29; WO2008EP09097 Applic. Date: 2008-10-28

Inventor: SANTUS GIACOMO [IT]; BARBERI LAURA [IT]; SCHUBERT CRISTINA [IT]


Application No.: US20100297048A1  Published: 25/Nov/2010

Title: Use of Derivatives of 4-Hydroxyphenoxy Acetic Acid

Applicant/Assignee: COGNIS IP MANAGEMENT GMBH

Application No.: 12/530342   Filing Date: 26/Feb/2008

Abstract:The present invention relates to substances which can be used as cosmetic ingredients, especially for skin whitening and as cosmetic agents against signs of ageing skin. The present invention also relates to the use of such substances for the manufacture of a medicament for the treatment of disorders related to the pigmentation of the skin.

Priority: EP20070004524 Applic. Date: 2007-03-06; WO2008EP01491 Applic. Date: 2008-02-26

Inventor: MOUSSOU PHILIPPE [FR]; FREIS OLGA [FR]; RATHJENS ANDREAS [DE]


Application No.: US20100297054A1  Published: 25/Nov/2010

Title: 1,2,3-TRIAZOLE DERIVATIVES FOR USE AS STEAROYL-COA DESATURASE INHIBITORS

Applicant/Assignee: SMITHKLINE BEECHAM CORPORATION

Application No.: 12/741637   Filing Date: 07/Nov/2008

Abstract:The present invention relates to substituted triazole compounds of the formula (I): and pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing them and their use in medicine. In particular, the invention relates to compounds for modulating SCD activity.

Priority: GB20070022077 Applic. Date: 2007-11-09; WO2008EP65104 Applic. Date: 2008-11-07

Inventor: BOUILLOT ANNE MARIE JEANNE [FR]; LAROZE ALAIN [FR]; TROTTET LIONEL [FR]


Application No.: US20100297097A1  Published: 25/Nov/2010

Title: COMPOUNDS

Applicant/Assignee:

Application No.: 12/741629   Filing Date: 07/Nov/2008

Abstract:The present invention relates to substituted triazole compounds of the formula (I): and salts thereof, to pharmaceutical compositions containing them and their use in medicine. In particular, the invention relates to compounds for inhibiting SCD activity, such as diseases related to elevated lipid levels, cardiovascular disease, diabetes, obesity, metabolic syndrome, skin disorders such as acne, diseases or conditions related to cancer and the treatment of symptoms linked to the production of the amyloid plaque-forming A[beta]42 peptide such as Alzheimer's disease and the like.

Priority: GB20070022075 Applic. Date: 2007-11-09; WO2008EP65105 Applic. Date: 2008-11-07

Inventor: BOUILLOT ANNE MARIE JEANNE [FR]; LAROZE ALAIN [FR]


Application No.: US20100297150A1  Published: 25/Nov/2010

Title: DISEASE TREATMENT VIA ANTIMICROBIAL PEPTIDE INHIBITORS

Applicant/Assignee:

Application No.: 12/850829   Filing Date: 05/Aug/2010

Abstract:A method of treating a disease in a subject in need thereof is disclosed. The method comprises providing to the subject a therapeutically effective amount of a compound being capable of decreasing an activity and/or level of an antimicrobial peptide (AMP) and/or AMP-like molecule, thereby treating the disease in the subject in need thereof.

Priority: IL20020153557 Applic. Date: 2002-12-19; IL20030156980 Applic. Date: 2003-07-17; US2005-539558 Applic. Date: 2005-06-17; WO2003IL01094 Applic. Date: 2003-12-21

Inventor: HILLMAN YITZCHAK [IL]


Application No.: US20100297194A1  Published: 25/Nov/2010

Title: FORMULATION FOR ORAL ADMINISTRATION OF APOPTOSIS PROMOTER

Applicant/Assignee:

Application No.: 12/770299   Filing Date: 29/Apr/2010

Abstract:An orally deliverable pharmaceutical composition comprises as a sole or first active ingredient a compound of Formula I defined herein or a pharmaceutically acceptable salt thereof, for example ABT-263 free base or ABT-263 bis-HCl salt, dispersed, in a free base equivalent amount of at least about 2.5% by weight of the composition, in a pharmaceutically acceptable carrier

wherein said active ingredient is in solid-state form and/or the composition further comprises, dispersed in the carrier, a pharmaceutically acceptable heavier-chalcogen antioxidant in an amount effective to inhibit oxidation of the active ingredient at a thioether linkage thereof. The composition is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

Priority: US20090174299P Applic. Date: 2009-04-30; US20090174318P Applic. Date: 2009-04-30; US20090185105P Applic. Date: 2009-06-08; US20090185130P Applic. Date: 2009-06-08; US20090218281P Applic. Date: 2009-06-18; US20090289254P Applic. Date: 2009-12-22; US20090289289P Applic. Date: 2009-12-22

Inventor: CATRON NATHANIEL [US]; FICKES MICHAEL G [US]; FISCHER CRISTINA M [US]; GOKHALE RAJEEV [US]; HAIGHT ANTHONY R [US]; HEEMSTRA KATHERINE [US]; HILL DAVID [US]; KNOBLOCH MARTIN [DE]; KOSTELAC DRAZEN [DE]; LAFOUNTAINE JUSTIN S [US]; LI YANXIA [US]; LIEPOLD BERND [DE]; MARSH KENNAN [US]; MILLER JONATHAN M [US]; PACKHAEUSER CLAUDIA [DE]; SANZGIRI YESHWANT D [US]; SCHMITT ERIC A [US]; SHI YI [US]; STEIGER NORBERT [DE]; TONG PING [US]; WU HUAILIANG [US]; ZHANG GEOFF G Z [US]; ZHOU DELIANG [US]


Application No.: US20100297205A1  Published: 25/Nov/2010

Title: PATCH FOR THE EXPULSION OF INSECT POISON FROM THE SKIN AFTER STINGS FROM MEMBRANOUS INSECTS (HYMENOPTERA)

Applicant/Assignee:

Application No.: 12/377796   Filing Date: 20/Aug/2007

Abstract:This invention relates to a patch for the expulsion of insect poison from the skin after stings from membranous insects (Hymenoptera). The patch is characterized in comprising a poison-aspirating matrix comprising an expulsion agent as well as a swell layer, which swells after the addition of a liquid through a hole on the top of the patch and thus adds a light pressure to the poison-aspirating matrix towards the skin, whereby a local and relieving effect is achieved. In one embodiment, the matrix further comprises a local anesthetic. The expulsion agent is e.g. a carbohydrate. The swell layer consists e.g. of a silica gel.

Priority: DK20060001095 Applic. Date: 2006-08-23; DK20070000706 Applic. Date: 2007-05-11; WO2007IB02386 Applic. Date: 2007-08-20

Inventor: WENCKENS MARTIN [DK]


Application No.: US20100297270A1  Published: 25/Nov/2010

Title: COMPOSITION FOR TREATMENT OF ISCHEMIC HEART DISEASE, FACILITATION OF BLOOD CIRCULATION AND ANGIOGENESIS, IMPROVING SKIN BEAUTY, IMPROVING MALE SEXUAL FUNCTION CONTAINING GINSENG BERRY EXTRACT

Applicant/Assignee: AMOREPACIFIC CORPORATION

Application No.: 12/602457   Filing Date: 28/May/2008

Abstract:A composition containing ginseng berry extract as active ingredient is for facilitation of blood circulation, for prevention of vascular aging, for treatment of vascular inflammation, for facilitation of angiogenesis, for treatment of ischemic heart disease, for improvement and treatment of local blood circulation insufficiency, for improvement of skin beauty and for improvement of male sexual function. More particularly, the compositions containing ginseng berry extract as active ingredient facilitate nitric oxide (NO) generation in endothelial cells, improve viability of endothelial cells, and facilitate angiogenesis through increased mobility of endothelial cells and vascular tube formation

provide antioxidative effect, facilitate biosynthesis of collagen, provide skin aging inhibiting and wrinkle improving effects through inhibition of MMP-1, provide skin whitening effect through inhibition of melanin synthesis, and provide skin moisturizing effect

and improve male sexual function through relaxation of the corpus cavernosum and enhancement of penial erection, and, as used in combination with l-arginine, which is a substrate of nitric oxide synthase, provide synergically enhanced NO generation.

Priority: KR20070051593 Applic. Date: 2007-05-28; KR20080043488 Applic. Date: 2008-05-09; WO2008KR02996 Applic. Date: 2008-05-28

Inventor: PARK CHAN-WOONG [KR]; YEOM MYEONG HOON [KR]; CHO NAM HOON [KR]; LEE SANG JUN [KR]; LEE SANG MIN [KR]; LEE JIN YOUNG [KR]; JEON HEE YONG [KR]; KIM YOUNG-MYEONG [KR]; KIM CHUN-KI [KR]; CHOI YOUNG DEUK [KR]


Application No.: US20100298191A1  Published: 25/Nov/2010

Title: Functionalized Substrates Comprising Perfume Microcapsules

Applicant/Assignee:

Application No.: 12/796730   Filing Date: 09/Jun/2010

Abstract:An article comprising: a functionalized substrate comprising: a composition susceptible to aqueous attack, comprising a water-soluble material, a partially water soluble material, a water-dispersible materials, a water-disintegrating materials, and mixtures thereof

a plurality of microcapsules encapsulating a perfume, wherein said plurality of microcapsules is incorporated with said functionalized substrate

and a total perfume loading level of from about 1% to about 95% by weight of said functionalized substrate.

Priority: US2007-895602 Applic. Date: 2007-08-24; US2007-800616 Applic. Date: 2007-05-07; US20060798158P Applic. Date: 2006-05-05

Inventor: DENOME FRANK WILLIAM [US]; BERGES-CABRERA TANIA EDMEE [US]; WAHL ERROL HOFFMAN [US]; BROWN JODI LEE [US]; FOSSUM RENAE DIANNA [US]; CATALFAMO VINCENZO [US]; GIZAW YONAS [US]; BOEKLEY LOIS JEAN [US]; ROSELLE BRIAN JOSEPH [US]; EDWARDS MICHAEL BRUCE [US]


Application No.: US20100298226A1  Published: 25/Nov/2010

Title: POLYPEPTIDES AND POLYNUCLEOTIDES ENCODING SAME AND USE THEREOF IN THE TREATMENT OF MEDICAL CONDITIONS ASSOCIATED WITH ISCHEMIA

Applicant/Assignee: VASCULAR BIOGENICS LTD

Application No.: 12/309856   Filing Date: 31/Jul/2007

Abstract:An isolated polynucleotide is disclosed comprising a nucleic acid sequence encoding a polypeptide having an amino acid sequence of HIF-1alpha, the polypeptide being stably expressed and constitutively active. Isolated polypeptides encoded by same are also disclosed and uses thereof.

Priority: US20060834157P Applic. Date: 2006-07-31; WO2007IL00959 Applic. Date: 2007-07-31

Inventor: BREITBART EYAL [IL]; BANGIO LIVNAT [IL]


Application No.: US20100298231A1  Published: 25/Nov/2010

Title: PMMA BINDING PEPTIDES

Applicant/Assignee: E. I. DU PONT DE NEMOURS AND COMPANY

Application No.: 12/778167   Filing Date: 12/May/2010

Abstract:Peptides are provided that have binding affinity for polymethyl methacrylate (PMMA). The polymethyl methacrylate-binding peptides may be used to prepare peptide-based reagents suitable for use in a variety of applications. The peptide-based reagents may be used to couple benefit agents to a PMMA polymer surface or may be used to couple a benefit agent comprising a PMMA polymer surface to a target surface, such as a body surface.

Priority: US20090179740P Applic. Date: 2009-05-20

Inventor: SCHNEIDER EBERHARD [DE]; SCHURMANN GREGOR [DE]; WAGNER PETER [DE]; WANG HONG [US]


Application No.: US20100298240A1  Published: 25/Nov/2010

Title: PMMA BINDING PEPTIDES

Applicant/Assignee: E. I. DU PONT DE NEMOURS AND COMPANY

Application No.: 12/778169   Filing Date: 12/May/2010

Abstract:Peptides are provided that have binding affinity for polymethyl methacrylate (PMMA). The polymethyl methacrylate-binding peptides may be used to prepare peptide-based reagents suitable for use in a variety of applications. The peptide-based reagents may be used to couple benefit agents to a PMMA polymer surface or may be used to couple a benefit agent comprising a PMMA polymer surface to a target surface, such as a body surface.

Priority: US20090179741P Applic. Date: 2009-05-20

Inventor: SCHNEIDER EBERHARD [DE]; SCHURMANN GREGOR [DE]; WAGNER PETER [DE]; WANG HONG [US]


Application No.: US20100298241A1  Published: 25/Nov/2010

Title: PMMA BINDING PEPTIDES

Applicant/Assignee: E.I. DU PONT DE NEMOURS AND COMPANY

Application No.: 12/778180   Filing Date: 12/May/2010

Abstract:Peptides are provided that have binding affinity for polymethyl methacrylate (PMMA). The polymethyl methacrylate-binding peptides may be used to prepare peptide-based reagents suitable for use in a variety of applications. The peptide-based reagents may be used to couple benefit agents to a PMMA polymer surface or may be used to couple a benefit agent comprising a PMMA polymer surface to a target surface, such as a body surface.

Priority: US20090179831P Applic. Date: 2009-05-20

Inventor: SCHNEIDER EBERHARD [DE]; SCHURMANN GREGOR [DE]; WAGNER PETER [DE]; WANG HONG [US]


Application No.: US20100298249A1  Published: 25/Nov/2010

Title: PHARMACEUTICAL OR COSMETIC PREPARATIONS FOR TOPICAL AND/OR PARENTERAL APPLICATION, PREPARATION METHODS THEREOF AND USE OF SAME

Applicant/Assignee:

Application No.: 12/599645   Filing Date: 22/Apr/2008

Abstract:The invention relates to a pharmaceutical or cosmetic composition for topical and/or parenteral application comprising, in a physiologically acceptable medium, at least one retinoid or salts and derivatives thereof, and at least one inhibitor of hyaluronic acid degradation. The invention is of use in particular in human dermatology or in reconstructive surgery.

Priority: FR20070055026 Applic. Date: 2007-05-11; WO2008FR50726 Applic. Date: 2008-04-22

Inventor: MOUTET MARC [FR]; YADAN JEAN-CLAUDE [FR]


Application No.: US20100298259A1  Published: 25/Nov/2010

Title: PHARMACEUTICAL OR COSMETIC PREPARATIONS FOR TOPICAL AND/OR PARENTERAL APPLICATION, PREPARATION METHODS THEREOF AND USE OF SAME

Applicant/Assignee:

Application No.: 12/599510   Filing Date: 22/Apr/2008

Abstract:The invention relates to a pharmaceutical or cosmetic composition for topical and/or parenteral application comprising, in a physiologically acceptable medium, at least one retinoid or salts and derivatives thereof, and at least one hyaluronic acid oligomer chosen from compounds containing from 1 to 6 disaccharide units. The invention is of use in particular in human dermatology or in reconstructive surgery.

Priority: FR20070055034 Applic. Date: 2007-05-11; WO2008FR50728 Applic. Date: 2008-04-22

Inventor: MOUTET MARC [FR]; YADAN JEAN-CLAUDE [FR]


Application No.: US20100298289A1  Published: 25/Nov/2010

Title: HETEROBICYCLIC COMPOUNDS AS HISTAMINE H4-RECEPTOR ANTAGONISTS

Applicant/Assignee: UCB PHARMA, S.A

Application No.: 12/682093   Filing Date: 07/Oct/2008

Abstract:The present invention concerns heterobicyclic compounds of formula (I) processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals.

Priority: GB20070019651 Applic. Date: 2007-10-09; EP20070020963 Applic. Date: 2007-10-26; WO2008EP63413 Applic. Date: 2008-10-07

Inventor: RAPHY GILLES [BE]; PEGURIER CECILE [BE]; MEISSNER HANS [BE]; KNIGHT ROLAND [BE]; OWEN DAVID ALAN [BE]


Application No.: US20100298337A1  Published: 25/Nov/2010

Title: Organic Compounds

Applicant/Assignee:

Application No.: 12/810948   Filing Date: 09/Jan/2009

Abstract:Compounds of formula (I) in free or salt or solvate form, where T1, T2, and T3 have the meanings as indicated in the specification, are useful for treating inflammatory or obstructive airways, pulmonary hypertension, pulmonary fibrosis, liver fibrosis, muscle diseases and systemic skeletal disorders. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

Priority: EP20080150194 Applic. Date: 2008-01-11; EP20080157985 Applic. Date: 2008-06-10; WO2009EP50222 Applic. Date: 2009-01-09

Inventor: HUNT PETER [GB]; LEBLANC CATHERINE [GB]; PULZ ROBERT ALEXANDER [CH]; STIEFL NIKOLAUS JOHANNES [CH]


Application No.: US20100298370A1  Published: 25/Nov/2010

Title: BENZOTHIAZOLYL THIENOPYRIDINE DERIVATIVES AND USES THEREOF

Applicant/Assignee:

Application No.: 12/377536   Filing Date: 14/Aug/2007

Abstract:Novel benzothiazolyl thienopyridine compounds are provided and pharmaceutical compositions comprising benzothiazolyl thienopyridine compounds. The benzothiazolyl thienopyridine compounds are capable of inhibiting the interactions between vascular endothelial growth factor (VEGF) and heparan sulfate glycosaminoglycans (HS-GAGs), and are useful for prevention or treatment of diseases and disorders such as inflammation, autoimmune diseases and cancer.

Priority: GB20060005581 Applic. Date: 2006-03-20; WO2007IL01016 Applic. Date: 2007-08-14

Inventor: GREGOR PAUL [IL]; ZHUK REGINA [IL]; HARRIS NICOLAS [IL]; KOPPEL JURAJ [IL]


Application No.: US20100298374A1  Published: 25/Nov/2010

Title: NITRILE DERIVATIVES AND THEIR PHARMACEUTICAL USE AND COMPOSITIONS

Applicant/Assignee: CELLCEUTIX CORPORATION

Application No.: 12/780132   Filing Date: 14/May/2010

Abstract:Disclosed are nitrile derivatives and pharmaceutical compositions comprising nitrile derivatives. The pharmaceutical compositions comprise compounds of the formula I and the pharmaceutically acceptable salts of such compounds. Also disclosed are processes for the preparation of such compounds, intermediates used in the preparation of such compounds, and the uses of such compounds in treating hyperproliferative diseases, inflammatory diseases and viral and bacterial infections and inducing apoptosis in cancer cells.

Priority: US20090180121P Applic. Date: 2009-05-20

Inventor: MENON KRISHNA [US]


Application No.: US20100298531A1  Published: 25/Nov/2010

Title: PMMA BINDING PEPTIDES

Applicant/Assignee: E.I. DU PONT DE NEMOURS AND COMPANY

Application No.: 12/778174   Filing Date: 12/May/2010

Abstract:Peptides are provided that have binding affinity for polymethyl methacrylate (PMMA). The polymethyl methacrylate-binding peptides may be used to prepare peptide-based reagents suitable for use in a variety of applications. The peptide-based reagents may be used to couple benefit agents to a PMMA polymer surface or may be used to couple a benefit agent comprising a PMMA polymer surface to a target surface, such as a body surface.

Priority: US20090179824P Applic. Date: 2009-05-20

Inventor: SCHNEIDER EBERHARD [DE]; SCHURMANN GREGOR [DE]; WAGNER PETER [DE]; WANG HONG [US]


Application No.: US20100298532A1  Published: 25/Nov/2010

Title: PMMA BINDING PEPTIDES

Applicant/Assignee: E.I. DU PONT DE NEMOURS AND COMPANY

Application No.: 12/778178   Filing Date: 12/May/2010

Abstract:Peptides are provided that have binding affinity for polymethyl methacrylate (PMMA). The polymethyl methacrylate-binding peptides may be used to prepare peptide-based reagents suitable for use in a variety of applications. The peptide-based reagents may be used to couple benefit agents to a PMMA polymer surface or may be used to couple a benefit agent comprising a PMMA polymer surface to a target surface, such as a body surface.

Priority: US20090179827P Applic. Date: 2009-05-20

Inventor: SCHNEIDER EBERHARD [DE]; SCHURMANN GREGOR [DE]; WAGNER PETER [DE]; WANG HONG [US]


Application No.: US20100298533A1  Published: 25/Nov/2010

Title: PMMA BINDING PEPTIDES

Applicant/Assignee: E.I. DU PONT DE NEMOURS AND COMPANY

Application No.: 12/778186   Filing Date: 12/May/2010

Abstract:Peptides are provided that have binding affinity for polymethyl methacrylate (PMMA). The polymethyl methacrylate-binding peptides may be used to prepare peptide-based reagents suitable for use in a variety of applications. The peptide-based reagents may be used to couple benefit agents to a PMMA polymer surface or may be used to couple a benefit agent comprising a PMMA polymer surface to a target surface, such as a body surface.

Priority: US20090179838P Applic. Date: 2009-05-20

Inventor: SCHNEIDER EBERHARD [DE]; SCHURMANN GREGOR [DE]; WAGNER PETER [DE]; WANG HONG [US]


Application No.: US20100298534A1  Published: 25/Nov/2010

Title: PMMA BINDING PEPTIDES

Applicant/Assignee: E.I. DU PONT DE NEMOURS AND COMPANY

Application No.: 12/778194   Filing Date: 12/May/2010

Abstract:Peptides are provided that have binding affinity for polymethyl methacrylate (PMMA). The polymethyl methacrylate-binding peptides may be used to prepare peptide-based reagents suitable for use in a variety of applications. The peptide-based reagents may be used to couple benefit agents to a PMMA polymer surface or may be used to couple a benefit agent comprising a PMMA polymer surface to a target surface, such as a body surface.

Priority: US20090179842P Applic. Date: 2009-05-20

Inventor: SCHNEIDER EBERHARD [DE]; SCHURMANN GREGOR [DE]; WAGNER PETER [DE]; WANG HONG [US]


Application No.: US20100298535A1  Published: 25/Nov/2010

Title: PMMA BINDING PEPTIDES

Applicant/Assignee: E. I. DU PONT DE NEMOURS AND COMPANY

Application No.: 12/778199   Filing Date: 12/May/2010

Abstract:Peptides are provided that have binding affinity for polymethyl methacrylate (PMMA). The polymethyl methacrylate-binding peptides may be used to prepare peptide-based reagents suitable for use in a variety of applications. The peptide-based reagents may be used to couple benefit agents to a PMMA polymer surface or may be used to couple a benefit agent comprising a PMMA polymer surface to a target surface, such as a body surface.

Priority: US20090179849P Applic. Date: 2009-05-20

Inventor: SCHNEIDER EBERHARD [DE]; SCHURMANN GREGOR [DE]; WAGNER PETER [DE]; WANG HONG [US]


Application No.: US20100298808A1  Published: 25/Nov/2010

Title: METHOD AND A DELIVERY DEVICE FOR ADMINISTERING AN ACTIVE SUBSTANCE TO A SUBJECT

Applicant/Assignee: JANISYS LIMITED

Application No.: 12/744786   Filing Date: 28/Nov/2008

Abstract:A delivery device (1) for administering an active substance to a subject transdermal comprises a first plate member (7) having a plurality of first chambers (8) formed therein. Solid form structures (2) comprising the active substance and of conical shape having a pointed skin penetrating tip (5) are located in the first chambers (8). A second plate member (12) having a plurality of second chambers (16) comprising a driving substance (18) is secured to the first plate member (7) with a first membrane (20) of an expandable material sealably located between the respective first and second plate members (7,12). Expansion of the driving substance (18) in the second chambers (22) urges the first membrane (20) into the corresponding first chambers (8) for in turn urging the solid form structures (2) to penetrate through a second membrane (22) into the skin of the subject. A third plate member (24) comprises a plurality of electrically powered heating elements (28) aligned with the second chambers (22) for heating the driving substance (18) in the second chambers (16) for in turn expanding the driving substances (18) therein.

Priority: IE20070000861 Applic. Date: 2007-11-28; IE20080000884 Applic. Date: 2008-11-04; WO2008IE00115 Applic. Date: 2008-11-28

Inventor: O'DEA JOHN [IE]; BAMBURY EOIN [IE]


Application No.: US20100299845A1  Published: 02/Dec/2010

Title: Hand Fabric Laundering Method

Applicant/Assignee:

Application No.: 12/475698   Filing Date: 01/Jun/2009

Abstract:An improved laundering method for hand washing fabrics such as clothes, curtains, sheets, tablecloths, etc. includes the steps of providing a laundering system, adding water to a wash basin, dispersing the laundry detergent in a wash basin, adding a fabric to the wash basin, forming a wash liquor by combining the water and the laundry detergent, soaking the fabric in the wash liquor for a washing time period of from about 30 minutes to about 12 hours to form a soaked fabric, removing the soaked fabric from the wash liquor, removing wash liquor from the soaked fabric, dispersing the rinsing composition in water in a rinse basin to form a rinse solution, adding the soaked fabric to the rinse solution, soaking the soaked fabric in the rinse solution for a rinsing time period of from about 1 minute to about 1 hour to form a rinsed fabric, removing the rinsed fabric from the rinse solution, removing rinse solution from the rinsed fabric, and drying the rinsed fabric. The laundering system contains a laundry detergent and a rinsing composition. The laundry detergent is suitable for overnight soaking containing therein a bactericide and retards bacterial growth upon soaking a bacteria-contaminated fabric in a wash liquor for 6 hours at 25 DEG C.

Priority:

Inventor: LAPINIG DANIEL VICTORIA [PH]


Application No.: US20100303722A1  Published: 02/Dec/2010

Title: ARTICLES COMPRISING LARGE-SURFACE-AREA BIO-COMPATIBLE MATERIALS AND METHODS FOR MAKING AND USING THEM

Applicant/Assignee:

Application No.: 12/305887   Filing Date: 22/Jun/2007

Abstract:The present invention provides articles of manufacture comprising biocompatible nanostructures comprising significantly increased surface area for, e.g., organ, tissue and/or cell growth, e.g., for bone, tooth, kidney or liver growth, and uses thereof, e.g., for in vitro testing of drugs, chemicals or toxins, or as in vivo implants, including their use in making and using artificial tissues and organs, and related, diagnostic, screening, research and development and therapeutic uses, e.g., as drug delivery devices. The present invention provides biocompatible nanostructures with significantly increased surface area, such as with nanotube and nanopore array on the surface of metallic, ceramic, or polymer materials for enhanced cell and bone growth, for in vitro and in vivo testing, cleansing reaction, implants and therapeutics. The present invention provides optically transparent or translucent cell-culturing substrates. The present invention provides biocompatible and cell-growth-enhancing culture substrates comprising elastically compliant protruding nanostructure substrates coated with Ti, TiO2 or related metal and metal oxide films.

Priority: US20060816221P Applic. Date: 2006-06-23; WO2007US71947 Applic. Date: 2007-06-22

Inventor: JIN SUNGHO [US]; OH SEUNGHAN [US]


Application No.: US20100303743A1  Published: 02/Dec/2010

Title: Personal Care Compositions Containing Hydrophobic Silicone-Organic Gel Blends

Applicant/Assignee:

Application No.: 12/680246   Filing Date: 25/Sep/2008

Abstract:Personal care or healthcare compositions are disclosed comprising a hydrophobic silicone organic elastomer gel blend having viscosity of at least 50 Pa-s. The hydrophobic silicone organic elastomer gel blend contains a silicone organic elastomer and a carrier fluid. The gel blend may be prepared by shearing a silicone organic elastomer or silicone organic elastomer gel with the carrier fluid.

Priority: US20070975344P Applic. Date: 2007-09-26; WO2008US77591 Applic. Date: 2008-09-25

Inventor: KENNAN JOHN JOSEPH [US]; LIN SHAOW BURN [US]; MESSNER KATHRYN ELIZABETH [US]; VAN REETH ISABELLE [CN]; GARAUD JEAN-LUC [FR]; HALLER ROXANNE [US]; LACHER ERIN D [US]


Application No.: US20100303744A1  Published: 02/Dec/2010

Title: PERSONAL-CARE COMPOSITION COMPRISING OIL-SOLUBLE SOLID SUNSCREENS

Applicant/Assignee:

Application No.: 12/728183   Filing Date: 19/Mar/2010

Abstract:In one embodiment, a personal-care composition in the form of a water-in-oil emulsion comprises at least about 10% of a non-polar silicone oil

from about 0.1% to about 10% of a first oil-soluble solid sunscreen

and from about 0.1% to about 10% of a second oil-soluble solid sunscreen. The weight ratio of the first sunscreen to the second sunscreen may be from about 0.8 to about 2.0, or from about 1.0 to about 1.5. The first sunscreen may be oxybenzone. The second sunscreen may be avobenzone. The composition may further comprise a skin-care active selected from the group consisting of a vitamin B3 compound, a sugar amine, a peptide, a hexamidine compound, and combinations thereof. In another embodiment, the invention relates to a method for improving the solubility of a second oil-soluble solid sunscreen in the oil phase of a water-in oil emulsion.

Priority: US20090161953P Applic. Date: 2009-03-20

Inventor: BREYFOGLE LAURIE ELLEN [US]; FINLEY REBECCA ANN [US]


Application No.: US20100303745A1  Published: 02/Dec/2010

Title: SKIN BRONZER

Applicant/Assignee: BROWNBERRY

Application No.: 12/689519   Filing Date: 19/Jan/2010

Abstract:The invention provides a composition having a sunblock and tanning effect containing dihydroxyacetone and a broad spectrum UV blocker having a SPF of at least about 25.

Priority: US20090182688P Applic. Date: 2009-05-29

Inventor: FISH MEREDITH [US]; CHANG PAULEY FEI-ZAN [US]


Application No.: US20100303758A1  Published: 02/Dec/2010

Title: Novel Glucocorticoid Receptor Agonists

Applicant/Assignee:

Application No.: 12/787444   Filing Date: 26/May/2010

Abstract:This invention relates to novel glucocorticoid receptor agonists of formula (I): and to processes and intermediates for their preparation. The present invention also relates to pharmaceutical compositions containing these compounds, to their combination with one or more other therapeutic agents, as well as to their use for the treatment of a number of inflammatory and allergic diseases, disorders and conditions.

Priority: US20090182266P Applic. Date: 2009-05-29

Inventor: GLOSSOP PAUL ALAN [GB]; MILLAN DAVID SIMON [GB]; PRICE DAVID ANTHONY [US]


Application No.: US20100303760A1  Published: 05/Feb/2009

Title: TREATMENT AND/OR PREVENTION OF CANCER AND/OR ARTHRITIS

Applicant/Assignee: LABORATOIRES SERONO SA

Application No.: 11/912432   Filing Date: 20/Apr/2006

Abstract:The invention relates to the use of INSP163 for treatment and/or prevention of cancer and/or musculoskeletal/connective tissue disorder, in particular of lung cancer and/or osteoarthritis. Combinations of INSP163 with an interferon, a TNF antagonist or a further anti-cancer or anti-arthritis agent are also within the present invention.

Priority: EP20050103402 Applic. Date: 2005-04-26; WO2004GB04544 Applic. Date: 2004-10-27; US20050681731P Applic. Date: 2005-05-17; WO2006EP61710 Applic. Date: 2006-04-20

Inventor: POWER CHRISTINE [FR]; YORKE-SMITH MELANIE [GB]


Application No.: US20100303839A1  Published: 02/Dec/2010

Title: METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER USING ONCOLYTIC RSV ACTIVITY

Applicant/Assignee:

Application No.: 12/601030   Filing Date: 21/May/2008

Abstract:The present invention relates generally to methods and compositions employing the oncolytic activity of respiratory syncytial virus (RSV) to treat cancer and other neoplastic disorders.

Priority: US20070931029P Applic. Date: 2007-05-21; WO2008US06499 Applic. Date: 2008-05-21

Inventor: BOSE SANTANU [US]; CHATTERJEE BANDANA [US]


Application No.: US20100303872A1  Published: 02/Dec/2010

Title: USE OF A POLYPHENOL-RICH PLANT EXTRACT AS ANTIOXIDANT IN COMBINATION WITH A HYDRATING OR HUMECTANT AGENT

Applicant/Assignee: LVMH RECHERCHE

Application No.: 12/731838   Filing Date: 25/Mar/2010

Abstract:A polyphenol-rich plant extract is used in combination with at least one hydrating or humectant agent, as cosmetic active agents in a cosmetic composition. The combination improves hydrating and antioxidant cosmetic care.

Priority: FR20090053608 Applic. Date: 2009-06-01

Inventor: DUMAS MARC [FR]; NEVEU MICHELE [FR]; BEAUFRERE-SERON BEATRICE [FR]; CAUCHARD JEAN-HUBERT [FR]; KRZYCH VALERIE [FR]


Application No.: US20100305053A1  Published: 02/Dec/2010

Title: USE OF HESPERIDIN OR OF A DERIVATIVE THEREOF FOR THE PREVENTION AND/OR TREATMENT OF SLACKENED SKIN

Applicant/Assignee: L'OREAL NESTEC SA

Application No.: 12/671591   Filing Date: 01/Aug/2008

Abstract:The present invention relates to the oral use of an effective amount of hesperidin or of a derivative thereof as a skin finning agent.

Priority: FR20070056898 Applic. Date: 2007-08-02; WO2008FR51453 Applic. Date: 2008-08-01

Inventor: GUENICHE AUDREY [FR]; CASTIEL ISABELLE [FR]


Application No.: US20100305062A1  Published: 02/Dec/2010

Title: USE OF ALGINATE OLIGOMERS IN COMBATING BIOFILMS

Applicant/Assignee: ALGIPHARMA IPR AS

Application No.: 12/745058   Filing Date: 24/Oct/2008

Abstract:The invention provides a method for combating biofilm, said method comprising contacting a biofilm with an alginate oligomer. The biofilm may be on an animate or inanimate surface and both medical and non-medical uses and methods are provided. In one aspect the invention provides an alginate oligomer for use in the treatment or prevention of a biofilm infection in a subject. In another aspect the method can be used to combat biofilms, on abiotic surfaces, e.g., for disinfection and cleaning purposes.

Priority: US20070996611P Applic. Date: 2007-11-27; WO2008GB03607 Applic. Date: 2008-10-24

Inventor: ONSOYEN EDVAR [NO]; MYRVOLD ROLF [NO]


Application No.: US20100305070A1  Published: 02/Dec/2010

Title: TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS

Applicant/Assignee: THE UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE

Application No.: 12/771923   Filing Date: 30/Apr/2010

Abstract:The disclosure relates to novel compounds for use in the treatment or prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express cytochrome P450 1B1 (CYP1B1) and allelic variants thereof. Also provided are pharmaceutical compositions comprising one or more such compounds for use in medical therapy, for example in the treatment of prophylaxis of cancers or other proliferative conditions, as well as methods for treating cancers or other conditions in human or non-human animal patients. Provided are methods for identifying novel compounds for use in the treatment of prophylaxis of cancers and other proliferative conditions that are for example characterized by cells that express CYP1B1 and allelic variants thereof. Finally, provided is a method for determining the efficacy of a compound as described herein in treating cancer.

Priority: GB20090007551 Applic. Date: 2009-05-01; US20090174884P Applic. Date: 2009-05-01

Inventor: EVERETT STEVEN ALBERT [US]; ULHAQ SARAJ [GB]


Application No.: US20100305081A1  Published: 02/Dec/2010

Title: ORGANO-GEL FORMULATIONS FOR THERAPEUTIC APPLICATIONS

Applicant/Assignee: MEDIQUEST THERAPEUTICS, INC

Application No.: 12/856292   Filing Date: 13/Aug/2010

Abstract:A composition suitable for the local delivery of cosmetic and/or pharmaceutical agents into the skin containing at least two biocompatible organic solvents, a polar lipid, a surfactant, water, urea and a thickener wherein the organic solvents include an ester and a dihydric and/or polyhydric alcohol is provided. Also disclosed are compositions that further contain a cosmetic and/or pharmaceutical agent, along with the preparation and use thereof

Priority: US2005-246296 Applic. Date: 2005-10-11; US2005-150254 Applic. Date: 2005-06-13; US2005-066485 Applic. Date: 2005-02-28; US2004-960516 Applic. Date: 2004-10-08

Inventor: DECHOW FREDERICK J [US]


Application No.: US20100305104A1  Published: 02/Dec/2010

Title: Oxadiazole Diaryl Compounds

Applicant/Assignee: MERCK SERONO SA

Application No.: 12/675254   Filing Date: 01/Oct/2008

Abstract:The invention relates to compounds of formula (I): wherein R1, R2, Ra, Rb, Rc and W, have the meanings given in claim 16. The compounds are useful e.g. in the treatment of autoimmune disorders, such as multiple sclerosis.

Priority: EP20070117925 Applic. Date: 2007-10-04; US20070998136P Applic. Date: 2007-10-09; WO2008EP63185 Applic. Date: 2008-10-01

Inventor: MONTAGNE CYRIL [FR]; QUATTROPANI ANNA [CH]; SAUER WOLFGANG [CH]; BOMBRUN AGNES [CH]


Application No.: US20100307553A1  Published: 09/Dec/2010

Title: ENGINEERING LIGHT MANIPULATION IN STRUCTURED FILMS OR COATINGS

Applicant/Assignee:

Application No.: 12/546559   Filing Date: 24/Aug/2009

Abstract:The present disclosure concerns a means to use light manipulation in engineered or structured coatings for thermal or photothermal effects and/or refractive and reflective index management. Such metallic, nonmetallic, organic or inorganic metamaterials or nanostructures could be used to manipulate light or energy for thermal or photothermal effects and/or refractive and reflective index management on or in any material or substrate on or in any material or substrate. The light scattering properties of metallic particles and film can be used to tune such coatings, structures or films over a broad spectrum.

Priority: US20080091997P Applic. Date: 2008-08-26; US20080094331P Applic. Date: 2008-09-04

Inventor: DEFRIES ANTHONY [US]; BRONGERSMA MARK [US]


Application No.: US20100310461A1  Published: 09/Dec/2010

Title: BINDING OF PATHOLOGICAL FORMS OF PROTEINS USING CONJUGATED POLYELECTROLYTES

Applicant/Assignee: BIOCHROMIX PHARMA AB

Application No.: 12/793564   Filing Date: 03/Jun/2010

Abstract:A method for treatment of a disease caused by aggregation of misfolded proteins including subjecting a body fluid of a patient to a separation of an aggregated misfolded protein which includes contacting both the misfolded and normal protein with a conjugated polyelectrolyte (CPE) and separating the CPE/protein complex from the other constituents of the sample.

Priority: WO2007SE50253 Applic. Date: 2007-04-18

Inventor: AASBERG PETER [SE]; INGANAES OLLE [SE]; ANGHUS FREDRIK [SE]


Application No.: US20100310462A1  Published: 09/Dec/2010

Title: BINDING OF PATHOLOGICAL FORMS OF PROTEINS USING CONJUGATED POLYELECTROLYTES

Applicant/Assignee: BIOCHROMIX AB

Application No.: 12/793570   Filing Date: 03/Jun/2010

Abstract:A method for separation of an aggregated misfolded protein from an environment including a non-aggregating normal form of the protein includes contacting both the misfolded and normal protein with a conjugated polyelectrolyte (CPE) and separating the CPE/protein complex from the other constituents of the sample.

Priority: WO2007SE50253 Applic. Date: 2007-04-18

Inventor: AASBERG PETER [SE]; INGANAES OLLE [SE]; ANGHUS FREDRIK [SE]


Application No.: US20100310476A1  Published: 09/Dec/2010

Title: CARRIERS, FORMULATIONS, METHODS FOR FORMULATING UNSTABLE ACTIVE AGENTS FOR EXTERNAL APPLICATION AND USES THEREOF

Applicant/Assignee: FOAMIX LTD

Application No.: 12/795164   Filing Date: 07/Jun/2010

Abstract:The present disclosure teaches unique formulations for topical administration of tetracycline antibiotics, in which the tetracycline antibiotics remain stable.

Priority: WO2008IB03932 Applic. Date: 2008-12-08; US20070012414P Applic. Date: 2007-12-07; US20080103500P Applic. Date: 2008-10-07

Inventor: TAMARKIN DOV [IL]; FRIEDMAN DORON [IL]; EINI MEIR [IL]; BESONOV ALEX [IL]; SHIFRIN HELENA [IL]


Application No.: US20100310482A1  Published: 09/Dec/2010

Title: 3-Deoxyglucosone And Skin

Applicant/Assignee: DYNAMIS THERAPEUTICS, INC

Application No.: 12/793520   Filing Date: 03/Jun/2010

Abstract:The invention relates to a method of removing 3-deoxyglucosone and other alpha-dicarbonyl sugars from skin. The invention further relates to methods of inhibiting production and function of 3-deoxyglucosone and other alpha-dicarbonyl sugars in skin. The invention also relates to methods of treating 3-deoxyglucosone and other alpha-dicarbonyl sugars associated diseases and disorders of skin.

Priority: US2007-818997 Applic. Date: 2007-06-15; US2002-198706 Applic. Date: 2002-07-18; US20020373103P Applic. Date: 2002-04-17; US20020392530P Applic. Date: 2002-06-27

Inventor: TOBIA ANNETTE [US]; KAPPLER FRANCIS [US]


Application No.: US20100310484A1  Published: 09/Dec/2010

Title: NOVEL PEPTIDES, USE THEREOF IN COSMETIC AND COSMECEUTIC APPLICATIONS, AND COMPOSITIONS COMPRISING SAME

Applicant/Assignee: INNOVACTIV INC

Application No.: 12/452381   Filing Date: 30/Jun/2008

Abstract:A peptide of formula I (SEQ ID NO: 1): Lip-A-Gly-His-B-R (I) wherein: Lip is a lipoyl residue of R or S configuration

A is absent or is a lysine residue of configuration L or D

GIy is a glycine residue

His is a histidine residue of configuration L or D

B is a lysine residue of configuration L or D, or a lysine residue of configuration L or D in which the NH2 group of the side chain comprises a modification, wherein said modification is (i) a replacement with a hydrogen or (ii) a modification with a protecting group selected from the group consisting of acetyl, benzoyl, tosyl, sulfonyl benzene, benzyloxycarbonyle and palmitoyl

wherein R is O(Z) or N(Z')(Z'), and wherein Z, Z' and Z' are independently of each other a hydrogen or a protecting group selected from the group consisting of methyl, ethyl, propyl, phenyl, hexyl, decyl and hexadecyl, or a racemate, an enantiomer or a diastereomer thereof, or a mixture thereof, or a salt thereof. A peptide of formula II (SEQ ID NO: 2): Lip-A-His-B-C-Trp-R (II) wherein: Lip is a lipoyl residue of configuration R or S

His is a histidine residue of configuration L

Trp is a tryptophane residue of configuration L

A is absent, is an amino acid residue of configuration L or D selected from the group consisting of a lysine residue, an alanine residue, a glutamic acid residue and a glycine residue, or is a spacer of formula: NH-(CH2)n-CO- wherein n is an integer comprised between 2 and 14

B is an aromatic amino acid residue of configuration D selected from the group consisting of a phenylalanine residue, a homophenylalanine residue, a tryptophane residue, a [beta]-(1-Naphthyl)-alanine residue, a [beta]-(2-Naphthyl)-alanine residue and a phenylglycine residue

C is a basic amino acid residue of configuration L selected from the group consisting of an arginine residue, a lysine residue, an ornithine residue and a homoarginine residue

wherein R is O(Z) or N(Z')(Z'),

Priority: US20070947148P Applic. Date: 2007-06-29; WO2008CA01227 Applic. Date: 2008-06-30

Inventor: HOCQUAUX MICHEL [FR]; LOING ESTELLE [CA]; BEDOS PHILIPPE [FR]


Application No.: US20100310485A1  Published: 09/Dec/2010

Title: USE OF MELANIN BIOSYNTHESIS INHIBITORS FROM KOREAN GINSENG AND THE COSMETIC COMPOSITION CONTAINING THEREOF FOR SKIN WHITENING

Applicant/Assignee:

Application No.: 12/740212   Filing Date: 26/Jul/2010

Abstract:Disclosed herein is a whitening cosmetic composition containing plant-derived ginsenoside Fl (20-O-[beta]-D-glucopyranosyl-20(S)-protopanaxatriol) as an active ingredient. More specifically, the ginsenoside Fl is obtained from particularly a ginseng extract using an acid, a base, an enzyme or microorganism, and a whitening cosmetic composition containing the ginsenoside Fl has an excellent effect of inhibiting melanin biosynthesis, and thus provides an excellent skin whitening effect.

Priority: WO2007KR05454 Applic. Date: 2007-10-31

Inventor: PARK JUN SEONG [KR]; PARK HYE YOON [KR]; AHN SOO MI [KR]; KANG BYUNG YOUNG [KR]; LEE JIN YOUNG [KR]; KIM EUN JOO [KR]; KIM DUCK HEE [KR]; JANG IH SEOP [KR]


Application No.: US20100310488A1  Published: 09/Dec/2010

Title: SELECTING/IDENTIFYING AND ADMINISTERING ACTIVE AGENTS USEFUL FOR MODIFYING THE SHAPE OF KERATIN/HAIR FIBERS

Applicant/Assignee: L'OREAL

Application No.: 12/796839   Filing Date: 09/Jun/2010

Abstract:A method of selecting/identifying an active agent for modifying the shape of keratin fibers, includes the following steps: a) culturing mammalian cells, b) adding a test substance to the mammalian cell culture, c) after incubation thereof, assaying the amount of glycosaminoglycans (GAGs) in the mammalian cells or in the mammalian cell culture medium, d) comparing the amount of GAGs measured in step c) with that measured starting from a control culture of mammalian cells, obtained under the same conditions, but in the absence of test substance, and selecting the substances for which the amount of GAGs is modified by at least a factor of 0.5 relative to the amount measured in the control culture

the active agents thus selected/identified are useful for modifying the shape of keratin fibers.

Priority: WO2008EP67240 Applic. Date: 2008-12-10; FR20070059675 Applic. Date: 2007-12-10

Inventor: MALGOURIES SYLVAIN [FR]; THIBAUT SEBASTIEN [FR]


Application No.: US20100310495A1  Published: 09/Dec/2010

Title: PEPTIDES HAVING AFFINITY FOR POLY (BENZYL METHACRYLATE-CO-METHACRYLIC ACID) POTASSIUM SALT COPOLYMERS AND METHODS OF USE

Applicant/Assignee: E. I. DU PONT DE NEMOURS AND COMPANY

Application No.: 12/785694   Filing Date: 24/May/2010

Abstract:Peptides are provided that have binding affinity for poly(benzyl methacrylate-co-methacrylic acid) potassium salt copolymers ("BzMA-binding peptides"). The BzMA-binding peptides may be used to prepare peptide-based reagents suitable for use in a variety of applications. The peptide-base reagents may be used to couple benefit agents to a poly(benzyl methacrylate-co-methacrylic acid) potassium salt copolymer surface or may be used to couple a benefit agent comprising a poly(benzyl methacrylate-co-methacrylic acid) potassium salt copolymer surface to a target surface, such as a body surface.

Priority: US20090184912P Applic. Date: 2009-06-08

Inventor: SCHNEIDER EBERHARD [DE]; SCHURMANN GREGOR [DE]; WAGNER PETER [DE]; WANG HONG [US]; COHEN GORDON MARK [US]


Application No.: US20100310498A1  Published: 09/Dec/2010

Title: ACTIVE AGENTS AND THEIR OLIGOMERS AND POLYMERS

Applicant/Assignee:

Application No.: 12/813776   Filing Date: 11/Jun/2010

Abstract:Conjugates comprising at least two active agents linked by a diglycolic acid or polyglycol diacid linker are disclosed. The invention also concerns oligomers and polymers of these conjugates and their use in therapeutic and industrial applications for localized, immediate or fast release delivery of an active agent, such as an anti-microbial, anti-infective, or antiseptic agent.

Priority: US2009-441347 Applic. Date: 2009-03-13; WO2007US78426 Applic. Date: 2007-09-13; US20060825465P Applic. Date: 2006-09-13

Inventor: KANAMATHAREDDY SUSEELA [US]; GIROUX KAREN J [US]


Application No.: US20100310517A1  Published: 09/Dec/2010

Title: GROWTH FACTOR MEDIATED COSMECEUTICALS AND USE THEREOF TO ENHANCE SKIN QUALITY

Applicant/Assignee: NEW YORK UNIVERSITY

Application No.: 12/858828   Filing Date: 18/Aug/2010

Abstract:It has been discovered that vascular endothelial growth factor ("VEGF") promotes migration of activated (but not differentiating) keratinocytes to skin. This growth factor specifically increases migration of keratinocytes of the "wounded skin" phenotype but does not have significant effects upon differentiated keratinocytes. It also increases collagen deposition and reduces wrinkles, enhances skin quality, and increases skin thickness to normal levels in individuals where skin has thinned due to age or disorder such as diabetes. It is particularly well suited for use as cosmeceuticals when applied in purified form and in known amounts. The data presented in the examples demonstrate efficacy and specificity of VEGF in enhancing migration of normal human keratinocytes as well as formation of new granulation tissue including collagen formation. VEGF induces keratinocyte and fibroblast migration, formation of new tissue, and not only induces deposition of collagen but improves alignment of the collagen fibers. Accordingly, this growth factor is highly suitable for use as a cosmeceutical, especially for skin resurfacing and reduction in wrinkles.

Priority: US2008-052672 Applic. Date: 2008-03-20; US20070895942P Applic. Date: 2007-03-20

Inventor: BREM HAROLD [US]; TOMIC-CANIC MARJANA [US]


Application No.: US20100310615A1  Published: 09/Dec/2010

Title: COMPOSITIONS COMPRISING STILBENE POLYPHENOL DERIVATIVES AND USE THEREOF FOR COMBATING THE AGEING OF LIVING ORGANISMS AND DISEASES AFFECTING SAME

Applicant/Assignee:

Application No.: 12/734677   Filing Date: 17/Nov/2008

Abstract:The invention relates to compositions comprising pholyphenol derivatives, characterised in that said polyphenols contain monomers, oligomers or polymers with units having formula (I), said units being characterised by the simultaneous presence of a resorcinol nucleus (nucleus A) and a para-phenol nucleus (nucleus B) which are interconnected by a carbon bond C, said derivatives being over-activated, in respect of the nucleophilic power thereof, by alkylation of at least one phenol function of each constituent monomer unit and stabilised by sterification by mixtures of fatty acids in proportions reflecting those of vegetable oils formed mainly by unsaturated fatty acids of all of the other phenol functions. The invention is suitable for use in cosmetics, dietetics and therapeutics.

Priority: FR20070008020 Applic. Date: 2007-11-15; WO2008IB54818 Applic. Date: 2008-11-17

Inventor: VERCAUTEREN JOSEPH [FR]


Application No.: US20100310616A1  Published: 09/Dec/2010

Title: METHOD OF COSMETIC CARE STIMULATING MITOCHONDRIAL ACONITASE

Applicant/Assignee: LVMH RECHERCHE

Application No.: 12/751677   Filing Date: 31/Mar/2010

Abstract:The invention relates to a cosmetic care method for preventing or retarding the appearance of the signs of ageing of the skin or for attenuating the effects thereof. This method is characterized in that it comprises the delivery, to at least part of the skin of the face or body, of an effective amount of at least one cosmetically acceptable active agent that activates or stimulates the activity of cutaneous mitochondrial aconitase. The invention makes it possible to achieve an anti-ageing effect.

Priority: FR20090052050 Applic. Date: 2009-03-31

Inventor: NIZARD CARINE [FR]; MOREAU MARIELLE [FR]; ARCHAMBAULT JEAN-CHRISTOPHE [FR]; FRIGUET BERTRAND [FR]; BULTEAU ANNE-LAURE [FR]


Application No.: US20100310634A1  Published: 09/Dec/2010

Title: TRANSDERMAL THERAPEUTIC SYSTEM HAVING UREA COMPONENTS

Applicant/Assignee:

Application No.: 12/865465   Filing Date: 09/Dec/2008

Abstract:The invention relates to a transdermal therapeutic system (TTS) for administering pharmaceutical agents through the skin, comprising a back layer (R) impermeable to the agent and at least one layer (S) comprising the agent, wherein the layer (H) facing the skin comprises urea in solid form, allowing continuous administration of large quantities of agent over a long period of time.

Priority: DE200810006791 Applic. Date: 2008-01-30; WO2008EP10426 Applic. Date: 2008-12-09

Inventor: HORSTMANN MICHAEL [DE]; HOFFMANN GERD [DE]; WIEDERSBERG SANDRA [DE]


Application No.: US20100310644A1  Published: 09/Dec/2010

Title: ANTI-DANDRUFF COMPOSITIONS CONTAINING PEPTIDES

Applicant/Assignee: BASF ,TRADEMARKS AND LICENSES

Application No.: 12/809102   Filing Date: 19/Dec/2008

Abstract:The present invention relates to the use of special peptides in composition which can be used in particular in hair and skin cosmetics, and to such peptide-containing compositions. In particular, the present invention relates to the use of such peptides as active ingredient for inhibition or treatment of dandruff which does not accumulate in the body or in the environment. Furthermore, the invention relates to the production of such compositions, to the peptides used themselves, to their production and to coding nucleotide sequences for such peptides, to dispensing systems for such peptides and to screening methods for identifying suitable further peptides.

Priority: EP20070024988 Applic. Date: 2007-12-21; EP20080159834 Applic. Date: 2008-07-07; US20080080705P Applic. Date: 2008-07-15; WO2008EP10912 Applic. Date: 2008-12-19

Inventor: LIEBMANN BURGHARD [DE]; BRUESER HEIKE [DE]; BARG HEIKO [DE]; HUEMMERICH DANIEL [DE]; BELL HUBERTUS PETER [DE]


Application No.: US20100311666A1  Published: 09/Dec/2010

Title: COSMETIC USE OF A PROTEIN BELONGING TO THE RIBONUCLEASE FAMILY

Applicant/Assignee: L'OREAL

Application No.: 12/515198   Filing Date: 16/Nov/2007

Abstract:The present invention relates to the use, in cosmetics and in therapeutics, of at least one antimicrobial protein belonging to the ribonuclease family, ribonuclease 7, or of polypeptides derived from said protein, notably as a marker for evaluating the condition of the epidermis. It further relates to the use of at least one polypeptide according to the invention, of at least one nucleic acid sequence coding for a polypeptide according to the invention, or of at least one agent that modulates the expression or the activity, notably biological, of said polypeptide or of its interaction with an element of the extracellular matrix, for the preparation of compositions intended for the prevention and/or treatment of skin disorders.

Priority: FR20060054965 Applic. Date: 2006-11-17; US20060874257P Applic. Date: 2006-12-12; WO2007FR01887 Applic. Date: 2007-11-16

Inventor: DONOVAN MARK [FR]; BERNARD DOMINIQUE [FR]; CASTIEL ISABELLE [FR]; CHAUSSADE VERONIQUE [FR]


Application No.: US20100311667A1  Published: 09/Dec/2010

Title: NOVEL COMPOUNDS, USE THEREOF IN COSMETIC AND COSMECEUTIC APPLICATIONS, AND COMPOSITIONS COMPRISING SAME

Applicant/Assignee: INNOVACTIV INC

Application No.: 12/452368   Filing Date: 30/Jun/2008

Abstract:A compound of the formula I: R-A-Gly-His-B (I) wherein: A and B are independently of each other a L-lysine residue, a D-lysine residue, or a L- or D-lysine residue in which the NH2 group of the side chain comprises a modification, where-in said modification is (i) a replacement with a hydrogen, (ii) an acetylation, (iii) a benzoylation, or (iv) a palmitoylation

GIy is a glycine residue

His is a L- or D-histidine residue

R is CH3-(CH2)n-CO-, wherein n=2, 3, 4, 5, 6, 7 or 8

R' is a group of formula (II): N(Z)(Z') (II) wherein: Z and Z' is hydrogen, a methyl group, an ethyl group, a phenyl group, an hexyl group, a decyl group or an hexadecyl group

or a racemate, an enantiomer or a diastereomer thereof, or mixtures thereof, or a salt thereof.

Priority: US20070947144P Applic. Date: 2007-06-29; US20070984136P Applic. Date: 2007-10-31; WO2008CA01226 Applic. Date: 2008-06-30

Inventor: HOCQUAUX MICHEL [FR]; LOING ESTELLE [CA]; BEDOS PHILIPPE [FR]


Application No.: US20100311668A1  Published: 09/Dec/2010

Title: PERSONAL CARE AND COSMETIC COMPOSITION CONTAINING TETRAPEPTIDES WITH THE MOTIFS GX1X2G, PX1X2P, OR PX1X2K

Applicant/Assignee: EVONIK GOLDSCHMIDT GMBH

Application No.: 12/745636   Filing Date: 01/Oct/2008

Abstract:The present invention relates to topical personal care and skin care compositions comprising: a) a safe and effective amount of a tetrapeptide selected from the group of tetrapeptides with the motif GX1X2G, PX1X2P, or PX1X2K, derivatives thereof, and mixtures thereof

b) a safe and effective amount of at least one additional active ingredient selected from the group consisting of hydroxy acids, radical scavengers, UV absorbers, vitamins, anti-aging actives, barrier lipids, desquamatory actives, retinoids, anti-acne actives, tanning actives, anti-cellulite actives, anti-inflammatory actives, antimicrobial actives, antifungal actives, skin lightening agents, skin energizing agents, skin healing agents, moisturizing actives, and mixtures thereof

and c) a dermatologically acceptable carrier.

Priority: EP20070121954 Applic. Date: 2007-11-30; WO2008EP63120 Applic. Date: 2008-10-01

Inventor: FARWICK MIKE [DE]; LERSCH PETER [DE]


Application No.: US20100311687A1  Published: 09/Dec/2010

Title: POLYSACCHARIDES DERIVATISED WITH CITRIC ACID

Applicant/Assignee:

Application No.: 12/521308   Filing Date: 18/Dec/2007

Abstract:Non-crosslinked derivatives of oligo/polysaccharides of formula I, wherein: X is OH, OM, NH-R1, O-R1

M is an alkaline or alkaline-earth metal, transition metal, or cation containing a quaternary nitrogen atom

Y is H or R2

R1: the residue of an oligo/polysaccharide

R2: the residue of a C1-C4 linear chain aliphatic carboxylic acid or citric acid

provided that at least one X is NH-R1 or O-R1, while the other two X are present in acid (OH) or salified form (OM).

Priority: EP20060425873 Applic. Date: 2006-12-29; WO2007IB03980 Applic. Date: 2007-12-18

Inventor: BOSCO MARCO [IT]; STUCCHI LUCA [IT]; PICOTTI FABRIZIO [IT]; GIANNI RITA [IT]


Application No.: US20100311696A1  Published: 09/Dec/2010

Title: TOPICAL SKIN TREATMENT COMPOSITION

Applicant/Assignee:

Application No.: 12/796213   Filing Date: 08/Jun/2010

Abstract:The present invention relates to compositions and methods for transdermal drug delivery comprising formulating a phosphatidylcholine carrier composition containing the drug and applying the composition to the skin. The present invention further relates to the topical application to the skin of such compositions, and/or preparations containing them, for the prevention and/or treatment of damage to skin.

Priority: US2006-506137 Applic. Date: 2006-08-17; US2003-749914 Applic. Date: 2003-12-31; US2003-448632 Applic. Date: 2003-05-30; US20020437279P Applic. Date: 2002-12-31; US20020384597P Applic. Date: 2002-05-31

Inventor: PERRICONE NICHOLAS V [US]


Application No.: US20100311751A1  Published: 09/Dec/2010

Title: SOLID DISPERSIONS CONTAINING AN APOPTOSIS-PROMOTING AGENT

Applicant/Assignee: ABBOTT LABORATORIES

Application No.: 12/796061   Filing Date: 08/Jun/2010

Abstract:A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a Bcl-2 family protein inhibitory compound, e.g., ABT-263, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises dissolving the compound, the polymeric carrier and the surfactant in a suitable solvent, and removing the solvent to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.

Priority: US20090185105P Applic. Date: 2009-06-08

Inventor: SCHMITT ERIC A [US]; TONG PING [US]; HEEMSTRA KATHERINE [US]; FISCHER CRISTINA M [US]; WU HUAILIANG [US]; MILLER JONATHAN MARK [US]; LI YANXIA [US]; LAFOUNTAINE JUSTIN S [US]


Application No.: US20100313362A1  Published: 16/Dec/2010

Title: HENNA AND VEGETABLE DYE BASED COMPOSITIONS FOR COLORING OF HUMAN HAIR

Applicant/Assignee:

Application No.: 12/816005   Filing Date: 15/Jun/2010

Abstract:New, effective and non-toxic compounded henna based hair dyes that are non-toxic, natural and hypoallergenic that provide an alternative to conventional hair color. The products are made using 100% Green Chemistry and do not utilize encapsulation.

Priority: US20090187062P Applic. Date: 2009-06-15

Inventor: VAINSHELBOIM ALEX [US]; VAINSHELBOIM TATYANA [US]


Application No.: US20100316683A1  Published: 16/Dec/2010

Title: HYALURONIC ACID GEL FOR INTRADERMAL INJECTION

Applicant/Assignee: PIERRE FABRE DERMO-COSMETIQUE

Application No.: 12/517862   Filing Date: 06/Dec/2007

Abstract:Implant that is injectable by a sub-cutaneous or intradermal route in the form of a monophasic hydrogel comprising a gel made up of cross-linked hyaluronic acid and one of its physiologically acceptable salts.

Priority: FR20060010645 Applic. Date: 2006-12-06; WO2007EP63384 Applic. Date: 2007-12-06

Inventor: PIRON ESTELLE [FR]; BOGDANOWICZ PATRICK [FR]


Application No.: US20100316684A1  Published: 16/Dec/2010

Title: Surfactant-Free Foam Formulations

Applicant/Assignee: NEUBOURG SKIN CARE GMBH & CO. KG

Application No.: 12/599561   Filing Date: 09/May/2008

Abstract:The invention relates to a foam formulation comprising an essentially emulsifier-free emulsion of the oil in water type, comprising an oil phase and a water phase.

Priority: EP20070107950 Applic. Date: 2007-05-10; WO2008EP55760 Applic. Date: 2008-05-09

Inventor: DANIELS ROLF [DE]


Application No.: US20100316697A1  Published: 16/Dec/2010

Title: METHODS AND COMPOSITIONS FOR DRUG TARGETING

Applicant/Assignee: CLEAR DIRECTION LTD

Application No.: 12/599667   Filing Date: 07/May/2008

Abstract:The present invention provides methods and compositions for targeting a drug to a specific desired location, such as an intracellular location in a mammalian cell, by causing said drug to migrate along a pH gradient to the specific location, where the drug preferentially accumulates at a pH range of the specific location. Accordingly, the invention described herein is based on providing a drug which is "pH matched" with that of a particular location, such that the drug preferentially migrates to and accumulates at the pH or pH range at that location. The location may be a type of tissue, a type of cell, a sub-cellular location or an intracellular location, such as an organelle. Without being bound to any theory, the drug migrates along or across a pH gradient, and stops migrating and accumulates at a location of specific pH or range of pH at which the drug is energetically neutral, or where its diffusion potential is at a minimum.

Priority: US20070917073P Applic. Date: 2007-05-10; WO2008IL00637 Applic. Date: 2008-05-07

Inventor: BUKSHPAN SHMUEL [IL]; ZILBERSTEIN GLEB [IL]


Application No.: US20100316701A1  Published: 16/Dec/2010

Title: COMPOSITIONS AND METHOD FOR MANIPULATING PIM-1 ACTIVITY IN CIRCULATORY SYSTEM CELLS

Applicant/Assignee: SAN DIEGO STATE UNIVERSITY FOUNDATION, DBA SAN DIEGO STATE UNIVERSITY RESEARCH FOUNDATION

Application No.: 12/742871   Filing Date: 14/Nov/2008

Abstract:The invention provides compositions (e.g., pharmaceutical compositions) comprising nucleic acids encoding the serine/threonine kinase PIM-1, and methods for making and using them

including methods for inducing cellular proliferation, and protecting cardiac cells from hypoxia and cellular apoptosis. The invention provides compositions (e.g., pharmaceutical compositions) comprising nucleic acids encoding PIM-1, and methods for enhancing the regenerative potential of stem cells in the heart.

Priority: US20070988753P Applic. Date: 2007-11-16; US20080091698P Applic. Date: 2008-08-25; WO2008US83693 Applic. Date: 2008-11-14

Inventor: SUSSMAN MARK A [US]; MURASKI JOHN A [US]


Application No.: US20100316743A1  Published: 16/Dec/2010

Title: INHIBITION OF THE FORMATION OF AGEs

Applicant/Assignee: BASF BEAUTY CARE SOLUTIONS FRANCE S.A.S

Application No.: 12/667872   Filing Date: 09/Jul/2008

Abstract:The present invention relates to the use of an active substance that promotes the inhibition of the formation of AGEs, for preparing a composition to prevent and/or combat the reduction in elastic and plastic properties of tissues, and in particular of the skin, for inhibiting the formation of AGEs, or for preventing and/or combating glycation of proteins in the skin. The invention also relates to a method of screening such active substances.

Priority: FR20070056343 Applic. Date: 2007-07-09; US20080078910P Applic. Date: 2008-07-08; WO2008EP58954 Applic. Date: 2008-07-09

Inventor: ABDUL-MALAK NABIL [FR]; ALTOBELLI CECILE [FR]; PERRIER ERIC [FR]


Application No.: US20100316749A1  Published: 16/Dec/2010

Title: TOPICAL DELIVERY OF L-ARGININE TO CAUSE BENEFICIAL EFFECTS

Applicant/Assignee: STRATEGIC SCIENCE & TECHNOLOGIES, LLC

Application No.: 12/608169   Filing Date: 29/Oct/2009

Abstract:The application of L-arginine and its derivatives to the skin causes beneficial effects of wound healing, increasing erectile function and increased growth of hair when applied in sufficient quantity to the skin. A hostile biophysical agent may be combined with the L-arginine to increase its absorption into the skin. The desired concentrations of the hostile biophysical agent is increased when concentration of L-arginine is less than 20% of the concentration of the substance applied to maximize its effect.

Priority: US2002-201635 Applic. Date: 2002-07-22; US1997-932227 Applic. Date: 1997-09-17

Inventor: FOSSEL ERIC T [US]


Application No.: US20100316752A1  Published: 16/Dec/2010

Title: Method for extracing substances from soapberry fruit and seed and products made therefrom

Applicant/Assignee:

Application No.: 12/457398   Filing Date: 10/Jun/2009

Abstract:An exclusive manufacturing technique for extracting active interface saponin and organic substances from soapberry

organic elements and oleic alcohol products from soapberry seeds through the process of fermentation and end products made therefrom, wherein the manufacturing process includes: 1. Pre-ferment soapberry fruit (1). 2. Processing said fruit (1) by a dialysis device (2). 3. Separating the soapberry flesh (12) and fiber (13) by a separation device (3). 4. Extracting soapberry dialytic liquid (A) through a grinding and compression device (4) and separating the fiber (13). 5. Eliminating bacteria inside the dialytic liquid (A) by a huge stewing device (5). 6. A second fermenting process by a vacuum device (6) and generating a soapberry syrup (D). Said method is healthy, toxin free and biologically safe, produce no wastage, zero carbon emissions, zero pollution, low energy production and is ecologically friendly. End products produced by said method are variables with excellent economic viability.

Priority:

Inventor: HSU HENG-JUI [TW]


Application No.: US20100317518A1  Published: 16/Dec/2010

Title: MEADOWFOAM-BASED BIOHERBICIDE PRODUCTS

Applicant/Assignee:

Application No.: 12/664984   Filing Date: 21/Jul/2008

Abstract:Particular aspects provide methods for converting glucosinolate in a glucosinolate-containing plant material to glucosinolate breakdown products (GBPs), comprising: providing an amount of processed glucosinolate-containing plant material, the processed material being depleted of oil and glucosinolate converting enzyme activity by virtue of said processing

providing an amount of glucosinolate converting enzyme activity

mixing the processed material with the amount enzyme activity

hydrating the mixture

and incubating the hydrated mixture, wherein the glucosinolates are enzymatically converted to GBPs. Preferably, the processed plant material comprises a oilseed-derived seedmeal material (e.g., meadowfoam seedmeal) from which the oil has been removed by the processing (e.g., solvent extraction and/or heat treatment). In particular embodiments, the glucosinolate converting enzyme activity comprises at least one of a myrosinase activity and a nitrile-forming activity. Additional aspects provide low-fat compositions (e.g., herbicide, fungicide, insecticide, bacteriostatic or bactericidal, cosmetic, cosmeceutical or pharmaceutical) comprising GBPs derived from a glucosinolate-containing plant material.

Priority: US20070961323P Applic. Date: 2007-07-19; WO2008US70632 Applic. Date: 2008-07-21

Inventor: STEVENS JAN F [US]; MACHADO STEPHEN [US]; REED RALPH [US]; MARTINEZ MICHAEL S [US]


Application No.: US20100317541A1  Published: 16/Dec/2010

Title: Method of Determining the Probability of a Therapeutic Response in Cancer Chemotherapy With Cardiac Glycoside

Applicant/Assignee: PHOENIX BIOTECHNOLOGY, INC

Application No.: 12/773540   Filing Date: 04/May/2010

Abstract:A prognostic assay and kit and method of use thereof are provided. The kit and assay are used to determine the likelihood of a diseased cell or tissue having a therapeutic response to treatment with a cardiac glycoside in a disease having an etiology associated with excessive cell proliferation. The kit and assay are used to determine the ratio of isoforms of the [alpha] subunit of Na, K-ATPase obtained from the diseased cell or tissue. The kit can be used to predict the therapeutic responsiveness of cancer or tumor in a subject to treatment with a cardiac glycoside. The kit and assay can be incorporated in a method of treating a disease or disorder having an etiology associated with excessive cell proliferation with a composition comprising a cardiac glycoside.

Priority: WO2008US82641 Applic. Date: 2008-11-06; US20070987501P Applic. Date: 2007-11-13

Inventor: ADDINGTON OTIS CRANDELL [US]; NEWMAN ROBERT A [US]; YANG PEIYING [US]


Application No.: US20100317736A1  Published: 16/Dec/2010

Title: COMPOSITION OF THE SKIN EXTERNAL APPLICATION OR THE FOOD FOR ACCELERATING PROLINE RECYCLING BY CONTAINING THEANINE

Applicant/Assignee:

Application No.: 12/808238   Filing Date: 28/Nov/2008

Abstract:Disclosed herein is a composition for promoting proline recycling, and more particularly, to a composition for external application to skin or cosmetic food comprising theanine as an active ingredient for promoting expression or activity of prolidase, which is an enzyme to promote proline recycling, thereby increasing collagen synthesis and restoring wrinkle.

Priority: KR20070132054 Applic. Date: 2007-12-17; WO2008KR07029 Applic. Date: 2008-11-28

Inventor: SHIN HYUN JUNG [KR]; KIM JEONG KEE [KR]; LEE JI HAE [KR]; LEE SANG MIN [KR]; BAIK JOO HYUN [KR]


Application No.: US20100322876A1  Published: 23/Dec/2010

Title: COMPOSITIONS AND METHODS FOR TREATING KERATINOUS SUBSTRATES

Applicant/Assignee: L'OREAL

Application No.: 12/677246   Filing Date: 10/Sep/2008

Abstract:The disclosure relates to compositions and methods of using the compositions to treat keratinous substrates. The compositions provide a water resistant and non-transferable protective barrier on the substrate. The compositions contain at least one polyamine, at least one acid, at least one water-insoluble ingredient, solvent and at least one auxiliary ingredient. The methods for treating keratinous substrates involve contacting the keratinous substrates with the compositions of the disclosure.

Priority: US20070972649P Applic. Date: 2007-09-14; WO2008US75851 Applic. Date: 2008-09-10

Inventor: NGUYEN NGHI VAN [US]; CANNELL DAVID W [US]; HASHIMOTO SAWA [US]


Application No.: US20100322878A1  Published: 23/Dec/2010

Title: Personal Care Composition Comprising a Synthetic Cationic Polymer

Applicant/Assignee:

Application No.: 12/817786   Filing Date: 17/Jun/2010

Abstract:A personal care composition that comprises a synthetic random polymer comprising a net positive charge

said synthetic random polymer comprising an acrylamide monomer unit

and a cationic monomer unit comprising 3 or more positive charges

wherein said synthetic random polymer comprises a ratio of said acrylamide monomer unit to said cationic monomer unit comprising from about 55:45 to about 97:3

and a surfactant component

and an aqueous carrier.

Priority: US20090218342P Applic. Date: 2009-06-18

Inventor: STELLA QING [US]; SMITH III EDWARD DEWEY [US]; THOMPSON TODD RYAN [US]; SCHUBERT BETH ANN [US]; WHITELY NATHAN RAY [US]; GARZA CYNTHIA ANN [US]


Application No.: US20100322880A1  Published: 23/Dec/2010

Title: UVA FILTERS BASED ON ASCORBIC ACID DERIVATIVES

Applicant/Assignee: MERCK PATENT GMBH

Application No.: 12/866281   Filing Date: 14/Jan/2009

Abstract:The invention relates to compounds of formula (I) wherein R1, R2, R3, R4 have the meaning cited in the claims, to methods for the production thereof, to agents containing said compounds and to their use for the functionalisation of matrices, in particular their use as skin and/or hair-binding UV filters.

Priority: EP20080002176 Applic. Date: 2008-02-06; WO2009EP00183 Applic. Date: 2009-01-14

Inventor: RUDOLPH THOMAS [DE]; BUEHLE PHILIPP [DE]


Application No.: US20100322881A1  Published: 23/Dec/2010

Title: UVB FILTER BASED ON ASCORBIC ACID DERIVATIVES

Applicant/Assignee: MERCK PATENT GESELLSCHAFT

Application No.: 12/866297   Filing Date: 15/Jan/2009

Abstract:The invention relates to compounds of formula (I), wherein R1, R2, R3, R4 have the meaning cited in the claims, to methods for the production thereof, agents containing said compounds and to their use for the functionalisation of matrices, in particular their use as skin and/or hair-binding UV filters.

Priority: EP20080002167 Applic. Date: 2008-02-06; WO2009EP00211 Applic. Date: 2009-01-15

Inventor: RUDOLPH THOMAS [DE]; BUEHLE PHILIPP [DE]


Application No.: US20100322886A1  Published: 23/Dec/2010

Title: USE OF A CRUCIFEROUS PROTEIN HYDROLYSATE AS A DEPIGMENTATION AGENT OR FOR A COSMETIC AND/OR PHARMACEUTICAL COMPOSITION

Applicant/Assignee:

Application No.: 12/854334   Filing Date: 11/Aug/2010

Abstract:Method for skin bleaching or depigmentation using an effective amount of a protein hydrolysate from plants belonging to the cruciferous family.

Priority: FR20040004192 Applic. Date: 2004-04-21; US2006-578507 Applic. Date: 2006-10-16; WO2005FR00985 Applic. Date: 2005-04-21

Inventor: DAL FARRA CLAUDE [FR]; DOMLOGE NOUHA [FR]; PEYRONEL DOMINIQUE [FR]


Application No.: US20100322983A1  Published: 23/Dec/2010

Title: Personal-Care Composition

Applicant/Assignee:

Application No.: 12/818246   Filing Date: 18/Jun/2010

Abstract:A personal-care composition in the form of an oil-in-water emulsion is disclosed that provides improved skin feel and effective wrinkle-filling. The personal-care composition comprises a silicone elastomer

a silicone fluid

a combination of particulate materials

a polymeric thickener

and water. The combination comprises at least three particulate materials which pack together in order to fill wrinkles.

Priority: US20090219313P Applic. Date: 2009-06-22

Inventor: GRIFFITHS-BROPHY SUSAN ADAIR [US]; ELSBROCK ROBERT JOHN [US]


Application No.: US20100323020A1  Published: 23/Dec/2010

Title: STABLE NANOPARTICULATE DRUG SUSPENSION

Applicant/Assignee: ABBOTT LABORATORIES

Application No.: 12/817640   Filing Date: 17/Jun/2010

Abstract:A liquid pharmaceutical composition comprises an aqueous medium having suspended therein a solid particulate Bc1-2 family protein inhibitory compound such as ABT-263, having a D90 particle size not greater than about 3 [mu]m

wherein the aqueous medium further comprises at least one pharmaceutically acceptable surfactant and at least one pharmaceutically acceptable basifying agent such as sodium bicarbonate in amounts that are effective together to inhibit particle size increase. The composition is suitable for oral or parenteral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bc1-2 family proteins, for example cancer.

Priority: US20090218281P Applic. Date: 2009-06-18

Inventor: GOKHALE RAJEEV [US]; MARSH KENNAN C [US]; SHI YI [US]


Application No.: US20100323963A1  Published: 23/Dec/2010

Title: CONJUGATES OF DISORAZOLES AND THEIR DERIVATIVES WITH CELL-BINDING MOLECULES, NOVEL DISORAZOLE DERIVATIVES, PROCESSES OF MANUFACTURING AND USES THEREOF

Applicant/Assignee: AETERNA ZENTARIS GMBH

Application No.: 12/728075   Filing Date: 19/Mar/2010

Abstract:The present invention provides conjugates of disorazoles and their derivatives with cell-binding molecules, such as peptides, proteins, hormones, blood proteins and antibodies. The present invention further provides novel disorazole derivatives and processes of manufacturing such conjugates and disorazole derivatives. These compounds can be used as medicaments for the treatment of physiological and/or pathophysiological conditions in mammals, in particular for the treatment of various tumors.

Priority: EP20060018750 Applic. Date: 2006-09-07; US2007-850747 Applic. Date: 2007-09-06; US20060842357P Applic. Date: 2006-09-06

Inventor: GUENTHER ECKHARD [DE]; SCHAEFER OLAF [DE]; TEIFEL MICHAEL [DE]; PAULINI KLAUS [DE]


Application No.: US20100323983A1  Published: 23/Dec/2010

Title: PHARMACEUTICAL OR COSMETIC PREPARATIONS FOR TOPICAL AND/OR PARENTERAL APPLICATION, PREPARATION METHODS THEREOF, AND USES THEREOF

Applicant/Assignee:

Application No.: 12/599657   Filing Date: 22/Apr/2008

Abstract:The invention relates to the combination of hyaluronic acid and of at least one hyaluronic acid oligomer constituted of 1 to 2 disaccharide units. The invention is of use in particular in human dermatology or in reconstructive surgery.

Priority: FR20070055028 Applic. Date: 2007-05-11; WO2008FR50727 Applic. Date: 2008-04-22

Inventor: MOUTET MARC [FR]; YADAN JEAN-CLAUDE [FR]


Application No.: US20100323984A1  Published: 23/Dec/2010

Title: COSMETIC ORAL AND/OR PARENTERAL USE OF GLUCOSAMINE OPTIONALLY IN COMBINATION WITH AT LEAST ONE POLYPHENOL COMPOUND, AND CORRESPONDING COMPOSITION

Applicant/Assignee: LABORATOIRES INNEOV

Application No.: 12/445960   Filing Date: 19/Oct/2007

Abstract:The present invention relates to the cosmetic oral and/or parenteral use of glucosamine as an active agent for preventing and/or treating the cutaneous signs of ageing, optionally in combination with at least one polyphenol compound. The present invention also relates to a composition for oral and/or parenteral administration comprising, as active agent, the combination of glucosamine and of at least one polyphenol compound derived from pine bark.

Priority: FR20060054425 Applic. Date: 2006-10-20; FR20060054426 Applic. Date: 2006-10-20; WO2007FR52202 Applic. Date: 2007-10-19

Inventor: PICCIRILLI ANTOINE [FR]; MANISSIER PATRICIA [FR]; MONTASTIER CHRISTIANE [FR]


Application No.: US20100323985A1  Published: 23/Dec/2010

Title: PHARMACEUTICAL OR COSMETIC PREPARATIONS FOR TOPICAL AND/OR PARENTERAL APPLICATION, PREPARATION METHODS THEREOF AND USE OF SAME

Applicant/Assignee:

Application No.: 12/599674   Filing Date: 22/Apr/2008

Abstract:The invention relates to a combination of hyaluronic acid and of at least one inhibitor of hyaluronic acid degradation, for use in particular in human dermatology or in reconstructive surgery.

Priority: FR20070055023 Applic. Date: 2007-05-11; WO2008FR50724 Applic. Date: 2008-04-22

Inventor: MOUTET MARC [FR]; YADAN JEAN-CLAUDE [FR]


Application No.: US20100324089A1  Published: 23/Dec/2010

Title: Anti-inflammatory composition

Applicant/Assignee: CAMBRIDGE ENTERPRISE LIMITED

Application No.: 12/671785   Filing Date: 01/Aug/2008

Abstract:The invention relates to 3-(2',2'-dimethylpropanoylamino)-tetrahydropyridin-2-one, and its pharmaceutical compositions and its use for preparing a medicament intended to prevent or treat inflammatory disorders.

Priority: GB20070015068 Applic. Date: 2007-08-02; WO2008GB02635 Applic. Date: 2008-08-01

Inventor: GRAINGER DAVID JOHN [GB]; FOX DAVID [GB]


Application No.: US20100324109A1  Published: 23/Dec/2010

Title: Composition for Topical Use

Applicant/Assignee:

Application No.: 12/863251   Filing Date: 23/Jan/2009

Abstract:The use, as a dermatological or cosmetic medicament, of compounds capable of transiently interacting with the AhR receptor (aryl hydrocarbon receptor) as agents for modulating skin functions such as sebaceous function, skin healing, skin atrophy termed "dermatoporosis", estrogen deprivation and defense against infection, without inducing other toxic effects of the TCDD type. The compounds that interact with the AhR receptor are chosen in that they have a metabolism favorable to the dissociation of these effects, in particular by virtue of in situ production from a precursor and/or metabolization modulated in situ.

Priority: EP20080150554 Applic. Date: 2008-01-23; WO2009IB50271 Applic. Date: 2009-01-23

Inventor: SAURAT JEAN HILAIRE [CH]


Application No.: US20100324152A1  Published: 23/Dec/2010

Title: USE OF 1,2-DECANEDIOL FOR SEBUM REDUCTION AND COSMETIC AND/OR DERMATOLOGICAL FORMULATIONS COMPRISING 1,2-DECANEDIOL

Applicant/Assignee: SMYRISE GMBH & CO. KG

Application No.: 12/446190   Filing Date: 12/Oct/2007

Abstract:The present invention relates to a use of 1,2-decanediol for reduction of the sebum concentration of the skin, a cosmetic and/or dermatological formulation for topical application comprising 1,2-decanediol, a method for reduction of the sebum concentration of the skin and a use of 1,2-decanediol and a method for assisting the penetration of one, two, three, four or more active compounds into areas of the skin with increased sebum production.

Priority: EP20060122665 Applic. Date: 2006-10-20; US20060852975P Applic. Date: 2006-10-20; WO2007EP60903 Applic. Date: 2007-10-12

Inventor: SCHMAUS GERHARD [DE]; LANGE SABINE [DE]; RODING JOACHIM [DE]


Application No.: US20100324470A1  Published: 23/Dec/2010

Title: Dosage Control Electrode for Iontophoresis Device

Applicant/Assignee: TRAVANTI PHARMA INC

Application No.: 12/868123   Filing Date: 25/Aug/2010

Abstract:An electrode assembly for use in an iontophoresis device for the transcutaneous administration of an active therapeutic species has a base layer of including a linking conductive base material which is consumed (oxidizes or reduces) preferentially to water, a first upper layer of sacrificial material coated on a first portion of the base layer wherein the sacrificial material is consumed preferentially to the linking conductive base material of the base layer. A second upper layer of non-conducting material is coated on a second portion of the base layer, the second upper layer being spaced from the first upper layer, connected by a narrow exposed linking area of the base layer material remaining exposed therebetween. During operation of an associated iontophoresis device, the sacrificial material will be sequentially consumed

the first upper layer will be fully consumed followed by the linking conductive base material of the exposed linking area of the base layer which severs the base layer thereby breaking circuit continuity disabling activity in the device. A visual indicator may be provided allowing a wearer to monitor the state of reaction of the linking area.

Priority: US2005-545761 Applic. Date: 2005-08-15; WO2003US31373 Applic. Date: 2003-10-02; US2003-371532 Applic. Date: 2003-02-21

Inventor: ANDERSON CARTER R [US]; MORRIS RUSSELL L [US]


Application No.: US20100325812A1  Published: 30/Dec/2010

Title: Rinse Added Aminosilicone Containing Compositions and Methods of Using Same

Applicant/Assignee:

Application No.: 12/827769   Filing Date: 30/Jun/2010

Abstract:The instant disclosure relates to rinse-added fabric care compositions containing aminosilicones, a deposition aid, and microcapsules, wherein the composition has improved deposition of the microcapsule and/or improved release of the encapsulated agents. In one aspect, the microcapsule is a perfume microcapsule, and the composition has an improved freshness effect. Methods of making and using the compositions are also disclosed.

Priority: US20090221670P Applic. Date: 2009-06-30

Inventor: PANANDIKER RAJAN KESHAV [US]; DYKSTRA ROBERT RICHARD [US]; VETTER NICHOLAS DAVID [US]; O'NEIL JULIE ANN [US]; BELANGER DENISE MALCUIT [US]; DITULLIO JR DANIEL DALE [US]; PONDER JENNIFER BETH [US]; BAKER KEITH HOMER [US]


Application No.: US20100330009A1  Published: 30/Dec/2010

Title: COUMESTAN-LIKE ANTIOXIDANTS AND UV ABSORBANTS

Applicant/Assignee: CIBA CORPORATION

Application No.: 12/528357   Filing Date: 29/Feb/2008

Abstract:The present invention relates to derivatives of the 1H-pyrano[4,3-b]benzofuran-1-one structure and their nitrogen analogues which possess powerful antioxidant properties combined with a highly effective UV absorbing functionality in one molecule. These compounds are especially useful in cosmetical and dermatological formulations.

Priority: EP20070103820 Applic. Date: 2007-03-09; WO2008EP52463 Applic. Date: 2008-02-29

Inventor: WAGNER BARBARA [DE]; MONGIAT SEBASTIEN [FR]; HERZOG BERND [DE]; BASCHONG WERNER [CH]; BUTHE ANDREAS [DE]; OHRLEIN REINHOLD [DE]


Application No.: US20100330086A1  Published: 30/Dec/2010

Title: CATIONIC STEROID ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE

Applicant/Assignee:

Application No.: 12/876993   Filing Date: 07/Sep/2010

Abstract:The invention provides methods for decreasing or inhibiting herpesviridae (HV) infection or pathogenesis of a cell in vitro, ex vivo or in vivo, a symptom or pathology associated with a herpesviridae (HV) infection or pathogenesis in vitro, ex vivo or in vivo, or an adverse side effect of herpesviridae (HV) infection or pathogenesis in vitro, ex vivo or in vivo. In one embodiment, a method of the invention includes treating a subject with an invention compound (e.g., cationic steroid antimicrobial or CSA).

Priority: US2007-669803 Applic. Date: 2007-01-31; US20060764129P Applic. Date: 2006-02-01

Inventor: SAVAGE PAUL B [US]; LEUNG DONALD [US]


Application No.: US20100330134A1  Published: 30/Dec/2010

Title: Depilatory Composition

Applicant/Assignee: RECKITT BENCKISER (UK) LIMITED

Application No.: 12/527354   Filing Date: 19/Feb/2008

Abstract:A depilatory composition comprising glucose syrup and a viscosity modifier comprising dextrose powder and/or crystals.

Priority: GB20070003174 Applic. Date: 2007-02-19; WO2008GB00569 Applic. Date: 2008-02-19

Inventor: ELLIS PAUL [GB]; CALDWELL TRACEY [GB]


Application No.: US20100330148A1  Published: 30/Dec/2010

Title: MEHODS AND COMPOSITIONS FOR INHIBITING IMPDH-1 ISOFORM 1

Applicant/Assignee: THE JOHNS HOPKINS UNIVERSITY

Application No.: 12/225391   Filing Date: 20/Mar/2007

Abstract:Described herein are methods of inhibiting IMPDH type 1, and treating or preventing a disease or disorder (or symptoms thereof) associated with IMPDH type 1, wherein an IMPDH type 1 inhibitor compound is administered to a subject.

Priority: US20060784332P Applic. Date: 2006-03-20; WO2007US07287 Applic. Date: 2007-03-20

Inventor: LIU JUN O [US]; CHONG CURTIS ROBERT [US]; SULLIVAN DAVID J [US]


Application No.: US20100330201A1  Published: 30/Dec/2010

Title: Therapeutic methods and pharmaceutical compositions for treating warts with tellurium compounds

Applicant/Assignee:

Application No.: 10/586746   Filing Date: 23/Jan/2005

Abstract:A novel method for treating skin and mucosal membrane ailments caused by human papilloma viruses, which utilizes tellurium-containing compounds, is disclosed. Also disclosed are pharmaceutical compositions containing tellurium-containing compounds for treating such ailments.

Priority: US20040538635P Applic. Date: 2004-01-22; WO2005IL00084 Applic. Date: 2005-01-23

Inventor: SREDNI BENJAMIN [IL]; ALBECK MICHAEL [IL]


Application No.: US20100331235A1  Published: 30/Dec/2010

Title: Histidine and/or Histidine Derivative for the Treatment of Inflammatory Skin Diseases

Applicant/Assignee: THE UNIVERSITY OF MANCHESTER

Application No.: 12/918701   Filing Date: 18/Feb/2009

Abstract:Histidine and/or a derivative thereof. In some embodiments, the histidine and/or a derivative thereof is used in maintaining and/or improving barrier function of the skin of a subject. In some embodiments, the histidine and/or a derivative thereof is used for the prevention and/or treatment of an inflammatory skin disease.

Priority: GB20080003054 Applic. Date: 2008-02-20; WO2009GB00430 Applic. Date: 2009-02-18

Inventor: GIBBS NEIL KERSLAKE [GB]


Application No.: US20100331259A1  Published: 30/Dec/2010

Title: USE OF A NEUROTOXIC COMPONENT OF A CLOSTRIDIUM BOTULINUM TOXIN COMPLEX TO REDUCE OR PREVENT SIDE EFFECTS.

Applicant/Assignee: MERZ PHARMA GMBH & CO., KGAA

Application No.: 12/735144   Filing Date: 17/Dec/2008

Abstract:Use of a neurotoxic component of a Clostridium botulinum toxin complex for the facial cosmetic treatment of a human or animal susceptible to suffering from doll's face or frozen face, or the neurotoxic component of a Clostridium botulinum toxin complex for the treatment of a disease or disorder caused by or associated with hyperactive cholinergic innervation of muscles or exocrine glands in a human or animal susceptible to side effects associated with the treatment of said disease or disorder with a Clostridium botulinum toxin complex:

Priority: EP20070024961 Applic. Date: 2007-12-21; US20070009010P Applic. Date: 2007-12-21; WO2008EP10782 Applic. Date: 2008-12-17

Inventor: HAUNOLD ERICH [AT]; MARX MATTHIAS [DE]


Application No.: US20100331260A1  Published: 30/Dec/2010

Title: Stabilized bitamin c derivatives having a peptide molecule, preparation method thereof, and composition containing the same

Applicant/Assignee: Peptron Co.Ltd. Daejeon KR

Application No.: 12/308604   Filing Date: 05/Sep/2006

Abstract:Stabilized bitamin c derivatives having a peptide molecule, preparation method thereof, and composition containing the same

Priority: PCT/KR2006/003520

Inventor: Park; Jong-II; (Daejeon, KR) ; Kim; Heung-Jae; (Daejeon, KR) ; Kim; Dong-Won; (Daejeon, KR) ; Lim; Chae-Jin; (Daejeon, KR) ; Kang; Jong-Phil; (Daejeon, KR) ; Park; Kyeong-Yong; (Daejeon, KR) ; Yoon; Seok-Jeong; (Daejeon, KR) ; Kwon; Seon-Deok; (Daejeon, KR) ; Choi; Ho-Il; (Daejeon, KR)


Application No.: US20100331272A1  Published: 30/Dec/2010

Title: Agent for Preventing or Ameliorating Skin Aging

Applicant/Assignee: KAO CORPORATION

Application No.: 12/867958   Filing Date: 26/Feb/2009

Abstract:An agent for preventing or ameliorating skin aging, which exhibits a more excellent effect on the suppression of formation, or the amelioration, of wrinkles on the skin or sagging skin. An agent for preventing or ameliorating skin aging, containing triterpenoid saponins represented by the following formula (1) as an active ingredient, wherein at least one of R1 and R2 is a tigloyl group and the other represents a tigloyl group or an angeloyl group

R3 represents a methyl group or a hydroxymethyl group

and R4 represents Glc, Xyl or Gal.

Priority: JP20080046490 Applic. Date: 2008-02-27; JP20090032434 Applic. Date: 2009-02-16; WO2009JP54097 Applic. Date: 2009-02-26

Inventor: KAMEYAMA AKIYO [JP]; FUJIMURA TSUTOMU [JP]


Application No.: US20100331343A1  Published: 30/Dec/2010

Title: NOVEL TRIAZOLE DERIVATIVES AS GHRELIN ANALOGUE LIGANDS OF GROWTH HORMONE SECRETAGOGUE RECEPTORS

Applicant/Assignee: ZENTARIS GMBH LE CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE UNIVERSITY OF MONTPELLIER I UNIVERSITY OF MONTPELLIER II

Application No.: 12/880774   Filing Date: 13/Sep/2010

Abstract:The present invention provides novel triazole derivatives as ghrelin analogue ligands of growth hormone secretagogue receptors according to formula (I) that are useful in the treatment or prophylaxis of physiological and/or pathophysiological conditions in mammals, preferably humans, that are mediated by GHS receptors. The present invention further provides GHS receptor antagonists and agonists that can be used for modulation of these receptors and are useful for treating above conditions, in particular growth retardation, cachexia, short-, medium- and/or long term regulation of energy balance

short-, medium- and/or long term regulation (stimulation and/or inhibition) of food intake

adipogenesis, adiposity and/or obesity

body weight gain and/or reduction

diabetes, diabetes type I, diabetes type II, tumor cell proliferation

inflammation, inflammatory effects, gastric postoperative ileus, postoperative ileus and/or gastrectomy (ghrelin replacement therapy).

Priority: EP20050017732 Applic. Date: 2005-08-16; US2006-502473 Applic. Date: 2006-08-11; US20050707941P Applic. Date: 2005-08-15; US20060787543P Applic. Date: 2006-03-31

Inventor: PERRISSOUD DANIEL [DE]; MARTINEZ JEAN [FR]; MOULIN ALINE [FR]; FEHRENTZ JEAN-ALAIN [FR]; BOEGLIN DAMIEN [FR]; DEMANGE LUC [FR]


Application No.: US20100331381A1  Published: 30/Dec/2010

Title: Substituted Phenylureas and Phenylamides as Vanilloid Receptor Ligands

Applicant/Assignee: GRUENENTHAL GMBH

Application No.: 12/775235   Filing Date: 06/May/2010

Abstract:The invention relates to substituted phenylureas and phenylamides, to processes for the preparation thereof, to pharmaceutical compositions containing these compounds and also to the use of these compounds for preparing pharmaceutical compositions.

Priority: EP20090006237 Applic. Date: 2009-05-07; US20090176284P Applic. Date: 2009-05-07

Inventor: FRANK ROBERT [DE]; BAHRENBERG GREGOR [DE]; CHRISTOPH THOMAS [DE]; SCHIENE KLAUS [DE]; DE VRY JEAN [DE]; DAMANN NILS [DE]; FRORMANN SVEN [DE]; LESCH BERNHARD [DE]; LEE JEEWOO [KR]; KIM YONG-SOO [KR]; KIM MYEONG-SEOP [KR]


Application No.: US20100331978A1  Published: 30/Dec/2010

Title: Antipathogenic Biomedical Implants, Methods and Kits Employing Photocatalytically Active Material

Applicant/Assignee:

Application No.: 12/918698   Filing Date: 20/Feb/2009

Abstract:An antipathogenic biomedical implant is formed throughout its structure of a matrix material comprising at least about 1 weight percent of a photocatalytically active filler which exhibits an antipathogenic effect upon irradiation with light. The photocatalytically active filler is arranged in the matrix material in the implant to receive light irradiated from an external light source. In another embodiment, an antipathogenic biomedical implant comprises at least about 1 weight percent of a photocatalytically active material which exhibits an antipathogenic effect upon irradiation with light, wherein the photocatalytically active material is arranged in the implant to receive light irradiated from an external light source. Methods for providing an antipathogenic biomedical implant, methods for reducing pathogens on a biomedical implant, methods for reducing the bioburden in a biomedical implant installation, and kits for providing an antipathogenic biomedical implant employ the antipathogenic biomedical implants.

Priority: US20080138300P Applic. Date: 2008-12-17; WO2009IB50715 Applic. Date: 2009-02-20

Inventor: STROEMME MARIA [SE]; WELCH KEN [SE]; ENGQVIST HAAKAN [SE]

US Patent Applications  in 2011
 
US Patent Applications  in 2009
...or use our Search Engine to
search for patent documents by
number.
Search for anything. Simply
type the words in the box..
US PROVISIONAL PATENT APPLICATIONS IN SKIN CARE ACTIVES PUBLISHED IN 2010
This list includes Provisional Patent Applications published in the United States. The list was retrieved by searching the claims section of all patent applications published. Salient search
terms include skin care active ingredients having properties such as anti-ageing, anti-wrinkle, antioxidant, acne control benefits, skin whitening or lightening, blemish removal, etc. This
category includes technology related to the synthesis and delivery of actives such as peptides, exfoliants, α-hydroxy acids, herbals, free radical scavengers, "green" derived molecules and
compounds having unique sensory properties.
Clck to enlarge and view details